<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">From the Science of Tobacco Consumption to the SyNAPSE Model of Addiction and CLEAR-PATH Cessation Program &quot;Freedom begins with seeing the threads.&quot;</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Kshiteesh</forename><surname>Bhardwaj</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pragathi</forename><forename type="middle">Priyadarsini</forename><surname>Balasubramani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Student</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Pragathi</forename><forename type="middle">Priyadharsini</forename><surname>Balasubramani</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Cognitive Science</orgName>
								<orgName type="institution">Indian Institute of Technology Kanpur</orgName>
								<address>
									<region>Uttar Pradesh</region>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Cognitive Science</orgName>
								<orgName type="institution">Indian Institute of Technology</orgName>
								<address>
									<settlement>Kanpur</settlement>
									<region>Uttar Pradesh</region>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">From the Science of Tobacco Consumption to the SyNAPSE Model of Addiction and CLEAR-PATH Cessation Program &quot;Freedom begins with seeing the threads.&quot;</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">9304AB73E7F77D006DA4BC5C2CF33370</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-11-18T15:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=0, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], sentenceSegmentation=false, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preface</head><p>This book, Live Free Again, offers a comprehensive exploration of tobacco use, the mechanisms of nicotine addiction, and the strategies that can help people quit. It weaves together scientific research, behavioral insights, and lived experiences within the SyNAPSE framework and the CLEAR-PATH Cessation program, aiming to give readers both a deep understanding of addiction and practical pathways to freedom.</p><p>The motivation for this work lies in the urgent global challenge posed by tobacco. Despite decades of research and public health efforts, tobacco use continues to exact an enormous toll on health and society. Yet the harm extends beyond disease and premature death: addiction erodes autonomy, reshapes identity, and narrows the possibilities of daily life. This book is a step toward reclaiming that autonomy, informed by evidence and guided by compassion.</p><p>The chapters follow a clear path: they begin with the history and cultural context of smoking, move through the molecular and behavioral science of addiction, and conclude with today's challenges and the development of the SyNAPSE framework, and its implications and applications.</p><p>This work is written for researchers, healthcare professionals, policymakers, educators, and anyone concerned with the science and practice of tobacco control, as well as for those seeking to quit themselves. By integrating established knowledge into a coherent framework, the hope is to inspire more effective interventions and, ultimately, to support lives lived free from addiction.  . Upregulation initially rises with repeated smoking but then plateaus, forming a stable smoking dosage, where natural receptor decline between cigarettes balances the increase after smoking. This plateau explains how steady, longterm smoking behaviors are biologically sustained. The half-life for this modeling was taken as 2 hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.6 Effect of upregulation susceptibility, reflecting variability in nicotine metabolism and receptor response. High-susceptibility individuals (i.e., slow metabolizers) exhibit stronger receptor upregulation per cigarette and are therefore more prone to dependence, even when smoking the same or fewer cigarettes as their peers. He flicked the lighter with trembling hands. The flame caught, the smoke curled upward, and with it came the familiar sting of guilt. He had promised himself and others that this time would be different. He had reasons that could not be ignored:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>List of Figures</head><p>his health, his family, his daughter's hopeful face. For a few days, that conviction held steady. Then the cravings returned with a force that felt larger than his will. The cigarette brought no comfort, only a hollow quiet and a sharper sense of failure.</p><p>It was not just smoke he inhaled, but another crack in his trust in himself. The future seemed distant, unreachable, veiled in haze. In that moment, there was no next time, only the bitter taste of ash and the ache of defeat. This is not the story of one man alone. It is a reflection shared by millions. Across the world, in countless forms, the same struggle unfolds every day.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Gravity of the Situation</head><p>Smoking remains one of the most urgent and stubborn public health challenges. Every year it claims more than 8 million lives, and more than 1 million of these deaths are caused not by smokers themselves, but by secondhand exposure <ref type="bibr" target="#b144">(Ritchie and Roser, 2023)</ref>. Tobacco does not simply shorten lives. It diminishes the quality of life long before death arrives, leaving behind years of illness, disability, and strained healthcare systems.</p><p>The toll is global, but not evenly distributed. In wealthier countries, cigarette use has declined, yet the gains are fragile and often offset by rising e-cigarette and vaping use among youth <ref type="bibr" target="#b112">(McCabe et al., 2017)</ref>. In lower-and middle-income countries, tobacco companies continue to expand aggressively, exploiting regulatory gaps and economic vulnerabilities. The harms ripple across generations: adolescents are primed for early dependence, pregnant women pass risk onto unborn children, and families in poverty spend scarce resources on a product that shortens their lives <ref type="bibr" target="#b86">(Huisman et al., 2011;</ref><ref type="bibr" target="#b57">Garrett et al., 2019;</ref><ref type="bibr" target="#b27">Cnattingius, 2004)</ref>.</p><p>The picture is clear: tobacco use is not a relic of the twentieth century. It is an adaptive, persistent crisis that continues to evolve in form and reach. Behind every statistic are stories like the one above: moments of resolve undone by craving, and lives reshaped by dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">The Complex Nature of Tobacco Addiction</head><p>If the evidence is overwhelming, why do millions continue to smoke? The reasons are as layered as the addiction itself. Nicotine hijacks the brain's reward system with speed and intensity, creating a cycle of dependence that can form after only a few exposures <ref type="bibr" target="#b177">(Tiwari et al., 2020)</ref>. Withdrawal delivers a storm of irritability, craving, and anxiety that is difficult to endure without help <ref type="bibr" target="#b83">(Hughes and Hatsukami, 1986)</ref>.</p><p>But the chemical hook is only part of the story. Smoking is interwoven with daily rituals and personal identity. The morning coffee feels incomplete without a cigarette. A break at work feels unfinished without stepping outside for a smoke. A stressful day feels heavier without the familiar pause of inhaling. Over time, the cigarette becomes more than a device for nicotine delivery. It becomes a companion, a ritual, a coping mechanism, and sometimes even a marker of belonging <ref type="bibr" target="#b184">(Van Gucht et al., 2010;</ref><ref type="bibr" target="#b158">Shiffman, 1993)</ref>.</p><p>Every failed quit attempt adds weight to the burden. Shame and self-blame accumulate, eroding confidence. For many smokers, the most painful aspect of addiction is not the craving itself but the sense of failure it leaves behind <ref type="bibr" target="#b72">(Halding et al., 2010;</ref><ref type="bibr" target="#b59">Gibbons et al., 1997)</ref>. Addiction is therefore not only a biological dependency but also an injury to identity and self-trust. To address smoking, then, is not simply to end a habit. It is to restore autonomy, dignity, and hope.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3">What We Know and Where We Fall Short</head><p>There is reason for optimism. Evidence-based treatments do exist. Nicotine replacement therapies, medications such as varenicline or bupropion, and structured counseling programs have helped millions successfully quit <ref type="bibr" target="#b140">(Reus and Smith, 2008)</ref>. These interventions show us that tobacco dependence is treatable.</p><p>Yet the gap between what we know and what we do remains troubling. Many smokers never gain access to these treatments, or they encounter barriers of cost, availability, or stigma <ref type="bibr" target="#b84">(Hughes et al., 2011;</ref><ref type="bibr" target="#b56">Fu et al., 2005)</ref>. Even when treatments are available, they may not fit the lived realities of the people who need them. Healthcare providers often have limited training or time to deliver comprehensive cessation care <ref type="bibr" target="#b147">(Rojewski et al., 2016;</ref><ref type="bibr" target="#b15">Blumenthal, 2007)</ref>. At the same time, public health responses are constrained by industry lobbying, uneven political will, and social inequalities.</p><p>We are left with a paradox. Science has produced effective tools, yet millions continue to smoke without adequate support. This signals not only a failure of individual willpower, but also a failure of systems, policies, and imagination.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4">The Need for a New Approach</head><p>What is required is a broader vision of addiction and its treatment. Tobacco addiction is not a simple problem, and so it cannot have simple solutions. It is a dynamic interplay of biology, psychology, behavior, culture, and economics. Effective strategies must reflect this complexity, integrating multiple levels of influence into a coherent framework that is practical in real life.</p><p>This book offers such a framework. It introduces the SYNAPSE Model of Smoking Addiction, a model that explains addiction as the outcome of dynamic competition among signals in the brain, shaped by influences that range from molecular to cultural. From this foundation, we present the CLEAR-PATH Program, a structured and adaptive approach to cessation that translates theory into practical guidance for smokers and clinicians alike <ref type="bibr" target="#b95">(Kshiteesh, 2025)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.5">What This Book Will Cover</head><p>The chapters that follow are written with three intertwined audiences in mind. For the smoker, they offer clarity, compassion, and practical guidance: a map through the fog of cravings, relapse, and guilt toward a more autonomous life. For the clinician, they provide a toolkit that blends evidence-based interventions with fresh frameworks that are attuned to patients' lived realities. For the researcher, they are an invitation to engage with a new integrative model of addiction that connects biology, psychology, and society, generating testable hypotheses and new directions for study.</p><p>This book unfolds across nine chapters, each building on the last to develop a complete picture of smoking addiction and how to address it.</p><p>‚Ä¢ Chapter 2: Tobacco: From Sacred Plant to Biochemical Trap This chapter traces tobacco's historical journey, from its sacred and ritual use in pre-Columbian societies to its global diffusion, industrialisation, and transformation into a driver of mass addiction. It reviews changing models of understanding, including behavioral, cognitive, neuroscientific, and policy perspectives, and highlights remaining gaps.</p><p>‚Ä¢ Chapter 3: Smoking as a Journey: Pathways, Processes, and Outcomes Smoking is examined as a developmental pathway with identifiable stages and transitions. The chapter discusses susceptibility, experimentation, escalation, reduction, stability, cessation, and relapse across the life course, providing a structured behavioral framework for the rest of the book.</p><p>‚Ä¢ Chapter 4: Nicotine's Grip: How Smoking Hooks the Brain This chapter explores the biological, chemical, and cognitive mechanisms that make tobacco so addictive.</p><p>It explains how nicotine acts on receptors and brain circuits, how these effects shape cognition and experience, and how rituals and social contexts deepen the habit. It integrates molecular, neural, psychological, and phenomenological perspectives.</p><p>‚Ä¢ Chapter 5: Too Clever to Quit: The Misadventures of a Thoughtful Smoker Addiction is also cognitive. This chapter examines the rationalisations, identity narratives, and mental loops that sustain smoking. It shows how thought can trap individuals, but also how cognitive processes can be turned into tools for change.</p><p>‚Ä¢ Chapter 6: The State of Smoking Cessation: Practices and Constraints The current landscape of cessation efforts is reviewed, including pharmacological, behavioral, technological, and clinical approaches. The chapter highlights structural and systemic barriers, inequities, and the reasons why global progress has slowed despite the availability of effective treatments.</p><p>‚Ä¢ Chapter 7: The SyNAPSE Model of Addiction This chapter introduces the SyNAPSE model, which conceptualises addiction as a dynamic competition among neural signals that are modulated by biological, psychological, and contextual factors. It outlines the model's principles, explores implications for smoking behavior, and shows how computational modeling can explain real-world patterns of addiction and cessation.</p><p>‚Ä¢ Chapter 8: The CLEAR-PATH Cessation Program Building on the SyNAPSE model, this chapter presents the CLEAR-PATH program, a structured and adaptive approach to smoking cessation. Each stage, from understanding the smoker to relapse prevention, is operationalised with tools and strategies, supported by a personalised digital application.</p><p>‚Ä¢ Chapter 9: Dear Smoker, Hear Me Out! The final chapter speaks directly to smokers.</p><p>It reframes quitting as a strategic and humane process rather than a test of willpower. It guides the reader through five key challenges of quitting, including cravings, triggers, inner voices, lapses, and envisioning the future self, while offering encouragement and practical steps for change.</p><p>This book is not only about quitting smoking. It is about understanding addiction as a human phenomenon that emerges at the intersection of biology, psychology, and society. Smokers will find insight and guidance, clinicians will find tools and frameworks, and researchers will find integrative theory and testable ideas. Each chapter offers a different perspective, but all converge on a single goal: building more humane and effective responses to smoking addiction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NOTE TO CLINICIANS</head><p>Your role is not only to provide medication or advice, but also to understand the lived complexity of smoking. Patients carry shame, identity conflicts, and social pressures alongside nicotine dependence. The SYNAPSE Model and CLEAR-PATH Program aim to provide you with a framework that makes sense of these layers and translates them into adaptive, patient-centered care.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NOTE TO SMOKERS</head><p>If you have struggled to quit, it is not because you are weak. It is because smoking is a powerful addiction that touches every part of life: your brain, your routines, your relationships, and your emotions. This book is written to honor your struggle and to provide practical guidance. Each attempt to quit is progress, and there is always a clearer path forward. Change is not only possible, it is within your reach.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NOTE TO RESEARCHERS</head><p>Addiction science is at a crossroads. We know much about isolated mech-</p><p>anisms, yet less about how they interact across levels of biology, psychology, and society. The SYNAPSE Model is offered as a unifying framework that reframes these elements as modulators of a single competitive process in the brain. For researchers, this book provides testable predictions, computational formulations, and an integrative agenda that bridges neuroscience, behavioral science, and public health. It is an invitation to deepen the science of addiction by connecting mechanisms with lived experience.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHAPTER 2</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tobacco, From Sacred Plant to Biochemical Trap</head><p>Centuries ago, deep in the forests of the Americas, a shaman sat beside a fire. In his hands was a bundle of dried tobacco leaves. He lit them carefully, letting the smoke rise in slow spirals toward the night sky. Each breath was a prayer, each exhale a bridge to the spirit world. To his people, tobacco was not a habit but a sacred tool, believed to connect the human and the divine . Now, half a world away and half a millennium later, another figure stands alone on a balcony. He lights a cigarette with shaking hands, inhaling quickly, eyes clouded with guilt. For him the smoke is not sacred. It is a burden, a craving he cannot shake, a reminder of promises broken. What once carried prayers to the heavens now carries tar and toxins into the lungs.</p><p>Between these two scenes stretches the history of tobacco: from ritual to commodity, from healing plant to global epidemic.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Introduction</head><p>Tobacco's story spans ritual, empire, science, and commerce. First cultivated and revered by Indigenous peoples of the Americas as a sacred and medicinal plant, it was rapidly transformed by colonial trade into one of the world's most profitable commodities, deeply entangled with slavery and empire. By the nineteenth and twentieth centuries, industrialization and advertising had made cigarettes ubiquitous symbols of modern life, only to be recast decades later as drivers of disease and addiction through the lens of epidemiology, psychology, and neuroscience.</p><p>Today, tobacco use continues to evolve. While smoking has declined in many high-income countries due to regulation and public awareness, it remains entrenched and in some cases is rising in low-and middle-income regions where populations are growing and health systems are under strain. New nicotine technologies such as e-cigarettes, heated tobacco, and pouches have further complicated the picture, presented as harm-reduction tools but also extending dependence and attracting new generations of users.</p><p>The consequences are immense. Tobacco kills more than 7 million people annually, including around 1.6 million non-smokers exposed to second-hand smoke (World Health <ref type="bibr">Organization, 2025)</ref>. Nearly 1.3 billion people use tobacco worldwide, with 80% living in low-and middleincome countries where the burden of disease and death is heaviest. Beyond health, tobacco entrenches poverty, diverts resources from food and education, and imposes economic costs in the hundreds of billions each year through treatment expenses and lost productivity.</p><p>Thus, tobacco is not merely a medical hazard but a global social and economic force; at once sacred plant, colonial commodity, addictive product, and public health catastrophe. This chapter traces its long trajectory while critically examining the shifting models used to explain tobacco use, from ritual and commerce to dependence and control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Timeline of Tobacco's Global Journey</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pre-1500s</head><p>Indigenous peoples in the Americas use tobacco in ritual, medicine, and community life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1492</head><p>Columbus encounters tobacco in the Caribbean; Europeans begin experimenting.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1612</head><p>First Virginia tobacco exports; tobacco becomes central to colonial economies and slavery. 1600s</p><p>Global spread: hookah in Mughal India, Ottoman coffeehouses, and snuff in Europe. 1800s</p><p>Cigars gain prestige; cigarettes appear; rolling machines enable mass production.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1914-1945</head><p>Cigarettes distributed widely to soldiers in both World Wars, accelerating global adoption. 1964 U.S. Surgeon General's Report links smoking to cancer; public health debates intensify.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Late 1900s</head><p>Anti-smoking campaigns, advertising bans, cessation resaerch, and restrictions expand worldwide.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2003</head><p>WHO Framework Convention on Tobacco Control (FCTC) adopted, the first global health treaty. 2010s E-cigarettes and heated tobacco products rise; harm-reduction debates intensify. 2000s-Present Smoking declines in high-income countries, but rises in Asia, Africa, and Latin America; new nicotine products reshape markets.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Sacred Roots: Tobacco in the Pre-Columbian Americas</head><p>The story of tobacco begins not with factories or billboards, but with ritual and reverence. Archaeological and ethnobotanical evidence suggests that Indigenous peoples have cultivated and consumed tobacco for at least 3,000 years <ref type="bibr" target="#b187">(Winter, 2000)</ref>. Among the Maya, Aztec, and Ta√≠no, tobacco was far more than a crop. Its smoke was thought to carry prayers to the gods, to open pathways into trance, and to heal the body as well as the soul. Shamans inhaled it not for leisure but to step into other realms. In this world tobacco was ceremony, medicine, and sacred power.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Encounter and Diffusion: Tobacco Meets Europe (1492-1600s)</head><p>This deep-rooted spiritual practice, however, entered a radically new trajectory with European contact. When Columbus arrived in the Caribbean in 1492, his crew observed people rolling dried leaves, setting them alight, and breathing in the fragrant smoke <ref type="bibr" target="#b107">(Mancall, 2004)</ref>. What seemed unusual to Europeans soon became fascination. Within a few decades, tobacco was growing on European soil. Physicians hailed it as a wonder drug, prescribing it for ailments ranging from headaches to plague. Jean Nicot, the French ambassador who helped popularize it, even gave his name to nicotine <ref type="bibr" target="#b167">(Stewart, 1967</ref>).</p><p>Yet tobacco in Europe was more than medicine. It was also commerce. By the early seventeenth century, the Virginia colony was exporting tobacco on a vast scale, quickly becoming its economic lifeline. The fields were worked by enslaved Africans, binding tobacco's prosperity to the brutal machinery of slavery and empire. A sacred plant of the Americas had been remade as a profitable commodity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">The Global Spread (1600s-1700s)</head><p>Once transplanted to Europe and tied to colonial economies, tobacco rapidly exceeded its Atlantic cradle. Over the seventeenth century it adapted to diverse cultural milieus, embedding itself in daily life across Africa, Asia, and the Middle East. In Africa it became both stimulant and currency, traded in markets and carried along coastal routes <ref type="bibr" target="#b97">(Laufer et al., 1930)</ref>. In the Ottoman Empire, it filled the smoky interiors of Istanbul coffeehouses despite repeated bans by sultans who considered it sinful <ref type="bibr" target="#b70">(Grehan, 2006)</ref>. In China, it was first used as medicine, later as a leisure habit <ref type="bibr" target="#b9">(Benedict, 2011)</ref>. In Japan, it took the elegant form of the slender kiseru pipe, immortalized in art and poetry <ref type="bibr" target="#b74">(Handa, 2014)</ref>. In Southeast Asia, tobacco blended with betel nut and lime, adapting to local traditions with ease <ref type="bibr" target="#b79">(H√∂llmann, 2000)</ref>. Introduced by Portuguese traders in the late sixteenth century, in India, it soon reached the Mughal courts, where the hookah became a symbol of refinement and hospitality <ref type="bibr" target="#b65">(Gokhale, 1974;</ref><ref type="bibr" target="#b106">Mahmood et al., 2024)</ref>.</p><p>By 1700, tobacco had achieved global reach. It appeared as snuff in European salons, as smoke in Asian courts, and as barter in African markets. What had once been ceremonial was now ordinary, a daily practice spread across continents.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">Industrialisation and the Rise of the Cigarette (1800s-Early 1900s)</head><p>By the nineteenth century, tobacco's diffusion had created a global consumer base. What transformed the habit further was not geography but technology: industrialisation and advertising propelled the cigarette into a mass-market product. Cigars became symbols of power and masculinity, while cigarettes, at first handmade luxuries, were transformed by mechanized rolling machines in the 1880s <ref type="bibr" target="#b28">(Cox, 2000)</ref>. With mass production, cigarettes became cheap, portable, and easily distributed.</p><p>Advertising magnified their reach. Posters, newspapers, and eventually films cast cigarettes as modern, stylish, even healthy <ref type="bibr" target="#b152">(Saffer and IV, 1999)</ref>. Hollywood stars smoked them with ease, while soldiers in World War I received them as rations, a comfort in the trenches. By the early twentieth century, cigarettes had become more than a habit. They were woven into the rhythms of modern life. In many contexts, smoking served ritualistic or communal functions, from Indigenous ceremonial use to everyday social bonding. Although some religious or moral perspectives occasionally cast smoking in a negative light, viewing it as a vice or indulgence, these views were not predominant and rarely shaped public policy or mainstream opinion. At this stage, there were no formal health models addressing smoking, and it was not seen as a public health issue. Rather, it was a socially accepted habit, free from medical stigma or widespread moral judgment (Roper <ref type="bibr" target="#b148">Organization and Roper, 1953)</ref>.</p><p>By the nineteenth century, tobacco use in India reflected social diversity: bidis served the working classes <ref type="bibr" target="#b96">(Lal, 2009)</ref>, chewing tobacco cut across castes, and British-made cigarettes entered colonial markets as markers of modernity and progress.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">Epidemiological Awakening and the Medical Framing of Smoking</head><p>By the mid-twentieth century, science began to confront the industry. Studies in the 1950s revealed the strong link between smoking and lung cancer. Landmark investigations by Doll and Hill in the UK, and Hammond and Horn in the US, established clear statistical links between cigarette smoking and chronic diseases such as lung cancer and coronary heart disease <ref type="bibr" target="#b37">(Doll and Hill, 1950)</ref>. These findings culminated in the 1964 United States Surgeon General's Report (U.S. Department of <ref type="bibr">Health and Welfare, 1964)</ref>, which marked a paradigm shift: smoking was no longer a benign personal habit but a medically significant behavior with lethal consequences.</p><p>Central to this shift was the application of linear causal models that conceptualized smoking as an isolated exposure producing predictable health outcomes. This framing supported the rise of early behavioral health theories, particularly the Health Belief Model (HBM), which proposed that individuals would take preventive action if they perceived themselves to be susceptible to a serious condition, believed the action would reduce risk, and were prompted by appropriate cues <ref type="bibr" target="#b149">(Rosenstock, 1974)</ref>. While this model was effective for health messaging, it reflected a biomedical individualism that largely ignored the broader psychological, social, cultural, and structural contexts in which smoking occurred <ref type="bibr" target="#b126">(Pederson et al., 1984)</ref>.</p><p>According to the medical framing, governments responded with warning labels, advertising bans, and awareness campaigns, but tobacco companies resisted fiercely. They funded counterstudies, introduced so-called "low-tar" cigarettes, and turned to marketing strategies that targeted women and young people <ref type="bibr" target="#b99">(Leavell, 1999;</ref><ref type="bibr">?)</ref>. The battle lines were clear: profit on one side, public health on the other.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7">Behavioral Models: Conditioning and Habit (1960s-1980s)</head><p>If epidemiology revealed smoking's dangers, it did not fully explain why people continued. To address this paradox, researchers turned to psychology, framing smoking as a behavior shaped by learning and reinforcement. Behavioral psychology framed it as a learned behavior maintained by operant and classical conditioning <ref type="bibr" target="#b162">(Skinner, 1984;</ref><ref type="bibr" target="#b176">Tiffany, 1995)</ref>: nicotine's immediate rewards reinforced use, while cues like coffee or alcohol triggered automatic cravings. Cuereactivity models showed how such stimuli could elicit relapse, leading to interventions such as cue exposure, aversive conditioning, and contingency management <ref type="bibr" target="#b40">(Drummond et al., 1995;</ref><ref type="bibr" target="#b120">Niaura et al., 1988;</ref><ref type="bibr" target="#b114">Mees et al., 1968;</ref><ref type="bibr" target="#b138">Reichert et al., 2021)</ref>. These models highlighted smoking's habitual, stimulus-response nature but underplayed cognitive, emotional, and social dimensions that later theories addressed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8">Cognitive and</head><p>Meta-Cognitive Models: Control, Self-Efficacy, Coping (1970s-1990s)</p><p>Yet habit alone could not account for the persistence of smoking. Attention soon shifted toward cognition, belief systems, and self-regulation, emphasizing the smoker's active role in sustaining or resisting the habit. From the 1970s to 1990s, research shifted from behaviorism toward cognitive models that emphasized self-monitoring, belief systems, and volitional control. Bandura's Social Cognitive Theory made self-efficacy central, framing smokers as active agents rather than passive responders <ref type="bibr" target="#b35">(DiClemente et al., 1985)</ref>. CBT approaches, especially Marlatt's relapse prevention, treated smoking as maladaptive coping and focused on restructuring thoughts and managing high-risk situations <ref type="bibr" target="#b109">(Marlatt, 1979)</ref>. Other models, such as the Theory of Planned Behavior and Self-Attribution Theory, linked smoking to attitudes, norms, and self-perceptions <ref type="bibr" target="#b64">(Godin et al., 1992;</ref><ref type="bibr" target="#b43">Eiser et al., 1977)</ref>. Dual-process theories like the Reflective-Impulsive Model explained lapses as conflicts between automatic impulses and reflective control <ref type="bibr" target="#b169">(Strack and Deutsch, 2004)</ref>, while affect regulation perspectives highlighted smoking's role in managing anxiety or low mood <ref type="bibr" target="#b22">(Carmody, 1992)</ref>. Together, these frameworks reframed smoking as cognitively mediated, driven by coping deficits, emotional regulation, and perceived capacity to change.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9">Neuroscience and Dependence: Biological Mechanisms (1980s-Ongoing)</head><p>Still, cognition provided only part of the answer. By the 1980s, advances in neuroscience recast smoking as a biological dependence rooted in the brain's reward circuitry and genetic vulnerabilities. Nicotine was identified as a psychoactive compound acting on nicotinic acetylcholine receptors (nAChRs) in the mesolimbic dopamine system <ref type="bibr" target="#b11">(Benowitz and Jacob, 1987)</ref>. Studies of pharmacokinetics, neuroadaptation, sex differences, and adolescent vulnerability deepened this view, while neuroimaging linked craving and regulation to regions such as the insula, anterior cingulate, and prefrontal cortex.</p><p>Several models emerged. Opponent-Process Theory described shifting hedonic states <ref type="bibr" target="#b165">(Solomon, 1980)</ref>; the Allostasis Model emphasized chronic stress and reward dysregulation <ref type="bibr" target="#b93">(Koob, 2001)</ref>; Incentive-Sensitization Theory distinguished "wanting" from "liking" and explained cue-driven relapse <ref type="bibr" target="#b63">(Robinson and Berridge, 2008)</ref>; habit-based models traced a shift from ventral to dorsal striatal control <ref type="bibr" target="#b48">(Everitt and Robbins, 2015)</ref>; and executive-function models highlighted deficits in control and interoception, especially involving the insula <ref type="bibr" target="#b117">(Naqvi et al., 2007)</ref>. Each contributed insights but none fully captured dependence in isolation.</p><p>Genetic research identified variants such as CHRNA5 polymorphisms linked to vulnerability <ref type="bibr" target="#b131">(Picciotto and Kenny, 2012)</ref>, while twin studies confirmed substantial heritability <ref type="bibr" target="#b101">(Li, 2003)</ref>. Nicotine use was also shown to cluster with alcohol, cannabis, and other drugs via overlapping neural pathways, reinforcing the need for integrated treatment approaches <ref type="bibr" target="#b135">(Rajabi et al., 2021;</ref><ref type="bibr" target="#b91">Kandel et al., 2001)</ref>. This framing culminated in nicotine dependence being recognized as a clinical disorder (DSM-III-R onward), spurring pharmacotherapies. Nicotine Replacement Therapies (patches, gums, lozenges, sprays) stabilized plasma nicotine levels but struggled to replicate rapid delivery <ref type="bibr" target="#b166">(Stead et al., 2012)</ref>. Bupropion, a norepinephrine-dopamine reuptake inhibitor with nAChR antagonist effects, reduced withdrawal and craving <ref type="bibr" target="#b89">(Jim√©nez-Ruiz et al., 2009)</ref>. Varenicline, a partial ùõº 4 ùõΩ 2 agonist, combined withdrawal relief with blockade of nicotine's rewarding effects, showing superior efficacy <ref type="bibr">(Richmond and Zwar, 2003a)</ref>. Despite advances, relapse rates remained high, underscoring the complexity of dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10">Motivational and Stage-Based Models (1990s-2000s)</head><p>Even as neurobiology deepened understanding, it risked reducing smokers to passive bodies. In the 1990s, motivational and stage-based models reintroduced agency, framing cessation as a dynamic, intentional process of change, shifting from mechanistic accounts toward autonomy and readiness. The Transtheoretical Model (TTM) framed cessation as a cyclical process of stages, precontemplation through maintenance, encouraging stage-matched interventions <ref type="bibr" target="#b50">(Fava et al., 1995)</ref>. Motivational Interviewing (MI) complemented this by treating motivation as a dynamic state, strengthened through empathic dialogue <ref type="bibr" target="#b77">(Hettema et al., 2004)</ref>. Self-Determination Theory (SDT) added that lasting change depends on satisfying autonomy, competence, and relatedness <ref type="bibr" target="#b150">(Ryan and Deci, 2000)</ref>.</p><p>In parallel, behavioral economics highlighted how delay discounting, loss aversion, and time inconsistency bias smokers toward immediate relief over long-term health (?). Collectively, these models reframed quitting as a self-directed, staged journey shaped by fluctuating motivation and decision biases, underscoring the need for adaptive and autonomy-supportive interventions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.11">Social and Structural Models: Inequity, Context, Ecology (2000s-2010s)</head><p>But individual motivation unfolded within broader contexts. From the 2000s, scholars increasingly emphasized how poverty, inequality, and industry tactics sustained smoking, shifting focus from the individual to the social and structural. Prevalence remained highest among marginalized groups, where poverty, stress, and limited healthcare access reinforced vulnerability <ref type="bibr" target="#b86">(Huisman et al., 2011;</ref><ref type="bibr" target="#b57">Garrett et al., 2019)</ref>. Frameworks such as the Social Ecological Model and Theory of Triadic Influence situated tobacco use within nested individual, social, and policy systems <ref type="bibr" target="#b168">(Stokols, 2000;</ref><ref type="bibr" target="#b53">Flay, 1999)</ref>.</p><p>Developmental and life-course perspectives emphasized adolescence as a critical period, with peer pressure, marketing, and neighborhood disadvantage amplifying risk <ref type="bibr" target="#b105">(Lydon et al., 2014)</ref>. Broader theories, including Fundamental Cause and Syndemics, showed how socioeconomic status and co-occurring adversities perpetuate disparities <ref type="bibr" target="#b130">(Phelan and Link, 2013;</ref><ref type="bibr" target="#b161">Singer, 2009)</ref>. Social Practice Theory further reframed smoking as a routinized practice embedded in daily life <ref type="bibr" target="#b154">(Schane et al., 2009)</ref>.</p><p>Finally, commercial determinants research revealed the tobacco industry's active role in sustaining dependence through marketing, lobbying, and strategic targeting of vulnerable groups <ref type="bibr" target="#b60">(Gilmore et al., 2015)</ref>. Together, these models positioned smoking as socially and structurally embedded, requiring systemic as well as individual-level interventions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.12">Policy Responses and Global Tobacco Control</head><p>These insights fed directly into policy. Recognizing that smoking was not merely a private choice but a socially patterned epidemic, governments and global institutions began to implement coordinated tobacco control measures. In 2003, the World Health Organization adopted the Framework Convention on Tobacco Control (FCTC), the first international treaty negotiated under WHO auspices <ref type="bibr">(World Health Organization, 2003)</ref>. Today, 183 countries are Parties to this treaty, covering over 90% of the global population. The FCTC sets international standards on taxation, advertising bans, health warnings, cessation support, and smoke-free policies. In 2003, India enacted the Cigarettes and Other Tobacco Products Act (COTPA), banning public smoking, restricting advertising, mandating health warnings, and regulating sales to minors, though enforcement remains uneven <ref type="bibr" target="#b71">(Gupta et al., 2025)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.13">The Contemporary Era: Transformation and Uncertainty (2000s-Present)</head><p>The early twenty-first century has seen smoking decline in many high-income countries, driven by taxation, regulation, and cultural shifts (World Health <ref type="bibr">Organization, 2018</ref>). Yet the tobacco industry has adapted by targeting Asia, Africa, and Latin America, where populations are growing and regulations are weaker, leading to stable or rising prevalence. This divergence underscores tobacco's persistence as both a commercial enterprise and a public health crisis.</p><p>At the same time, nicotine delivery has been transformed. E-cigarettes, heated tobacco products, and nicotine pouches are marketed as harm-reduction tools, offering reduced exposure to toxins compared to combustible cigarettes. Supporters see them as aids to quitting, but critics argue they prolong dependence, encourage dual use, and normalize smoking-like behaviors among youth, especially with flavors and algorithm-driven marketing .</p><p>Cessation techniques have also advanced. Nicotine replacement therapies, bupropion, and varenicline remain core treatments, while digital platforms, smartphone apps, and AI-driven interventions deliver personalized support at scale. Ecological Momentary Assessment and Just-in-Time Adaptive Interventions allow real-time adaptation to users' stress, cravings, or environments, signaling a move toward "precision cessation" <ref type="bibr" target="#b118">(Naughton, 2017)</ref>. Despite these innovations, relapse rates remain high, reflecting the complexity of nicotine addiction. This persistence is shaped by an evolving understanding of smoking. Research increasingly frames tobacco use as a biopsychosocial phenomenon, rooted not only in pharmacology but also in habit loops, emotional regulation, structural inequities, and commercial determinants of health. These insights have influenced both interventions and policy, encouraging integrated approaches that address neurobiological dependence, psychological coping, and the wider social environment simultaneously.</p><p>Policy frameworks continue to expand, from high excise taxes and advertising bans to nudges that reshape choice environments and bold "endgame" strategies such as generational sales bans . Yet moral framings that stigmatize smokers raise ethical concerns about autonomy and justice.</p><p>Overall, the contemporary era is defined by both innovation and uncertainty: smoking is declining in many regions, but new products, evolving cessation strategies, and complex social dynamics ensure the global tobacco epidemic is far from resolved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.14">Challenges and Gaps in Tobacco Control and Research</head><p>Taken together, these developments reveal both progress and fragility. To close the chapter, it is necessary to examine the persistent challenges and research gaps that continue to shape tobacco control today. Despite decades of progress, tobacco control remains incomplete and uneven. Clinical interventions such as counseling, nicotine replacement therapy, bupropion, and varenicline can double quit rates, yet global access is highly unequal. Only about one third of the world's population has comprehensive cessation support, with the starkest gaps in low-and middle-income countries where tobacco-related harm is greatest <ref type="bibr">(World Health Organization, 2025)</ref>. Even where treatments are available, relapse rates remain high, reflecting both the potency of nicotine dependence and the under-resourcing of cessation infrastructure.</p><p>Structural measures have also fallen short. The Framework Convention on Tobacco Control and its MPOWER strategies have reduced smoking in many high-income settings, but implementation is patchy. Taxes remain far below recommended levels in most countries, smoke-free laws are inconsistently enforced, and aggressive industry marketing continues to exploit regulatory gaps. Meanwhile, novel nicotine products, including e-cigarettes, heated tobacco, and pouches, have complicated the picture. Promoted as harm-reduction tools, they have also re-normalized smoking-like behaviors, fueled youth uptake, and sustained nicotine dependence in new forms <ref type="bibr" target="#b69">(Grana et al., 2014)</ref>.</p><p>Research, too, faces critical limitations. Many models remain siloed, emphasizing either biology, cognition, or social structure without integrating these dimensions into a coherent account of smoking as a dynamic, context-sensitive behavior. Static or stage-based frameworks fail to capture the fluctuations of craving and relapse in real-world environments. Computational and dual-process models add precision but often remain abstract and detached from practice. Moreover, much of the evidence base reflects Western, individualist perspectives, neglecting cultural, relational, and structural contexts that shape smoking in other settings.</p><p>These shortcomings reveal a landscape where progress is real but fragile: treatments are effective yet inaccessible, policies are impactful yet uneven, and research is advanced yet fragmented. The persistence of tobacco use, despite knowledge of its harms for more than half a century, underscores the need for integrative approaches that link neurobiology, psychology, culture, and structure into models capable of guiding more adaptive, equitable, and effective interventions. In that waiting room, the silence spoke volumes. What had begun as a single moment of curiosity in youth had split into divergent pathways, each carrying its own weight. None of them had known how those small choices would echo through their lives.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Introduction</head><p>It often begins quietly, with a single puff taken out of curiosity or in the company of friends. For some, that moment never arrives. Others try once, cough through the smoke, and never return. Yet for many, the first puff is not the end but the beginning. What starts as experimentation can grow into a pattern, a habit, and eventually a dependence that reshapes health, relationships, and identity.</p><p>The pathways that follow are not uniform. Some drift in and out of smoking without ever feeling attached. Others find themselves caught in daily use, wrestling with cravings and relapse. Still others leave smoking behind, sometimes permanently, sometimes only until life's pressures pull them back. This chapter traces smoking as a set of processes. From susceptibility to experimentation, from escalation to cessation, and from former-smoker latency back into renewed susceptibility, each pathway reflects behaviors that can be observed, measured, and compared. Although the inner meanings of smoking vary greatly, outward trajectories are surprisingly patterned across populations. Our aim here is to map these outward trajectories, while later chapters turn inward to their psychological, biological, and social underpinnings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">From Stages to Processes</head><p>Earlier models depicted smoking as a ladder of stages: susceptibility, experimentation, occasional use, habit, dependence, remission, relapse. These frameworks provided clarity but imposed linearity on what is in fact recursive and looping <ref type="bibr" target="#b111">(Mayhew et al., 2000;</ref><ref type="bibr" target="#b104">Lloyd-Richardson et al., 2002)</ref>. A superficial, theory-guided application of stage models, classifying smokers into fixed categories without examining the underlying processes of initiation, escalation, or relapse, is unlikely to yield meaningful improvements in cessation outcomes <ref type="bibr" target="#b143">(Riemsma et al., 2003)</ref>.</p><p>Three consistent findings undermine the idea of a linear, stage-like ladder: 1. Discontinuation. A substantial share of adolescents try cigarettes but do not progress to regular or daily smoking. Longitudinal studies show that only a minority of experimenters escalate: for example, in a national U.S. cohort, about two-thirds of youth experimenters discontinued without establishing sustained use <ref type="bibr" target="#b41">(Dutra et al., 2017;</ref><ref type="bibr" target="#b24">Choi et al., 1997;</ref><ref type="bibr" target="#b180">Tucker et al., 2003)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.</head><p>Relapse. Many adults return to smoking even after years or decades of abstinence, demonstrating that cessation is better understood as provisional rather than final <ref type="bibr" target="#b171">(Swan et al., 1988)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Plateauing.</head><p>A subset of smokers sustain low-level, intermittent use across the life course, neither escalating into dependence nor quitting entirely <ref type="bibr" target="#b192">(Wortley et al., 2003)</ref>.</p><p>A process-based perspective instead emphasizes recurrent dynamics: escalation, stability, reduction, cessation, remission, and relapse, which can repeat across the life course. These can be represented both as stages of engagement and as processes of transition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Operational Definitions</head><p>Terms like "light smoker" or "social smoker" are ambiguous. To ground analysis, Table <ref type="table">3</ref>.1 defines states of engagement with empirical anchors.</p><p>Table 3.1: Empirical definitions of smoking states State Characteristics Empirical Indicators / Measures Susceptible Has never used tobacco but is receptive to trying.</p><p>Pierce Susceptibility Index; initiation risk ‚àº2-3 times higher <ref type="bibr" target="#b133">(Pierce et al., 1995)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimenter</head><p>Has tried one or more puffs, without a consistent pattern.</p><p>Self-report: "ever tried/puffed." Roughly 30-40% never progress to daily smoking <ref type="bibr" target="#b14">(Birge et al., 2018)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Occasional</head><p>Smokes intermittently, often in social or situational contexts.</p><p>About 8-12% maintain occasional use into adulthood <ref type="bibr" target="#b192">(Wortley et al., 2003)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Chipper</head><p>Long-term, low-rate smoker who resists dependence.</p><p>Typically ‚â•4 days/week but ‚â§5 cigarettes/day. Minimal to no withdrawal symptoms; intake remains stable across years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dependent</head><p>Daily smoking characterized by compulsive use, withdrawal, and craving.</p><p>Fagerstr√∂m Test for Nicotine Dependence (FTND) ‚â•4; DSM-5 Tobacco Use Disorder criteria.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Former smoker</head><p>Has quit, though relapse risk remains.</p><p>‚â•3 months abstinent. Relapse rate ‚àº50% in the first year <ref type="bibr" target="#b61">(Gilpin et al., 1997)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Characterizing Current smokers</head><p>"Current smoker" collapses heterogeneous subgroups. A minimum characterization should include:</p><p>1. Frequency / intensity (days smoked, CPD).</p><p>2. Pattern type (occasional/social, chipper, daily).</p><p>3. Dependence severity (FTND/HSI, biomarkers).</p><p>4. Motives (social, stress relief, habit, hedonic).</p><p>5. Trajectory (stable, escalating, declining).</p><p>6. Willingness or dissonance (desire to quit, perceived control, ambivalence).</p><p>7. Product and co-use profile (combustible vs. non-combustible, alcohol/cannabis).</p><p>Relying on the simple label of "current smoker" obscures critical differences that matter for both science and practice. While dosage-based typologies (e.g., light, moderate, heavy smokers) are common, they are insufficient on their own. Smoking is not only about how much is consumed, but also about the underlying patterns, neurobiology, motives, and orientations toward change.</p><p>For clinicians, finer distinctions clarify intervention priorities. A chipper who shows minimal withdrawal but strong dissonance may benefit most from motivational and identity-focused strategies, whereas a dependent daily smoker is more likely to require pharmacotherapy combined with behavioral support. Accounting for co-use with alcohol or cannabis is equally important, as polysubstance use complicates both cessation and relapse trajectories. From a policy perspective as well, refining the broad category of "current smoker" into more precise subgroups enables more targeted prevention.</p><p>Ultimately, moving beyond the crude binary of current versus non-current smoking is essential. Tobacco use should be understood not as a static status but as a dynamic set of processes, each with its own vulnerabilities, intervention points, and opportunities for prevention.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">Before the First Puff: Susceptibility</head><p>Susceptibility is not a behavior but a risk orientation, i.e., a psychological and social readiness that precedes any tobacco use. It is best understood as a spectrum shaped by individual dispositions, cultural framings, and structural conditions <ref type="bibr" target="#b46">(Evans et al., 1995)</ref>.</p><p>Importantly, from a practical perspective, there are at least two kinds of susceptibility already present before smoking begins: the likelihood of initiation and the likelihood of dependence once exposure occurs.</p><p>Early work, such as Pierce and colleagues' influential susceptibility index, showed that neversmokers who did not firmly reject future smoking were two to three times more likely to initiate than their peers, but this measure captured only initiation risk, leaving dependence vulnerability in the background.</p><p>Initiation susceptibility. The likelihood of trying smoking if given the opportunity. This is shaped by sensation-seeking and impulsivity , family and peer modeling, cultural framings of smoking as rebellious or glamorous, and structural factors such as retail density, flavored products, and marketing <ref type="bibr" target="#b136">(Ranaei et al., 2022)</ref>. Adolescents who endorse anything other than a firm "definitely not" on Pierce Index items are classified as susceptible, and are two to three times more likely to experiment. This susceptibility is a strong predictor of initiation <ref type="bibr" target="#b87">(Jackson, 1998)</ref> Dependence susceptibility. The likelihood of progressing to compulsive use once exposed varies across individuals. Genetic variants such as CHRNA5, dopaminergic sensitivity, and stress reactivity influence whether nicotine is experienced as rewarding or aversive at first trial <ref type="bibr" target="#b156">(Sellings et al., 2008)</ref>. Adolescents are especially vulnerable, as ongoing brain maturation heightens reward sensitivity while executive control systems remain underdeveloped, amplifying reinforcement and weakening resistance. Beyond biology, psychosocial factors matter: individuals who rely on substances for mood regulation or stress relief are more prone to escalation, highlighting how coping styles and environmental stressors interact with neurobiological predispositions <ref type="bibr" target="#b183">(Van Den Bree et al., 2004)</ref>.</p><p>Interplay and life-course relevance. Initiation and dependence susceptibility are distinct but</p><p>interwoven. An individual may be open to trying but resistant to dependence, or biologically vulnerable yet socially shielded from exposure. Both forms are strongest in adolescence, but dependence susceptibility resurfaces across the life course as vulnerability to relapse, especially under stress, bereavement, or illness. Adults who quit remain more relapse-prone than neversmokers, reflecting the persistence of biological embedding.</p><p>Implications. Effective prevention must address both pathways of susceptibility. Reducing openness to trial requires reinforcing anti-smoking norms, limiting marketing and retail access, raising price barriers, and proper awareness campaigns. Addressing dependence susceptibility involves more than postponing first use: it also requires building psychological resilience and adaptive coping, particularly for individuals prone to using substances for stress regulation. Delaying initiation reduces the chance that experimentation progresses into dependence, as adolescent neurodevelopment magnifies reinforcement sensitivity and weakens self-control. Finally, cultivating smoke-free identities embeds non-use into the self-concept, offering durable protection against both initiation and relapse across the life course. Effective implementation must extend from broad policy measures to everyday practices, shaping family life, childrearing, and school environments to reinforce and normalize non-smoking as part of growing up.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6">The Threshold: Experimentation</head><p>Experimentation marks the shift from susceptibility to action, the moment when a first puff or cigarette moves tobacco use from possibility into behavior. Outcomes of this threshold depend heavily on the initial experience, which is shaped simultaneously by bodily responses, social surroundings, and subjective meaning (Table <ref type="table">3</ref>.2).</p><p>Table 3.2: Dimensions shaping outcomes of first smoking experience Dimension Possible range Impact on trajectory Initial bodily response Aversive (cough, nausea) -Neutral -Positive (buzz, relaxation) Negative responses discourage continuation; neutral lowers barriers to retrying; positive reinforces repetition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Social context Restrictive vs permissive environments</head><p>Norms and access strongly influence the likelihood of repeating use.</p><p>Subjective meaning Shame, curiosity, bonding Shapes whether smoking is avoided, reconsidered, or repeated.</p><p>Estimates suggest that around 40-60 percent of experimenters never escalate to regular use, but the proportion who quit immediately (or within a very short interval after first exposure) is not well quantified. This gap matters because early quitting may involve different psychological and biological processes (strong negative response, strong dissonance, social constraints) than quitting later.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biological underpinnings</head><p>Nicotine binds to nicotinic acetylcholine receptors, triggering dopamine release in mesolimbic reward circuits. Genetic variation and developmental stage influence whether this first trial feels aversive, neutral, or rewarding, making dependence susceptibility visible early. Concurrent alcohol or cannabis use amplifies reinforcement, raising the odds of progression. The neurobiological mechanisms underlying these differences will be examined in greater detail in subsequent chapters. Here, it is sufficient to note that even a single trial can begin conditioning reward pathways, laying the groundwork for future escalation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transitions</head><p>Trajectories are not linear but recursive and path-dependent. Experimentation marks a branching point: some discontinue after one or a few puffs, while others establish intermittent patterns that may either extinguish or consolidate into regular use. Occasional smokers face a pivotal fork. Some sustain low-frequency use for years, but the reinforcing pharmacology of nicotine and the embedding of smoking into routines bias trajectories toward escalation rather than reduction.</p><p>Importantly, stability itself carries inertia. Patterns that persist across adolescence into early adulthood, whether occasional, chipper, or dependent, are more likely to remain entrenched for decades. Reduction, though possible, is rarer than escalation because tolerance, cueconditioning, and withdrawal create asymmetry. Each episode of use strengthens neural pathways of reinforcement, whereas cutting down requires sustained effort against biological and social pressures.</p><p>Former smokers occupy yet another transitional state. Many relapse, re-entering cycles of dependence, especially under stress, social exposure, or life disruption. Others sustain abstinence, though the persistence of relapse vulnerability differentiates them from never-smokers.</p><p>Figure <ref type="figure" target="#fig_6">3</ref>.1 illustrates these pathways as a dynamic system rather than a linear ladder, emphasizing that smoking careers are shaped by loops, branching, and the sticky force of stabilization.</p><p>Overall, experimentation is less a single gateway than a branching point into multiple futures.</p><p>Most progress to daily smoking, but a substantial minority exit early or stabilize into enduring low-level use. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7">Post-Initiation Processes</head><p>After initiation, smoking behavior unfolds through a limited set of dosage-based processes. These are not discrete stages but dynamic adjustments in how much, how often, and under what conditions cigarettes are consumed. Over time, these processes compound, producing both short-term fluctuations and long-term trajectories.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.1">Escalation</head><p>An upward shift in dosage, reflected in more days smoked or more cigarettes per day, driven by reinforcement, habit learning, and neuroadaptation. Escalation is the dominant tendency since repeated nicotine exposure strengthens receptor binding and cue associations. Median time from weekly use to dependence is under three years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.2">Reduction</head><p>A downward shift in dosage, whether deliberate (health, cost, self-control) or situational (restricted access, illness). Reduction may be temporary, stabilize at light use, or act as a transition toward cessation. However, because nicotine reinforcement remains active, sustained reduction is less common than escalation. 3.7.3 Stability Dosage remains relatively constant over time. This can take the form of stable occasional use (social-only smoking) or consistent daily intake at a fixed level. Stability is more likely when smoking patterns are tied to narrow routines or social scripts. If stabilized through adolescence and early adulthood, such patterns often persist into later life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.4">Cut-off (Cessation)</head><p>Complete discontinuation of smoking. For some, this occurs immediately after experimentation (due to aversive reactions or dissonance), for others only after years of use. While cut-off ends dosage entirely, relapse remains common, reflecting the enduring vulnerability of prior smokers.</p><p>Bias toward escalation. While all four processes are possible, continued nicotine use inherently biases toward escalation rather than reduction. This asymmetry 3.1 arises from receptor upregulation, habit formation in the dorsal striatum, the relief of withdrawal symptoms, and social felicitation, all of which reinforce greater frequency and intensity over time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.8">Emergent Behavior</head><p>The first puff does not commit every experimenter to a lifetime of smoking. Instead, multiple trajectories emerge, shaped by biology, psychology, and social context. A recent meta-analysis of representative surveys estimated that nearly 69% of individuals who try a single cigarette progress to daily smoking, at least temporarily <ref type="bibr" target="#b14">(Birge et al., 2018)</ref>. Once established as daily smokers, many oscillate in dosage and frequency over years, reducing, relapsing, or intensifying, until eventual cessation (if achieved) <ref type="bibr" target="#b23">(Chaiton et al., 2016)</ref>.</p><p>Yet not all experimenters follow this path. A substantial minority desist after brief trial, plateau at intermittent or low-intensity use, or oscillate at the margins without ever consolidating into daily smoking. These patterns suggest that both short-term and long-term trajectories must be distinguished and analyzed separately.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Short-term trajectories (first 1-2 years)</head><p>‚Ä¢ Immediate discontinuation: A substantial proportion of experimenters never smoke again after the first trial, often due to aversive initial reactions (e.g., coughing, nausea) or strong cognitive dissonance.</p><p>‚Ä¢ Intermittent use: Some smoke sporadically without escalation. This may resolve into cessation, consolidate into an "occasional" pattern, or transition toward dependence.</p><p>‚Ä¢ Rapid escalation: Many progress quickly to habitual or daily use, especially when early experiences are rewarding and social contexts are permissive. Meta-analysis suggests that about 69% of ever-initiators become daily smokers at least temporarily <ref type="bibr" target="#b14">(Birge et al., 2018)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Long-term trajectories (stable patterns)</head><p>‚Ä¢ Stable occasional use: A subset maintain non-daily smoking for years, typically limited to social or situational contexts. While often transitional, some sustain this pattern into adulthood.</p><p>‚Ä¢ Chippers: A distinct minority (roughly 8-15%) sustain long-term, low-rate smoking (typically ‚â§5 cigarettes/day, several days per week) without developing dependence. Unlike occasional smokers, whose use is primarily situational, chippers show remarkably stable intake across years, minimal withdrawal, and resistance to both escalation and cessation <ref type="bibr" target="#b192">(Wortley et al., 2003;</ref><ref type="bibr" target="#b158">Shiffman, 1993)</ref>.</p><p>‚Ä¢ Chronic dependence: Many daily smokers develop compulsive patterns marked by withdrawal, tolerance, and loss of control, consistent with DSM-5 tobacco use disorder.</p><p>‚Ä¢ Cessation: Some succeed in quitting, though relapse risk remains high; about half of former smokers relapse within the first year <ref type="bibr" target="#b61">(Gilpin et al., 1997)</ref>. Relapse likelihood is shaped by dependence severity, co-use of alcohol or cannabis, stress exposure, cuereactivity, and the availability of cessation supports.</p><p>‚Ä¢ Relapse cycles: Even long-term former smokers may return to smoking, often triggered by stress, bereavement, or major life disruptions. This enduring vulnerability distinguishes former smokers from never-smokers, as relapse risk, while declining over time, never fully disappears <ref type="bibr" target="#b159">(Shiffman, 2005)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.9">Cessation, Remission, and Relapse</head><p>Discontinuing smoking, whether temporary or permanent, rarely unfolds as a linear process. Instead, it is marked by cycles of abstinence, vulnerability, and possible re-engagement.</p><p>Remission. Abstinence may be short-term (3-12 months) or sustained (‚â•12 months). Most quit attempts require multiple iterations, with lapses and relapses often part of the trajectory toward lasting cessation.</p><p>Relapse. The highest risk occurs in the first year, when 50-60% of quitters return to smoking.</p><p>Although relapse probability declines over time, it never disappears entirely, even after a decade. Neurobiological factors such as cue-reactivity within hippocampal-amygdala circuits and stress-driven HPA axis activation preserve residual vulnerability.</p><p>Latent non-use. Former smokers occupy a distinct state: abstinent yet permanently different from never-smokers. Neuroplastic imprints of nicotine conditioning and epigenetic changes may persist for years, leaving the system primed for reactivation. Stress, cues, or bereavement can reignite craving even after decades of abstinence.</p><p>Clinical implications. Lasting cessation typically requires addressing both the neurobiology of dependence and the psychosocial context of smoking. Pharmacotherapies (NRT, varenicline, bupropion) reduce withdrawal and craving, while behavioural interventions (CBT, motivational counselling, contingency management) strengthen coping. Structural supports, including taxation, smoke-free environments, and social reinforcement, further reduce relapse risk and help consolidate remission.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.10">Transitions and Hazards Across the Life Course</head><p>Smoking trajectories are shaped by developmental stage, with different vulnerabilities and triggers dominating at different ages:</p><p>‚Ä¢ Adolescence: Heightened reward sensitivity, peer influence, and targeted marketing amplify the risk of initiation and rapid escalation. Early exposure also increases the likelihood of long-term dependence.</p><p>‚Ä¢ Young adulthood: Use is often embedded in nightlife and social rituals, reinforced by alcohol or cannabis co-use. Identity denial ("I only smoke when I drink") sustains intermittent patterns that can nevertheless consolidate into regular use.</p><p>‚Ä¢ Midlife: Persistence is reinforced by stress regulation, work and family routines, and emerging comorbidities such as depression or cardiovascular risk. Smoking becomes more habitual and harder to dislodge.</p><p>‚Ä¢ Later life: Bereavement, illness, and social isolation can precipitate relapse, while health scares may prompt cessation. Motivation to quit often rises, but biological embedding and long-standing routines make abstinence more difficult to sustain.</p><p>Hazards are temporally concentrated: initiation risk peaks in adolescence, while relapse risk is steepest in the first year of cessation yet persists indefinitely. Transitions are not one-way but dynamic:</p><p>‚Ä¢ Forward transitions: susceptibility ‚Üí experimentation ‚Üí occasional or daily use.</p><p>‚Ä¢ Backward transitions: dependence ‚Üí remission ‚Üí latent non-use.</p><p>‚Ä¢ Looping cycles: repeated iterations of quit attempts, lapses, and relapses across the life course.</p><p>Smoking, therefore, is best understood as a shifting balance of progression, stabilization, cessation, and relapse, each patterned by age-specific contexts and vulnerabilities.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.11">Implications for Research, Policy, and Practice</head><p>A process-based model reframes smoking not as a series of discrete stages, but as a set of recurrent transitions such as initiation, escalation, stabilization, cessation, and relapse that loop across the life course. Research should therefore focus on how and why people move between these states, and on the factors that increase the chances of escalation or relapse at different ages. These factors are not universal but shaped by culture, context, and life events, making cross-cultural and high-resolution studies especially important. Linking biological risks with social influences will help explain why the same exposure leads some people to dependence and others to discontinuation. Policy should remain flexible: while early prevention is most effective, measures such as taxation, plain packaging, and restrictions on retail and marketing also help at later stages and must adapt to new products and changing norms. For clinical practice, relapse should be seen as part of the process rather than as failure, and support should be tailored to the particular transition a person is facing. Finally, framing smoking as a journey rather than a fixed identity reduces stigma, highlights resilience, and shows that even small steps toward change can matter for long-term health.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHAPTER 4</head><p>Nicotine's Grip, How Smoking Hooks the Brain</p><p>It was four in the morning on the terrace, the city below still wrapped in silence, the air cool and faintly damp with the last trace of night. He lit his first proper cigarette, the flame trembling briefly in the darkness, and drew the smoke deep into his lungs. The taste was sharp and unfamiliar, yet what followed was overwhelming. A wave rose within him, spreading from chest to head, a strange mixture of dizziness, clarity, and warmth that seemed to arrive all at once. For a few moments, the world felt different, as if he had stumbled upon a hidden door in the ordinary fabric of life. That instant imprinted itself so vividly that it became a memory to return to again and again, a private landmark in time.</p><p>No cigarette that came afterward, not the dozens smoked in the days and weeks that followed, ever recreated that first surge. The later ones became routine, sometimes pleasant, sometimes harsh, but never again that extraordinary. The first puff stood apart, a singular moment that refused to be repeated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Introduction</head><p>The initial inhalation of cigarette smoke or vapor delivers only a trace amount of nicotine into the bloodstream, yet the ensuing effects are profound. Within seconds, nicotine traverses the pulmonary circulation, passes through the heart, and crosses the blood-brain barrier. There it binds to neuronal proteins originally evolved to recognize acetylcholine. This molecular substitution initiates a cascade of events at multiple biological levels: ion channels open and close, sodium and calcium ions alter electrical states and intracellular signaling, and transcription factors modulate gene expression. The subjective experiences of calm, alertness, or relief from tension are the macroscopic correlates of these microscopic processes.</p><p>This chapter examines the progression from molecular interactions to long-term neural adaptations. The goal is to trace smoking-related mechanisms across levels of analysis: from genetic to cellular, to circuit, to psycho-cognitive, and finally to behavioral outcomes. The intention is to provide a comprehensive account that leaves no aspect unaddressed.</p><p>We begin with the structural diversity of nicotinic acetylcholine receptors (nAChRs), their stoichiometry, and the mechanisms of ion flux. We then examine how nicotine's actions shape neural circuits, particularly within the ventral tegmental area (VTA), leading to dopaminergic reinforcement. In parallel, we address the dynamics of receptor desensitization and upregulation, the rapid pharmacokinetics and metabolism of nicotine, and the influence of additional constituents of tobacco smoke. Genetic variability in receptor structure and metabolic pathways is also reviewed, alongside evidence for intracellular signaling and epigenetic modifications that consolidate nicotine's effects into enduring patterns of craving and dependence.</p><p>Our trajectory proceeds from the synaptic level to circuit-level implications, and from there to cognitive, psychological, and behavioral manifestations of smoking. While the discussion necessarily involves some looping and cross-referencing between levels of analysis, the central aim of this chapter is to establish the underlying mechanisms. Later chapters will integrate these mechanisms and present them more directly in relation to behavioral outcomes.</p><p>Note: Much of the evidence on receptor-level mechanisms and intracellular processes is derived from rodent studies. Circuit-level investigations are increasingly supported by imaging and electrophysiological data in humans, while psychological and behavioral studies rely primarily on clinical and observational research. Genetic contributions are assessed through genome-wide association studies and candidate gene approaches.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Nicotine in the Tobacco Plant</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.1">Why Plants Make Nicotine</head><p>Nicotine is a defensive alkaloid. Tobacco plants synthesize it to deter insects and grazing animals, exploiting its bitter taste and neurotoxic properties <ref type="bibr" target="#b160">(Shoji and Hashimoto, 2011)</ref>. For most herbivores ingestion is harmful or fatal. In humans, however, the same molecule interacts with neural circuits in a way that paradoxically reinforces use <ref type="bibr" target="#b54">(Foll et al., 2022)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.2">Biosynthesis: From Roots to Leaves</head><p>Nicotine is produced in the roots of the plant. Two biosynthetic routes converge: the pyrrolidine ring is derived from putrescine through the enzyme putrescine N-methyltransferase (PMT), and the pyridine ring is derived from nicotinic acid. Enzymes such as A622 and berberine bridge enzyme-like proteins (BBLs) link these building blocks to form nicotine. Once synthesized, nicotine is transported upward through the xylem and accumulates in the leaves <ref type="bibr" target="#b160">(Shoji and Hashimoto, 2011)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.3">Stereochemistry and Potency</head><p>Nicotine has a single stereocenter and therefore exists in two mirror-image forms: (S)-nicotine and (R)-nicotine. Tobacco plants overwhelmingly produce the (S)-enantiomer. This is significant because (S)-nicotine binds more strongly to neuronal nicotinic acetylcholine receptors (nAChRs) <ref type="bibr" target="#b6">(Barlow and Hamilton, 1965)</ref>. Natural tobacco therefore delivers a more potent psychoactive effect than a racemic mixture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.4">Concentration and Processing</head><p>Nicotine content varies within the plant, usually highest in the lower leaves and influenced by genetics, soil, and environmental stressors . Post-harvest processes such as curing and fermentation alter chemical composition, changing both nicotine distribution and the profile of other compounds <ref type="bibr" target="#b55">(Frankenburg, 1946)</ref>. Despite these modifications, nicotine consistently remains the dominant alkaloid in tobacco.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">The Chemical Composition of Tobacco Smoke</head><p>The combustion of tobacco generates a complex aerosol containing more than 7,000 identified chemicals, of which several hundred are toxic and at least 70 are established human carcinogens <ref type="bibr" target="#b181">(Tudor and Ene, 2024)</ref>. These compounds span gases, volatile organics, and particulate matter, producing the characteristic combination of addictive, toxic, and carcinogenic properties of cigarette smoke.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.1">Pharmacologically Active Constituents</head><p>Nicotine is the principal psychoactive alkaloid, acting as an agonist at nicotinic acetylcholine receptors to drive pleasure and dependence. Reinforcement is potentiated by other smoke constituents, notably monoamine oxidase inhibitors (e.g., harman, norharman), which prevent dopamine degradation and enhance nicotine reward <ref type="bibr" target="#b100">(Lewis et al., 2007)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.2">Carcinogens</head><p>The major carcinogenic classes include:</p><p>‚Ä¢ Tobacco-specific nitrosamines (TSNAs) such as NNK and NNN, potent initiators of lung and pancreatic cancers <ref type="bibr" target="#b78">(Hoffman and Evans, 2013)</ref>.</p><p>‚Ä¢ Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene, generated by incomplete combustion and strongly mutagenic <ref type="bibr" target="#b75">(Hecht, 2003)</ref>.</p><p>‚Ä¢ Aromatic amines, linked particularly to bladder cancer <ref type="bibr" target="#b75">(Hecht, 2003)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.3">Flavor and Aroma Compounds</head><p>Sugars, aldehydes, phenols, and other volatiles influence the flavor and aroma of tobacco smoke <ref type="bibr" target="#b116">(Mookherjee and Wilson, 1990</ref>). These compounds shape the sensory experience of smoking and strengthen conditioned associations. The smell of burning leaf, the taste of smoke, and the ritual of inhalation all become paired with the pharmacological reward of nicotine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.4">Toxic Gases and Volatile Compounds</head><p>Key toxicants include carbon monoxide (reducing oxygen transport), hydrogen cyanide (impairing respiratory defenses), and reactive aldehydes such as acrolein, formaldehyde, and acetaldehyde, which are irritant and mutagenic <ref type="bibr" target="#b174">(Talhout et al., 2011)</ref>. Volatile organics including benzene and 1,3-butadiene contribute hematotoxic and leukemogenic risk <ref type="bibr" target="#b52">(Fiebelkorn and Meredith, 2018)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.5">Heavy Metals and Radionuclides</head><p>Tobacco plants accumulate heavy metals such as cadmium, arsenic, lead, and chromium, which contribute to carcinogenesis and systemic toxicity <ref type="bibr" target="#b174">(Talhout et al., 2011)</ref> . In addition, trace levels of polonium-210 deliver chronic alpha radiation to bronchial tissues <ref type="bibr" target="#b198">(Zaga et al., 2011)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.6">Minor Alkaloids</head><p>The plant produces smaller amounts of related alkaloids including nornicotine, anatabine, and anabasine. These molecules are weaker at neural receptors but may contribute to reinforcement and toxicity <ref type="bibr" target="#b54">(Foll et al., 2022)</ref>. Nornicotine is especially important because it can transform into nitrosamines during curing and combustion, and nitrosamines are among the most potent carcinogens in tobacco smoke <ref type="bibr" target="#b78">(Hoffman and Evans, 2013)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4">Pharmacokinetics of Nicotine</head><p>The pharmacokinetics of nicotine describe how the drug is absorbed, distributed, metabolized, and eliminated in the body. Understanding these processes is essential because the speed and efficiency of nicotine delivery strongly influence its addictive potential <ref type="bibr" target="#b98">(Le Houezec, 2003)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.1">Absorption</head><p>Cigarette smoke delivers nicotine primarily through the pulmonary route. Each inhalation exposes the large alveolar surface area of the lungs, where nicotine, in its volatile free-base form, rapidly diffuses across the alveolar membranes into the pulmonary circulation. The drug reaches the brain within 10-20 seconds of inhalation, a speed comparable to intravenous administration <ref type="bibr" target="#b11">(Benowitz and Jacob, 1987)</ref>. This extremely rapid delivery is a key factor in the reinforcing properties of smoking, as it allows tight temporal coupling between the act of smoking and its psychoactive effects.</p><p>Nicotine can also be absorbed through other routes, such as the buccal and nasal mucosa (e.g., in smokeless tobacco, snuff, or nicotine replacement therapies), though these pathways are slower compared to smoking.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.2">Bioavailability Across Delivery Systems</head><p>Nicotine delivery efficiency varies markedly across routes. Cigarette smoking delivers the highest plasma nicotine, averaging ‚àº22-23 mg/day (about 1.4 mg per cigarette) with threefold interindividual variability. Transdermal patches provide more stable levels at ‚àº11 mg/day, but with a narrower twofold variability. Nasal spray achieves ‚àº13 mg/day, but exhibits the greatest variability (fivefold across individuals). These differences reflect both the pharmacokinetics of absorption and the consistency of dose delivery. Clearance of nicotine was identified as the strongest determinant of plasma nicotine concentration, whereas cotinine levels were driven primarily by total absorbed dose <ref type="bibr" target="#b10">(Benowitz et al., 1997)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.3">Distribution</head><p>Once in circulation, nicotine is widely distributed throughout the body, with a volume of distribution estimated at approximately 1-3 L/kg <ref type="bibr" target="#b170">(Svensson, 1987)</ref> , meaning it distributes widely into body tissues rather than staying confined to blood. Its lipophilic nature allows it to cross biological membranes easily, including the blood-brain barrier, which it penetrates rapidly.</p><p>In addition to the brain, nicotine accumulates in tissues with high perfusion rates, such as the liver, kidneys, and spleen. Protein binding in plasma is relatively low (&lt; 5%), meaning that most circulating nicotine is in the free, active form. It also crosses the placenta and is secreted in breast milk, with implications for fetal and neonatal exposure.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.4">Metabolism</head><p>Nicotine is primarily metabolized in the liver, where the cytochrome P450 enzyme CYP2A6 plays a dominant role <ref type="bibr" target="#b195">(Yildiz, 2004)</ref>. Approximately 70-80% of nicotine is converted to cotinine, its major metabolite. Cotinine has a much longer half-life (16-20 hours) compared to nicotine (1-2 hours), making it a reliable biomarker of nicotine exposure in both research and clinical contexts. Other minor metabolites include nicotine-N'-oxide, norcotinine, and nornicotine.</p><p>Extrahepatic metabolism also occurs in the lungs and kidneys, but to a lesser extent. Conjugation via UDP-glucuronosyltransferases (UGTs) facilitates renal excretion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.5">Elimination</head><p>Nicotine and its metabolites are primarily eliminated by the kidneys. Renal clearance is pHdependent: acidic urine increases ionization and accelerates excretion, while alkaline urine slows it. The systemic clearance of nicotine is about 1.2 L/min, approximating liver blood flow, consistent with its predominantly hepatic metabolism <ref type="bibr" target="#b170">(Svensson, 1987)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.6">Half-life of Nicotine</head><p>The plasma half-life (ùë° 1/2 ) of nicotine is typically 1-2 hours in humans. This relatively short half-life is a key factor driving frequent cigarette use, as plasma concentrations decline rapidly between smoking episodes.</p><p>Pharmacokinetically, the half-life is related to the volume of distribution (ùëâ ùëë ) and clearance (ùê∂ùëô) by the equation below <ref type="bibr" target="#b108">(Mansoor and Mahabadi, 2025)</ref>.</p><formula xml:id="formula_0">ùë° 1/2 = 0.693 ‚Ä¢ ùëâ ùëë</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ùê∂ùëô</head><p>For nicotine, the apparent volume of distribution can be taken as 2.5 L/kg (about 175 L in a 70-kg individual), and systemic clearance as about 1.2 L/min (72 L/h). Substituting these values:</p><formula xml:id="formula_1">ùë° 1/2 ‚âà 0.693 √ó 175 72 ‚âà 1.7 h</formula><p>This calculation is consistent with observed human data. Because elimination follows first-order kinetics, plasma concentrations decline exponentially over time:</p><formula xml:id="formula_2">ùê∂ ùë° = ùê∂ 0 ‚Ä¢ ùëí -ùëòùë° , where ùëò = 0.693 ùë° 1/2</formula><p>Thus, nicotine levels fall substantially within a few hours of the last cigarette.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.7">Time Course and Peak Plasma Nicotine Dynamics</head><p>Nicotine delivery differs markedly by route: cigarette smoking produces the fastest and highest spikes, with arterial concentrations reaching 30-50 ng/mL within 20 s and venous means around 16 ng/mL ; nasal spray rises rapidly but less abruptly, yielding 8-12 ng/mL with peaks near 15 ng/mL ; nicotine gum produces slower, delayed increases, 10-23 ng/mL depending on dose, with peaks after 20-30 min ; and transdermal patches maintain steady 9-12 ng/mL without fluctuations. Nicotine's addictive potential is governed not only by dose but by the rapidity and temporal profile of delivery <ref type="bibr" target="#b49">(Fagerstr√∂m et al., 1993;</ref><ref type="bibr" target="#b10">Benowitz et al., 1997)</ref>.</p><p>Table 4.1: Steady-state venous plasma nicotine levels across routes of administration. Route Mean plasma nicotine (ng/mL) Profile Cigarette smoking (16/day) 16.3 (6.3-30.9) Sharp arterial spikes, rapid surges Nasal spray (24/day) 8-12 (peaks 9-15) Fast rise, high variability Nicotine gum (2-4 mg) 10-23 Slower rise, delayed peaks (20-30 min) Transdermal patch (15 mg/16 h) 9-12 Flat, steady levels</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.8">Genetic Variability</head><p>Genetic polymorphisms in CYP2A6 significantly influence nicotine metabolism. Individuals with high-activity variants metabolize nicotine more rapidly, leading to lower plasma nicotine levels per cigarette and often heavier smoking to maintain desired nicotine concentrations. Conversely, slow metabolizers experience prolonged nicotine exposure, which may reduce cigarette consumption but can increase difficulty in cessation due to prolonged receptor stimulation <ref type="bibr" target="#b90">(Jones et al., 2022)</ref>.</p><p>Functional genetic polymorphisms in CYP2A6 produce a continuum from "slow" to "fast" metabolizer phenotypes. The behavioural consequences follow from the pharmacokinetic principle of self-titration:</p><p>‚Ä¢ Slow metabolizers: Retain nicotine longer after each cigarette, resulting in more sustained receptor occupancy and higher plasma levels. Consequently, they often require fewer cigarettes per day to achieve a desired nicotine state. Paradoxically, although smoking intensity is lower, slow metabolizers may develop dependence more rapidly in early smoking experiences because each exposure is more reinforcing <ref type="bibr" target="#b123">(O'Loughlin et al., 2004)</ref> and woudl likely lead to greater Upregulation (discussed later). Once dependent, they show slower escalation of cigarette consumption, yet prolonged nicotine exposure sustains craving and promotes receptor upregulation and neuroadaptations that can complicate cessation <ref type="bibr" target="#b103">(Liu et al., 2024)</ref>.</p><p>‚Ä¢ Fast metabolizers: Clear nicotine quickly, leading to shorter-lived subjective effects and faster onset of craving. To maintain reinforcement, they tend to smoke more cigarettes per day or inhale more intensely, which increases cumulative exposure to nicotine and tobacco toxicants. Dependence may develop more gradually, but once established it is typically more severe, with stronger withdrawal symptoms, greater cue reactivity, and lower quit success without tailored pharmacotherapy.</p><p>Several past studies have examined differences between slow and fast nicotine metabolizers in terms of treatment efficacy and dependence severity. A common limitation, however, is the limited consideration of cigarettes-per-day (CPD) as a mediating factor. For a comparable level of dependence, slow metabolizers typically maintain nicotine exposure with fewer cigarettes, whereas fast metabolizers must smoke more frequently to offset rapid clearance. This greater cigarette consumption not only increases cumulative toxicant exposure but also strengthens the behavioral conditioning of smoking. Accordingly, the poorer quit outcomes and more intense withdrawal often observed in fast metabolizers may reflect not only pharmacokinetic differences in nicotine metabolism, but also the deeper habit formation and stronger reinforcement patterns that accompany higher daily smoking.</p><p>CYP2A6 activity also varies by sex, ethnicity, and drug interactions (e.g., oral contraceptives can induce metabolism) <ref type="bibr" target="#b175">(Tanner and Tyndale, 2017)</ref>. Pharmacogenetic studies suggest that genotype partially determines individual vulnerability to nicotine dependence and the likelihood of success with cessation therapies, underscoring the potential for personalized treatment approaches.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5">Pharmacodynamics of Nicotine</head><p>Pharmacodynamics describes what a drug does to the body, including its molecular targets, mechanisms of action, and resulting physiological and behavioral effects. Nicotine exerts its primary effects by binding to nicotinic acetylcholine receptors (nAChRs), a diverse family of ligand-gated ion channels normally activated by the neurotransmitter acetylcholine. By acting as an exogenous agonist, nicotine co-opts endogenous cholinergic signaling and produces widespread central and peripheral effects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.1">nAChR Structure and Diversity</head><p>Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels of the Cys-loop receptor family that mediate fast synaptic transmission. They are physiologically activated by acetylcholine and pharmacologically by nicotine, coupling ligand binding to cation flux (Na + , K + , and in some subtypes Ca 2+ ) across the membrane. This conductance depolarizes neurons and can initiate intracellular signaling cascades, thereby linking chemical neurotransmission to rapid electrical and molecular responses. As an exogenous agonist, nicotine hijacks this cholinergic system to produce widespread effects.</p><p>Structurally, nAChRs are pentamers assembled from subunits of the ùõº2-ùõº10 and ùõΩ2-ùõΩ4 gene families, arranged around a central aqueous pore <ref type="bibr" target="#b31">(Dani, 2001)</ref>. Mammalian genomes encode 16 homologous subunits (ùõº2-ùõº7, ùõº9, ùõº10, ùõΩ2-ùõΩ4, plus muscle-specific subunits), which can combine into a wide variety of receptor subtypes <ref type="bibr" target="#b32">(Dani, 2015)</ref>. Each subunit contributes an extracellular ligand-binding domain, four transmembrane helices with the M2 helix lining the ion channel pore, and a cytoplasmic loop that mediates trafficking and protein interactions.</p><p>The precise subunit composition determines receptor affinity, ion conductance, gating kinetics, calcium permeability, and pharmacological profile, giving rise to receptor subtypes with specialized functional roles <ref type="bibr" target="#b125">(Papke, 2014)</ref>.</p><p>Despite this diversity, the functional roles of many receptor assemblies remain incompletely understood. Much of the current knowledge derives from rodent models using pharmacological tools and genetic knockout approaches. These strategies have identified the contributions of specific subunits to nicotine's behavioral and physiological effects, but translation to human neurobiology remains an ongoing challenge. Although thousands of theoretical pentameric ar-rangements are possible, only a limited set of subtypes dominate in vivo, reflecting evolutionary and functional constraints.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.2">Localization of nAChR Subtypes in Neural Circuits</head><p>The physiological effects of nicotine depend not only on the intrinsic properties of individual receptor subtypes but also on their localization within neural circuits. Nicotinic acetylcholine receptors are distributed across distinct cellular compartments, where their placement determines how they influence network activity:</p><p>‚Ä¢ Presynaptic sites: nAChRs facilitate or inhibit neurotransmitter release, modulating dopamine, glutamate, GABA, and other transmitter systems.</p><p>‚Ä¢ Postsynaptic sites: receptor activation directly depolarizes neurons, shaping excitatory and inhibitory drive within circuits.</p><p>‚Ä¢ Extrasynaptic sites: receptors located outside classical synapses adjust overall neuronal excitability and input-output gain.</p><p>The distribution of nAChR subtypes is highly region-and cell-type specific. Moreover, subunit composition and stoichiometry confer distinct functional properties, such as differences in ion permeability, desensitization kinetics, and pharmacological sensitivity, which, combined with localization patterns, generate a complex mosaic of nicotine actions across the nervous system The behavioral and physiological outcomes of nicotine exposure emerge from the interplay between nAChR subtype diversity and their strategic localization within neural circuits, underpinning the multifaceted effects of nicotine on brain function. In the following sections, we will examine the major nicotinic acetylcholine receptor subtypes in detail, exploring their functional properties, precise localization within neural circuits, and the resulting implications for behavior and physiology.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.3">Receptor Occupancy of Nicotine</head><p>The pharmacodynamic effect of nicotine depends on how many nicotinic acetylcholine receptors (nAChRs) it occupies at a given concentration. This relationship is described by the law of mass action <ref type="bibr" target="#b81">(Horn and Jackson, 1972)</ref>. For a drug concentration [ùê∑] and equilibrium dissociation constant ùêæ ùê∑ , the fraction of receptors bound is</p><formula xml:id="formula_3">ùëì ùêµ ([ùê∑]) = [ùê∑] [ùê∑] + ùêæ ùê∑ .</formula><p>To express this as a percentage of total receptors:</p><formula xml:id="formula_4">Occupancy(%) = 100 √ó [ùê∑] [ùê∑] + ùêæ ùê∑ .</formula><p>Because plasma nicotine is typically reported in ng/mL, conversion to molar concentration is necessary for receptor-level interpretation. With nicotine's molecular weight of 162.2 g/mol, 1 ng/mL ‚âà 6.2 nM. Thus, venous concentrations of 10-20 ng/mL (typical for smokers and NRT use) correspond to ‚àº0.06-0.12 ¬µM, well within the affinity range of high-sensitivity ùõº4ùõΩ2 * receptors (ùêæ ùê∑ ‚âà 0.1-1.0 ¬µM). By contrast, lower-affinity subtypes such as ùõº7 (ùêæ ùê∑ ‚âà 100 ùúáM) are minimally occupied at these levels.</p><p>For example:</p><formula xml:id="formula_5">‚Ä¢ If [ùê∑] = 0.1 ùúáM and ùêæ ùê∑ = 0.5 ùúáM, occupancy is 100 √ó 0.1 0.1 + 0.5 ‚âà 16.7%. ‚Ä¢ If [ùê∑] = 0.1 ùúáM and ùêæ ùê∑ = 0.1 ùúáM, occupancy is 100 √ó 0.1 0.1 + 0.1 = 50%.</formula><p>More generally, cooperative binding can be modeled with the Hill equation <ref type="bibr" target="#b58">(Gesztelyi et al., 2012)</ref>:</p><formula xml:id="formula_6">Occupancy(%) = 100 √ó [ùê∑] ùëõ [ùê∑] ùëõ + ùê∏ùê∂ ùëõ 50 ,</formula><p>where ùëõ is the Hill coefficient (often approximated as ùëõ = 1), and ùê∏ùê∂ 50 is the concentration producing half-maximal effect. Receptor subtype differences in ùê∏ùê∂ 50 explain why typical smoking levels strongly engage ùõº4ùõΩ2 * receptors but leave ùõº7 receptors largely unoccupied.</p><p>ùê∏ùê∂ 50 is an indicator of the sensitivity of the receptors to nicotine. It varies greatly across various kinds of receptors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.4">EC 50 of Nicotine at Different nAChR Subtypes</head><p>The potency of nicotine varies markedly depending on the nicotinic acetylcholine receptor (nAChR) subtype <ref type="bibr" target="#b67">(Grady et al., 2010)</ref>. Among these, ùõº4ùõΩ2 * and ùõº6ùõΩ2 * receptors are the most sensitive to nicotine and play a critical role in dopaminergic signaling within the mesolimbic pathway. In contrast, ùõº7 and ùõº3ùõΩ4 * receptors require much higher nicotine concentrations to reach half-maximal activation, consistent with their distinct physiological roles. Table <ref type="table" target="#tab_5">4</ref>.2 summarizes representative EC 50 values for nicotine at major brain nAChR subtypes, as measured in in-vitro functional assays. These values highlight that nicotine exhibits nanomolar potency at ùõΩ2 * -containing receptors (ùõº4ùõΩ2 * , ùõº6ùõΩ2 * ), but micromolar potency at ùõº7 and ùõº3ùõΩ4 * receptors. This selectivity explains why ùõΩ2 * -nAChRs are considered the primary mediators of nicotine's reinforcing and addictive effects.</p><p>The EC 50 represents the concentration of nicotine required to produce 50% of the maximal functional response of a given receptor subtype. Lower EC 50 values indicate greater receptor sensitivity to nicotine's activating effects. Importantly, these values reflect functional activation rather than simple ligand binding, underscoring the difference between receptor occupancy and downstream signaling. Binding affinity measures (K d ) for high-sensitivity ùõº4ùõΩ2 receptors are typically reported in the low nanomolar range <ref type="bibr" target="#b18">(Brody et al., 2009)</ref>, equivalent to sub-ng/mL concentrations (e.g., ‚àº0.75 ng/mL). By contrast, functional EC 50 values for receptor activation are generally higher, in the micromolar range (hundreds of ng/mL), highlighting the gap between binding and activation thresholds <ref type="bibr" target="#b20">(Buchwald, 2025)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.5">Desensitization of nAChRs</head><p>A distinctive feature of nicotinic acetylcholine receptors (nAChRs) is their tendency to undergo desensitization after prolonged or repeated exposure to agonists. During desensitization, nAChRs transition into long-lived nonconducting states in which ligands remain bound but the ion channel is closed <ref type="bibr" target="#b94">(Koranda et al., 2013)</ref>. This process is time-and concentration-dependent and strongly shapes the pharmacological and physiological profile of nicotine.</p><p>nAChRs cycle among at least three principal conformational states: resting (R), open/activated (O), and desensitized (D). Agonist binding to both recognition sites is required for channel opening, but occupancy of a single site can be sufficient to drive receptors into desensitization. Importantly, the desensitized state has a higher agonist affinity than the resting state, so prolonged low-level exposure (as with tobacco smoking) preferentially stabilizes desensitization rather than activation.</p><p>The kinetics of desensitization vary by receptor subtype. ùõº7 receptors desensitize extremely rapidly (milliseconds to seconds) but require higher concentrations to do so, while heteromeric</p><p>ùõº4ùõΩ2 receptors desensitize at much lower nicotine concentrations (nanomolar range) and more slowly recover. ùõΩ subunits strongly influence the speed of desensitization: ùõΩ2-containing receptors desensitize faster than ùõΩ4-containing receptors.</p><p>Increasing desensitization effectively shifts the dose-response curve to the right, requiring higher agonist concentrations to maintain the same functional output. .5.6 DC 50 of Nicotine-Induced Desensitization at Different nAChR Subtypes</p><p>The concentration required for half-maximal desensitization (DC 50 ) provides a measure of how sensitive each receptor subtype is to sustained nicotine exposure, while the maximal desensitization indicates the greatest fraction of receptor function that can be silenced <ref type="bibr" target="#b68">(Grady et al., 2012)</ref>.</p><p>The desensitization response can be described by the following equation:</p><formula xml:id="formula_7">ùëì = ùëâ 1 + [ùëÅ (ùë°)] DC 50 + ùëâ ùëü (4.1)</formula><p>where ùëì is the measured functional response after nicotine exposure, ùëâ is the maximum desensitizable fraction of receptor-mediated function, ùëâ ùëü is the residual (non-desensitizable) function, and [ùëÅ (ùë°)] is the nicotine concentration. DC 50 is the concentration of nicotine that produces half-maximal desensitization.</p><p>ùõº4ùõΩ2 receptors exhibit very low DC 50 values (‚àº10 nM) and high maximal desensitization (‚àº60%), meaning they are strongly inhibited even at the low nicotine concentrations found in smokers.</p><p>In contrast, incorporation of the ùõº5 subunit shifts the DC 50 into the 70-120 nM range, making these receptors more resistant to desensitization.</p><p>Finally, ùõº6ùõΩ2ùõΩ3 receptors display intermediate DC 50 values (‚àº22 nM), but their maximal desensitization is limited (‚àº38%), allowing a substantial portion of their function to remain active even at high nicotine levels.</p><p>Table 4.4 summarizes representative DC 50 and maximal desensitization values for major highsensitivity (HS) nAChR subtypes. Table 4.4: Nicotine-induced desensitization parameters for major neuronal nAChR subtypes (10 min exposure). Receptor subtype DC 50 (nM) Max desensitization (%) ùõº4ùõΩ2 (no ùõº5) 9 ¬± 4 53-65 ùõº4ùõΩ2 + ùõº5 (cortex) 71 ¬± 17 63 ¬± 8 ùõº4ùõΩ2 + ùõº5 (striatal DA terminals) 117 ¬± 12 77 ¬± 4 ùõº6ùõΩ2ùõΩ3 22 ¬± 11 38 ¬± 9</p><p>These findings demonstrate that ùõº4ùõΩ2 receptors without ùõº5 are highly vulnerable to desensitization at nanomolar nicotine concentrations. By contrast, ùõº4ùõΩ2ùõº5 receptors resist desensitization and recover more quickly, while ùõº6ùõΩ2ùõΩ3 receptors undergo only partial desensitization, preserving dopaminergic signaling during smoking-level nicotine exposure.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.7">Upregulation of nAChRs</head><p>Chronic nicotine exposure not only drives desensitization but also produces a compensatory increase in the number of nAChRs at the cell surface, a phenomenon termed upregulation <ref type="bibr" target="#b66">(Govind et al., 2012;</ref><ref type="bibr" target="#b132">Picciotto and Kenny, 2020;</ref><ref type="bibr" target="#b88">Jackson et al., 2014)</ref>. Paradoxically, while desensitization reduces receptor responsiveness in the short term, upregulation expands the pool of available receptors over the long term.</p><p>Upregulation is most prominent for ùõΩ2 * -containing receptors, particularly ùõº4ùõΩ2 * assemblies, which are strongly implicated in the reinforcing properties of nicotine. Several mechanisms contribute to this process:</p><p>‚Ä¢ Stabilization of receptor proteins: Nicotine binding increases receptor half-life by reducing degradation in the endoplasmic reticulum and Golgi <ref type="bibr" target="#b51">(Fenster et al., 1999)</ref>.</p><p>‚Ä¢ Enhanced trafficking: Chronic exposure promotes transport of assembled receptors to the cell surface <ref type="bibr" target="#b113">(McManus et al., 2019)</ref>.</p><p>‚Ä¢ Altered subunit stoichiometry: Nicotine favors receptor assemblies with higher sensitivity, such as (ùõº4) 2 (ùõΩ2) 3 , further amplifying signaling <ref type="bibr" target="#b88">(Jackson et al., 2014)</ref>. Modest, regiondependent Some upregulation in habenula/interpeduncular circuits; contributes to aversive signaling As we will discuss in detail later, upregulation plays a central role in our SyNAPSE model. The presence of ùõº4ùõΩ2 nicotinic acetylcholine receptors on GABAergic neurons means that greater upregulation of these receptors produces a larger pool of unoccupied receptors once blood nicotine levels decline. This, in turn, reduces cholinergic activation of GABAergic inhibition, thereby lowering tonic inhibitory control over dopamine release. The result is diminished basal dopamine tone. Moreover, ùõº4ùõΩ2 receptors are also expressed directly on dopaminergic neurons, where their upregulation enhances responsivity to phasic stimuli. Together, these mechanisms imply that greater receptor upregulation increases vulnerability both to cue-induced dopamine release, driving craving, and to nicotine withdrawal, deepening the cycle of dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.8">Distribution of Nicotinic Acetylcholine Receptors Across Brain Circuits</head><p>Nicotinic acetylcholine receptors (nAChRs) are not uniformly distributed; instead, distinct subtypes are strategically positioned across brain regions and circuits to regulate excitability, transmitter release, and plasticity. Their localization determines whether nicotine promotes reinforcement, enhances cognition, or induces aversion. Table <ref type="table" target="#tab_5">4</ref>.6 summarizes the principal receptor subtypes, their anatomical localization, and associated circuit roles <ref type="bibr" target="#b33">(Dani and Bertrand, 2007)</ref>. Detailed functional implications will be developed in later sections.</p><p>In summary, the distribution of nAChR subtypes reflects the brain's functional organization.</p><p>ùõΩ2-containing receptors (ùõº4ùõΩ2 * , ùõº6ùõΩ2 * ) are concentrated in mesolimbic and striatal circuits, positioning them as the primary mediators of nicotine reinforcement and habit formation. ùõº7 receptors, abundant in cortical and hippocampal networks, couple cholinergic signaling to glutamate release and synaptic plasticity, thereby shaping attention, learning, and memory. By contrast, ùõº3ùõΩ4 * assemblies, enriched in the medial habenula-interpeduncular axis and autonomic ganglia, provide a counterweight: they encode aversion, regulate visceral responses, and set natural limits on intake. Together, these receptor systems create a layered architecture in which reward, cognition, and aversion are integrated. This arrangement explains why nicotine's effects are multifaceted, simultaneously reinforcing, cognitively engaging, and physiologically regulating, and why dependence emerges from the interplay rather than the dominance of any single receptor type or circuit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.9">Temporal Cascade of Nicotine</head><p>When nicotine binds to nicotinic acetylcholine receptors (nAChRs), the channel pore opens, allowing sodium (Na + ) and calcium (Ca 2+ ) ions to enter while potassium (K + ) exits. This dual action produces two immediate effects: Aversive signaling, intake brake; autonomic regulation</p><p>(1) depolarization of neuronal membranes, increasing the probability of action potential firing; and</p><p>(2) activation of calcium-dependent intracellular signaling cascades that couple transient electrical events to long-lasting biochemical and structural plasticity <ref type="bibr" target="#b34">(Daoudal and Debanne, 2003)</ref>.</p><p>These ionic events form the starting point of a cascade of adaptations that unfold across multiple timescales, progressively reshaping synaptic strength, circuit connectivity, and ultimately behavior.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Milliseconds to Seconds: Acute Excitability Nicotine acutely enhances excitability in ventral</head><p>tegmental area (VTA) dopamine neurons, biasing them toward burst firing and thereby elevating dopamine release in the nucleus accumbens. Presynaptic nAChRs also facilitate glutamate and GABA release in cortical, hippocampal, and amygdala circuits. Importantly, these effects vary by receptor subtype, dose, and neuronal subpopulation: nicotine can simultaneously excite some dopamine projections while inhibiting others. These acute changes produce nearinstantaneous sensations of alertness, mild euphoria, or calmness. At the network level, transient synchronization of dopamine bursts with environmental stimuli provides the temporal precision necessary for Hebbian associations between nicotine intake and reward <ref type="bibr" target="#b157">(Shen and Yakel, 2009)</ref>.</p><p>Minutes to Hours: Short-Term Synaptic Modulation Sustained receptor activation drives desensitization, reducing responsiveness even in nicotine's continued presence. Concurrently, Ca 2+ -dependent kinases phosphorylate receptor subunits, scaffolding proteins, and transcrip-tional regulators, altering vesicle recycling and receptor trafficking <ref type="bibr" target="#b19">(Brunzell et al., 2003)</ref>. These modifications contribute to early-phase synaptic plasticity and transient changes in synaptic strength. Behaviorally, this dynamic has been linked to the characteristic "rise and crash" of smoking: an initial reinforcing phase followed by reduced receptor responsiveness , though direct causation in humans remains inferred rather than proven.</p><p>Hours to Days: Synaptic Plasticity and Learning Repeated Ca 2+ entry activates transcription factors such as CREB, biasing plasticity toward long-term potentiation (LTP) or depression (LTD) depending on circuit context <ref type="bibr" target="#b200">(Zhong et al., 2013;</ref><ref type="bibr" target="#b179">Toyoda and Koga, 2022)</ref>. In rodent mesolimbic circuits, excitatory potentiation onto dopamine neurons and reduced GABAergic inhibition increase the salience of nicotine-paired cues. In hippocampal networks, nicotine can enhance glutamatergic LTP, strengthening contextual associations, while in the amygdala it facilitates conditioning of both reward-and fear-related cues. These processes exemplify Hebbian learning principles, with nicotine acting as a chemical amplifier of associative plasticity. Evidence in humans remains indirect, largely extrapolated from imaging and behavioral studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Days to Weeks: Homeostatic and Network Adaptations</head><p>With chronic exposure, neurons adjust receptor availability and localization in an effort to maintain stability. A well-documented adaptation is the upregulation of ùõº4ùõΩ2 * nAChRs, often favoring high-sensitivity stoichiometries <ref type="bibr" target="#b62">(Rogers and Lorise, 2015)</ref>. Receptors redistribute between synaptic and extrasynaptic compartments, reshaping both phasic responses and baseline excitability. At the circuit level, mesolimbic reward pathways become relatively hypoactive during withdrawal, while stress-and aversionrelated circuits (habenula-interpeduncular, amygdala) become hyperactive <ref type="bibr" target="#b82">(Huang et al., 2008)</ref>. These adaptations underlie tolerance (the need for higher intake) and withdrawal (low dopamine, high stress signaling), though much of this evidence derives from animal models.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Weeks to Months: Transcriptional and Epigenetic Reprogramming Chronic nicotine</head><p>persistently activates transcription factors including CREB, FosB, and NF-ùúÖB <ref type="bibr" target="#b73">(Hamilton and Nestler, 2019)</ref>. Their downstream actions remodel chromatin architecture via DNA methylation, histone acetylation, and microRNA regulation. These epigenetic marks alter receptor subunit gene expression, synaptic scaffolding proteins, and stress-response genes, creating stable molecular "memories" of nicotine exposure. Once established, these epigenetic signatures outlast drug clearance, biasing circuits toward relapse by maintaining heightened cue reactivity and dysregulated affective states <ref type="bibr" target="#b157">(Shen and Yakel, 2009)</ref>.</p><p>Taken together, nicotine transforms brief ionic events into enduring circuit-level adaptations. This temporal cascade, from millisecond depolarization to epigenetic remodeling, helps explain the paradox of smoking: immediate reinforcement, escalating tolerance, dependence, and relapse vulnerability long after cessation. At its core, nicotine acts as a chemical amplifier of learning, strengthening associations between drug, context, and reward while remodeling circuits so that absence itself becomes aversive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.10">From Receptors to Circuits: Linking Molecular Action to Network</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dynamics</head><p>Occupancy, desensitization, and upregulation describe nicotine's influence at the molecular and synaptic scale. Yet smoking alters not only individual receptors but also the collective dynamics of neural systems. Nicotine converts fast ion fluxes into coordinated patterns of activity across distributed circuits, shaping motivation, learning, mood, and stress reactivity. Understanding these network effects is essential, because the persistence of dependence arises from changes that span beyond single receptors to entire brain systems.</p><p>We focus here on seven circuits with the strongest evidence for mediating nicotine's central effects: the mesolimbic reward pathway, prefrontal cortical networks, striatal habit circuits, basal forebrain and hippocampal memory systems, the habenula-interpeduncular aversion axis, amygdala-stress pathways, and insular circuits. Together, they form the neural architecture through which nicotine transforms acute reinforcement into chronic dependence <ref type="bibr" target="#b32">(Dani, 2015)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mesolimbic (VTA-NAc) reward pathway</head><p>Anatomy &amp; connectivity. The ventral tegmental area (VTA) provides dopaminergic input to the nucleus accumbens (NAc), prefrontal cortex, amygdala, and hippocampus. Excitatory inputs arise from prefrontal cortex and laterodorsal tegmentum, while inhibitory control comes from local GABA interneurons and the rostromedial tegmental nucleus (RMTg).</p><p>Receptor placement. VTA dopamine neurons express both ùõº4ùõΩ2 * and ùõº6ùõΩ2 * receptors.</p><p>ùõº4ùõΩ2 * receptors drive excitability at the soma, while ùõº6ùõΩ2 * receptors, concentrated on terminals projecting to the nucleus accumbens, regulate phasic dopamine release. Thus, ùõº4 boosts overall firing, and ùõº6 fine-tunes reward signaling. In addition, ùõº7 receptors on presynaptic glutamate terminals enhance excitation, and ùõΩ2-containing receptors on GABA interneurons desensitize, weakening inhibition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional consequences. Nicotine excites dopamine neurons, increases glutamatergic drive,</head><p>and reduces GABA inhibition. The combined effect is to generate sharp, phasic bursts of dopamine release in the nucleus accumbens (NAc) shell. With repeated exposure, these dopamine signals induce plasticity: excitatory synapses onto dopamine neurons become stronger, and corticostriatal inputs to the NAc are potentiated. Functionally, this means that environmental cues associated with smoking gain exaggerated motivational value. Ordinary sights, smells, or routines linked to nicotine become capable of triggering strong craving states. Over time, the brain shifts from responding primarily to the drug itself to responding powerfully to the cues that predict it as well <ref type="bibr" target="#b25">(Clarke, 2007)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mesocortical and prefrontal circuits</head><p>Anatomy &amp; connectivity. The mesocortical pathway arises from dopamine neurons in the VTA projecting to the prefrontal cortex (PFC), where it regulates executive control, attention, and decision-making. The PFC in turn sends glutamatergic projections back to the VTA and striatum, forming reciprocal control loops.</p><p>Receptor placement. Within the PFC, pyramidal neurons express both ùõº4ùõΩ2 * and ùõº7 nicotinic receptors, while GABAergic interneurons (including parvalbumin-positive cells) predominantly carry ùõº4ùõΩ2 * . Cholinergic inputs from the basal forebrain provide phasic acetylcholine release onto these receptors.</p><p>Functional consequences. Nicotine stimulates ùõº7 receptors on pyramidal cells and presynaptic terminals to enhance glutamate release, while ùõº4ùõΩ2 * receptors on interneurons modulate inhibitory tone. The net acute effect is an increase in cortical signal-to-noise, which can transiently sharpen attention and working memory. With chronic exposure, however, receptor desensitization and altered interneuron-pyramidal dynamics disrupt oscillatory balance in the PFC. This weakens top-down control over reward circuits, increasing susceptibility to cue-driven relapse <ref type="bibr" target="#b134">(Proulx et al., 2014;</ref><ref type="bibr" target="#b199">Zhang et al., 2012)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Striatal circuits: habit formation</head><p>Anatomy &amp; connectivity. The striatum integrates excitatory glutamatergic input from cortex with modulatory dopaminergic input from the midbrain. The ventral striatum (nucleus accumbens, NAc) is central to reward processing, whereas the dorsal striatum supports habit learning. Medium spiny neurons (MSNs) are the principal output cells, organized into direct (D1 receptor-expressing) and indirect (D2 receptor-expressing) pathways.</p><p>Receptor placement. Dopamine terminals contain both ùõº6-containing and ùõº4ùõΩ2 * nicotinic receptors that regulate release probability. Striatal cholinergic interneurons (CINs) express ùõº4ùõΩ2 and ùõº7 receptors, positioning them to control local excitability and dopamine-acetylcholine interactions.</p><p>Functional consequences. Nicotine enhances dopamine release via presynaptic ùõº6-and ùõº4ùõΩ2 * receptors and disrupts CIN firing patterns. The result is a bias toward reinforcement of stimulus-response associations. With repeated exposure, corticostriatal synapses undergo long-term plasticity that shifts behavioral control from ventral, goal-directed circuits to dorsal, habitual ones. This transition underlies the progression from voluntary smoking to compulsive, automatic responding <ref type="bibr" target="#b26">(Clemens et al., 2014;</ref><ref type="bibr" target="#b102">Lipton et al., 2019)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Basal forebrain and hippocampal circuits</head><p>Anatomy &amp; connectivity. The basal forebrain cholinergic system innervates both neocortex and hippocampus, where it regulates arousal, attention, and memory encoding. The hippocampus integrates contextual information with motivational states, allowing environments to acquire predictive value for reward.</p><p>Receptor placement. Pyramidal neurons express ùõº4ùõΩ2 * receptors, while presynaptic glutamate terminals carry ùõº7. Local interneurons express both receptor subtypes, enabling nicotine to influence excitatory-inhibitory balance.</p><p>Functional consequences. Nicotine enhances presynaptic glutamate release via ùõº7 receptors and facilitates long-term potentiation (LTP), which strengthens memory traces for smokingrelated cues and contexts. With chronic exposure, receptor desensitization and compensatory upregulation disturb hippocampal oscillatory rhythms that normally support flexible memory. This bias makes drug-associated contexts disproportionately salient and harder to extinguish, thereby heightening vulnerability to relapse <ref type="bibr" target="#b92">(Kenney and Gould, 2008)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Habenula-interpeduncular aversion pathway</head><p>Anatomy &amp; connectivity. The medial habenula (MHb) projects cholinergic axons to the interpeduncular nucleus (IPN), while the lateral habenula (LHb) projects to the RMTg, which suppresses VTA dopamine neurons. These circuits mediate aversion and negative reward prediction.</p><p>Receptor placement. MHb-IPN synapses are enriched in ùõº3ùõΩ4 * receptors, often incorporating ùõº5. These receptors are highly Ca 2+ -permeable and rapidly desensitizing.</p><p>Functional consequences. At higher doses, nicotine activates MHb-IPN receptors, generating aversive responses that limit intake. Genetic variants in the CHRNA5-A3-B4 cluster blunt this mechanism, predisposing to heavier smoking. During withdrawal, LHb-RMTg hyperactivity suppresses dopamine release, producing anhedonia and dysphoria <ref type="bibr" target="#b3">(Antolin-Fontes et al., 2015)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Amygdala and Stress Circuits</head><p>Anatomy &amp; connectivity. The basolateral amygdala (BLA) integrates sensory and cortical inputs and projects to the nucleus accumbens (NAc) and prefrontal cortex (PFC). The central amygdala (CeA) coordinates hypothalamic and brainstem outputs, contributing to affective responses and HPA axis regulation.</p><p>Receptor placement. Both ùõº4ùõΩ2 and ùõº7 receptors are expressed on BLA pyramidal neurons, presynaptic glutamatergic terminals, and local interneurons, positioning the amygdala to be strongly modulated by nicotine.</p><p>Functional consequences. Nicotine enhances synaptic plasticity in the BLA, strengthening conditioned associations between environmental cues and drug reward. In the CeA, chronic nicotine exposure alters excitatory drive to stress pathways, shifting the system toward negative affect states. During withdrawal, reduced cholinergic stimulation and PVN remodeling (reduced CRF, increased AVP, and CRF/AVP coexpressing neurons) destabilize amygdala-hypothalamic interactions. This produces hyperreactivity to stress and negative affect, which intensifies craving and increases the likelihood of stress-induced relapse <ref type="bibr" target="#b196">(Yu et al., 2008;</ref><ref type="bibr" target="#b146">Rohleder and Kirschbaum, 2006;</ref><ref type="bibr" target="#b110">Matta and Desarmenien, 2012)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Insular circuits: interoception and craving</head><p>Anatomy &amp; connectivity. The insula integrates interoceptive signals from the body with emotional and cognitive states. It receives viscerosensory input via the thalamus and projects to the amygdala, striatum, and prefrontal cortex, placing it at the intersection of bodily state awareness and decision-making.</p><p>Receptor placement. Insular pyramidal neurons and interneurons express ùõº4ùõΩ2 * and ùõº7 nicotinic receptors. Cholinergic input from the basal forebrain provides modulatory acetylcholine release.</p><p>Functional consequences. Nicotine binding in the insula enhances interoceptive salience of bodily states, contributing to the conscious urge to smoke. Damage to the insula, as shown in stroke studies, can abruptly abolish craving and facilitate effortless cessation. During withdrawal, altered insula signaling amplifies negative bodily sensations such as tension or emptiness, which are then misattributed as cues to smoke. Thus, the insula provides the subjective "feeling" of craving and links interoception with motivational drive. <ref type="bibr" target="#b137">(Regner et al., 2019)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integration across Circuits</head><p>Nicotine's behavioral effects emerge from the interplay of reinforcement-promoting pathways (VTA-NAc, PFC, striatum, basal forebrain, insula) and aversion-signaling systems (MHb-IPN, LHb-RMTg, amygdala). Acutely, nicotine enhances transmitter release and depolarizes postsynaptic targets, producing dopamine bursts and attentional gain. With repeated exposure, nicotinic receptors desensitize, undergo compensatory upregulation (especially ùõΩ2-containing subtypes), and alter trafficking. These molecular adaptations drive circuit-level plasticity: excitatory inputs onto VTA dopamine neurons are potentiated, corticostriatal synapses in the NAc shift their AMPA/NMDA balance, and habenular output becomes dysregulated. The net result is a progression from initial reinforcement to habitual use, then to withdrawal-associated hypodopaminergia and stress recruitment that heighten relapse vulnerability.</p><p>Human studies align with these mechanisms. PET imaging shows upregulation of ùõΩ2-containing nAChRs in smokers, correlating with craving and dependence severity. Genetic variants in the CHRNA5-A3-B4 cluster weaken habenula-mediated aversive signaling, predisposing carriers to heavier use. Impaired ùõº7 receptor function contributes to sensory gating deficits in schizophrenia, providing a mechanistic basis for high rates of nicotine self-medication in this group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Modulatory Arousal and Autonomic Pathways</head><p>Beyond the core reinforcement-aversion circuitry, nicotine also influences thalamocortical sensory gating, brainstem arousal nuclei such as the locus coeruleus (noradrenaline) and dorsal raphe (serotonin), and peripheral autonomic ganglia <ref type="bibr" target="#b188">(Wittenberg et al., 2020)</ref>. These systems regulate arousal, vigilance, mood, and physiological state, thereby shaping how nicotine is experienced and how cues gain salience. While they are not primary drivers of dependence, their modulatory influence interacts with other circuits to affect craving intensity, stress responsivity, and relapse risk. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6">Additional Considerations</head><p>While this chapter has emphasized the direct actions of nicotine on neuronal nAChRs and their downstream circuits, additional mechanisms contribute to the biology of dependence. These include interactions with other receptor systems, signaling in non-neuronal cells, synergistic compounds in tobacco smoke, biological context such as sex and developmental stage, and even epigenetic and intergenerational influences. Together, these factors extend nicotine's impact beyond classical receptor pharmacology and highlight the multifactorial complexity of tobacco dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.1">Receptor Cross-Talk</head><p>Nicotinic acetylcholine receptors (nAChRs) operate within a web of receptor interactions that broaden nicotine's impact. Calcium influx through nAChRs facilitates NMDA receptor activation, strengthening glutamatergic plasticity. In striatal circuits, functional coupling between ùõΩ2-containing nAChRs and dopamine D2 receptors modulates the balance between phasic bursts and tonic release, influencing reinforcement versus habit learning. Nicotine-driven activation of interneurons also alters GABA ùê¥ receptor activity, shaping oscillatory dynamics. Beyond these examples, nAChRs intersect with muscarinic acetylcholine, metabotropic glutamate, and endocannabinoid signaling, embedding nicotinic input into the broader receptor networks that regulate learning and motivation <ref type="bibr" target="#b151">(Sadler et al., 2020)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.2">Glial Receptors and Inflammatory Signaling</head><p>Astrocytes and microglia also express nAChRs, particularly ùõº7 subtypes. In astrocytes, activation enhances glutamate release and modulates synaptic strength, while in microglia, ùõº7 signaling can suppress pro-inflammatory cytokine release. Such non-neuronal actions show that nicotine influences both neuronal circuits and the brain's immune environment. Chronic exposure, however, can recruit glial cells into a pro-inflammatory state, releasing cytokines such as TNF-ùõº and IL-1ùõΩ, which disrupt synaptic plasticity and alter nAChR expression in corticolimbic regions <ref type="bibr" target="#b164">(Soares and Picciotto, 2023)</ref>. Nicotine's impact on neuroinflammation is thus context-dependent and increasingly recognized as integral to dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.3">Monoamine Oxidase Inhibition</head><p>Tobacco smoke contains monoamine oxidase (MAO) inhibitors that significantly enhance dependence <ref type="bibr" target="#b80">(Hong et al., 2022)</ref>. While nicotine itself does not inhibit MAO, smoke constituents prolong dopamine lifetime in reward circuits. In rodents, nicotine paired with MAO inhibition is more rewarding than nicotine alone, and the MAO inhibitor tranylcypromine markedly potentiates nicotine-induced dopamine release in the nucleus accumbens <ref type="bibr" target="#b185">(Vill√©gier et al., 2007)</ref>. MAO inhibition therefore amplifies reinforcement and contributes to the unique addictiveness of tobacco products <ref type="bibr" target="#b38">(Dome et al., 2010)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.4">Nicotine Metabolites and Secondary Alkaloids</head><p>Nicotine's metabolites and minor alkaloids add further complexity. Cotinine, the major metabolite, has little psychoactivity but is widely used as a biomarker of exposure. Nornicotine directly acts on nAChRs and serves as a precursor to carcinogenic tobacco-specific nitrosamines (TSNAs). Other alkaloids, including anatabine and anabasine, interact weakly with nAChRs. Though less potent than nicotine, these compounds may prolong receptor activation and subtly reinforce use.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.5">Sex Hormones and Endocrine Modulation</head><p>Nicotine pharmacokinetics and receptor regulation are strongly influenced by hormonal context. Estrogen accelerates nicotine metabolism primarily through induction of the CYP2A6 enzyme <ref type="bibr" target="#b12">(Benowitz et al., 2006)</ref> , resulting in faster clearance and altered blood nicotine levels in females. Progesterone and testosterone exert distinct modulatory effects on cholinergic and dopaminergic signaling pathways, contributing to differential nicotine sensitivity and reinforcement between sexes <ref type="bibr" target="#b30">(Damaj, 2001)</ref> . These influences contribute to observed sex differences in smoking initiation, maintenance, and cessation. While much mechanistic evidence comes from animal studies, clinical data support the need for sex-specific approaches to treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.6">Developmental Vulnerability</head><p>The timing of exposure critically shapes nicotine's effects on the brain. Adolescence is a period of heightened mesolimbic and cortical plasticity, during which dopaminergic reward circuits and prefrontal control systems are still maturing. Nicotine exposure during this window amplifies receptor regulation, accelerates habit learning, and makes cue conditioning particularly durable. As a result, adolescents not only acquire dependence more rapidly but also exhibit stronger relapse vulnerability in adulthood <ref type="bibr" target="#b42">(Dwyer et al., 2008)</ref>.</p><p>Prenatal exposure adds another layer of risk. Nicotine readily crosses the placenta and disrupts fetal cholinergic development, leading to altered cortical layering, altered nAChR density, and long-lasting changes in neurotransmitter system <ref type="bibr" target="#b44">(Ernst et al., 2001)</ref>. These developmental alterations increase the probability of later dependence and may also affect cognitive and emotional regulation.</p><p>While human evidence is largely epidemiological, i.e., linking early exposure to higher rates of smoking initiation and persistence, converging animal studies demonstrate causal mechanisms, underscoring adolescence and prenatal life as sensitive windows where nicotine leaves enduring neurobiological imprints.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.7">Epigenetic and Transgenerational Effects</head><p>Nicotine produces lasting epigenetic modifications, including DNA methylation, histone acetylation, and microRNA regulation, which can alter neuronal development and synaptic plasticity <ref type="bibr" target="#b73">(Hamilton and Nestler, 2019)</ref>. Rodent studies show that such changes extend to offspring, as parental nicotine exposure modifies germline marks and influences neurodevelopment in the next generation.</p><p>In humans, evidence is mainly epidemiological, with maternal smoking during pregnancy linked to altered DNA methylation in children. While the permanence and cross-generational transmission remain uncertain, these findings highlight a possible pathway by which nicotine dependence risk is biologically inherited.</p><p>In summary, nicotine dependence arises from a convergence of mechanisms: receptor-level dynamics, circuit adaptations, receptor cross-talk, non-neuronal modulation, smoke-derived compounds, biological context, and even potential intergenerational effects. This complexity underscores why tobacco dependence is uniquely powerful and difficult to treat.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7">Cognitive and Psychological Effects of Nicotine</head><p>The receptor-and circuit-level adaptations described above do not remain confined to synapses. They shape the way the brain processes information, regulates mood, and guides action. Subjective experiences of alertness, calm, craving, or dysphoria are the macroscopic correlates of molecular events such as ùõº4ùõΩ2 receptor desensitization, hippocampal ùõº7-mediated plasticity, and mesolimbic dopamine bursts. These neural dynamics cascade upward into changes in attention, memory, affect regulation, decision-making, and self-concept. In this sense, cognition and psychology provide the experiential bridge between microscopic neurobiology and outward behavior.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.1">Attention and Executive Function</head><p>Nicotine's modulation of cortical networks reflects the interplay of ùõº7-mediated glutamate release and ùõº4ùõΩ2 receptor desensitization on inhibitory interneurons. The net effect is sharper gamma-band synchrony (30-80 Hz) in prefrontal circuits, which supports selective attention and working memory. EEG and MEG studies show nicotine enhances gamma power, correlating with faster reaction times and reduced variability in vigilance tasks <ref type="bibr" target="#b8">(Bekker et al., 2005)</ref>. During withdrawal, these gains collapse as cholinergic drive falls and receptor states reset, producing attentional lapses and executive control deficits. <ref type="bibr" target="#b186">(Wesnes et al., 2013)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.2">Memory Encoding and Retrieval</head><p>In hippocampal circuits, ùõº7 receptor activation facilitates Ca 2+ -dependent long-term potentiation (LTP). Rodent studies show increased dendritic spine density and NMDA receptor phosphorylation with nicotine exposure, while human fMRI demonstrates stronger hippocam-pal engagement during episodic encoding <ref type="bibr" target="#b119">(Newhouse et al., 2011)</ref>. Withdrawal, by contrast, produces hippocampal hypoactivation and impaired recall, a direct consequence of reduced cholinergic signaling and receptor resensitization. Thus, the molecular mechanisms of synaptic plasticity map onto subjective fluctuations in memory performance <ref type="bibr" target="#b2">(Alhowail, 2021)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.3">Affect and Stress Regulation</head><p>Nicotine acutely stimulates the hypothalamic-pituitary-adrenal (HPA) axis, increasing ACTH and cortisol via CRF activation in the paraventricular nucleus (PVN) <ref type="bibr" target="#b146">(Rohleder and Kirschbaum, 2006;</ref><ref type="bibr" target="#b110">Matta and Desarmenien, 2012)</ref>. Smokers often misinterpret relief of withdrawal-induced tension as stress reduction, even though cortisol rises. With chronic use, basal cortisol remains largely unchanged, but HPA responses to psychosocial stress become blunted, while responses to nicotine or CRH remain intact . At the molecular level, chronic self-administration reduces CRF, increases arginine vasopressin (AVP), and produces CRF/AVP coexpressing neurons that sensitize the system to novel stressors <ref type="bibr" target="#b196">(Yu et al., 2008)</ref>. Thus, nicotine initially heightens stress hormones but ultimately remodels stress circuits in ways that increase vulnerability to external stress and relapse.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.4">Learning, Cues, and Incentive Salience</head><p>Nicotine strengthens dopamine-dependent plasticity in corticostriatal loops, as described in the VTA-NAc pathway. When environmental cues are paired with nicotine-induced dopamine bursts, they acquire motivational salience. Over time, these cues alone can evoke dopaminergic activity and craving, even in the absence of nicotine <ref type="bibr" target="#b145">(Robinson et al., 2013)</ref>. This process reflects Hebbian principles introduced in previous section, where transient phasic bursts consolidate lasting associative traces.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.5">Attentional Bias and Intrusive Cognition</head><p>At the psychological level, this translates into attentional bias toward smoking-related stimuli <ref type="bibr" target="#b39">(Drobes et al., 2019)</ref>. Eye-tracking and Stroop tasks show that smokers preferentially orient to tobacco cues, especially during withdrawal. These attentional distortions manifest subjectively as intrusive craving episodes, often vivid images or thoughts of smoking, analogous to the intrusive cognitions observed in obsessive-compulsive disorder. Here, the cue-driven dopamine responses described earlier become lived as mental preoccupation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.6">Expectancies and Beliefs</head><p>Beyond pharmacology, cognition is filtered through beliefs. Smokers often endorse expectancies such as "smoking relaxes me" or "cigarettes help me concentrate." These amplify perceived benefits and blunt awareness of aversive effects. Placebo studies demonstrate that expectancy alone can reduce craving, even in the absence of nicotine delivery, underscoring how top-down interpretation overlays bottom-up receptor activity <ref type="bibr" target="#b129">(Perkins et al., 2003)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.7">Decision-Making Biases</head><p>Orbitofrontal and striatal dysregulation manifests cognitively as systematic distortions in decisionmaking. Diffusion tensor imaging studies reveal reduced integrity of ventral (mOFC-NAc) and dorsal (DLPFC-caudate) frontostriatal tracts in young smokers, with ventral abnormalities correlating with craving and dorsal abnormalities with impaired cognitive control <ref type="bibr" target="#b197">(Yuan et al., 2018)</ref>. These structural vulnerabilities translate into steep delay discounting, whereby immediate relief is prioritized over long-term health, and into optimism bias ("I can quit anytime") and risk underestimation ("one cigarette won't hurt"). Nicotine dependence thus reshapes not only motivational circuits but also the cognitive frameworks by which risks and rewards are evaluated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.8">Implicit Cognitions and Automaticity</head><p>Nicotine-driven corticostriatal plasticity facilitates the development of implicit associations (such as the expectancy that smoking provides relief) and habitual procedural routines (lighting, inhaling, exhaling). Dual-process frameworks describe this interaction: rapid associative processes generate automatic urges, while slower reflective mechanisms attempt top-down regulation. With chronic nicotine exposure, this balance shifts as prefrontal control is progressively weakened, thereby increasing relapse risk despite explicit intentions to quit <ref type="bibr" target="#b139">(Ren et al., 2019)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.9">Metacognition and Self-Regulation</head><p>Smokers not only hold outcome expectancies (e.g., "cigarettes reduce stress"), but also metabeliefs about their own cravings. Qualitative profiling shows that they endorse both positive beliefs (smoking enhances concentration, regulates emotion) and negative beliefs ("my urges are uncontrollable," "smoking reflects low willpower") <ref type="bibr" target="#b121">(Nikƒçeviƒá and Spada, 2010)</ref>. These recursive beliefs amplify distress and paradoxically strengthen craving, particularly when attention is externally focused and stop-signals are missed, fostering chain smoking. Such metacognitions constitute part of a cognitive-attentional syndrome that maintains dependence. Interventions such as mindfulness and metacognitive therapy target this layer by reframing cravings as transient and tolerable rather than overwhelming, thereby restoring agency over automatic impulses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8">Behavioral Manifestations of Smoking</head><p>The neurocognitive adaptations outlined above surface in recognizable patterns of smoking behavior. Processes such as initiation, maintenance, habit formation, withdrawal, relapse, and comorbidity represent the behavioral "tip of the iceberg", visible actions underpinned by hierarchies of receptor-and circuit-level changes. As detailed in the previous chapter, these manifestations are not independent phenomena but the translation of molecular and neural adaptations into lived experience. This section therefore situates smoking behavior as the emergent outcome of interacting cognitive, affective, and neurobiological processes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.1">Initiation</head><p>Initiation represents the translation of susceptibility into action. Smoking typically begins in adolescence or early adulthood, when curiosity, peer influence, and permissive environments intersect with heightened neurobiological vulnerability. First exposures to nicotine activate mesolimbic dopaminergic pathways, producing subjective novelty such as dizziness, a buzz, or clarity that can strongly imprint in memory. Genetic factors (for example, CYP2A6 metabolism or CHRNA5-A3-B4 receptor variants) shape whether early experimentation leads to discontinuation, occasional use, or the beginnings of dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.2">Maintenance and Dependence</head><p>As smoking becomes regular, behavior shifts from curiosity-driven to homeostatically maintained. Because nicotine clears rapidly, individuals learn to titrate intake by spacing cigarettes to prevent withdrawal while avoiding overexposure, and at the same time to preserve the desired buzz. This daily rhythm becomes synchronized with routines such as morning coffee, work breaks, commutes, or bedtime rituals. Over time, these repeated pairings strengthen stimulusresponse associations, so that contexts like finishing a meal or starting the car come to trigger smoking automatically. Neurobiologically, upregulation of ùõº4ùõΩ2 * receptors on dopaminergic and GABAergic neurons enforces the pattern, making absence increasingly aversive. Dependence emerges when smoking transitions from voluntary use to a felt necessity, reinforced both by relief of withdrawal and by modest dopaminergic reward. Habits consolidate as striatal plasticity gradually shifts control from goal-directed to habitual circuits, embedding smoking into everyday life with little need for conscious deliberation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.3">Escalation of Dosage</head><p>Over time, tolerance and habit plasticity drive escalation in the form of more cigarettes per day, deeper inhalation, or shorter intervals between puffs. Striatal circuitry, particularly the dorsal striatum, increasingly automates responses, while higher receptor thresholds caused by desensitization and habituation demand more nicotine for equivalent subjective effects. Pharmacokinetics also play a role: fast metabolizers tend to escalate in dosage more quickly, since rapid clearance leaves receptors unoccupied for longer periods, whereas slow metabolizers may become dependent more rapidly because sustained nicotine exposure reinforces receptor adaptations at lower intake levels. Although some smokers stabilize at low consumption, the asymmetry described in the previous chapter holds, with continuation more often biased toward upward rather than downward adjustment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.4">Reduction of Dosage</head><p>Periods of reduction often occur in response to health concerns, financial cost, or external constraints such as smoke-free policies or illness. However, compensatory smoking usually undermines these efforts. Smokers may take longer or deeper puffs, shorten the interval between cigarettes, or relapse from partial reduction into heavier use after a brief lapse. These adjustments tend to preserve nicotine intake even when the number of cigarettes declines. Sustained reduction without complete cessation is rare, because receptor-level reinforcement and conditioned routines resist downward adjustment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.5">Quit Attempts</head><p>Quit attempts mark deliberate efforts to override mesolimbic drive with prefrontal control. Most smokers report wanting to quit, but success rates are modest without pharmacological or behavioral support. Pharmacotherapies buffer withdrawal, behavioral strategies reconfigure coping, and structural interventions such as restrictions, and denormalization reduce cues. Yet cessation typically requires multiple attempts, reflecting the recursive and non-linear nature of smoking careers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.6">Withdrawal</head><p>Within hours of abstinence, nicotine levels fall below thresholds needed to stabilize desensitized receptors. Resensitization without occupancy produces hyperexcitability, hypodopaminergia, and stress-circuit activation. Subjectively, this appears as irritability, anxiety, loss of focus, restlessness, and craving. These aversive states provide powerful negative reinforcement, teaching the body and brain that relapse equals relief.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.7">Relapse Cycles</head><p>Relapse illustrates the recursive nature of dependence. Environmental cues such as the smell of smoke, the sight of a lighter, or familiar social settings trigger dopaminergic bursts in sensitized circuits, while stress reactivates amygdala-HPA pathways. The insula translates these activations into conscious urges, often experienced as bodily tension or emptiness. Relapse may appear sudden, but it represents re-entry of long-embedded circuits into action. Vulnerability persists even after years of abstinence due to durable cue associations and epigenetic adaptations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.8">Ritualization and Habit Formation</head><p>With chronic exposure, smoking becomes increasingly procedural. Lighting, inhaling, and exhaling are automated routines executed with minimal deliberation, often embedded into daily rituals such as morning coffee, post-meal relaxation, or commuting. Striatal plasticity shifts control from ventral, goal-directed circuits to dorsal, habitual ones. Ritualization bridges biology and culture, since conditioned sensory cues including taste, smell, and hand-to-mouth movement align with social scripts to embed smoking deeply in everyday life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9">Social and Cultural Modulators of Smoking Behavior</head><p>Nicotine dependence is not only rooted in receptor biology, circuit plasticity, or cognition. It also unfolds within social and cultural environments that shape when, how, and why nicotine is consumed. These environments do not merely overlay biology but actively interact with it, providing cues, meanings, and reinforcements through which neural adaptations gain behavioral expression. In this sense, the neurobiology of nicotine is embedded within a broader biopsychosocial system.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.1">Social Networks and Peer Influence</head><p>Adolescents and young adults are particularly sensitive to peer modeling. Exposure to smoking peers increases initiation risk through observational learning, social reinforcement, and shared rituals. At the neural level, such contexts serve as salient cues paired with dopaminergic surges, strengthening associative loops described earlier. Longitudinal network studies confirm that smoking tends to cluster within peer groups and diffuse across social ties <ref type="bibr" target="#b153">(Schaefer et al., 2013)</ref>. Dependence thus propagates not only individually but socially.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.2">Cultural Norms and Ritualization</head><p>Cultural frameworks determine whether smoking is seen as normative, stigmatized, or symbolic. In many societies, cigarettes are woven into daily routines, such as after meals, during breaks, or at gatherings, providing reliable temporal cues that reinforce learning. Gender norms also shape prevalence: historically higher male smoking rates in East Asia reflect cultural permissiveness for men but restrictions for women <ref type="bibr" target="#b7">(Bauer et al., 2007)</ref>. Where smoking is ritualized or tied to identity scripts (e.g., maturity, rebellion, solidarity), the associated cues acquire exceptional durability, persisting even when nicotine exposure is reduced.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.3">Economic and Policy Contexts</head><p>Structural conditions powerfully shape smoking behavior. Higher taxation reduces consumption and promotes cessation, especially among youth and low-income groups <ref type="bibr" target="#b4">(Bader et al., 2011)</ref>. Conversely, marketing, price promotions, and wide availability lower barriers to initiation and relapse. These economic and policy levers determine the frequency, accessibility, and context of nicotine exposure, thereby indirectly shaping the receptor and circuit adaptations that underlie dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.4">Stigma, Identity, and Psychological Mediation</head><p>The cultural meaning of smoking modulates its psychological impact. In stigmatizing environments, smokers may internalize shame or guilt, amplifying stress and relapse risk <ref type="bibr" target="#b47">(Evans-Polce et al., 2015)</ref>. In contrast, within subcultures that frame smoking as rebellious, stylish, or socially binding, the act is positively reinforced beyond its pharmacology. These symbolic associations recruit the same amygdala-striatal pathways that encode drug cues, but layered with meaning that deepens persistence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.5">How Social Context Enters the Brain</head><p>Taken together, social and cultural contexts amplify and reshape nicotine's associative learning processes. Peer presence, ritualized routines, economic conditions, and cultural meanings all function as powerful external cues tightly coupled to dopaminergic reinforcement and receptor adaptations. The brain does not encode nicotine in isolation, but nicotine-in-context: the shared cigarette with friends, the ritual break after work, the relief during stress. These contextual pairings become inseparable from pharmacological reinforcement, helping to explain why smoking remains resistant to extinction even after long abstinence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10">Phenomenology of Smoking Behavior</head><p>The previous sections have described nicotine's progression from receptor binding to circuit adaptation, cognition, behavior, and culture. Yet smoking is not lived as receptor occupancy or synaptic plasticity. It is experienced in concrete moments that carry meaning: the relief of a morning cigarette, the pairing with coffee, the compulsion during stress, or the sense of betrayal in relapse. Phenomenology provides the bridge between biology and lived experience, showing how molecular and cultural mechanisms are translated into daily life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.1">The First Cigarette: Shock and Threshold</head><p>The first encounter is often harsh. Smoke irritates the throat, dizziness and nausea are common, and yet curiosity, peer influence, or the desire for experimentation sustains the act. The experience imprints strongly because it marks a threshold: the beginning of smoking. Neurobiologically, this moment reflects the balance between VTA-NAc dopaminergic reinforcement and habenular aversion mediated by ùõº3ùõΩ4 * receptors. Psychologically, it becomes a landmark memory, often recalled with unusual clarity. Importantly, the state of mind during this first puff, and the motives for taking it, strongly influence future behavior: whether smoking is remembered as curiosity satisfied, social bonding achieved, or tension relieved, or a guilt trip, the framing shapes the likelihood of continued use.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.2">The Morning Cigarette: Resetting the Self</head><p>After overnight abstinence, withdrawal symptoms often appear: irritability, low mood, and impaired concentration. The first morning cigarette restores dopamine tone by occupying upregulated ùõº4ùõΩ2 * receptors. It is frequently described as the most pleasurable cigarette of the day, because resensitized ùõº6ùõΩ2 * receptors on dopaminergic terminals, along with a large fraction of ùõº4ùõΩ2 * receptors, are vacant after sleep. Their rapid re-occupation produces a strong dopaminergic response and a marked sense of relief.</p><p>The strength of this experience depends on the degree of dependence. Highly dependent smokers often regard the morning cigarette as indispensable, since receptor resensitization during sleep amplifies both craving and withdrawal intensity. By contrast, individuals with lower dependence may not feel a strong urge upon waking. Their overnight "reset" permits greater cognitive control over the timing of the first cigarette. In this way, the morning cigarette becomes a marker of dependence severity: for some it restores equilibrium, while for others it remains optional.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.3">The Post-Meal Cigarette: Completion and Closure</head><p>Many smokers describe a cigarette after eating as a natural conclusion to a meal. Nicotine engages vagal and striatal circuits, while the ritual provides closure. Hippocampal and amygdala associations link food cues with nicotine reward, embedding the act into the structure of daily routines. When no alternative behavior is available, or when the individual is unsure how to transition after eating, the absence of smoking can create unease and restlessness. In these cases, the cigarette provides a reliable sense of completion, transforming a potentially awkward pause into a predictable and satisfying ritual.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.4">The Coffee-and-Cigarette: Intensification and Pairing</head><p>Nicotine and caffeine act synergistically on dopaminergic and noradrenergic systems. Smokers often report that coffee feels incomplete without a cigarette. Cortical ùõº7 receptor activation sharpens attentional focus, while caffeine sustains arousal through adenosine blockade. The combination is experienced as a heightened and complete stimulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.5">The Stress Cigarette: Soothing and Containing</head><p>In stressful moments, smokers often report that a cigarette calms them. The act of pausing to smoke provides structure, and relief from withdrawal is misinterpreted as relief from stress. Neurobiologically, nicotine acutely activates the HPA axis, raising cortisol even as it dampens subjective tension. With chronic use, stress circuits adapt: baseline responses become blunted, but withdrawal heightens reactivity. The stress cigarette is therefore experienced as soothing, while in fact reinforcing dependence on nicotine for emotional regulation. Part of this also comes from the pause itself: stepping away, inhaling deeply, and exhaling slowly. Such breathing has intrinsic relaxing effects, independent of nicotine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.6">The Boredom Cigarette: Passing Time</head><p>When little is happening, smoking structures otherwise empty time. The ritual of lighting, inhaling, and extinguishing provides rhythm and activity. Striatal habit circuits automate this pattern, while nicotine's modulation of attention makes the act feel purposeful rather than idle. At the same time, dopaminergic reward prediction assigns value to smoking in a context of low stimulation, making the cigarette feel like something worth pursuing. In this way, boredom transforms a neutral moment into a cue for reinforcement.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.7">The Social Cigarette: Belonging and Synchrony</head><p>In groups, cigarettes function as social synchronizers. Shared breaks, gestures, and timing provide a sense of belonging. Reinforcement comes not only from nicotine but also from faces, voices, and contexts that hippocampal circuits bind together. Cultural norms shape the meaning, framing smoking as maturity, rebellion, or marginalization. In these settings, self-reflection is often muted, and the pleasure remembered later is stored as the event as a whole, even if the cigarette itself added little. This integrated memory acts as a powerful reinforcer, increasing the likelihood of future smoking in social contexts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.8">The Solitary Cigarette: Reflection and Distance</head><p>Alone, smoking can serve as a moment of contemplation. The visible smoke and rhythmic breathing create structure. Prefrontal and hippocampal circuits support focused thought, while the ritual itself functions as a temporal anchor. Here, the cigarette is experienced less as stimulation than as personal pause.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.9">The Work Cigarette: Break and Reward</head><p>At work, smoking often marks a sanctioned pause. Smokers describe leaving the workspace to smoke as regaining autonomy. Dopamine release becomes associated not only with nicotine but also with the relief of stepping away from obligation. The sight of a designated smoking area can itself become a powerful cue. Over time, a loop develops in which smoking is linked to productivity: work is felt to go better after a cigarette, while thoughts of smoking can intrude and distract until the break is taken. This reinforces the cycle of smoking as both relief and preparation for further effort.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.10">The Creative Cigarette: Inspiration and Flow</head><p>Many report smoking during writing, art, or music. Nicotine transiently enhances attentional control and dopamine signaling, which can feel like opening a channel for ideas. The effect is modest and short-lived, reflecting temporary cortical modulation rather than true enhancement of creativity. Yet because inspiration is often remembered in conjunction with smoking, the cigarette becomes part of the creative ritual. This associative link reinforces the belief that creativity flows better with nicotine, even when the pharmacological contribution is minimal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.11">The Craving Cigarette: Urgency and Release</head><p>Craving builds as a state of restlessness, tension, and narrowed attention. Lighting a cigarette restores receptor occupancy and dampens habenular hyperactivity, leading to a sharp sense of relief. The experience is rarely described as pleasure but as release, the lifting of discomfort. This illustrates the shift from positive to negative reinforcement: smoking is pursued not for added reward but to end an aversive state.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.12">The Nighttime Cigarette: Transition and Closure</head><p>For many smokers, the final cigarette of the day serves as a ritual of transition. Nicotine restores dopamine tone enough to ease tension, creating a subjective sense of winding down, even though it physiologically disrupts sleep architecture. The act becomes a conditioned signal that the day is ending, much like brushing teeth or turning off the lights. Over time, bedtime itself functions as a powerful cue for smoking, so that the absence of the cigarette may feel unsettling or incomplete. In this way, the nighttime cigarette provides not only pharmacological relief but also psychological closure, reinforcing its place in daily routine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.13">The Celebratory Cigarette: Marking the Moment</head><p>At times of success or joy, some smokers light a cigarette to mark the occasion. Nicotine interacts with the endogenous dopamine surge that follows achievement, amplifying the sense of reward. The act is remembered not only for its pharmacological effect but also for its symbolic role, punctuating the event with a ritual gesture. Over time, such pairings condition the brain to associate cigarettes with milestones, embedding smoking into the way moments of celebration are recognized and remembered.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.14">Quit Attempts: Effort and Fragility</head><p>During intentional cessation, the cigarette becomes both target and temptation. Smokers often describe constant self-monitoring, intrusive urges, and reliance on routines to resist relapse. Reduced prefrontal control and enhanced cue-reactivity circuits explain the fragility of abstinence. Phenomenologically, quitting is lived as sustained effort under pressure.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.15">The Lapse: Slippage and Rationalization</head><p>A lapse, smoking a single cigarette during an attempt to quit, is often described as both trivial and catastrophic. The act is frequently rationalized as a one-time relief, yet it reactivates associative networks and restores receptor occupancy, producing a disproportionate sense of comfort. This makes return to abstinence more difficult. Psychologically, a lapse can also undermine motivation by eroding the salience of reasons to quit. For individuals who think in all-or-nothing terms, even a single cigarette may be interpreted as failure, leading to resignation and progression toward full relapse.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.16">Nostalgia: Remembering the Cigarette</head><p>Former smokers often report missing cigarettes in specific contexts, morning coffee, social gatherings, or stressful situations. The nostalgia is not for nicotine itself but for the layered memories of ritual, context, and identity. Hippocampal and amygdala circuits encode these associations long after pharmacological dependence fades, explaining why longing can persist for years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.10.17">The Lived Architecture of Smoking</head><p>Taken together, these accounts show smoking as more than nicotine delivery. It is a repertoire of moments: initiation, restoration, relief, ritual, belonging, compulsion, withdrawal, abstinence, lapse, relapse, and nostalgia. Each is grounded in receptor occupancy, dopamine signaling, and associative learning, yet lived as mood, meaning, and habit. Phenomenology therefore brings the account full circle: from molecules and circuits, through cognition and culture, to the felt realities of dependence and its absence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.11">Modern-Day Challenges: Continuity and Change in the</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Architecture of Dependence</head><p>The biology of nicotine dependence, from receptor adaptation to cue learning, remains the same. What has shifted is the context of use: new products, earlier exposure, more environmental triggers, and changing global patterns. Today's smoker or vaper inhabits a world that looks very different, yet rests on the same underlying mechanisms.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.11.1">What Is New in the Modern Landscape</head><p>Delivery speed. Electronic nicotine devices, heated tobacco, and nicotine salts all preserve the central feature of rapid delivery to the brain. Nicotine salts in particular allow higher doses with less irritation, which encourages deeper inhalation and faster spikes in the bloodstream. This quick delivery strengthens dependence, especially in new users.</p><p>Adolescent risk. The rise of vaping has sharply increased nicotine use among teenagers. At this stage, reward circuits are highly sensitive while self-control systems are still maturing. Nicotine exposure during adolescence is therefore more likely to cause lasting changes and make dependence harder to reverse.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dual use and multiple products.</head><p>Many people now combine cigarettes with vaping or other nicotine products. This creates more layers of triggers: the act of smoking, the flavors and sensations of vaping, and the rituals that surround them. The denser the web of triggers, the harder it is to quit.</p><p>Marketing and culture. Nicotine products are now sold through flavors, sleek design, and lifestyle branding as much as through the substance itself. These features become part of the reward system, embedding dependence in cultural as well as chemical cues.</p><p>Global patterns and inequality. Nicotine use is increasingly concentrated in low-and middleincome countries, where treatment is scarce and policy enforcement uneven. The biology of dependence is the same everywhere, but in these contexts it interacts with poverty and stress to deepen health disparities.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.11.2">What Remains the Same</head><p>The receptor at the core. Whatever the source, whether cigarette, vape, or patch, nicotine binds to the same brain receptors and drives the same cycle of activation and adaptation.</p><p>Withdrawal as the return path. The irritability, low mood, and poor concentration of withdrawal still arise from the same stress circuits in the brain. The discomfort feels the same whether someone is abstaining from smoking or vaping.</p><p>Triggers that hold the habit. The brain continues to link nicotine to places, rituals, and moods. The objects may have changed, but the associative architecture has not.</p><p>Social pressures. Stress, disadvantage, and targeted marketing still magnify vulnerability and make quitting harder. The social context shifts, but its role in shaping dependence endures.</p><p>The cycle of nicotine dependence therefore remains constant: activation, adaptation, craving, withdrawal. What has changed is the timing of exposure, the density of cues, and the cultural environment in which use takes place.</p><p>The challenge is twofold. We must retain effective tools such as medications, withdrawal support, and strategies for breaking triggers, since the biology has not changed. At the same time we must adapt by regulating delivery speed, protecting adolescents, addressing multiple product use, and widening access to care, because the context has evolved. Nicotine dependence today is continuous with its past yet reshaped by modern environments: a familiar biology expressed in new technologies and cultures.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.12">Moral of the Story</head><p>Nicotine is absorbed rapidly when someone smokes or vapes, reaching the brain in under half a minute. There it binds to receptors that normally respond to acetylcholine, a natural signal for attention and alertness. This binding triggers a burst of dopamine, which the brain interprets as reward and marks smoking as worth repeating. Over time, receptors adapt to constant nicotine: many become desensitized while the brain increases their number to restore balance. When nicotine levels fall, too many receptors are left empty, causing restlessness, irritability, poor concentration, and craving. Smoking again temporarily fills these receptors and restores dopamine activity, so the relief from withdrawal feels like "becoming normal" rather than true pleasure.</p><p>These receptor changes extend across larger brain systems. Reward circuits become tuned to nicotine and to the sights, smells, and rituals that accompany smoking, so cues like coffee, breaks, or social gatherings trigger craving. Habit circuits make smoking automatic. Stress and mood circuits, initially calmed by nicotine, grow overactive during withdrawal, amplifying anxiety. Memory and learning systems link nicotine to routines and emotions, embedding cigarettes into daily identity. Over time, smoking shifts from a voluntary pleasure to a cycle of avoidance, driven mainly by the wish to escape withdrawal. This blend of rapid drug delivery, receptor adaptation, circuit rewiring, and learned associations explains the power of nicotine dependence and the difficulty of quitting.</p><p>These processes form a hierarchy, building on the one below it. At the base are the molecular events, where nicotine binds to receptors and changes their sensitivity and number. These molecular shifts ripple upward into cells, where chemical signals and gene activity change the way neurons function. At the next level, networks of neurons, or circuits, are reshaped, altering how reward, stress, memory, and habit systems respond. These circuit changes then shape cognition and psychology, influencing attention, mood, motivation, and decision-making. At the behavioral level, these forces appear as starting to smoke, maintaining the habit, struggling with withdrawal, and often relapsing. Beyond the individual, the environment, society, and culture add another layer: peers and family influence initiation, workplace routines and rituals reinforce smoking, marketing and availability make access easier, and cultural meanings attach identity and symbolism to cigarettes. These social contexts do not simply sit outside the biology but interact with it, providing the cues, reinforcements, and meanings that embed smoking even more deeply. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1">Introduction: Cleverness as a Trap</head><p>For many, to smoke is to think. Where many intoxicants blunt or cloud consciousness, smoking entwines itself with it. The smoker's mind is rarely silent: it produces reasons, excuses, narratives, identities, and distortions that keep the cigarette in hand. On the biological side, nicotine modifies receptor function, increases incentive salience in mesolimbic pathways, and consolidates stimulus-response habits in the dorsal striatum. On the cognitive side, the mind supplies stories that transform urges into decisions: one cigarette will not matter, tomorrow is a better day to quit, stress demands relief, or smoking is simply part of who I am. Smoking is therefore not only a disorder of the body but also a disorder of thought. This makes smoking a uniquely "thoughtful" addiction. Alcohol and opioids impair reasoning through intoxication, but cigarettes exploit intact cognition: narrative construction, identity work, forward planning, and coherence-seeking. They enlist the mind's highest capacities of explanation and self-reflection to perpetuate dependence. Reflection, reasoning, and awareness, the very faculties that should aid freedom, become instead the scaffolding of relapse.</p><p>The dynamics of smoking can be understood as a hierarchy: molecules alter receptors, receptors bias circuits, circuits shape thought, thought becomes narrative, and narratives are stabilized by surroundings and identity. This chapter focuses on the middle of that chain, the level of thought and rationalization. Within the SYNAPSE framework introduced later, in Chapter 7, cognition is an active modulatory layer in the neural competition between craving and abstinence. Beliefs, expectations, and attentional bias amplify some signals and suppress others, shifting which representations gain access to consciousness and guide action. Rationalization, narrative, and identity are thus the cognitive manifestations of deeper neural dynamics.</p><p>A central theoretical question is whether smoking-related thoughts cause relapse or rationalize it. In the causal account, cognitions such as "just one will not hurt" narrow attention to immediate reward and act as proximal triggers. In the defensive account, subcortical or habitual processes initiate smoking and thought arrives afterward to justify the act and repair self-image. Both accounts capture part of the truth. Sometimes thought precedes action, and sometimes it follows, but in both cases it reshapes behavior.</p><p>The timing of these cognitions is equally revealing. Pre-lapse rationalizations appear in cue-rich or emotionally charged contexts, lowering the threshold for acting. Post-lapse narratives arise after smoking, integrating the event into memory, softening guilt, and preserving social face. These phases are not random but patterned responses to the fluctuations of craving, stress, and executive control.</p><p>These dynamics reflect interactions among distributed neural systems. Dorsal striatal circuits encode cue-driven stimulus-response associations that automatically draw attention to smoking cues . Dorsolateral prefrontal cortex supports goal maintenance and inhibitory control, but it falters under stress, fatigue, or withdrawal, allowing permissive thoughts to dominate. Medial prefrontal and default mode networks generate self-relevant narratives that integrate smoking into identity. The insula converts bodily states of withdrawal or tension into interoceptive signals experienced as urgency. Together, these systems form a loop in which bodily unease generates permissive thought, thought intensifies craving, action brings relief, and relief reinforces the cycle. The previous chapter examined in detail the systems that would generate, support, and stabilize these smoking-related thoughts.</p><p>Consider the smoker stepping outside after a stressful meeting. The insula amplifies agitation into urgency, cue-reactive circuits pull attention to the pack of cigarettes, the prefrontal cortex weakened by stress fails to sustain abstinence goals, and the default mode network supplies the thought "I deserve this break." The cigarette is lit, relief follows, and the loop is strengthened. What begins as a physiological ripple cascades into thought, action, and reinforcement, tightening the cycle of dependence.</p><p>Rationalizations therefore deserve reinterpretation. They are not just weak excuses or mistakes in reasoning but natural mental processes that help people make their thoughts and actions feel consistent and protect their sense of self. Addiction takes over these processes and uses them to maintain smoking. Common thoughts like "I deserve this," "just one won't hurt," or "it helps me think" are not harmless, they act as signals that strengthen craving and weaken the motivation to stay abstinent, tilting the balance toward relapse.</p><p>The good news is that the very faculties which sustain smoking can also support abstinence. The same reasoning that once produced "one will not hurt" can also produce "I have endured this urge before and I can do it again." Identity narratives that once made cigarettes central can be rewritten around health, autonomy, or the needs of loved ones. In some contexts thought fuels relapse, in others it anchors resolve. Cleverness becomes a cage, and it can also become the key. By treating thoughts not as truths but as signals, smokers and clinicians can turn cognition from accomplice to ally.</p><p>In this chapter we develop the argument in five parts. First, we examine the machinery of smoking-related thought and the cognitive-emotional loops that stabilize episodes. Second, we trace how narratives and identity frames embed smoking into selfhood and social practice. Third, we consider modes in which thought is absent or overrun, including habitual smoking, compulsive urges, and negative-affect episodes, each with its own vulnerabilities. Fourth, we explore common rationalizations, distortions, and recurring patterns of thinking that sustain dependence. Finally, we translate these insights into clinical implications: how to anticipate rationalizations, re-author identity, time interventions to moments of greatest risk, and harness the smoker's own thoughtfulness as a tool for quitting rather than a trap</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2">The Machinery of Rationalization</head><p>The most familiar expressions of smoking's cognitive trap are the little thoughts that slip between craving and action: "Just one will not hurt." "I will quit tomorrow." "I need this to calm down."</p><p>At first glance these appear to be flimsy excuses. From a cognitive-scientific standpoint, however, they are structured mental operations that serve four interlocking functions:</p><p>1. Redirecting attention toward immediate reward and away from long-term costs.</p><p>2. Resolving dissonance between the smoker's health values and their craving.</p><p>3. Preserving self-narrative by allowing the smoker to maintain the identity of a rational agent rather than a reckless addict.</p><p>4. Diminishing the perceived urgency of abstinence by reducing the discomfort associated with acting against prior intentions to quit.</p><p>From a neurobiological perspective, rationalizations are not meaningless inner chatter but part of the brain's decision-making system. They arise from the interaction of several processes: prediction circuits that interpret smoking as a source of relief, conflict-monitoring systems in the anterior cingulate cortex that work to reduce dissonance, self-referential networks in the medial prefrontal cortex that integrate the behavior into personal narrative, and default mode networks that maintain a sense of coherence. Together, these systems do more than justify a choice after the fact, they actively shift the balance of decision-making. By strengthening reward-related activity in mesolimbic circuits and dampening abstinence-related signals in executive control regions, rationalizations tilt the brain toward relapse.</p><p>This helps explain why such thoughts feel persuasive. They are not arbitrary excuses but the expected outcome of evolved mechanisms whose normal role is to keep behavior and identity consistent. Addiction co-opts these mechanisms, redirecting them to protect the smoking habit. A thought like "just one won't hurt" is therefore not only a mistake in reasoning but the cognitive reflection of underlying neural competition in which craving gains an upper hand over self-control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.1">Rationalization in Moments of Crisis</head><p>Rationalizations do not surface evenly across time. For much of the day, smokers may think in terms of abstinence, health, or even quitting. Yet in moments of crisis, stress, fatigue, social pressure, or sudden withdrawal, thoughts that justify smoking rapidly dominate awareness. These thoughts act as permissive keys, transforming a bodily urge into a decision.</p><p>From the outside, this looks like a simple stimulus-response chain. From the inside, it is experienced as reasoning: the mind supplies explanations that make smoking appear not only permissible but necessary. In such moments, ambivalence collapses and craving is framed as choice. Outside of crisis, however, the same person may rehearse the opposite narrative, why not to smoke, why to quit. Thus the timing of rationalizations is central: they emerge not as constant beliefs but as context-bound stories that favor the body's demand.</p><p>This mechanism reframes rationalizations as more than flimsy excuses. They serve as the final arbiters in neural competition. At the circuit level, receptor adaptations and synaptic biases tip the scales toward craving. At the cognitive level, thought provides the justification that seals the outcome. Rationalizations resolve ambivalence by granting permission, even if only momentarily.</p><p>Clinically, this suggests that intervention must not only target the craving itself but also the reasoning that authorizes it. One strategy is to prepare counter-thoughts that accompany permissive rationalizations whenever they arise. For example, the moment "I need this to cope" emerges, it is paired with "this will increase my stress later." Such pairing preserves ambivalence instead of collapsing it into relapse. Ambivalence, though uncomfortable, is preferable to justification, because justification resolves conflict in favor of smoking. Still, ambivalence is cognitively costly, and prolonged conflict can lead to fatigue and surrender. This is why cognitive strategies must be combined with behavioral and pharmacological supports.</p><p>If left unchecked, rationalizations create positive feedback loops: each time smoking is justified, the justification itself grows stronger and more accessible. Breaking this loop requires exposing rationalizations as fallible stories, not truths, and training the smoker to recognize them as signals within competition rather than verdicts of reason.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.2">The Cognitive-Emotional Loop</head><p>Cognition does not operate in isolation; it is entangled with affect in a reciprocal loop. A craving state, experienced as tension, emptiness, or restlessness, stimulates permissive thoughts such as "this will calm me." These thoughts, in turn, intensify craving by narrowing attention and making smoking appear the only viable option. Relief follows once the cigarette is smoked, reinforcing both the urge and the plausibility of the thought.</p><p>From a brain perspective, this loop is a two-way exchange between emotional reward systems and the regions that evaluate and justify behavior. When stress activates the amygdala, attention is drawn more strongly to smoking cues. The prefrontal areas then supply reasons to smoke, which in turn increase activity in reward pathways such as the nucleus accumbens, making the urge even stronger. The cycle reinforces itself: stress triggers rationalization, rationalization heightens craving, craving leads to smoking, smoking brings relief, and that relief makes the rationalization seem valid.</p><p>In the SYNAPSE model, this cycle is seen as a self-stabilizing network in which thoughts and feelings continually reinforce one another. It is hard to disrupt because the system adapts if only one part is addressed. Calming stress alone does not erase the justifications, and challenging the justifications alone does not ease the physical tension. Breaking the cycle requires targeting both body and mind together rather than treating stress and thought as separate problems.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Memory, Episodic Recall, and Narrative Consolidation</head><p>An important neural dimension that deserves explicit attention is memory, especially hippocampal and episodic systems, and their role in sustaining smoking narratives. The hippocampus and adjacent medial temporal structures index contextual details of smoking episodes: the place, the people, the affective tone, and the sensory elements. Through repeated pairing of nicotine effects with specific contexts, episodic memory encodes richly textured event representations that are highly retrievable. When those contextual cues reappear, they spontaneously reinstantiate the entire episode, including its justificatory narrative, producing vivid mental simulations that feel convincing and immediate.</p><p>This mechanism does three things. First, it strengthens cue reactivity because retrieval is not abstract; it recreates an embodied memory trace. Second, episodic recall fuels narrative identity, because repeated retrieval makes particular smoking episodes salient in autobiographical memory, and salient memories disproportionately shape self-concept. Third, memory consolidation transforms idiosyncratic occasions into stable scripts, allowing a single experience to generalize into an enduring rationalization.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3">The Architecture of Smoking Thoughts</head><p>Smoking-related cognitions are not scattered fragments of inner speech but components of a patterned network. Each thought, whether a justification, excuse, or dismissal, can be situated along several dimensions. Three central dimensions organize the majority of these cognitions:</p><p>‚Ä¢ Content domain: Thoughts vary in focus. Some minimize health risks, others emphasize reward, highlight identity, reinforce social belonging, add instrumental value to smoking, or protect self-image and avoid recognition of dependence.</p><p>‚Ä¢ Temporal orientation: Cognitions emerge at different phases of the lapse cycle. Prelapse rationalizations lower resistance and make smoking feel permissible. Peri-lapse thoughts legitimate the behavior, mute concern for future consequences, and heighten absorption in the immediate act. Post-lapse narratives reframe the event afterward, softening guilt and preserving self-image.</p><p>‚Ä¢ Emotional valence: Some thoughts soothe ("I deserve kindness"), others neutralize harm ("At least I do not smoke as much as others"), and still others heighten craving ("I cannot cope without this").</p><p>Beyond these, other dimensions add nuance. Cognitions differ in their level of automaticity, from deliberate reasoning to barely conscious mental habits. They vary in abstraction, ranging from concrete urges to identity-level narratives. Some are private, while others are socially shared and reinforced in groups.</p><p>Taken together, these dimensions produce a repertoire of smoking-related thoughts that feel instantly available, as if spontaneous. In fact they are the products of rehearsal. Years of pairing nicotine with relief, routine, and social ritual engrain these cognitive patterns, creating a mental toolkit ready to be deployed whenever cues or stressors appear.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4">The Catalogue of Rationalizations</head><p>These are the everyday "permission-granting" thoughts that thoughtful smokers generate to resolve dissonance and legitimize relapse. Each one biases attention toward immediate relief and away from long-term cost. Although each rationalization looks different, they tend to fall into families: permissive thoughts ("just one won't hurt"), deferring thoughts ("I'll quit tomorrow"), coping thoughts ("this calms me"), identity-based thoughts ("this is who I am"), and fatalistic thoughts ("it's too late anyway"). Grouping them this way makes clear that they are not random excuses but patterned strategies that serve the same purpose of keeping smoking alive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"Just one won't hurt."</head><p>This rationalization is perhaps the most insidious because it frames relapse as trivial. It often arises after a period of abstinence when cravings spike or when a situational cue such as alcohol, stress, or being around other smokers reactivates the urge. The thought presents itself as harmless because it emphasizes the singularity of the act, ignoring addiction's cumulative nature. Neurobiologically, this is reinforced by the dopaminergic system's sensitivity to "tasting" the reward again, which reawakens dormant associative pathways. Psychologically, the smoker downplays risk by temporal framing: focusing on the present moment rather than long-term consequences. The lie here is that "just one" rarely remains one. Nicotine's pharmacology ensures rapid reinstatement of craving and neuroadaptations ensure that pathways reignite. The truth is that one cigarette is often a gateway back to full relapse. To overcome this, interventions must dismantle the illusion of harmlessness by highlighting the all-or-nothing nature of addictive memory. One evidence-based tool is "urge surfing," which involves mindfully observing the craving without acting. Another is pre-commitment, where the smoker writes down in advance why "just one" is never just one. By reframing "just one" as the first step toward a slippery slope, the rationalization loses its deceptive innocence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"I'll quit tomorrow / once I'm ready."</head><p>This rationalization delays change by creating the illusion of control. The smoker acknowledges the need to quit but projects the act into the future, where motivation is always imagined to be stronger. This form of procrastination reflects temporal discounting: the brain values immediate gratification (nicotine relief) more than distant outcomes (health, freedom). Mechanistically, this bias is linked to prefrontal-striatal imbalances, where impulsive systems overpower planning systems under stress or craving. The rationalization feels comforting because it preserves selfimage ("I am the kind of person who will quit") while avoiding the discomfort of quitting now. The lie here is that "tomorrow" rarely comes. Each day repeats the same cycle, reinforcing helplessness and eroding confidence. Overcoming this requires disrupting the future illusion. Motivational interviewing often highlights the gap between intentions and actions, forcing recognition that "not now" is often "not ever." Concrete tools include setting an immediate quit attempt, no matter how imperfect, and treating it as data gathering rather than final success. This reframes quitting as a process, not a postponed heroic act. By collapsing the imagined future into the present, smokers should be made to learn that readiness is not a prerequisite, action itself builds readiness.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"Smoking calms my stress."</head><p>This rationalization is one of the most persistent because it seems subjectively true. Smokers often report feeling calmer after smoking, especially during stressful times. But this is largely an illusion created by withdrawal relief. Nicotine temporarily alleviates the agitation produced by its own absence, creating a cycle where stress feels soothed only by smoking. Nicotine activates dopaminergic and cholinergic systems that blunt withdrawal, giving the impression of relaxation. Psychologically, smoking rituals such as stepping outside, breathing deeply, and pausing also mimic genuine stress-reduction techniques. The lie is that smoking worsens stress over time by increasing baseline anxiety, dysregulating mood, and perpetuating dependence. The calming effect is borrowed peace, paid for by the stress of future withdrawal. Overcoming this rationalization involves education and substitution. Smokers must learn that calmness can be achieved through nicotine-free methods such as diaphragmatic breathing, mindfulness, or physical movement, which provide genuine regulation without cost. Stress logs can also expose the deception: tracking stress levels before and after smoking often reveals only withdrawal relief, not true relaxation. By reframing smoking as a stress amplifier rather than reducer, the rationalization's power can be weakened.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"I deserve a reward."</head><p>This rationalization frames smoking as a positive reinforcement after effort, stress, or success. It arises especially during moments of accomplishment ("I finished a big project") or relief after stress. Psychologically, it reflects the brain's reward system hijacked by nicotine, where dopamine surges make smoking feel disproportionately rewarding compared to healthier alternatives. Social conditioning reinforces it as well, since many smokers build rituals of lighting up after work or after completing tasks. The lie here is that the "reward" is actually withdrawal relief disguised as luxury. Over time, smoking weakens the brain's natural sensitivity to reward, so everyday pleasures feel muted without nicotine. Overcoming this rationalization involves redefining what counts as reward. Behavioral activation can substitute non-smoking treats such as a walk, music, or social connection as genuine reinforcers. Cognitive therapy challenges the idea that smoking is a form of self-care and reframes it as self-sabotage. The deeper task is to restore natural reward pathways through abstinence, exercise, and novelty-seeking. Once smokers begin to experience genuine pleasure without nicotine, the illusion of cigarettes as a "reward" diminishes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"My social life needs it."</head><p>This rationalization flourishes in group settings where smoking is normalized. Smokers often believe cigarettes provide belonging, conversation starters, or bonding rituals. Social identity theory explains this: smoking becomes a marker of group membership, reinforcing identity through shared behavior. The lie here is that smoking does not create relationships, it merely occupies them. The friendship, empathy, and conversation are real, but the cigarette is incidental.</p><p>Overcoming this rationalization involves decoupling socializing from smoking. Smokers can be guided to notice that it is not the cigarette but the pause, the shared time, the gestures that bond them. Social substitution strategies such as inviting friends for coffee, taking walking breaks, or creating rituals without cigarettes preserve belonging while eliminating harm. At a deeper level, smokers must confront the false belief that without smoking they will be excluded. Many find that friendships survive and even deepen when cigarettes are removed, and those that weaken without smoking were never genuine bonds to begin with. By challenging the illusion of necessity, this rationalization loses hold.hold.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"It helps me think / concentrate."</head><p>This rationalization is rooted in nicotine's mild stimulant effects on attention and working memory. Smokers often notice sharper focus or faster recall after smoking, especially when fatigued or stressed. The brain interprets this boost as evidence that nicotine enhances cognition. Mechanistically, nicotine's activation of nicotinic acetylcholine receptors increases cortical arousal, improving certain performance metrics. However, the lie is that smokers' "normal" state is already lowered by withdrawal. The cigarette restores baseline functioning rather than enhancing it beyond natural levels. Non-smokers or ex-smokers perform as well or better on attention tasks without nicotine. Overcoming this rationalization involves exposing the relative illusion.</p><p>Smokers can be educated with data showing performance deficits during withdrawal, not true enhancements after smoking. Alternative cognitive boosters such as hydration, sleep, physical activity, and mindfulness can be practiced as healthier aids. Ultimately, reframing cigarettes as mental crutches that prevent natural cognitive performance undermines their perceived value.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"It keeps me thin."</head><p>This rationalization emerges from cultural pressures equating thinness with value. Smokers sometimes believe nicotine suppresses appetite or boosts metabolism, framing cigarettes as weight-control tools. Indeed, nicotine does increase metabolic rate slightly and blunt hunger, but at enormous cost. The lie here is twofold: first, weight differences between smokers and non-smokers are minimal long term; second, the health consequences of smoking far outweigh any marginal bodyweight benefit. Moreover, quitting does not inevitably cause major weight gain and behavioral interventions can mitigate it. This rationalization exploits bodyimage insecurities, particularly among adolescents and young adults. Overcoming it requires reframing smoking as a body-destroying behavior, not a slimming tool. Health professionals can highlight the cosmetic toll: yellowed teeth, aging skin, poor fitness, far more socially stigmatized than minor weight fluctuations. Teaching nutritional strategies, exercise, and selfcompassion provides safer paths to weight control. Once smokers internalize that cigarettes undermine appearance more than they protect it, this rationalization loses its grip "Quitting will make me miserable."</p><p>This rationalization anticipates the discomfort of withdrawal and projects it as unbearable. Smokers imagine themselves irritable, sleepless, and unhappy, and conclude that life without cigarettes is intolerable. This cognitive distortion arises from catastrophic thinking and withdrawal-related memories. Neurobiologically, nicotine withdrawal activates stress systems (CRF release, amygdala hyperactivity), which the brain remembers vividly. The lie here is that withdrawal, while unpleasant, is temporary and typically peaks within days to weeks. Life after quitting stabilizes into higher well-being and reduced baseline stress. Overcoming this rationalization involves re-educating about the timeline of withdrawal and highlighting success stories. Cognitive-behavioral strategies emphasize reframing discomfort as healing rather than suffering. Pharmacological aids (NRT, varenicline) can blunt symptoms, while mindfulness practices teach acceptance of temporary distress. By reframing withdrawal as proof of recovery, not doom, smokers can endure and escape the trap.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"It's in my genes / I'm doomed anyway."</head><p>This rationalization externalizes responsibility, attributing smoking to heredity. Smokers may cite family history or genetic research to justify helplessness. Indeed, genetic variants (e.g., CHRNA5 polymorphisms) increase vulnerability, but they do not dictate destiny. This belief arises from fatalism, sometimes reinforced by societal messaging around "addictive personalities." The lie is that environment, habits, and choices play massive roles. Many with genetic vulnerabilities quit successfully; genes tilt the playing field but do not determine the outcome. Overcoming this rationalization requires reframing genetics as risk rather than fate. Education about epigenetics, which explains how behavior and environment can modify gene expression, restores agency. Therapeutically, emphasizing self-efficacy is crucial. Behavioral scaffolding such as structured routines, support groups, and replacement strategies can counteract vulnerability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"I already have damage, it's too late."</head><p>This rationalization emerges in older smokers or those with health scares. They conclude that since harm is done, quitting is pointless. This reflects hopelessness and learned helplessness, where the brain avoids effort by framing action as meaningless. The lie is decisively false: quitting at any age improves health outcomes. Research shows lung function, cardiovascular risk, and cancer incidence all improve significantly after cessation, even late in life. Mechanistically, bodily repair processes begin within hours of quitting. Overcoming this rationalization requires direct confrontation with facts: quitting always extends life expectancy and improves quality of life. Clinicians can use visual tools showing before-and-after improvements to counter fatalism.</p><p>Reframing quitting as harm reduction, as buying more time and better living, helps rekindle motivation. The shift from "too late" to "better late than never" breaks the despair cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"Cigarettes help me cope with boredom."</head><p>This rationalization portrays smoking as a filler of empty moments. It arises in routines where time feels unstructured, waiting, commuting, breaks. Dopamine systems, dulled by nicotine dependence, crave stimulation, and cigarettes provide transient novelty. The lie is that smoking does not solve boredom but perpetuates it by narrowing life around cigarette breaks. Non-smokers fill time with richer activities, while smokers shrink their behavioral repertoire.</p><p>Overcoming this rationalization involves expanding engagement. Smokers can experiment with alternative micro-activities: short walks, stretching, journaling, or learning skills on the go. Therapy can reframe boredom as a signal for unmet needs (connection, purpose, novelty). By diversifying activities, the false link between cigarettes and boredom dissolves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"I only smoke socially / rarely."</head><p>This rationalization presents smoking as occasional, harmless, and thus exempt from the label of addiction. It usually arises in social contexts, parties, bars, or gatherings, where cigarettes are linked to bonding and identity. The lie is in downplaying frequency: even occasional smoking sustains nicotine receptor sensitization, cue conditioning, and identity reinforcement. The brain does not interpret "social" differently; reinforcement strengthens whenever nicotine is delivered. Social smoking is particularly dangerous because it embeds the habit in rewarding social memory networks, making cues like laughter, alcohol, or friendship powerful triggers for relapse. Given the opportunity, a social smoker can easily spiral into dependence. Overcoming this rationalization involves confronting the illusion of rarity. Tracking actual frequency often reveals that "rare" smoking occurs more often than acknowledged. Even when infrequent, the health risks remain significant, and the reinforcement of the behavior perpetuates vulnerability.</p><p>Therapeutically, it helps to reframe social identity so that resisting social smoking becomes a point of pride. Practicing alternative rituals such as holding a drink, stepping outside for fresh air, or chewing gum allows participation without relapse. The key is recognizing that "social smoking" is not harmless moderation but a maintenance loop disguised as casualness.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"It's part of my identity."</head><p>This rationalization treats smoking as part of the self, for example, "I'm the creative who smokes while writing" or "I'm a smoker, that's who I am." Because identity guides decisions, this belief is resistant to change. Repeated behaviors linked to self-concept engage brain circuits that embed smoking into autobiographical memory. The error is the assumption that identity is fixed. In reality, identity changes across life stages, and most smokers have experienced times when they identified differently. Overcoming this requires active identity work. Narrative therapy, journaling, or reflective practices can help reframe self-concept around health and resilience. Social modeling, such as spending time with ex-smokers who integrate quitting into their identity, provides new role models. By shifting from "smoker" to "resilient changer," quitting becomes not a loss of self but a natural evolution of it. Additionally, the very act of initiating a quit attempt naturally weakens the smoking identity, since behavior begins to shift away from the role it once reinforced.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"Nicotine stabilizes my mood."</head><p>This rationalization portrays cigarettes as pharmacological medicine for mood swings, particularly in those prone to anxiety or depression. It feels true because nicotine temporarily alters neurotransmission: increasing dopamine, serotonin and acetylcholine, dampening irritability. But the lie is in attribution: nicotine does not stabilize mood, it destabilizes it. Withdrawal creates the very mood dips that smoking appears to fix. Longitudinally, smokers report higher rates of depression, irritability, and stress compared to nonsmokers. Overcoming this distortion requires reframing nicotine not as medicine but as an unstable chemical rollercoaster. Psychoeducation on the withdrawal-relief-withdrawal cycle clarifies that cigarettes manufacture the problem they pretend to solve. For those with genuine mood disorders, integrated treatment is crucial, addressing depression or anxiety with evidence-based therapies and, if needed, pharmacological supports that do not perpetuate addiction. Mindfulness, exercise, and structured routines offer more stable mood regulation than nicotine ever can. Recognizing the false promise of "stabilization" is a turning point: cigarettes are not medicine, they are mood thieves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The catalogue of Cognitive Distortions</head><p>These distortions are not mere errors in logic but predictable modes of thought that bias neural competition toward smoking. If rationalizations are the content of smoking-related thought, distortions are the style of thinking that makes those rationalizations persuasive. They work together: distortions shape perception and reasoning, while rationalizations supply the specific stories that justify smoking.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>All-or-nothing thinking</head><p>This distortion frames quitting as either total success or complete failure. A single lapse, such as "I had one cigarette, so I may as well smoke the whole pack," is interpreted as total defeat. It often stems from perfectionism and difficulty tolerating ambiguity. Under stress, prefrontal control systems lose flexibility, making the brain more prone to rigid, black-andwhite categories. The mistake lies in assuming that one slip erases all progress. In reality, lapses are information, not destiny. To overcome this distortion, smokers can practice cognitive reframing, treating slips as partial successes ("I went a week without smoking, that proves I can") rather than collapses. Planned recovery strategies, such as pre-deciding what to do after a lapse, prevent a single cigarette from cascading into relapse.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Catastrophizing</head><p>This distortion exaggerates the difficulty of withdrawal or quitting. A smoker may think, "If I try, I'll be miserable and fail; I can't handle it." It is often rooted in memories of past attempts and is intensified by heightened activity in the amygdala, especially when prefrontal regulation is weak. The problem is the belief that discomfort will be unbearable and endless.</p><p>In reality, withdrawal symptoms peak within days and steadily decline, while coping capacity is usually greater than feared. Countering this distortion involves gradual exposure to manageable challenges, education about the withdrawal timeline, and mindfulness practices that anchor attention to the present rather than imagined disasters. By reframing quitting as survivable and even an opportunity for growth, catastrophic beliefs lose their force.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Magical thinking</head><p>This distortion invents shortcuts or exceptions, for example, "This time will be different because I have more willpower," or "If I switch brands, quitting will be easier." It reflects wishful thinking that avoids effort and planning. At the neural level, dopamine's role in signaling unexpected reward can create misplaced optimism when craving is high. What this overlooks is that lasting success almost never comes without deliberate preparation and change strategies. The remedy is grounding in evidence: reviewing past attempts, identifying what led to relapse, and designing new approaches. Motivational interviewing can highlight the gap between hopeful beliefs and actual outcomes, while practical steps such as setting a quit date and arranging supports replace magical optimism with structured confidence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Emotional reasoning</head><p>This distortion equates feelings with facts. A smoker may think, "I feel weak, so I must be unable to quit." It occurs when temporary emotional states are mistaken for predictors of longterm ability. Craving heightens limbic activity, which biases reasoning toward emotion-based logic. The flaw here is treating feelings as if they are evidence. In fact, emotions are transient and often misleading. Overcoming emotional reasoning involves explicitly separating emotions from evidence, for example, labeling thoughts as "I feel incapable" rather than "I am incapable." Journaling, mindfulness, and small mastery experiences show that action is possible even when confidence is low.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overgeneralization</head><p>This distortion takes one negative event and turns it into a sweeping conclusion. A smoker may think, "I failed last time, so I'll always fail." It arises from schemas of helplessness and is reinforced by memory biases that make failures easier to recall than neutral or positive experiences. The false assumption here is that the past dictates the future. In truth, every quit attempt builds skills, and repeated tries increase the odds of eventual success. Overcoming this distortion involves reframing attempts as learning experiences rather than final verdicts.</p><p>Behavioral experiments, such as testing new methods or supports, demonstrate that different approaches yield different outcomes. By replacing global conclusions with context-specific interpretations, hope is restored.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mind-reading and social projection</head><p>This distortion assumes that others are judging negatively. A smoker may think, "If I refuse a cigarette, they'll think I'm boring" or "Everyone expects me to fail." It often arises in peer settings where smoking is common. The misunderstanding is that other people's thoughts are known and fixed. In reality, most people are neutral or supportive, and social environments often adapt more easily than expected. At the neural level, social salience networks exaggerate the importance of others' cues when craving is strong. Overcoming this distortion involves behavioral experiments, such as refusing a cigarette and observing the actual response. Cognitive reframing emphasizes autonomy and reminds the smoker that peers rarely monitor as closely as imagined. Building alternative social scripts further reinforces confidence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Confirmation bias</head><p>This distortion highlights evidence that supports smoking and ignores evidence against it. A smoker may say, "My grandfather smoked and lived to 90," while dismissing the much larger body of evidence showing harm. It serves as a defense against cognitive dissonance by preserving justifications for continued use. At the neural level, dopaminergic salience systems favor information that aligns with desired outcomes. The error of reasoning here is treating isolated anecdotes as stronger than systematic evidence. Overcoming confirmation bias requires deliberately seeking counter-evidence. Structured journaling or therapeutic exercises can prompt smokers to list both pro-and anti-smoking evidence. Psychoeducation highlights the strength of epidemiological data compared to anecdotes. By broadening attention, the distortion weakens.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discounting the positive</head><p>This distortion minimizes progress and magnifies failure. A smoker may say, "I quit for two months, but that doesn't count because I relapsed." It arises from perfectionistic standards and negative self-schemas. At the neural level, negative prediction errors bias memory retrieval, making successes less salient. The trap here is assuming that progress has no value unless perfect. In reality, each period of abstinence strengthens skills and produces health benefits. Overcoming this distortion involves explicitly recognizing small victories. Therapists can highlight progress as cumulative, while gratitude journaling and reward systems retrain attention toward positive outcomes. By reclaiming successes as meaningful, smokers build momentum toward lasting change.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Temporal discounting (present bias)</head><p>This distortion prioritizes immediate relief over future benefits. A smoker may think, "One cigarette now is worth more than health later." It reflects a universal bias that addiction makes stronger. Neuroeconomically, reward systems in the ventral striatum overvalue short-term outcomes, while prefrontal regions undervalue long-term ones. The pitfall here is treating distant consequences as if they do not matter. In reality, small present choices accumulate into major health outcomes. Overcoming this distortion involves techniques that make the future feel more concrete, such as visualizing future health, writing letters to one's future self, or calculating immediate gains like "cigarettes not smoked." Commitment devices, such as financial stakes or social contracts, help align behavior with long-term goals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Automaticity</head><p>This distortion occurs when smoking feels mindless or inevitable, as if performed on autopilot. Habits in the basal ganglia encode cue-response loops that bypass conscious choice. The mistaken belief here is that automatic behavior cannot be interrupted. In reality, awareness can break the chain. Overcoming this distortion involves mindfulness training, which teaches smokers to notice urges before acting. Habit substitution, such as chewing gum when reaching for a cigarette, and environmental restructuring, such as removing ashtrays, both disrupt automatic responses. By shining conscious light on autopilot patterns, the illusion of inevitability dissolves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Self-handicapping</head><p>This distortion sabotages success in advance. A smoker may say, "I'll keep a pack nearby, just in case; if I fail, I wasn't really trying." It arises from fear of failure and preserves self-image by ensuring setbacks can be blamed on circumstance rather than effort. The faulty assumption is that keeping escape hatches protects dignity. In reality, it undermines commitment and increases relapse risk. Overcoming self-handicapping requires fostering full commitment. Discarding cigarettes, setting public quit dates, and embracing vulnerability reduce the need for protective excuses. Reframing failure as learning further decreases reliance on safety nets.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Attributional skew</head><p>This distortion misassigns responsibility for relapse. A smoker may say, "It wasn't me, it was stress at work," or "My friends made me smoke." It externalizes agency and reduces accountability. Psychologically, it serves as a defense against guilt or shame. The mistaken view is that external forces dictate behavior. While context influences risk, agency remains central. Overcoming attributional skew involves balanced accountability: acknowledging external triggers while reclaiming personal choice. Cognitive restructuring can highlight controllable factors, and building coping strategies restores a sense of authorship. By reframing relapse as influenced but not determined, smokers regain control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role preservation (identity-protective thinking)</head><p>This distortion maintains smoking in order to protect self-image or social role. A smoker may think, "I'm a rebel, smokers are nonconformists," or "I'm one of the guys at work." It overlaps with identity-based rationalizations but operates specifically to guard roles and belonging. The false belief is that quitting requires loss of identity. In reality, roles are multifaceted and change over time. Overcoming this distortion involves identity expansion. Narrative therapy can help reconstruct identity stories so that quitting is framed as empowerment rather than loss.</p><p>Exploring roles that align with valued traits such as resilience and independence allows smokers to preserve belonging while discarding cigarettes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.5">Narratives, Identity, and Social Ecology</head><p>Smoking-related thoughts cannot be reduced to isolated errors of reasoning. They are woven into broader narratives of selfhood: the hardworking employee who "deserves" a break, the artist who draws inspiration from smoke, the friend whose social life is tied to the ritual outside the office. In these identity-linked scripts, smoking is not simply a behavior but part of character. Rationalizations gain their power not from logic alone but from their coherence with these personal stories. These cultural and identity scripts connect directly to biology: cue-reactive circuits are trained by social rituals, memory systems embed shared narratives, and dopamine pathways amplify the rewards of belonging. Culture does not float above biology; it writes itself into it.</p><p>To quit, therefore, is not only to resist nicotine but to revise a self-story. And stories resist revision. They are emotionally charged, socially validated, and repeated until they feel synonymous with identity. Within the SYNAPSE framework, identity acts as a high-level biasing agent: when smoking is embedded in the self, abstinence signals must compete not only with craving but with the threat of self-fragmentation.</p><p>These narratives emerge from an interplay of physiology, environment, and cognition. Fluctuations in craving, stress, or fatigue bias which thoughts dominate awareness. Familiar contexts, coffee breaks, stressful meetings, or social gatherings, prime specific clusters of rationalizations. Over time, repeated pairing of nicotine's effects with relief, routine, and belonging builds a cognitive network of beliefs and memories that stabilize the smoker's self-narrative. Selective recall and motivated reasoning further reinforce this network, allowing the smoker to interpret experiences in ways that minimize dissonance and sustain smoking.</p><p>Despite individual variation, there is remarkable regularity across smokers. This universality reflects both evolutionary design and cultural transmission. Conserved cognitive and affective systems generate similar motivational conflicts and emotional reactions, while social norms, media portrayals, and family traditions provide shared scripts. Cultural reinforcement ensures that rationalizations such as "I need this to calm down" or "everyone smokes here" feel not only personally true but socially validated.</p><p>The social dimension multiplies the challenge. Rationalizations voiced collectively, "we deserve this break", are amplified by social reward circuits, making abstinence feel like abandonment of the group. In such contexts, smoking-related representations outcompete abstinence signals not simply because of craving but because they are socially stabilized. To quit is then experienced as more than a biological or psychological struggle; it carries the weight of social betrayal and the unraveling of a lived identity.</p><p>Individual narratives and group rituals are embedded in larger cultural and economic frameworks that make particular rationalizations available, persuasive, and durable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cultural, Economic, and Policy Contexts</head><p>Beyond individual cognition and interpersonal rituals, broader cultural and economic forces scaffold and amplify smoking rationalizations. Tobacco industry marketing, historical media portrayals, and workplace norms have constructed and normalized a repertoire of meanings around smoking. These meanings are not neutral background noise. They shape which narratives become available and credible. For example, advertising and cinematic portrayals have long associated smoking with glamour, toughness, or creativity, creating culturally shared scripts that individuals can draw on when they need a justification.</p><p>Economic structures and policy environments also matter. Work schedules, break policies, and designated smoking areas create routine opportunities for cigarette consumption and ritualization. In settings where breaks are scarce or where smoking areas become the primary communal space, the social costs of quitting rise. Conversely, strong public health policies, restrictions on tobacco advertising, smoke-free workplace laws, and taxation change the affordances of the environment and alter the cost-benefit calculus of rationalizations.</p><p>These macro-level forces interact with individual cognitive machinery. Cultural scripts make certain rationalizations feel plausible, economic arrangements create habitual contexts, and policy shapes the ease or difficulty of enacting abstinence. For clinical practice this means that individual-level interventions will be limited unless they are paired with environmental changes and advocacy for policies that reduce the social scaffolding of smoking.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.6">Beyond Rationalization: When Thought Falls Silent</head><p>Not every cigarette is accompanied by elaborate rationalization. Many are smoked with little or no conscious thought. Three modes illustrate how cognition can fall silent or turn against itself:</p><p>1. Habitual smoking: Automated acts triggered by cues such as coffee, driving, or finishing a meal, encoded in dorsal striatal circuits. Thought is bypassed and action flows directly from context.</p><p>2. Compulsive smoking: Urges so strong that awareness of risk remains intact but powerless. Here mesolimbic hyperactivation overwhelms prefrontal inhibition, producing action despite conscious resistance.</p><p>3. Negative-affect smoking: Episodes in which smokers light up while despising the act.</p><p>Relief is sought at the cost of self-condemnation, revealing overlap between addiction and mood disorders.</p><p>In these modes, cognition either collapses into silence or actively turns against the self. Addiction, therefore, cannot be reduced to rationalization alone. Thought is one pathway of entrapment, but habit, compulsion, and despair each provide distinct routes by which smoking maintains its hold.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.7">Meta-Cognition, Silence, and the Social Mind</head><p>Two further dimensions complicate the architecture of smoking-related thought.</p><p>First, some smokers experience what can be called a form of double awareness. They generate excuses for smoking while simultaneously recognizing that those excuses are weak. This resembles the ancient idea of akrasia, which means knowing the better course of action yet failing to follow it. The paradox arises because, in moments of craving, the salience of immediate relief outweighs the salience of long-term goals. The brain assigns more urgency and value to the thought that supports smoking, even when another part of awareness knows it is flimsy. In this way, rationalizations are not believed because they are convincing in a logical sense, but because they feel more pressing in the moment. Rather than dismissing this state as failure, it can be reframed as opportunity. The moment of recognition can be harnessed as a cue to pause, to label the thought as signal rather than truth, and to insert a deliberate coping strategy.Cessation programs should actively work to increase the salience of thoughts that challenge rationalizations, so that these corrective thoughts do not remain in the background but instead guide behavior toward quitting.</p><p>Second, there are episodes of cognitive silence, where smoking unfolds with no conscious thought at all. A cigarette is lit automatically in response to cues, coffee, driving, finishing a meal, before awareness even registers. These episodes reflect the dominance of habit circuitry in the dorsal striatum, where procedural memory bypasses deliberation. Cognitive interventions alone are ineffective here, since there is no thought to dispute. Instead, strategies must target context and routine: restructuring environments, disrupting cue-response loops, and cultivating mindfulness to reintroduce awareness at critical moments.</p><p>A third dimension is the social mind. Rationalizations are not purely individual but often co-constructed in groups. Collective narratives, "everyone deserves this break," "this is our ritual", reinforce smoking through shared meaning and social reward circuitry. In such contexts, quitting carries the felt risk of exclusion or betrayal, making abstinence not only a personal challenge but a relational one. For many smokers, change requires not just new cognitions but new communities that normalize and reward smoke-free identities.</p><p>Together, these dimensions highlight the complexity of smoking-related thought. Cognition may expose its own weakness (double awareness), fall entirely silent (automaticity), or be amplified by the presence of others (social narratives). Each mode demands a tailored response: meta-cognition harnessed as leverage, silence interrupted by habit restructuring, and social narratives countered by building new affiliations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.8">Cognition as Ally: Turning the Machinery</head><p>The same cognitive machinery that sustains dependence can also be reclaimed to support abstinence. Rationalizations can be inverted: "I deserve this break" becomes "I deserve the freedom of not smoking." Identity can be re-authored: the story shifts from "I am a smoker" to "I am a resilient changer" or "I am someone who protects health and autonomy." Schemas can be reshaped: stress is no longer read as a demand for nicotine but as a cue for healthier regulation, breathing, movement, or social connection.</p><p>Clinically, a range of methods can deliberately turn cognition from accomplice to ally. Narrative therapy helps patients rewrite identity stories. Cognitive-behavioral techniques target distortions and reframe rationalizations. Mindfulness trains recognition of thoughts as passing events rather than truths, weakening their automatic pull. Guided imagery and motivational interviewing strengthen positive schemas, aligning thought with long-term values.</p><p>Our CLEAR-PATH Program, described in detail later, is designed to help patients step out of the allure of cognitive traps. It aims to increase the salience of thoughts that protect against relapse, making them more noticeable and influential than the rationalizations that favor smoking. In addition, it provides patients with an interactive tool, a conversational agent that can engage them in real time. By talking through their urges and the justifications that arise, patients are guided to see the weakness and inconsistency of these rationalizations. In this way, the tool does not simply argue against smoking but helps patients recognize for themselves why the excuses lose their force, giving them a stronger sense of agency in resisting relapse.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.9">Closing Reflection: Cleverness as Cage and Key</head><p>The thoughtful smoker is ensnared not only by nicotine but by cognition itself. Rationalizations, identity, and narrative work in concert with habit, compulsion, and despair to form a multidimensional cage. Yet the same thoughtfulness that sustains smoking also contains the seeds of freedom. Reflection can amplify rationalization, but it can also expose the pattern, record the thought, and reframe the story. Within the SYNAPSE model, this is the shift from thought as biasing trap to thought as competitive ally.</p><p>The paradox, then, is not that smokers think too little, but that they think too well. Human cognition operates precisely as evolution designed it: coherence-making, dissonance-reducing, identity-preserving. Addiction commandeers these functions, bending them toward its own perpetuation. But the very mechanisms that protect the habit can also dismantle it. To see thought not as truth but as signal is to begin reclaiming the machinery of mind.</p><p>The lesson of this chapter is that smoking cannot be fully understood through pharmacology or reinforcement alone. It requires an account of cognition: how thoughts are generated, how they shape behavior, and how they can be turned. These thoughts are not random noise; they are structured, patterned, and neurocognitively grounded. That structure is what makes them powerful, but also what makes them open to intervention.</p><p>Because rationalizations follow predictable forms, they can be anticipated, named, and interrupted. Once visible, they lose their invisibility; once reframed, they can transform from accomplices of relapse into allies of abstinence. Cognitive traps can become cognitive tools.</p><p>In the end, the same mental abilities that keep a smoker trapped can also support quitting.</p><p>Reasoning, foresight, and self-narrative may generate excuses and rationalizations, but they can also be redirected to build persistence and new identities. Each level of the hierarchy, from receptor changes to cultural scripts, can reinforce smoking, yet each also offers a possible intervention point. By learning to see thoughts not as truths but as signals within this system, smokers and clinicians can shift the balance.</p><p>She sat in the clinic, staring at the options laid out before her: a patch, a pill, a flyer for a group. Each one carried a promise, each one a memory of disappointment. The patch had dulled the edges but never quieted the craving. The pill had worked, until it didn't. The group had lifted her for a time, until relapse filled her with shame too heavy to carry back.</p><p>She knew the rhythm well: the fragile hope of a fresh start, the weeks of endurance, the slip, the silence, the vow to try again.</p><p>It was not just nicotine she battled, but the cycle itself.</p><p>Across the world, millions live inside the same loop. Treatments exist, and they help, but rarely enough, rarely for all, and rarely for long. Science has advanced. The struggle endures.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.1">Introduction</head><p>Smoking cessation is among the most studied areas of behavioral medicine. Over decades, pharmacological and behavioral strategies have been tested, refined, and scaled. Meta-analyses leave no doubt: effective treatments exist, and when properly implemented they substantially improve quit rates compared to unassisted attempts <ref type="bibr" target="#b193">(Wu et al., 2006)</ref>.</p><p>And yet, real-world outcomes tell a sobering story. Relapse rates remain stubbornly high, progress is uneven, and the gap between trial efficacy and everyday effectiveness persists <ref type="bibr" target="#b84">(Hughes et al., 2011;</ref><ref type="bibr" target="#b56">Fu et al., 2005)</ref>. This chapter reviews current cessation practices, their mechanisms, and their impact, before examining where they fall short and why new frameworks are required.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2">Pharmacological Interventions: Biology Under Constraint</head><p>Nicotine Replacement Therapy (NRT) was the first widely available medical strategy to address tobacco dependence. By delivering nicotine without combustion, it reduces withdrawal and craving while avoiding tar and toxins. Patches, gum, lozenges, sprays, and inhalers offer different kinetics: the patch provides steady levels over 16-24 hours, while gum or sprays deliver faster relief during acute cravings. Dozens of randomized controlled trials show NRT increases quit rates by about 50-150% compared with placebo <ref type="bibr" target="#b45">(Etter and Stapleton, 2006;</ref><ref type="bibr" target="#b85">Hughes et al., 2003)</ref>, and combination therapy (patch plus short-acting form) is superior to monotherapy <ref type="bibr" target="#b172">(Sweeney et al., 2001</ref>).</p><p>Yet NRT often fails those most entrenched. Heavy smokers accustomed to rapid nicotine spikes find the pharmacokinetics unsatisfying. Adolescents, whose smoking is driven more by cues and peers than withdrawal, benefit little <ref type="bibr" target="#b155">(Scherphof et al., 2014)</ref>. Adherence is poor: many stop because "it doesn't feel like smoking." Cost is another barrier, NRT is subsidized in wealthy countries but remains prohibitive or unavailable in much of the Global South <ref type="bibr" target="#b115">(Mersha et al., 2020)</ref>.</p><p>Varenicline, a partial agonist at the ùõº4ùõΩ2 nicotinic receptor, is arguably the most effective pharmacotherapy <ref type="bibr" target="#b178">(Tonstad et al., 2006)</ref>. It both stimulates moderate dopamine release (easing withdrawal) and blocks nicotine's rewarding effects. In multiple meta-analyses, varenicline outperforms both NRT and bupropion. For highly dependent daily smokers who fail on NRT, it often offers the best chance. Still, its reach is limited by cost, prescription-only access, and lingering concerns about neuropsychiatric side effects (?).</p><p>Bupropion, a norepinephrine-dopamine reuptake inhibitor, was the first non-nicotine drug approved for cessation <ref type="bibr" target="#b142">(Richmond and Zwar, 2003b)</ref>. It reduces cravings and is particularly helpful in smokers with comorbid depression. But its efficacy is modest, and contraindications (e.g., seizure risk) limit its generalizability.</p><p>Pharmacotherapy is most effective for smokers with strong biological dependence, yet relapse driven by stress, cues, and social triggers often lies beyond its reach. Medications stabilize neurochemistry but cannot rewire the habits and contexts that sustain smoking. Additionally, as discussed later in our SyNAPSE model of addiction, pharmacotherapy is not universally beneficial. When used at improper dosages, NRT may not only be ineffective but can also cause harm. In practice, health care providers often rely on simplified heuristics when prescribing or advising on NRT, and a large proportion of its use occurs over the counter without professional supervision. This increases the risk of misuse and reduces the likelihood that the therapy will deliver its intended benefit, highlighting the gap between controlled trial conditions and real-world practice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.3">Behavioral and Psychosocial Interventions: Beyond Chemistry</head><p>Psychological interventions complement pharmacology by addressing meanings, routines, and emotions tied to smoking.</p><p>Cognitive Behavioral Therapy (CBT) is the most established, teaching smokers to identify triggers, challenge automatic beliefs ("I can't cope without a cigarette"), and rehearse coping strategies. Meta-analyses show CBT roughly doubles quit rates compared to minimal interventions <ref type="bibr" target="#b128">(Perkins et al., 2013)</ref>.</p><p>Motivational Interviewing (MI) helps smokers ambivalent about quitting explore their own motivations. Many are pressured by partners or doctors but feel conflicted. MI avoids confrontation, eliciting intrinsic reasons to change, and is particularly effective for those not yet ready to quit <ref type="bibr" target="#b76">(Heckman et al., 2010)</ref>.</p><p>Mindfulness-based interventions train smokers to observe cravings without reacting, reducing automaticity. These approaches show promise, especially for stress-driven smoking, though long-term evidence is mixed <ref type="bibr" target="#b17">(Brewer et al., 2011)</ref>.</p><p>Group programs leverage social accountability and peer support. They outperform self-help but may be avoided due to stigma or privacy concerns. Contingency management, providing rewards for abstinence, shows strong effects in trials but is difficult to sustain in practice.</p><p>In addition to these cognitive and motivational approaches, strictly behavioral methods such as cue exposure and stimulus control directly target the learning mechanisms that sustain smoking <ref type="bibr" target="#b13">(Betts et al., 2021)</ref>. Cue exposure therapy repeatedly presents smoking-related stimuli (such as the sight or smell of cigarettes) without allowing use, gradually weakening conditioned craving responses. Stimulus control techniques reduce exposure to triggers by restructuring environments, for example, removing ashtrays or avoiding smoking-associated contexts. Though effective in controlled trials, their impact is often limited in real-world settings, where complete avoidance of cues is difficult. These methods are therefore most effective when integrated with broader cognitive or pharmacological strategies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.4">Technological Innovations: Expanding Reach, Deepening Gaps</head><p>Digital interventions have broadened the cessation toolkit. Text messaging programs and smartphone apps deliver reminders and coping strategies. Ecological Momentary Assessment (EMA) and Just-in-Time Adaptive Interventions (JITAI) personalize support, responding to cravings as they arise <ref type="bibr" target="#b194">(Yang et al., 2023)</ref>.</p><p>Virtual Reality (VR) allows smokers to rehearse coping skills in simulated high-risk contexts (bars, parties) <ref type="bibr" target="#b127">(Pericot-Valverde et al., 2019)</ref>. Results are promising but scalability remains limited.</p><p>The most disruptive innovation is the electronic cigarette. Once marketed as lifestyle devices, they now figure prominently in harm-reduction debates. High-certainty evidence shows nicotine-containing e-cigarettes outperform NRT in some populations <ref type="bibr" target="#b21">(Caponnetto et al., 2015)</ref>.</p><p>For smokers failing traditional therapies, they may be the most realistic option. Yet they also perpetuate nicotine dependence, sustain dual use, and attract youth. Policymakers remain divided on whether to endorse or restrict them.</p><p>Digital tools extend reach but are not neutral. They assume literacy, connectivity, and device access. For some, they democratize cessation; for others, they deepen exclusion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.5">Clinical Practice: The Frontline Reality</head><p>In most systems, cessation begins in primary care. Guidelines recommend the "5A" model, Ask, Advise, Assess, Assist, Arrange, but in practice, time pressure reduces this to "Ask and Advise." <ref type="bibr" target="#b36">(Dixon et al., 2009)</ref>. Most smokers receive brief advice and perhaps a prescription, but rarely structured follow-up.</p><p>Specialist cessation services exist in some countries, offering integrated pharmacotherapy and counseling. They achieve higher quit rates but are concentrated in urban, high-income settings. Rural populations and LMICs remain underserved. Quitlines and digital platforms extend reach, but coverage is inconsistent and often underfunded.</p><p>Clinicians face barriers: limited training in behavioral methods, lack of reimbursement, and stigma toward smokers. Integration with mental health care is rare, though psychiatric comorbidity strongly predicts persistent smoking. In effect, the system delivers partial care, unevenly distributed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.6">Equity, Accessibility, and Cultural Fit</head><p>Globally, cessation support is marked by stark inequities. In wealthy nations, therapies are often subsidized and counseling available, yet low-income and marginalized groups still face barriers of cost, stigma, and literacy <ref type="bibr" target="#b5">(Bailey et al., 2018)</ref>. In LMICs, structured cessation services are scarce.</p><p>Cultural fit matters. In collectivist societies, family-or community-based interventions may be more effective than individualist CBT. In some cultures, female smokers face stigma that discourages help-seeking. Digital interventions, while scalable, risk excluding populations without internet access.</p><p>Equity is not a side issue, it is the central determinant of who benefits from cessation science. Without cultural adaptation and structural investment, effective tools remain tools for the privileged.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.7">Persistent Gaps and Structural Limitations</head><p>Despite decades of research and policy, major gaps persist:</p><p>‚Ä¢ Relapse remains the rule. Even with optimal treatment, most smokers relapse within a year. Cue-reactivity and stress-driven relapse are poorly addressed.</p><p>‚Ä¢ Fragmentation dominates. Pharmacotherapies target receptors, behavioral therapies target habits, policies target environments, rarely are they integrated.</p><p>‚Ä¢ Personalization is lacking. Genetic differences (e.g., CYP2A6, CHRNA5), psychiatric comorbidities, and social environments strongly shape outcomes, yet services apply onesize-fits-all protocols.</p><p>‚Ä¢ Timing mismatches. Relapse risk fluctuates dynamically, but interventions are delivered episodically. Few provide real-time adaptive support.</p><p>‚Ä¢ Systemic underfunding. Globally, fewer than one in ten smokers engage with structured cessation services. Investment in cessation lags far behind treatment of tobacco-related disease.</p><p>The result is a paradox: while evidence-based tools exist, their reach is uneven and their effects concentrated. Prevalence continues to fall in many high-income countries, but quit rates are flattening, and in large parts of the world, progress is stalling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.8">Evidence of a Plateau: Global and Regional Trends</head><p>The global story of tobacco control is one of both remarkable achievement and frustrating persistence. According to the World Health Organization's 2024 report, global tobacco use has declined in prevalence since 2000, yet in 2022 there were still about 1.25 billion users worldwide (World Health <ref type="bibr">Organization, 2024)</ref>. This means that while fewer people smoke proportionally, the absolute number of smokers remains very high.</p><p>This aggregate picture conceals important regional differences. In high-income countries, daily smoking rates have fallen steadily, but in several cases the decline has slowed or plateaued <ref type="bibr" target="#b29">(Dai et al., 2022)</ref>. In contrast, parts of Africa and the Eastern Mediterranean are seeing rising numbers of smokers <ref type="bibr">(World Health Organization, 2024;</ref><ref type="bibr" target="#b122">Odo et al., 2025)</ref>.</p><p>The consequence is sobering: despite progress, the world still sustains close to a billion smokers, and efforts remain off-track for achieving global reduction targets.</p><p>This plateau suggests a saturation point for broad, negative-framing interventions. Public health campaigns have largely succeeded in deterring new generations and motivating lighter users to quit. What remains is a resistant minority, less responsive to price increases, warnings, or restrictions. Their persistence is not due to ignorance, but to the layered effects of dependence, mental health, social context, and in some cases, genetic predisposition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.9">A Statistical Implication: From Normality to Skew</head><p>This slowdown in Tobacco Cessation and plateau is not a failure of science, but a failure of fit.</p><p>A majority of smokers who remain today are not those who could be nudged by a tax increase or a warning label. They are the survivors of decades of tobacco control, more biologically dependent, more socially disadvantaged, more entangled in comorbidity. This "hardening" of the smoking population explains why population-wide measures yield diminishing returns, and why the right-hand tail of persistent smokers has become the central challenge.</p><p>What is needed now is a shift in perspective: from universal solutions to adaptive, stratified ones; from interventions designed for the "average smoker" to frameworks that respond dynamically to individual vulnerabilities, contexts, and life-course trajectories.</p><p>The plateau in cessation rates also reflects a deeper statistical and epidemiological truth. Smoking behavior is not evenly distributed across populations, nor is it randomly resistant to interventions. Instead, decades of prevention and cessation efforts have reshaped the landscape of tobacco use. The smokers who remain today are not the same as those who smoked thirty or even twenty years ago.</p><p>The broad successes of taxation, bans, and cultural shifts have left behind a concentrated minority of smokers who are disproportionately characterized by biological dependence, psychological vulnerability, and adverse social conditions. This is the phenomenon of selection-driven survivorship: as prevalence falls, those who persist are increasingly those least responsive to conventional measures. Understanding this skewed distribution is essential for charting the road ahead.</p><p>If cigarettes were inexpensive, socially approved, and perceived as harmless, patterns of use might resemble a bell curve: most people smoking at moderate levels, with fewer at the extremes. But this world no longer exists. Over the past half-century, public health interventions have shifted the distribution in two profound ways:</p><p>1. The left-hand side has thickened, as most people today never initiate smoking or quit within the first few years.</p><p>2. The right-hand side has stretched, with remaining smokers persisting for decades, showing heavier dependence and repeated failed quit attempts.</p><p>The result is a sharply skewed distribution, where the majority cluster around zero use while a long tail of highly dependent smokers stretches outward. Importantly, this tail does not represent random survivors but a subgroup selected by policy and environment: smokers with Figure <ref type="figure">6</ref>.1: Typology of smoking behavior (L0-L7). The majority of the population (L0-L3) follows a bell-curve distribution, while the right-hand tail (L4-L7) represents progressively higher dependence, from light daily smokers to chain smokers.</p><p>higher physiological dependence, entrenched habits, and compounded social and psychological barriers.</p><p>This fact has profound clinical and policy implications. It means that what worked to reduce prevalence at the population level, such as graphic warnings, high excise taxes, and smoke-free legislation, now yields diminishing returns when applied to this resistant minority.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Clinical and Public Health Implications of Survivorship</head><p>Understanding selection-driven survivorship transforms how we should design tobacco control for the next decades. The logic can be summarized in layers:</p><p>‚Ä¢ Population layer (shifting the curve): Continue proven tools such as taxation, advertising bans, smoke-free laws, graphic warnings, and school-based programs. These remain highly cost-effective.</p><p>‚Ä¢ Clinical layer (stratified treatment): For moderate groups, brief advice, digital nudges, and standard pharmacotherapy are sufficient. For the right tail, intensive and multi-modal care must combine behavioral therapy, higher-dose pharmacological support, and longer follow-up.</p><p>‚Ä¢ Systems layer (addressing the hardening tail): Persistent smokers often carry burdens of poverty, unstable housing, psychiatric comorbidity, and marginalization. Here, tobacco use functions not only as addiction but also as coping and stress relief. Breaking such cycles requires integrated cessation embedded into mental health and social services.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.10">Why the Right Tail Persists</head><p>The resistant minority of smokers is sustained by multiple, overlapping reinforcers:</p><p>‚Ä¢ High nicotine dependence: Intense withdrawal, cue-driven cravings, and strong dopaminergic reinforcement maintain use <ref type="bibr" target="#b11">(Benowitz and Jacob, 1987)</ref>.</p><p>‚Ä¢ Mental health comorbidity: Depression, anxiety, and substance use disorders increase smoking prevalence and reduce cessation success <ref type="bibr" target="#b173">(Szatkowski and McNeill, 2015)</ref>.</p><p>‚Ä¢ Social determinants: Poverty, housing instability, and smoking-dense social networks embed tobacco use within daily life <ref type="bibr" target="#b16">(Brady, 2020)</ref>.</p><p>‚Ä¢ Genetic variation: Variants such as CYP2A6 alter nicotine metabolism and shape treatment response <ref type="bibr" target="#b175">(Tanner and Tyndale, 2017)</ref>.</p><p>‚Ä¢ Psychological traits: High impulsivity, low self-efficacy, and rigid cognitive styles undermine motivation and coping <ref type="bibr" target="#b163">(Smith, 2017)</ref>.</p><p>These forces combine to create what researchers call a "hardening" of the smoking population: fewer in number, but harder to treat, less responsive to standard tools, and increasingly concentrated in disadvantaged groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Road Ahead: Adaptive and Individualized Approaches</head><p>If the 20th century of tobacco control was about denormalization and mass deterrence, the 21st century must focus on adaptation and personalization. This means:</p><p>‚Ä¢ Personalized behavioral support: Cognitive-behavioral therapy, motivational interviewing, and counseling tailored to each smoker's triggers, routines, and social context.</p><p>‚Ä¢ Pharmacological precision: Adjusting beyond standard NRT doses, using combination therapies, and eventually incorporating genetic or metabolic profiling to match treatment.</p><p>‚Ä¢ Integrated mental health care: Addressing tobacco use together with depression, anxiety, or other substance use disorders rather than treating them separately.</p><p>‚Ä¢ Environmental scaffolding: Leveraging workplace initiatives, peer support groups, and community outreach to counteract pro-smoking social cues.</p><p>‚Ä¢ Continuous monitoring: Using digital tools and adaptive reminders or nudges to maintain motivation over time.</p><p>‚Ä¢ Engaging the smoker: Actively involving smokers in the process, keeping them informed, and leveraging their awareness to strengthen ownership of cessation efforts.</p><p>The SYNAPSE Model of Addiction and the CLEAR-PATH Program introduced later in this book are designed to meet this challenge. By conceptualizing smoking not as a fixed trait but as a dynamic competition of signals (biological, psychological, and social) they offer a framework that explains why some smokers relapse while others quit, and how treatment can be personalized accordingly. Where existing approaches have fragmented, SYNAPSE and CLEAR-PATH aim to integrate: stabilizing biology, reshaping cognition, addressing context, and adapting across time. It felt like a battle. As he paddled home, two voices clashed in his mind: one urging him to stop somewhere for a smoke, the other insisting he keep going. He himself did not know what might happen. At times the craving surged so strongly it seemed irresistible, and at other times the thought of abstaining managed to take hold. His mind was trapped in the contest. At that moment, his phone buzzed. A message from his mother read, \textit{How was the exam?} He pictured her concerned and caring face, and for a brief moment the craving lost its grip. His attention shifted, and the balance of control tipped. He kept paddling, now resolved to reach his room without detouring. The urge remained, but it was quieter and less commanding. When he finally arrived, relief washed over him. He had made it. The craving had not vanished entirely, but it no longer mattered or wasn't that intense. The sense of calm, achievement, and worthiness outweighed it. For that moment, he felt whole again.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.1">To begin with, What is Addiction?</head><p>Addiction has resisted simple explanations for centuries. At different times, it has been cast as a moral failing, a brain disease, a bad habit, or a by-product of social disadvantage. Each of these perspectives highlights part of the picture, but none captures the full complexity. Addiction does not belong solely to biology, psychology, or society. It emerges from the ongoing interplay among all three.</p><p>Addiction can appear in many forms: cigarette smoking, alcohol use, gambling, compulsive pornography use, or binge-watching television. At first glance these behaviors seem unrelated, but they share a set of defining features. Without identifying what unites them, the concept of addiction risks becoming so broad that it collapses into meaninglessness. Not every cigarette smoked or late-night television session is addiction. Confusing ordinary habits with pathological ones erodes the value of the term.</p><p>Equally, addiction cannot be reduced to biological dependence alone. If every repeated or necessary behavior counted, then eating, sleeping, or breathing would qualify as addictions. What matters is not repetition itself, but the way repetition takes on a life of its own and undermines personal agency.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.2">The Four Core Features of Addiction</head><p>Addiction is best understood as a pattern of behavior defined by four recurring features:</p><p>1. Impaired Control: A repeated inability to cut down or stop the behavior, despite intentions to do so.</p><p>2. Short-Term Reinforcement: Immediate rewards or relief sustain the behavior and encourage its repetition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Salience:</head><p>The behavior grows in importance, dominating thoughts, emotions, and priorities while crowding out other aspects of life.</p><p>4. Tolerance and Withdrawal: Over time, greater engagement is needed for the same effect, and distress or craving emerges when the behavior is resisted.</p><p>These features distinguish addiction from ordinary habits or natural needs. They capture the paradox at the core of addictive behavior: the person recognizes, "I do not want to keep doing this in the long run," yet simultaneously feels, "I cannot stop right now," or thinks, "I will stop tomorrow." Addiction is defined not just by repetition, but by the loss of control and the escalation of behavior even when it conflicts with long-term values. The result is often serious harm to health, relationships, and daily life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.3">Individual and Social Perspectives</head><p>There are two ways addiction is recognized. From the outside, society labels a person as addicted when a behavior becomes visibly excessive. From the inside, the person may experience restlessness, ambivalence, and a desire to change. Often these perspectives align, but not always.</p><p>Some people deny or rationalize their behavior and report little inner conflict. Others act automatically, experiencing the addiction as no different from any other habit. In such cases, the boundary between addiction and non-addiction becomes blurry. Yet the absence of conflict often signals limited readiness for change. When external pressure is applied in such situations, labeling can backfire. Rather than motivating recovery, it can reinforce resistance and deepen feelings of isolation.</p><p>The aim, therefore, should not be to label someone as "an addict." Such labeling rarely helps.</p><p>For those who already feel a loss of autonomy and express a desire to change, cessation should become the goal, and support should focus on keeping them engaged in the process. For those who do not recognize their behavior as harmful, the first step is not to force agreement but to carefully assess whether harm is present. If it is, effective support works by surfacing ambivalence, clarifying inner conflict, and strengthening the individual's own motivation to change.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.4">Vulnerability and Addictive Tendencies</head><p>Addiction also has a trait-like dimension. Some individuals carry predispositions that make them more likely to develop addictive patterns. This vulnerability may stem from psychological traits, such as a strong preference for immediate rewards or a tendency toward novelty-seeking, which in turn may be rooted in neurobiological differences within dopamine systems or prefrontal control mechanisms.</p><p>As discussed earlier, addiction rarely arises from a single factor. Instead, a range of influences interact to shape behavior. These forces can draw a person into actions they themselves recognize as harmful, yet continue to repeat. Over time, this cycle of repetition can leave the individual uncertain about when, or even whether, they can stop.</p><p>For these individuals, addictive behaviors can emerge quickly. Someone may feel "hooked" after only a handful of cigarettes, not because of deep physiological dependence on nicotine, but due to a broader susceptibility to compulsive engagement. In such cases, what we observe is not yet a fixed addiction to a single substance, but rather a general addictive tendency. Addressing this underlying vulnerability may be just as important as targeting the specific behavior, and in some instances, even more important to address first.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.5">From Description to Explanation</head><p>Taken together, the core features of addiction, the tension between individual and social perspectives, and the role of vulnerability sketch the outlines of what addiction looks like. They show us its surface: cycles of impaired control, reinforcement, salience, and escalation, lived within a context of ambivalence and harm.</p><p>What they do not yet reveal is how these dynamics arise moment by moment within the brain and behavior. Why does one urge overpower long-term goals at one time but not at another? Why do some individuals, given the same exposure, spiral into compulsion while others do not? And how do personal history, social environment, and biology all press on the same fragile balance?</p><p>To move beyond description, we need a framework that can account for these mechanisms. This is the aim of the SYNAPSE Model of Addiction. Although it will be presented here in relation to smoking behavior, the model is designed to be generalizable across all forms of addiction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.6">The SYNAPSE Model of Addiction</head><p>The SYNAPSE Model proposes that all cognitive and behavioral processes can be understood as the dynamic interplay of neural signals competing for dominance within the brain's networks.</p><p>Rather than treating receptor-level changes, epigenetic modifications, circuit reorganization, past experiences, cognitive schemas, interpersonal influences, or cultural contexts as independent causal forces, the model reframes them as modulators of signal competition. They bias the competition by amplifying some signals, suppressing others, and shaping which patterns emerge into sustained activity and which drive action.</p><p>In this view, the emergence of a thought such as the impulse to smoke is not a mysterious leap but the outcome of a signal pattern achieving network-level stability and salience. Its future trajectory, whether it fades, persists, or drives action, depends on how modulators and competing signals influence its maintenance.</p><p>The SYNAPSE Model emphasizes that mental life is not a layered stack of psychology on top of biology, or separated from social and cultural context. Instead, all such perspectives are different resolutions of the same process: dynamic signal competition shaped by modulators across levels. This framing connects micro-level changes such as receptor shifts with macrolevel factors such as social norms and policy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.7">Core Principles of the SYNAPSE Model</head><p>The SYNAPSE Model rests on four core principles that explain how addictive thoughts and behaviors arise, stabilize, and dominate. Each principle highlights a mechanism by which neural signals are shaped, biased, and resolved within the brain's competitive networks.</p><p>1. Signal Competition: At every moment, multiple patterns of neural activity compete for dominance. Only those that achieve sufficient stability and amplification across brain networks enter conscious awareness and guide behavior. Striatal-prefrontal circuits form the primary arena of this competition, where reward-related activity and control-related activity contend for influence.</p><p>2. Attention as a Biasing Force: Attention does not create signals but selectively boosts their strength, increasing the likelihood of dominance. Signals tagged as relevant by learning, motivation, or urgency receive greater amplification. In addiction, attentional biases toward drug-related cues magnify their effective input, tipping the competitive balance in their favor.</p><p>3. Automaticity and Deliberation: Signals associated with well-practiced or habitual behaviors stabilize quickly and automatically, often bypassing conscious deliberation. In contrast, when there is conflict or ambivalence, competing signals remain unstable and oscillate until one gains enough strength to prevail. Smoking therefore often occurs as an automatic act, but under conditions of self-control or ambivalence, deliberative processes shape the outcome.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Multilevel Modulation:</head><p>The strength of competing signals is modulated across multiple levels of influence:</p><p>‚Ä¢ Genetic: Variants in nicotinic acetylcholine receptor subunits, dopamine system genes, metabolism, and stress-response pathways shape baseline sensitivity to nicotine, vulnerability to dependence, and the efficiency of prefrontal control circuits.</p><p>‚Ä¢ Epigenetic: Chronic nicotine exposure modifies gene expression through DNA methylation and histone changes, priming neural circuits for stronger and faster drug-related responses. These adaptations provide a molecular mechanism by which experience and environment leave durable biological "signatures."</p><p>‚Ä¢ Molecular: Nicotine-induced receptor upregulation, desensitization, and sensitization lower the threshold for drug-related activation, making even small doses or subtle cues sufficient to trigger craving-related activity.</p><p>‚Ä¢ Cellular/Synaptic: Long-term potentiation and remodeling of glutamatergic and dopaminergic synapses bias plasticity toward drug-related pathways, while inhibitory inputs are weakened, consolidating learned patterns of craving and reinforcement.</p><p>‚Ä¢ Circuit-Level: Repeated nicotine use reconfigures brain networks: VTA-NAc reward loops become hyper-responsive, prefrontal control weakens, and activity shifts from ventral (goal-directed) to dorsal striatum (habitual responding). The insula amplifies interoceptive urgency, the amygdala-hippocampus strengthen cue associations, and stress circuits (habenula, extended amygdala) drive withdrawal dysphoria. These changes bias competition toward immediate reinforcement over long-term goals.</p><p>‚Ä¢ Developmental: Early exposure, adolescent brain plasticity, and adverse childhood experiences shape the maturation of reward and control systems, embedding susceptibility across the lifespan and increasing vulnerability to long-term dependence.</p><p>‚Ä¢ Psychological/Affective: Attentional biases, craving schemas, and expectancies (e.g., "smoking calms me") magnify the salience of drug-related thoughts. Stress, negative mood, and difficulties in emotion regulation further bias neural competition toward smoking-related activity.</p><p>‚Ä¢ Behavioral/Habitual: Conditioned associations between smoking and routine contexts (breaks, meals, socializing) embed automatic triggers, allowing smokingrelated signals to emerge without conscious deliberation.</p><p>Identity-Level: With repetition, smoking can become part of personal and social identity (e.g., "I am a smoker"), normalizing drug-related signals and reducing internal resistance. Identity amplifies urges by reinforcing habits and shaping how cues are interpreted and justified. Conversely, adopting a non-smoker identity can re-weight competition in favor of abstinence.</p><p>‚Ä¢ Social/Interpersonal: Peer norms, family modeling, and shared rituals reinforce smoking as a socially validated behavior, amplifying salience and making abstinence</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Emergence</head><p>Emergence occurs when nicotine-related signals gain sufficient strength to cross the activation threshold and enter conscious awareness. This idea is not entirely new; it closely parallels the Global Workspace Theory, which proposes that mental contents become conscious when they achieve enough salience to dominate and broadcast across neural networks. In the context of addiction, this process is not neutral but is systematically biased by modulators operating across multiple levels:</p><p>‚Ä¢ Genetic: Variants in receptor and dopamine system genes set baseline sensitivity, making some individuals more prone to rapid cue reactivity.</p><p>‚Ä¢ Epigenetic: Chronic nicotine exposure leaves lasting molecular marks that prime reward circuits for faster activation.</p><p>‚Ä¢ Receptor/Molecular: Nicotine binding to nAChRs triggers dopamine release; receptor upregulation lowers thresholds so even subtle cues can ignite craving, especially when the blood nicotine level falls below what the body expects as the baseline.</p><p>‚Ä¢ Circuit-Level: Hyper-responsive reward circuits and weakened prefrontal control allow smoking-related patterns to rise quickly into awareness.</p><p>‚Ä¢ Behavioral/Habitual: Conditioned routines (e.g., breaks, meals, socializing) act as automatic triggers for smoking-related activity.</p><p>‚Ä¢ Psychological/Affective: Stress, negative mood, and expectancies ("smoking calms me") heighten attentional focus on drug cues.</p><p>‚Ä¢ Identity-Level: Self-concepts such as "I am a smoker" normalize the thought, making its emergence feel natural and uncontested.</p><p>‚Ä¢ Social/Economic: Peer presence, cultural norms, and accessibility increase the plausibility and salience of smoking as an immediate option.</p><p>In combination, these forces lower the threshold for smoking-related activity to dominate awareness, explaining why urges often appear suddenly and powerfully in daily life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Maintenance</head><p>In the SYNAPSE Model, maintenance refers to the stabilization of a smoking-related thought once it has emerged. Persistence depends on reinforcement across multiple levels, each of which helps keep the signal dominant:</p><p>‚Ä¢ Genetic: Variants influencing dopamine clearance, drug metabolism, or receptor sensitivity prolong reward-related signaling, making smoking thoughts harder to disengage from.</p><p>‚Ä¢ Epigenetic: Nicotine-driven changes in gene expression strengthen synaptic proteins and plasticity, making drug-related networks increasingly "sticky."</p><p>‚Ä¢ Molecular: Upregulated nAChRs and sustained neurotransmitter release (dopamine, glutamate, acetylcholine) maintain heightened reactivity to cues.</p><p>‚Ä¢ Circuit-Level: Recurrent loops between VTA and NAc reinforce activity, while weakened prefrontal inhibition reduces the likelihood of suppression. Other neural circuits contribute additional salience to smoking-related thoughts, reinforcing their dominance and promoting persistence.</p><p>‚Ä¢ Developmental: Circuits shaped by early exposure or adolescence remain biased toward persistence, embedding a stronger default for craving-related activation.</p><p>‚Ä¢ Behavioral/Habitual: Ritualized routines provide constant reinforcement, reactivating smoking thoughts in predictable contexts, and creating a sense to act on the urges.</p><p>‚Ä¢ Psychological/Affective: Craving schemas, rumination, and negative mood states recycle attention back to smoking-related content.</p><p>‚Ä¢ Identity-Level: Self-concepts such as "I am a smoker" normalize the thought, making persistence feel natural rather than intrusive.</p><p>‚Ä¢ Social/Interpersonal: Ongoing exposure to peers who smoke or permissive environments reinforces salience and availability.</p><p>‚Ä¢ Economic/Structural: Easy affordability and access reduce practical barriers, sustaining the sense that smoking is immediately possible.</p><p>Through the convergence of these mechanisms, smoking-related thoughts are not fleeting intrusions but self-stabilizing configurations of activity that resist displacement by competing goals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fate</head><p>In the SYNAPSE Model, the fate of a smoking-related thought, whether it fades, lingers, or drives behavior, depends on the shifting balance of modulatory influences across levels:</p><p>‚Ä¢ Dissipation: Strong prefrontal inhibitory control, competing motivational signals, or the absence of reinforcing cues destabilize the smoking-related configuration, allowing the urge to fade from awareness.</p><p>‚Ä¢ Persistence: Ongoing reinforcement from molecular activity (dopamine release), withdrawal due to low blood nicotine levels, habitual routines, craving schemas, and permissive environments sustains recurrent activation, keeping the thought present and salient.</p><p>‚Ä¢ Action: If dominance is maintained long enough, and supported by accessibility, identity, and social facilitation, smoking-related activity recruits motor planning and execution systems, translating thought into behavior.</p><p>Thus, the same neural configuration may dissipate, persist, or culminate in action depending on how multilevel modulators shape competition over time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.9">Competition and Automaticity</head><p>The SyNAPSE Model proposes that smoking-related behavior can follow two distinct trajectories, depending on whether competing neural signals are present. At its core, the model emphasizes that the fate of a thought depends on the stability achieved by neural activity patterns within competitive brain networks. However, in conditions of strong habit or self-acceptance, the competitive stage may collapse, allowing emergence alone to drive behavior.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict-Driven Competition</head><p>When there is internal conflict, such as ambivalence about smoking, the neural activity pattern associated with smoking must compete against alternative patterns, such as inhibitory control signals or abstinence goals. This path involves the mechanism described above, i.e. Emergence, Maintenance and Subsequent Fate. This trajectory highlights the central role of signal competition in determining whether a smoking-related thought translates into action or fades.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Automatic or Accepted Pathways</head><p>In contrast, when smoking is habitual or integrated into self-identity, competition is minimal.</p><p>Here, the emergence of smoking-related activity is sufficient to trigger thought or behavior without requiring resolution of alternatives. ‚Ä¢ Habitual Pathway: Conditioned cues and restructured reward circuits produce highly stable neural pathways. Once activated, these configurations translate directly into motor action with little need for deliberation.</p><p>‚Ä¢ Self-Accepted Paradigm: When smoking is psychologically or socially accepted, competing abstinence or control signals are weak. The smoking-related configuration achieves dominance by default, manifesting either as an automatic thought or direct action. Social contexts strengthen this pathway, making the behavior feel natural and expected, while deliberation or conflict is largely absent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Mechanistic View</head><p>Together, these trajectories illustrate two operating modes within the SYNAPSE Model. In contexts of conflict, the outcome of a smoking-related thought is shaped by competition among signals across multiple levels of modulation. In contexts of habit or acceptance, competition collapses, and the mere emergence of smoking-related activity is sufficient to drive expression. Both modes are governed by the same underlying principle: neural activity patterns achieve stability through multilevel modulatory influences, and their fate depends on whether that stability is actively contested or remains uncontested. These modes should not be viewed as absolute opposites but as endpoints on a continuum, with most smoking episodes involving some intermediate degree of conscious conflict.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.10">Implications of the SYNAPSE Model</head><p>The SYNAPSE Model reframes addiction not as the product of separate biological, psychological, or social causes, but as a single process of biased signal competition shaped by modulators across levels. This perspective carries several key implications:</p><p>‚Ä¢ Intervention Design: Because any level of modulation can tip competition, effective treatments may act at the molecular (e.g., pharmacotherapies), circuit (e.g., neuromodulation, mindfulness training), cognitive (e.g., attentional retraining, expectancy challenge), behavioral (e.g., habit disruption), or structural (e.g., taxation, smoking bans) levels. The model highlights how these interventions, though diverse, converge on the same mechanism: shifting signal dominance. The goal should be to identify the factors that contribute to the initiation and persistence of smoking-related tendencies and to begin by addressing the most dominant factor, particularly the one that is most readily modifiable. This principle forms a central foundation of our CLEAR-PATH smoking cessation program.</p><p>‚Ä¢ Personalization: Individual vulnerability reflects differences in how modulatory forces bias competition, for example, genetic variation in receptor sensitivity, heightened stress reactivity, or strong social reinforcement. Understanding these unique biases allows for tailored strategies that target the most influential levels for a given individual.</p><p>‚Ä¢ Policy and Prevention: Structural and cultural interventions, such as pricing policies, marketing restrictions, smoke-free environments, or anti-smoking campaigns, operate on the same competitive process as biological or psychological interventions. This underscores the importance of coordinated, multilevel public health approaches that shift reinforcement landscapes away from smoking.</p><p>By integrating biology, psychology, identity, and society into a single explanatory framework, the SYNAPSE Model accounts for the persistence of addiction and provides a foundation for interventions that rebalance signal competition in favor of long-term goals and healthier patterns of behavior. The following sections will present computational models derived from the principles of the SYNAPSE Model, highlight the predictions and explanations generated by these models, and discuss their implications for the future of smoking cessation programs and cessation research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.11">Computational Modeling</head><p>Computational models of addiction provide tools for probing the mechanisms that drive craving, habit formation, and relapse. As outlined in Chapter 3, addiction arises from the interplay of biology, psychology, and society. No single model can capture this full complexity. The purpose of modeling is not to reproduce the entire phenomenon but to formalize specific processes, ground parameters in data, and test how manipulations alter outcomes.</p><p>Traditional models of smoking behavior, from reinforcement learning formulations of craving to system-dynamics simulations of prevalence, contribute in two ways: they make mechanisms explicit and they generate falsifiable predictions. Yet their limitations are equally clear. Each isolates a narrow segment of the cycle, and most remain too abstract to connect with lived experience or practical intervention.</p><p>Existing approaches can be grouped into several families:</p><p>‚Ä¢ Reinforcement learning models formalize how smoking shifts from a voluntary, goaldirected choice to a habitual behavior. Early in use, actions are reinforced by the immediate pharmacological and psychological rewards of nicotine. Over time, learning algorithms such as temporal-difference updating capture how cues acquire predictive value and smoking becomes automatic. These models help explain craving, relapse, and the persistence of smoking despite long-term costs.</p><p>‚Ä¢ Decision models describe how individuals balance immediate rewards against delayed costs. Delay-discounting frameworks show how smokers often assign disproportionately high value to short-term relief, while dual-process models highlight competition between fast, impulsive systems and slower, deliberative control systems. Such models clarify why smokers may simultaneously intend to quit yet continue to light up.</p><p>‚Ä¢ Bayesian and predictive coding models treat the brain as an inference machine that continually updates expectations about the world. In addiction, these models explain cue reactivity: drug-related cues carry strong prior expectations of reward, so even weak signals trigger craving. Prediction errors, when expectations and outcomes mismatch, reinforce smoking-related beliefs and behaviors.</p><p>‚Ä¢ Neurobiophysical models operate at the receptor and circuit level, simulating how nicotine alters brain function. Examples include models of nicotinic acetylcholine receptor kinetics, dopaminergic reward signaling, and striatal-prefrontal circuit interactions. These approaches explain how cellular adaptations consolidate craving, habit formation, and withdrawal dysphoria.</p><p>‚Ä¢ Population-level simulations examine how smoking behaviors spread and decline across communities. Agent-based models capture social influence, peer clustering, and initiation cascades, while system-dynamics models track prevalence in response to policy changes, taxation, or advertising restrictions. These simulations are crucial for linking individual psychology to public health outcomes.</p><p>‚Ä¢ Hybrid digital health models combine computational theory with real-time behavioral and sensor data, often through smartphones or wearables. These adaptive systems update predictions about craving and relapse risk on the fly, enabling just-in-time interventions.</p><p>They represent a bridge between abstract models and personalized clinical practice.</p><p>These traditions illustrate the richness of computational perspectives, but also their fragmentation. Biology, psychology, and society are often treated as separate domains, connected only loosely across levels. Parameters tend to remain abstract, which makes it difficult to translate predictions into interventions.</p><p>The SYNAPSE Model of Addiction addresses this gap by reframing addiction as biased neural signal competition shaped by modulators across genetic, molecular, psychological, social, and cultural levels. This perspective introduces three advances for computational modeling:</p><p>1. Unified process: Models need not treat biological, cognitive, and social influences as independent causes. All can be formalized as modulatory forces that bias which signals achieve dominance.</p><p>2. Dynamic timescales: Smoking unfolds across moment-to-moment urges and long-term trajectories. The SYNAPSE framing emphasizes that each decision leaves traces at molecular, cognitive, and social levels that bias the next moment of competition.</p><p>3. Translation to intervention: By mapping computational parameters onto lived processes such as stress sensitivity, attentional capture, or identity reinforcement, models can generate predictions that directly inform treatment. A parameter shift that reduces the dominance of smoking-related signals, whether through pharmacotherapy, attentional retraining, or policy, can be simulated and tested against empirical outcomes.</p><p>Our modeling strategy proceeds in stages. We begin with tractable models that isolate specific mechanisms of signal competition and validate these against empirical data or previous studies.</p><p>We then advance to models that capture dynamic fluctuations in decision-making and craving across contexts, guided by the SYNAPSE principles of competition, biasing, automaticity, and multilevel modulation. Finally, we evaluate how these models converge within the full SYNAPSE framework, moving from abstraction toward actionable strategies.</p><p>In this way, computational modeling serves not only to advance theory but also to inform practice. The SYNAPSE-based models provide the foundation for our CLEAR-PATH cessation program, which uses computational insights to design interventions that are personalized, testable, and implementable in real-world settings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.11.1">Modeling Upregulation</head><p>As discussed in Chapter 3, chronic nicotine exposure induces upregulation of nicotinic acetylcholine receptors (nAChRs), particularly the ùõº4ùõΩ2 subtype. In this section, we model this upregulation in response to nicotine consumption, with emphasis on individual variability arising from differences in hepatic nicotine metabolism. Although genetic variation in receptor subunits also influences upregulation, we do not consider this factor here, as it is far more difficult to quantify at the individual level. By contrast, metabolic variability is more tractable, and our CLEAR-PATH program incorporates questionnaires and standardized protocols to capture such information. Importantly, our modeling for upregulation focuses specifically on the ùõº4ùõΩ2 subtype, which is strongly implicated in nicotine withdrawal and the negative reinforcement that sustains nicotine use.</p><p>Nicotine from cigarette smoke enters the bloodstream and readily crosses the blood-brain barrier, where it binds to nAChRs in the brain. The degree of receptor occupancy depends on the plasma nicotine concentration ùëÅ (ùë°) (measured in ng/mL) and can be described by a Hill-type equation:</p><formula xml:id="formula_8">Occupancy(%) = 100 ‚Ä¢ ùëÅ (ùë°) ùêæ ùëë + ùëÅ (ùë°) ,<label>(1)</label></formula><p>where ùêæ ùëë = 0.75 ng/mL represents the half-saturation constant, i.e., the nicotine concentration at which 50% of ùõº4ùõΩ2 * nAChRs are occupied. This value reflects the receptor-binding affinity of nicotine. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicotine Concentration Dynamics</head><p>Nicotine concentration in the blood decays over time and can be modeled using exponential decay:</p><formula xml:id="formula_9">ùëÅ (ùë°) = ùëÅ 0 ùëí -ln(2) ùë°/ùëá 1/2 (2)</formula><p>where:</p><p>‚Ä¢ ùëÅ (ùë°) is the nicotine concentration at time ùë°,</p><p>‚Ä¢ ùëÅ 0 is the initial nicotine concentration immediately after smoking,</p><p>‚Ä¢ ùëá 1/2 is the biological half-life of nicotine (‚àº 2 hours).</p><p>Immediately after smoking one cigarette, blood nicotine concentration typically peaks around 10 ng/mL, assuming a yield of 1.2-1.4 mg of nicotine. At this level, based on Equation ( <ref type="formula" target="#formula_8">1</ref>), approximately 93% of brain nAChRs are occupied.</p><p>In the literature, the average half-life of nicotine in humans has been reported to be approximately 2 hours. However, due to genetic variation in the enzymes responsible for metabolizing nicotine into cotinine, the half-life can vary substantially across individuals. To account for this variability, we treat the nicotine half-life as a model parameter. Accordingly, we categorize individuals into three groups: slow, normal, and fast metabolizers, with assumed half-lives of 4, 2, and 1 hours, respectively. The downstream effects of these differences will be evident in the modeling results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicotine Yield and Systemic Absorption</head><p>A cigarette contains 5-15 mg of nicotine, but only about 1-2 mg is systemically absorbed per cigarette under typical smoking conditions. Immediately following inhalation, nicotine is rapidly taken up through the pulmonary circulation and distributed throughout the body. However, the observed venous plasma nicotine concentration after smoking a single cigarette is only ‚àº10-15 ng/mL, much lower than the value one would expect from a simple blood volume calculation.</p><p>This discrepancy is explained by the pharmacokinetics of distribution and clearance. Once in systemic circulation, nicotine distributes into a volume far larger than the blood pool alone. The apparent volume of distribution (ùëâ ùëë ) is approximately 2.5 L/kg, or ‚àº175 L in a 70 kg adult.</p><p>Thus, even if 1.5 mg (1500 ¬µg) of nicotine enters the body, the expected steady-state plasma concentration is:</p><formula xml:id="formula_10">ùê∂ = Dose ùëâ ùëë = 1500 ùúág 175 L ‚âà 8.6 ng/mL,</formula><p>which closely matches empirical post-cigarette plasma concentrations (10-15 ng/mL).</p><p>Nicotine's relatively high apparent volume of distribution (2-3 L/kg) arises from its small size, moderate lipophilicity, and weakly basic nature (pKa ‚àº8), which enable rapid membrane crossing and ion trapping in acidic tissues. Low plasma protein binding (&lt; 5%) and accumulation in highly perfused organs (brain, liver, kidneys) further expand its distribution, resulting in low plasma concentrations despite milligram-scale doses , as discussed earlier in chapter 3.</p><p>For modeling purposes, we make the simplifying assumption that:</p><p>‚Ä¢ Smoking one cigarette produces a peak venous plasma nicotine concentration of approximately 10 ng/mL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Model Parameter: Upregulation Susceptibility (Half-Life)</head><p>In our framework, receptor upregulation is governed by a single parameter that captures interindividual variability in nicotine metabolism: the effective plasma half-life of nicotine. We denote this parameter as Upregulation Susceptibility (ùúé). Higher values of ùúé correspond to slower metabolic clearance, yielding a longer half-life and thereby greater receptor upregulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicotine Receptor Upregulation</head><p>We define the upregulation factor ùëà (ùë°) as the ratio of the effective number of nicotine receptors in a smoker compared to a non-smoker:</p><formula xml:id="formula_11">Upregulation = Effective Receptor Count Smoker Receptor Count Non-Smoker<label>(3)</label></formula><p>A value ùëà = 10 indicates a tenfold increase in receptor count or sensitivity due to chronic nicotine exposure. This increased receptor density reinforces addiction mechanisms.</p><p>Upregulation is modeled dynamically as: ùëà (ùë° + 1) = max 1, ùëà (ùë°) + 10 -5 ‚Ä¢ (0.7 -ùëÄ (ùë°))</p><p>where:</p><p>‚Ä¢ ùëÄ (ùë°) is the number of unbound receptors at time ùë°,</p><p>The rate constant 10 -5 is empirically chosen to ensure receptor levels return to baseline within approximately 21 days of cessation, consistent with biological recovery patterns.</p><p>The unbound receptor count ùëÄ (ùë°) is derived as:</p><formula xml:id="formula_13">ùëÄ (ùë°) = 1 - ùëÅ (ùë°) 0.75 + ùëÅ (ùë°) ‚Ä¢ ùëà (ùë°)<label>(5)</label></formula><p>This accounts for both the percentage of receptors unoccupied and the absolute receptor number due to upregulation. Importantly, even if two individuals have similar percent occupancy, a smoker with elevated ùëà (ùë°) has more total empty receptors, contributing to stronger withdrawal.</p><p>Note that in Equation (4), at each time step, ùëà (ùë°) is affected by ùëÄ (ùë°), the fraction of unbound receptors. A lower blood nicotine level would lead to more empty receptors and may cause a reversal of upregulation; on the other hand, a higher blood nicotine level would lead to an increase in upregulation. This mimics the natural characteristics of smoking. Further, the equation ensures that the upregulation value does not fall below 1, to preserve its meaning and validity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.11.2">Incorporating Learning, Reinforcement, and Context</head><p>Withdrawal From the previous Model of Upregulation, we borrow withdrawal as a function of the absolute number of empty ùõº4ùõΩ2 receptors, denoted by ùëÄ (ùë°) in equation <ref type="bibr" target="#b0">(5)</ref>.</p><p>Formally, in the linear case we write</p><formula xml:id="formula_14">ùëä (ùë°) = ùúÇ ùëÄ (ùë°),</formula><p>where ùúÇ &gt; 0 is a scaling parameter controlling sensitivity.</p><p>More generally, we allow for nonlinear scaling by introducing an exponent ùëõ &gt; 0:</p><formula xml:id="formula_15">ùëä (ùë°) = ùúÇ ùëÄ (ùë°) ùëõ .</formula><p>Here ùëõ = 1 recovers the linear case, ùëõ &gt; 1 corresponds to superlinear growth of withdrawal with receptor emptiness, and 0 &lt; ùëõ &lt; 1 corresponds to sublinear growth.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicotine Dynamics and Acute Effects</head><p>Let ùëÅ (ùë°) denote the blood nicotine concentration at time ùë°. A smoking event produces a rapid increase in ùëÅ (ùë°), followed by exponential clearance through metabolism. Two acute effects are modeled:</p><p>1. Dopamine burst:</p><formula xml:id="formula_16">Œîùê∑ (ùë°) = ùëì ùê∑ ùëÅ (ùë°) -ùëÅ (ùë° -) ,</formula><p>where ùëÅ (ùë° -) is the level immediately before smoking and ùëì ùê∑ (‚Ä¢) is a nonnegative, saturating function mapping nicotine increments to dopaminergic response. The function ùëì ùê∑ (‚Ä¢) is a result of receptor kinetics, primarily the ùõº4ùõΩ2 and ùõº6ùõΩ2 subtypes.</p><p>While in principle ùëì ùê∑ (‚Ä¢) could be derived from receptor populations and their functional output (e.g., using EC 50 values rather than binding affinities ùêæ ùëë ), such an approach quickly becomes mathematically cumbersome. For tractability, we approximate the reward signal as a ratio of nicotine levels before and after intake, scaled by a parameter Œò. A more detailed model could incorporate functional receptor activation alongside desensitization dynamics, accounting for the proportion of receptors available versus those transiently inactivated.</p><p>ùëì ùê∑ ùëÅ (ùë°), ùëÅ (ùë° -) = Œò ‚Ä¢ ùëÅ (ùë°) ùëÅ (ùë° -) + ùúÄ , Note that the dopamine burst represents the subjective reward. A continuous increase in nicotine would raise the baseline, so subsequent intake would no longer produce the same burst sensation. The equation above captures this effect.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Withdrawal relief:</head><p>Œîùëä (ùë°) = ùëä (ùë° -) -ùëä (ùë°),</p><p>where ùëä (ùë°) is withdrawal severity (defined above). Thus Œîùëä (ùë°) &gt; 0 when nicotine occupancy alleviates receptor emptiness, primarily via action on GABAergic ùõº4ùõΩ2 subtypes, as discussed in Chapter 3.</p><p>Assuming ùëõ = 1 in earlier Equation for Withdrawal, we model</p><formula xml:id="formula_17">Œîùëä (ùë°) = ùúÇ ‚Ä¢ (ùëÄ (ùë°) -ùëÄ (ùë° -)) .</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reward from Smoking Behavior</head><p>Reward is defined as the net change in hedonic state following smoking, decomposed into additive reinforcement components:</p><formula xml:id="formula_18">ùëü (ùë°) = ùõΩ 1 Œîùê∑ (ùë°) dopaminergic burst + ùõΩ 2 Œîùëä (ùë°) withdrawal relief</formula><p>.</p><p>This reward is multiplicatively modulated by contextual factors:</p><formula xml:id="formula_19">ùëü (ùë°) ‚Üê ùëü (ùë°) 1 + ùõΩ 3 ùëÜ ctx (ùë°) ,</formula><p>where ùõΩ 1 , ùõΩ 2 ‚â• 0 and ùõΩ 3 ‚àà R. Here ùëÜ ctx (ùë°) is a normalized scalar function of context (defined below).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Context</head><p>Context at time ùë° refers to the set of modulatory factors that amplify or attenuate the reinforcement signal from smoking. These include emotional, interoceptive, and situational states that bias hedonic evaluation.</p><p>Formally, we represent context by a vector of state variables:</p><formula xml:id="formula_20">X(ùë°) = ùê∏ (ùë°), ùêº (ùë°), ùëÜ(ùë°) ,</formula><p>where</p><p>‚Ä¢ ùê∏ (ùë°) = affective or emotional state at time ùë°,</p><p>‚Ä¢ ùêº (ùë°) = interoceptive state (e.g., stress, arousal, fatigue),</p><p>‚Ä¢ ùëÜ(ùë°) = situational or social setting.</p><p>These factors are integrated into a normalized modulation signal,</p><formula xml:id="formula_21">ùëÜ ctx (ùë°) = ùúé ùõæ 0 + ùõæ ‚ä§ X(ùë°) ,</formula><p>where ùúé(‚Ä¢) is a bounded activation function (e.g., logistic), ùõæ 0 is a baseline bias, and ùõæ are weighting parameters.</p><p>This ensures that context enters the reward function as a scalar gain factor, consistent with the multiplicative modulation defined above.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Smoking Cue Set</head><p>Let ùúì denote the universal set of stimuli. The Smoking Cue Set is defined as</p><formula xml:id="formula_22">ùê∂ = { ùë† ‚àà ùúì | ùëÉ(craving | ùë†, ùêø = 1) &gt; ùúÉ },</formula><p>where ùêø = 1 indicates a nicotine-deprived state (blood nicotine below threshold ùúÇ) arising from external enforcement of abstinence, and ùúÉ ‚àà (0, 1) is a probability cutoff. The element ùê∂ ùëñ ‚äÜ ùê∂ denotes the ùëñ-th distinct cue or cue category.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cue Time Series and Learned Association</head><p>For each cue ùê∂ ùëñ , we define a binary time series of its instantiations since the initiation of smoking behavior. Instantiation basically represents cue activation. In the early phase, this corresponds to the physical presence of the cue, while in later phases it reflects the expectancy of smoking associated reward for that cue.</p><formula xml:id="formula_23">A ùëñ = {ùê¥ ùëñ (ùë°)} ùëá ùë°=0 , ùê¥ ùëñ (ùë°) ‚àà {0, 1},</formula><p>where ùê¥ ùëñ (ùë°) = 1 indicates that smoking occurred in response to ùê∂ ùëñ at time ùë°, and ùê¥ ùëñ (ùë°) = 0 indicates no smoking.</p><p>Associated variables are:</p><p>‚Ä¢ ùëü ùëñ (ùë°): observed reward at time ùë°,</p><p>‚Ä¢ ùëí ùëñ (ùë°): expected reward at time ùë°,</p><p>‚Ä¢ ùêø ùëñ (ùë°) ‚àà R ‚â•0 : learned association / strength of cue ùê∂ ùëñ .</p><p>Let (ùë•) + ‚â° max{ùë•, 0}. To capture the empirically observed bias whereby smokers underweight negative feedback and require confirmatory positive surprise to update, we use a hybrid asymmetric/thresholded update:</p><p>Œîùêø ùëñ (ùë°) = ùê¥ ùëñ (ùë°) ùõº ùëñ ùëöùëéùë•{0, (ùëü ùëñ (ùë°) -ùëí ùëñ (ùë°))} -ùúå ùëñ ùëöùëéùë•{0, (ùëí ùëñ (ùë°) -ùëü ùëñ (ùë°))} -1 -ùê¥ ùëñ (ùë°) ùõΩ ùëñ ùëí ùëñ (ùë°),</p><formula xml:id="formula_24">ùêø ùëñ (ùë° + 1) = ùêø ùëñ (ùë°) + Œîùêø ùëñ (ùë°)</formula><p>where</p><p>‚Ä¢ ùõº ùëñ ‚â• 0 is the learning rate for experienced outcomes,</p><p>‚Ä¢ ùúå ùëñ ‚àà [0, 1] attenuates negative prediction errors (ùúå ùëñ = 0 removes learning from worsethan-expected outcomes; ùúå ùëñ = 1 yields symmetric learning),</p><p>‚Ä¢ ùõΩ ùëñ ‚â• 0 is the passive extinction rate when no action occurs,</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expected Reward</head><p>The expected reward from smoking in response to cue ùê∂ ùëñ at time ùë° is defined as a weighted memory of past positive learning updates, with weights reflecting recency, magnitude, and effort. Larger learning updates receive disproportionately greater weight, capturing the idea that stronger events occupy memory and attention more than weaker ones. Lower effort makes smoking more readily rewarding, while higher effort diminishes the expected value.</p><formula xml:id="formula_25">ùëí ùëñ (ùë°) = 1 ùúò(ùë°) ùë°-1 ‚àëÔ∏Å ùë¢=0 ùëí -ùúÜ(ùë°-ùë¢) (Œîùêø ùëñ (ùë¢)) + ùëù ùë°-1 ‚àëÔ∏Å ùë¢=0 ùëí -ùúÜ(ùë°-ùë¢)</formula><p>, where</p><p>‚Ä¢ (Œîùêø ùëñ (ùë¢)) + = max{Œîùêø ùëñ (ùë¢), 0} includes only positive updates,</p><p>‚Ä¢ ùëù &gt; 1 is the power-law exponent; higher ùëù biases memory more strongly toward larger updates,</p><p>‚Ä¢ ùëí -ùúÜ(ùë°-ùë¢) applies exponential recency weighting, with ùúÜ &gt; 0 controlling how quickly older events lose influence,</p><p>‚Ä¢ ùúò(ùë°) &gt; 0 is the effort parameter at time ùë°, with lower values (less effort required) yielding higher expected reward.</p><p>This formulation emphasizes that smokers not only recall recent reinforcing episodes more vividly, but also that especially strong reinforcement events dominate memory and shape future expectations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Initialization</head><p>To ensure the update dynamics are well-defined, both the learned association and the expected reward must be given initial values at ùë° = 0. We set</p><formula xml:id="formula_26">ùêø ùëñ (0) = ùêø prior ùëñ , ùëí ùëñ (0) = ùëí prior ùëñ ,</formula><p>where ùêø</p><p>prior ùëñ</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>and ùëí</head><p>prior ùëñ are baseline parameters that may be positive or negative.</p><p>For a cue ùê∂ ùëñ , positive priors reflect a predisposition to associate that cue with smoking (e.g., prior exposure, higher sensitivity, or favorable expectations), while negative priors capture baseline resistance to that cue (e.g., parental restrictions, family disapproval, or other deterrents). This formulation allows the model to encode individual differences in cue salience and bias from the outset, before any learning has occurred..</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.11.3">Signal Competition and Decision Making</head><p>In the SYNAPSE Model, smoking-related and alternative action signals coexist in a competitive field. Multiple candidates may be active simultaneously, but only one stabilizes into the foreground of consciousness at a given time. The signal that dominates attention determines behavior.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Foreground and Candidate Signals</head><p>At time ùë°, the foreground corresponds to either smoking or an alternative action:</p><p>ùëÇ ‚Ñì (ùë°) ‚àà {smoking, alternative}.</p><p>The intrinsic values of these foreground bundles derive from the reward processes defined in earlier sections:</p><formula xml:id="formula_27">ùëâ smoke (ùë°) = ùëí(ùë°), ùëâ alt (ùë°) = ùëú(ùë°),</formula><p>where ùëí(ùë°) is the expected reward from smoking in that context, in response to some cue, and ùëú(ùë°) denotes the value of a competing alternative.</p><p>Surrounding the foreground is a candidate field C(ùë°) of latent signals, each partially organized but insufficiently stabilized to dominate. Competition with these candidates determines whether the foreground persists or switches.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effective Strength and Salience</head><p>The effective salience of a candidate ùëé ùëó is defined as</p><formula xml:id="formula_28">ùëÜ ùëó (ùë°) = ùê¥ ùëó (ùë°) √ó ùëâ ùëó (ùë°),</formula><p>where ùëâ ùëó (ùë°) denotes its intrinsic, bottom-up value, and ùê¥ ùëó (ùë°) is a top-down attentional weight. This modulation may either align with (congruent) or oppose (incongruent) the bottom-up drive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Foreground Selection</head><p>We allow for stochastic selection using a softmax rule:</p><formula xml:id="formula_29">ùëÉ ùëó * (ùë°) = ùëó = exp ùëÜ ùëó (ùë°) ùëò exp ùëÜ ùëò (ùë°)</formula><p>.</p><p>The softmax rule converts cue strengths ùëÜ ùëó (ùë°) into selection probabilities: cues with higher strength are more likely to be chosen as the foreground, while cues with similar strengths compete more evenly, allowing stochastic switching rather than deterministic choice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dwell and Switching Dynamics</head><p>Dwell and decay. Once a candidate ùëé ùëó enters the foreground, its salience begins to decline over time according to an exponential decay process:</p><formula xml:id="formula_30">ùëëùëÜ ùëó ùëëùë° = -ùõøùëÜ ùëó (ùë°), ùõø &gt; 0.</formula><p>This gradual reduction reflects attentional fatigue: the longer a candidate remains in focus, the less strongly it competes for continued selection. As a result, prolonged dwelling becomes increasingly unlikely, creating a natural pressure for attention to eventually shift to another candidate.</p><p>Reinforcement and re-entry. Foreground salience is not purely passive, however. External events such as cravings, environmental cues, interoceptive signals, or relevant beliefs can temporarily boost the salience of the current candidate. Such reinforcement can extend its dwell time or allow it to re-enter the foreground after being displaced. Conversely, sustained top-down attention toward a competing candidate can raise that alternative's salience, hastening a switch.</p><p>Overall, the dynamics combine a natural decay process (promoting eventual switching) with external modulation (allowing reinforcement, prolongation, or re-entry), thereby capturing the balance between spontaneous attentional drift and context-driven stabilization of foreground content.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stabilizing Role of Top-Down Attention</head><p>Top-down attention acts as a stabilizer of candidate salience:</p><p>‚Ä¢ For aligned signals (supporting the individual's goals), it prolongs dwell time, making the foreground more resilient to competing drives.</p><p>‚Ä¢ For misaligned signals (opposing goals), it accelerates destabilization and shortens dwell time.</p><p>Thus, deliberate focus, identity commitments, and social reminders extend alternative foregrounds, while stress or permissive schemas extend smoking-related foregrounds.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Close Contests and Switching Chains</head><p>When smoking and alternative options are nearly balanced (|ùëâ smoke (ùë°) -ùëâ alt (ùë°)| ‚â§ ùúñ), the system may enter a period of oscillation, where attention rapidly switches back and forth:</p><formula xml:id="formula_31">ùëÇ 1 ‚Üí ùëÇ 2 ‚Üí ‚Ä¢ ‚Ä¢ ‚Ä¢ ,</formula><p>before one option eventually stabilizes. Such "switching chains" reflect indecision: neither option is strong enough to dominate, and small perturbations can temporarily pull attention toward one or the other.</p><p>In this delicate state, even small biases can have outsized effects. Schemas (e.g., "smoking helps me calm down"), cognitive reappraisal, or external enforcement (e.g., social pressure, situational barriers) can shift attentional weights ùê¥ ùëó (ùë°) just enough to tip the balance.</p><p>Thus, decision making in the SYNAPSE model emerges from ongoing competition among candidate signals. Bottom-up values determine the intrinsic pull of each option, while topdown modulation influences which options can sustain dwell time. A behavioral outcome is reached once either the smoking-related reward ùëü (ùë°) or an alternative ùëú(ùë°) maintains foreground stability long enough to drive action.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Decision in Favor of Smoking</head><p>A decision to smoke is taken when the smoking-related option remains in the foreground without disruption for a sufficient period of time. Formally, let ùúÅ &gt; 0 denote a stability threshold for dwell time. If the smoking-related signal satisfies dwell smoke (ùë°) ‚â• ùúÅ, then the system commits to smoking as the chosen action.</p><p>This condition captures the idea that momentary salience or brief entry into the foreground is not enough to produce behavior. Instead, the smoking representation must persist stably, resisting competition from alternatives, until it crosses the temporal threshold ùúÅ. At that point, the option is consolidated sufficiently to guide downstream motor preparation and execution.</p><p>In psychological terms, ùúÅ represents the minimal attentional commitment needed for intention to translate into action. Smaller ùúÅ values correspond to more impulsive tendencies, while larger ùúÅ values capture greater resistance to acting on fleeting urges.</p><p>Importantly, ambivalence can lower the effective value of ùúÅ, collapsing the decision boundary. In this case, even short-lived foreground activation may be sufficient to trigger behavior, producing more impulsive and uncertain choices. Higher ambivalence thus increases the likelihood of lapses, since the system requires less stability before committing to smoking.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.11.4">Emergent Macro Parameter: ùúÖ</head><p>Averaged over multiple instances of interaction, we define an emergent parameter ùúÖ, the Homeostatic Coefficient, which represents the blood nicotine level below which an individual is likely to smoke a cigarette. The decision boundary for smoking behavior is strongly influenced by this parameter. Importantly, ùúÖ emerges from a combination of environmental and intrinsic factors, making an individual more or less prone to smoking.</p><p>This parameter reflects the effective number of unoccupied ùõº4ùõΩ2 receptors (after accounting for upregulation) at which the person initiates smoking. Thus, the average decision boundary for smoking can be expressed as</p><formula xml:id="formula_32">ùúÖ &lt; 1 - ùëÅ (ùë°) 0.75 + ùëÅ (ùë°) ùëà (ùë°),</formula><p>which leads to smoking behavior. In other words, as blood nicotine falls below a baseline level,</p><p>ùúÖ becomes smaller than the right-hand side, triggering smoking. The prognostic distribution of smoking episodes across a daytime interval can be considered as emerging from the fluctuations in this averaged decision boundary.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12">Explanations out of the SyNAPSE Model</head><p>The SYNAPSE model unifies receptor pharmacodynamics, reinforcement learning, and attentional competition into a single framework for understanding smoking behavior. This integration yields a set of explanatory principles and testable predictions:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.1">Metabolism Differences</head><p>The simulation illustrates how nicotine clearance varies across three metabolic profiles, represented by different half-lives. Low susceptibility (fast metabolism) results in a rapid decline of nicotine, creating frequent receptor vacancy and stronger withdrawal pressure. Medium susceptibility shows a more gradual decline, balancing clearance with sustained receptor occupancy. High susceptibility (slow metabolism) maintains elevated nicotine levels for extended periods, reducing acute withdrawal but promoting greater receptor upregulation over time. These trajectories demonstrate how individual metabolic differences critically shape both withdrawal severity and long-term dependence risk.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.2">Susceptibility to Upregulation and Stable Dosages</head><p>The model simulates how receptor upregulation evolves when individuals smoke a fixed number of cigarettes per day at regular intervals (1, 2, 3, or 4/day).</p><p>Central to this is upregulation susceptibility as defined earlier, which reflects individual variabil- ity in nicotine metabolism and receptor response. Even under identical smoking patterns, this variability produces different levels of biological dependence. Individuals with high susceptibility show stronger receptor upregulation per cigarette. While those with faster metabolism may smoke more frequently to maintain nicotine levels, highly susceptible individuals can become more vulnerable to dependence, even if they smoke the same or fewer cigarettes, especially in social contexts where their intake matches peers.</p><p>Across all dosage conditions, upregulation rises initially but then plateaus, defining a stable smoking dosage. At this stage, the natural decline in receptor levels between cigarettes balances the increase triggered by smoking, preventing unlimited escalation in nicotine demand. This plateau provides a biological explanation for the persistence of steady smoking patterns over time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.3">Abrupt Smoking Cessation</head><p>Consider an individual with a tenfold increase in nicotinic receptor density due to upregulation. Following abrupt cessation, nicotine levels decline while receptor downregulation remains slow. In the first few days, many receptor sites remain unbound, creating up to 8-9 times more empty sites than in a non-smoker. This vacancy drives excessive GABAergic inhibition and hypodopaminergia, providing a physiological basis for the intense cravings and withdrawal symptoms observed during early cessation.</p><p>This imbalance partially explains the intense cravings and withdrawal symptoms typically reported within 1-5 days of quitting. Over time, homeostatic mechanisms reduce excess receptors, but the model highlights how the sudden vacancy of binding sites drives the severity of early withdrawal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.4">Intervening Role of Sleep, and Implications for NRT</head><p>In terms of receptor dynamics, sleep provides a natural interruption in nicotine intake, slowing the trajectory of upregulation. During nightly breaks, nicotine is metabolized and partially cleared, while downregulation mechanisms reduce previously upregulated receptors. This reset tempers the overall rate of upregulation and delays dependence formation. However, overnight abstinence also lowers morning nicotine levels, leading to withdrawal symptoms and increased urge to smoke, particularly in individuals with higher dependence.</p><p>By contrast, continuous intake without sleep interruption produces a steeper and more sustained increase in receptor upregulation, thereby accelerating vulnerability to dependence.</p><p>These dynamics have direct implications for nicotine replacement therapy (NRT). Our modeling suggests that 24-hour patches may be less effective at reversing upregulation compared to 16hour patches, which better mimic the restorative interruption provided by sleep. In some cases, combining 16-hour patches with morning nicotine gum may be more effective than continuous 24-hour delivery.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.5">Visualizing Real-World Smoking Trajectories</head><p>From initiation, smoking behavior may follow two broad trajectories. In one, the individual experiments briefly without developing a sustained habit. In the other, smoking becomes recurrent, with gradual increases in frequency and dosage. This escalation often coincides with the embedding of smoking into daily routines (e.g., after meals, during breaks, while driving, or in social settings), creating strong behavioral associations.</p><p>To illustrate how our model reflects such dynamics, consider an individual with moderate susceptibility to upregulation who has just started smoking. The Homeostatic Quotient (ùúÖ) is used here as a composite variable capturing psychological, environmental, and self-regulatory influences. Importantly, ùúÖ being an emrgent macro parameter is dynamic, shifting with circumstances that either promote smoking (e.g., stress, peer influence) or discourage it (e.g., family pressure, financial constraints). Table 7.1: Hypothetical changes in ùúÖ over two years, reflecting real-world fluctuations in environmental and personal influences.</p><p>This simplified framework captures how periods of stress, novelty, or peer influence can elevate ùúÖ, making smoking more likely, while restrictions, family presence, or health concerns can reduce it. Although modeled as a single variable, smoking is shaped by both physical dependence and psychological craving. In practice, individuals may continue smoking even with minimal biological drive, but the model assumes a strong correlation between the two.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.6">Nicotine-Induced Dopamine Bursts</head><p>Building on our nicotine dynamics model, we represent the dopaminergic burst as a function of the nicotine increment relative to its pre-intake baseline. Our formulation captures the diminishing reward effect: as baseline nicotine rises, the relative increment becomes smaller, and the subjective dopamine response decreases, even if the same amount of nicotine is consumed. Thus, early cigarettes after abstinence produce stronger bursts, while subsequent cigarettes yield progressively weaker reinforcement.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.7">Asymmetric Cue Learning</head><p>The learning rule governing cue-reward associations, ùêø ùëñ (ùë°), places greater weight on positive prediction errors while down-weighting negative ones. This asymmetry biases memory toward rewarding experiences, such that smokers recall and re-experience rewarding cues more strongly than disappointing ones. Consequently, craving may persist even after multiple unsatisfying cigarettes. Empirically, this predicts biased recall and enhanced attentional capture by smoking-related stimuli compared to neutral or negatively valenced cues.</p><p>When cravings are consistently suppressed, the lack of reinforcement generates negative prediction errors that weaken or extinguish cue-reward associations; with repeated suppression, these associations may even reverse in polarity. Neurobiologically, reduced dopaminergic signaling combined with strengthened prefrontal control supports extinction and inhibitory learning, thereby diminishing the motivational power of smoking-related cues.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.8">Contextual Amplification of Reward</head><p>The multiplicative modulation factor ùëÜ ctx (ùë°) predicts that the same cigarette can feel more rewarding under stress, fatigue, or permissive social conditions. This explains why relapse is especially likely in stressful or socially permissive environments, even after periods of successful abstinence. Empirically, the model predicts stronger cue reactivity and higher smoking likelihood under adverse interoceptive or emotional states.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.9">Decision Instability and Ambivalence</head><p>When smoking and alternatives have near-equal values, the system exhibits oscillatory "switching chains." A decision occurs only when one option sustains dwell time beyond the stability threshold ùúÅ. Ambivalence lowers ùúÅ, collapsing the boundary and allowing even brief smoking salience to trigger action. This explains impulsive lapses, rapid switching between resolve and relapse, and the fragile nature of quit attempts. Empirically, the model predicts that higher self-reported ambivalence corresponds to shorter dwell thresholds and more unstable decisions.</p><p>Cognitive biases and distortions further shape this instability. In moments of ambivalence, attentional biases toward smoking cues, optimistic distortions of risk, or selective recall of rewarding episodes can amplify the salience of smoking and tip the system toward lapse.</p><p>Conversely, emotionally charged reasons to quit, such as guilt, concern for health, or social responsibility, can also acquire salience, competing with smoking cues and reversing the balance of ambivalence. Thus, ambivalence is not neutral but dynamically sculpted by cognitive distortions that favor smoking and by affective drivers that strengthen abstinence, both of which modulate decision thresholds and outcome trajectories.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.10">Effort Costs as Leverage Points</head><p>The effort parameter ùúò(ùë°) scales expected reward inversely. Increasing barriers (e.g., monetary cost, inconvenience, or restricted access) raises ùúò, reducing smoking's subjective value and tipping the balance toward alternatives. Conversely, easy availability (low ùúò) amplifies reward value. This explains why environmental restrictions and taxation reduce smoking rates, while availability promotes relapse. Empirically, the model predicts dose-response relationships between effort manipulations and smoking frequency.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.12.11">Relapse Through Re-Entry</head><p>Even after switching to an alternative, strong external triggers (stress, exposure to others smoking, or sudden craving) can re-boost salience ùëÜ ùëó (ùë°), allowing the smoking option to re-enter the foreground. This dynamic re-entry frames relapse as an attentional process rather than simply a failure of willpower. Empirically, the model predicts that relapse is most likely in environments rich in smoking cues, particularly shortly after abstinence when withdrawal is high and receptor upregulation remains elevated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.13">Key Highlights</head><p>Highlight Explanation (SyNAPSE Framing) Cue salience depends on competition, not mere exposure Smoking-related cues elicit craving only if they bias neural competition enough to achieve dominance. Strong alternative signals (focus on a task, social disapproval) can prevent urges from surfacing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Smoking opportunity predicts cue impact</head><p>The effect of smoking-related cues depends on perceived availability: when a chance to smoke is near, cues more strongly bias attention and decision-making. Under impulsive conditions, signals reach the decision threshold faster, amplifying cue-driven lapses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Withdrawal severity reflects receptor upregulation</head><p>Craving intensity corresponds to the number of unbound receptors multiplied by upregulation. Two people with similar percentage of occupancy may experience vastly different withdrawal if one has higher upregulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Continued on next page</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Highlight Explanation (SyNAPSE Framing)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Slow metabolizers become more dependent at equal intake</head><p>Nicotine lingers longer, promoting stronger receptor upregulation. Predicts higher long-term dependence even if cigarette count matches peers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sleep interruptions slow dependence</head><p>Nightly abstinence reduces receptor upregulation and destabilizes smoking-related dominance. Predicts steeper morning cravings but less long-term dependence versus continuous nicotine delivery (e.g. 24h patch).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ambivalence lowers decision thresholds</head><p>When smoking and abstinence signals are closely matched, dwell-time thresholds collapse. Even fleeting salience of smoking can trigger lapses. Ambivalent smokers should show rapid oscillations in choice tasks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Positive reinforcement is overweighted</head><p>Cue-reward learning is asymmetric: positive surprises strengthen associations more than negative ones weaken them. Predicts biased recall of satisfying cigarettes over disappointing ones.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stress and negative affect amplify reward</head><p>Context acts multiplicatively on reinforcement. Smoking feels disproportionately rewarding under stress or negative mood, tipping competition in its favor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Social and identity signals rival biological modulators</head><p>Identifying as a "smoker" or being embedded in smoker networks stabilizes smoking signals by default, reducing the salience of non-smoking signals. Adopting a "non-smoker" identity re-weights competition toward abstinence.</p><p>Environmental barriers reduce smoking value Raising effort costs (price, inconvenience, restricted access) increases effective ùúÖ, lowering the subjective reward value of smoking. Such barriers add a bias to conscious (non-impulsive) competition, reducing the likelihood that smoking signals dominate. Predicts dose-response reductions in smoking rates with taxation and restrictive policies. Relapse as re-entry of smoking signals After abstinence, smoking-related signals can re-dominate if boosted by cues, stress, or permissive context. Relapse is not a linear failure but an attentional re-entry process. Cue extinction itself is non-linear, shaped by memory strength and contextual factors, which can allow dormant signals to re-emerge under the right conditions. Continued on next page Highlight Explanation (SyNAPSE Framing)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Context-sensitive lapses</head><p>The same cigarette is rated more rewarding under stress or social permissiveness. Predicts relapse clustering in specific contexts (e.g. pubs, stressful workdays).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intervention convergence principle</head><p>Whether biological (NRT), psychological (attentional retraining), or structural (policy), interventions succeed by tipping competition away from smoking dominance. Predicts synergy when levels are targeted together.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Personalized cessation outcomes</head><p>Individual differences (genetics, stress reactivity, cue salience, identity) reflect which modulators dominate competition. Predicts that tailored interventions (matching modulator profiles) will outperform one-size-fits-all approaches.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NRT timing matters</head><p>16h patches (mimicking sleep breaks) reduce upregulation more effectively than 24h patches, but produce stronger morning cravings. Predicts better outcomes with hybrid regimens (16h patch + gum in morning).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ambivalence predicts fragile abstinence</head><p>Quit attempts made under unresolved ambivalence should show more unstable attention switching, shorter abstinence spans, and higher relapse risk.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cue extinction via suppression</head><p>Repeated suppression of smoking urges without reinforcement should weaken cue-reward associations and reduce attentional capture. Predicts measurable drops in cue reactivity after structured extinction training, though the trajectory is likely non-linear, with periods of resistance or sudden decline. Suppression is especially effective when it occurs during strong urges in contexts where smoking was genuinely possible, producing deeper reversal of psychological dependence than suppression imposed by external constraints.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Signal timing shapes dominance</head><p>When smoking-related and abstinence-related cues occur close in time, their order determines competition. Earlyarriving signals bias attention more strongly, predicting that pre-emptive coping cues (reminders, commitments) are more effective than post-urge corrections.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Continued on next page</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Highlight Explanation (SyNAPSE Framing)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Signal strength adapts with repetition</head><p>Repeated dominance of smoking signals reduces the threshold for future wins in competition (habit formation). Conversely, repeated dominance of abstinence signals gradually raises the competitive weight of non-smoking alternatives.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Attention bottlenecks amplify competition effects</head><p>When cognitive load is high, competition is decided faster with less deliberation, allowing the most salient signal (often smoking-related) to dominate. Predicts higher lapse risk under multitasking or fatigue.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Signal suppression rebounds under depletion</head><p>Active suppression of smoking signals temporarily reduces their influence, but under stress or self-control fatigue, suppressed signals can rebound with stronger competitive weight. Predicts elevated lapse risk late in the day or after self-regulatory strain.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pre-rationalization stabilizes smoking signals</head><p>When smokers pre-justify their behavior, smoking signals gain competitive stability while non-smoking signals lose salience. This predicts sudden shifts toward persistent smoking, where rationalization acts as a meta-signal that re-weights competition in favor of smoking dominance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Closure signals reduce competition</head><p>A subjective sense of closure (e.g., finishing a placebo cigarette, performing a smoking ritual) can satisfy the urge loop, lowering the competitive weight of smoking signals.</p><p>Predicts that non-nicotine substitutes and ritualized behaviors reduce craving by providing resolution without reinforcement.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mindfulness weakens cue dominance</head><p>Mindful awareness allows smoking urges to be observed without immediate reaction, preventing automatic amplification of smoking signals. By decoupling salience from action, mindfulness practice reduces competitive bias toward smoking and strengthens abstinence-related signals. Predicts lower lapse rates in individuals trained in mindfulnessbased interventions. Upregulation initially rises with repeated smoking but then plateaus, forming a stable smoking dosage, where natural receptor decline between cigarettes balances the increase after smoking. This plateau explains how steady, long-term smoking behaviors are biologically sustained. The half-life for this modeling was taken as 2 hours Figure <ref type="figure" target="#fig_9">7</ref>.6: Effect of upregulation susceptibility, reflecting variability in nicotine metabolism and receptor response. High-susceptibility individuals (i.e., slow metabolizers) exhibit stronger receptor upregulation per cigarette and are therefore more prone to dependence, even when smoking the same or fewer cigarettes as their peers.     CHAPTER 8 One week into rehabilitation, with no cigarettes since admission, the struggle was still real. He felt terrible at times, but something had shifted. The idea of quitting forever no longer seemed like a distant utopia. It was beginning to feel possible, perhaps even something he could manage on his own. It was hard to say what had changed. The thought of life without cigarettes no longer felt unbearable. It was as if his brain had loosened its grip, as though some hidden force had released him. He remained a witness to it all, uncertain but aware that a quiet change had taken root. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1">Introduction</head><p>Despite decades of progress in understanding nicotine addiction, the gap between evidencebased treatment and long-term cessation remains wide. Many smokers attempt to quit, but only a small fraction succeed in sustaining abstinence. This persistent challenge suggests that approaches focusing exclusively on either the physiological or the psychological dimensions of smoking are insufficient. What is needed is a framework that integrates both domains into a practical and adaptive strategy.</p><p>The CLEAR-PATH Program <ref type="bibr" target="#b95">(Kshiteesh, 2025)</ref>   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2">A Note for Clinicians</head><p>It is important to recognize that CLEAR-PATH is presently at the prototype stage. While it has not yet been evaluated in large-scale clinical trials, its structure is grounded in extensive literature review, behavioral interviews conducted during our study, and practical heuristics introduced to ensure feasibility. The program is not intended to function as a rigid protocol. Instead, it is designed to serve as a supportive scaffold that can be flexibly adapted to the unique needs of each smoker.</p><p>One of the strongest insights to emerge from our research is that smoking behavior is highly variable across individuals. There is no single trajectory and no one-size-fits-all solution. For this reason, the clinician's role is indispensable. If a standard intervention fails to yield results, adjustments must be made. Both the smoker and the clinician should retain a sense of agency and control over the quitting process, rather than relying passively on a fixed algorithm.</p><p>At the same time, the smoker must be encouraged to develop self-awareness. Understanding personal motives, recognizing triggers, and identifying vulnerabilities are crucial. Motivation and commitment to quit must ultimately come from within. No external program, however sophisticated, can substitute for this inner drive. What CLEAR-PATH can provide is a structured environment in which that drive is nurtured, supported, and sustained.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.3">Operationalization of the Program</head><p>The CLEAR-PATH framework is envisioned as a comprehensive, technology-supported system that combines clinical expertise with digital efficiency. Its primary objective is to support clinicians in making informed, evidence-based decisions through structured assessment, data analysis, and tailored intervention strategies. By integrating clinically validated questionnaires, psychological scales, digital support systems, and systematic smoker evaluations, the program enables identification of critical factors such as nicotine dependence, smoking motives, environmental influences, and individual strengths or vulnerabilities.</p><p>The strength of CLEAR-PATH lies in its scope. It goes beyond conventional nicotine replacement therapy (NRT) to incorporate customization along with pharmacological interventions such as varenicline and bupropion, as well as behavioral methods including cognitive-behavioral therapy, JITI counseling, mindfulness, thought reframing, and habit-replacement strategies. Daily reminders and craving management check-ins help keep the process moving forward, breaking the momentum of past habits and maladaptive thoughts. Weekly digital assessments provide timely updates, allowing for responsive adjustments. Future extensions may include the use of biofeedback and virtual reality to simulate high-risk situations and strengthen coping mechanisms.</p><p>Perhaps most importantly, the program shifts away from manual, paper-based assessments toward an automated, clinician-accessible digital portal. This enables real-time interpretation of data, reduces administrative burden, and allows for richer clinician-smoker interactions. Therapy plans, follow-up schedules, and adaptive recommendations can all be managed through a single interface, improving continuity of care and engagement.</p><p>In this book, we present not only the tools, techniques, and methodologies currently available in our Program for addressing nicotine addiction, but also those that may shape its future. At every stage, we emphasize for whom these approaches are most likely to work, and under what conditions. This book is intended to serve as a guiding companion in the application of the CLEAR-PATH program, offering support both to the clinician who delivers care and to the smoker who undertakes the journey of quitting.</p><p>The following steps outline the CLEAR-PATH program in detail. relevant, addressing ambivalence around the desire to change, and reflecting back moments of self-efficacy. Once a patient articulates even one self-generated reason to quit, this becomes the foundation upon which commitment is built.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Motivation to Stop Scale (MTSS) <ref type="bibr" target="#b207">(Kotz et al., 2013)</ref>: 4-item instrument yielding scores from 0 to 16. Scores 0-4 indicate low motivation requiring motivational enhancement; scores 5-8 indicate moderate motivation warranting cautious assessment; scores 9-16 indicate high motivation and readiness to proceed with structured cessation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.4.4">Motivational Enhancement Protocol</head><p>If motivation is low, brief motivational interviewing (MI) is employed before proceeding to formal cessation planning. The approach includes:</p><p>‚Ä¢ Open Exploration: Inviting the smoker to articulate their personal reasons for quitting, underlying values, and genuine concerns.</p><p>‚Ä¢ Respect for Autonomy: Supporting choice and self-direction rather than applying labels or pressure.</p><p>‚Ä¢ Making Harms Tangible: Translating abstract health risks into concrete, personally meaningful consequences.</p><p>‚Ä¢ Resolving Ambivalence: Gently addressing the inner conflict between the desire for change and the fear of loss.</p><p>‚Ä¢ Eliciting Self-Efficacy: Highlighting past achievements and existing strengths to reinforce a sense of capability and control.</p><p>Once readiness improves, the motivation assessment is re-administered. If the score rises above 4, formal cessation planning begins. If motivation remains low, follow-up is scheduled in 1 to 3 months, as readiness often fluctuates.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.5</head><p>Step 2: Assessing Physiological Dependence</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.5.1">Purpose and Functionality</head><p>To measure the biological component of nicotine addiction, understanding how deeply the drug has altered neurochemical systems and predicting withdrawal severity. This assessment distinguishes between primarily behavioral habits and strongly ingrained physiological dependence, guiding the intensity and type of pharmacological support needed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.5.2">Dependence Severity Measurement</head><p>Cravings often outlast physiological dependence, but understanding the biological component is critical for tailoring treatment. The assessment captures markers of dependence through six behavioral and subjective indicators. Responses are scored to yield a total that stratifies dependence into low, moderate, or high categories.</p><p>Treatment strategies vary by dependence level. Low dependence often signals a primarily psychological or behavioral habit addressed through coaching, self-monitoring, and habitreplacement techniques, with minimal or no pharmacological support. Moderate dependence calls for combining structured quit plans with cognitive-behavioral therapy and selective pharmacotherapy. High dependence requires multi-pronged interventions including pharmacological agents, NRT, counseling, and close monitoring.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Fagerstr√∂m Test for Nicotine Dependence (FTND) <ref type="bibr" target="#b204">(Heatherton et al., 1991)</ref> : 6-item scale yielding total scores from 0 to 10. Scores 0-4 indicate low dependence; scores 5-7 indicate moderate dependence; scores 8-10 indicate high dependence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.5.3">Biological Mechanisms and Precision Adjustment</head><p>The SyNAPSE model adds depth to dependence assessment by showing how neural receptor upregulation shapes dependence. Chronic nicotine exposure upregulates nicotinic acetylcholine receptors (nAChRs), shifting the brain's baseline state such that withdrawal emerges without the drug while the person feels "normal" with it. Standard tools capture severity in terms of frequency and intensity of use, but they do not always reveal the underlying receptor state.</p><p>Two smokers with identical dependence scores may have different receptor densities based on smoking duration and intensity, affecting withdrawal severity and pharmacotherapy needs. By integrating dependence assessment with SyNAPSE-based profiling, CLEAR-PATH ensures that treatment recommendations move beyond standard protocols, matching the right dose, intensity, and behavioral support to both measured dependence and underlying neural state.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.6</head><p>Step 3: Identifying Smoking Dependence Motives</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.6.1">Purpose and Functionality</head><p>To identify the psychological, behavioral, and social motives that maintain smoking, revealing why the behavior persists even when the smoker wishes to quit. Recognizing which motives exert the strongest influence allows the clinician to design targeted behavioral interventions that address the specific mechanisms keeping the smoker locked into the habit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.6.2">Motive Identification</head><p>Initiation explains how smoking begins, but maintenance explains why it persists. Learned associations such as stress relief, social bonding, and boredom relief persist long after physiological dependence resolves. These motives actively bias the competition of neural signals in moments of decision making, magnifying certain urges while diminishing competing thoughts about quitting.</p><p>The assessment identifies various motivational domains, ranging from emotional relief to social reinforcement, automaticity, loss of control, and taste preferences. Subscale scores above a certain threshold indicate strong influence, highlighting the specific motives that lock an individual into smoking. These motives are not passive descriptors but active drivers of behavior.</p><p>The assessment also surfaces the predictable distortions and rationalizations generated by these motives. Statements such as "one cigarette will not hurt" or "this is the last one" are not random excuses but systematic distortions emerging from the dominant motives. Once these patterns are recognized, their power diminishes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Wisconsin Inventory of Smoking Dependence Motives (WISDM) <ref type="bibr">(Piper et al., 2004)</ref> : 37-item questionnaire measuring 13 subscales on a 7-point Likert scale. Scores above ing signals and make withdrawal symptoms harder to tolerate. A highly neurotic smoker may exaggerate the threat of withdrawal, giving undue salience to the craving signal. Conscientiousness supports adherence by strengthening goal-directed control; low conscientiousness requires more structure and external accountability. Openness may encourage willingness to try novel strategies such as mindfulness or biofeedback. Extraversion increases both risk through social triggers and opportunity through peer support. Agreeableness may foster responsiveness to clinician guidance but also risk compliance without true internalization.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Five-Factor Model (OCEAN) <ref type="bibr" target="#b202">(Costa and McCrae, 1992)</ref>: Assessed through clinical interview, observation, or instruments such as the NEO-FFI. Dimensions include Openness to Experience, Conscientiousness, Extraversion, Agreeableness, and Neuroticism.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.7.3">Personality-Based Intervention Tailoring</head><p>High neuroticism calls for stronger emotional regulation training, mindfulness-based stress reduction, acceptance and commitment therapy, and pharmacological support to buffer against heightened withdrawal. Low conscientiousness requires highly structured, step-by-step guidance with behavioral contracts, goal-setting, external reminders, and automated digital workflows. High extraversion benefits from identifying and reducing smoking peer contact while redirecting social energy toward non-smoking groups. High agreeableness responds well to clinician partnership and values-based motivational messaging.</p><p>By surfacing personality tendencies, the program helps smokers recognize how their traits may bias their experience of cravings, risks, and decisions. Future iterations will integrate personality-based feedback into digital tools, offering prompts that not only identify distorted thoughts but also highlight how personality traits are amplifying them in the moment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.8">Step 5: Predisposition Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.8.1">Purpose and Functionality</head><p>To identify the intrinsic factors that shape susceptibility to nicotine addiction, predict withdrawal severity, and influence pharmacotherapy efficacy. This assessment recognizes that biological predisposition, such as the rate at which nicotine is metabolized, influences how rapidly dependence develops and guides decisions about cessation intensity and duration of pharmacological</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.9.2">How to Determine It</head><p>Estimation of the dip nicotine level is based on a combination of physiological and behavioral variables, including:</p><p>‚Ä¢ Nicotine half-life (adjusted for metabolic rate)</p><p>‚Ä¢ Number of cigarettes smoked per day</p><p>‚Ä¢ Average interval between cigarettes</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>‚Ä¢ Depth of inhalation and puff duration</head><p>‚Ä¢ Individual metabolic rate Using these parameters, clinicians can approximate the point at which plasma nicotine levels decline to the individual's craving threshold. This information can then guide nicotine replacement therapy (NRT) dosing to maintain baseline nicotine concentration near that critical level.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.9.3">Tools</head><p>A dedicated Nicotine Level Calculator has been developed within the CLEAR-PATH framework, based on established pharmacokinetic models and empirical data. The calculator integrates the parameters listed above to produce an individualized estimate of nicotine decline curves and projected craving onset windows. Clinicians can use these estimates to:</p><p>‚Ä¢ Schedule behavioral check-ins or digital reminders before expected craving peaks.</p><p>‚Ä¢ Optimize timing of NRT or pharmacotherapy doses to maintain sub-craving plasma levels.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.10">Step 7: Finalizing the Cessation Program</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.10.1">Purpose and Functionality</head><p>To synthesize data from all prior assessments into a personalized cessation program specifying the quit date, pharmacological regimen, behavioral intervention modules, monitoring schedule, and relapse prevention plan. This integration ensures that treatment intensity matches the smoker's unique profile.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.10.2">Tailored Program Design</head><p>The goal is not just to suppress cravings but to reverse dependence by normalizing receptor activity. Pathways differ by dependence level. Intermittent smokers may succeed with minimal pharmacological aid and behavioral strategies. Moderate dependence often requires structured quit plans with NRT or targeted pharmacotherapy. Heavy dependence, especially with high receptor upregulation, calls for multi-pronged care combining higher-dose or dual-form NRT, pharmacological agents, counseling, and close monitoring.</p><p>Over-medicating low-dependence smokers can worsen addiction by saturating receptors and amplifying reward circuits. Conversely, under-treating heavily dependent smokers invites relapse because their baseline neurochemistry sustains persistent withdrawal signals. By integrating dependence, motives, personality, and predisposition, CLEAR-PATH builds a cessation plan that is both effective and sustainable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.10.3">Pharmacotherapy Options and Selection</head><p>Nicotine Replacement Therapy (NRT) is available in multiple forms. The transdermal patch provides sustained release and convenient once-daily dosing but does not address immediate cravings. Gum provides rapid onset within minutes and flexible dosing but requires proper technique. Lozenges provide rapid onset and convenience without the need for chewing. Nasal spray provides rapid onset but carries higher abuse potential. Oral inhalers mimic the hand-tomouth ritual with rapid onset.</p><p>NRT baseline dosing is estimated by cigarette consumption. 1 to 10 cigarettes per day suggest 7 mg patch daily or 2 to 4 mg lozenge as needed. 11 to 20 cigarettes per day suggest 14 mg patch daily or combination therapy. 21 to 30 cigarettes per day suggest 21 mg patch daily plus 2 to 4 mg lozenge for breakthrough cravings. 31 or more cigarettes per day suggest 21 mg patch daily plus 4 mg lozenge plus consideration of varenicline or bupropion.</p><p>Varenicline is a partial agonist at the ùõº4ùõΩ2\alpha_4\beta_2ùõº4ùõΩ2 nicotinic receptor that reduces craving and blocks the rewarding effects of smoking. Its efficacy is superior to placebo and comparable to nicotine replacement therapy (NRT), and it is often considered a first-line option for individuals with moderate to high nicotine dependence. Common side effects include transient nausea, vivid dreams, insomnia, and occasional mood disturbances, which require monitoring.</p><p>Bupropion XL is an antidepressant that enhances dopaminergic and noradrenergic activity, thereby reducing craving and withdrawal symptoms. Its efficacy is comparable to NRT, and it is particularly useful in smokers with coexisting depression or anxiety. Side effects may include insomnia, dry mouth, and headache, with a rare risk of seizures in susceptible individuals.</p><p>Combination pharmacotherapy using NRT together with varenicline or bupropion can be beneficial for smokers with high dependence, though it requires clinical oversight to monitor for adverse effects and optimize tolerability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.10.4">Behavioral Modules and Counseling Structure</head><p>Based on motives, personality, and dependence, clinicians select from cognitive-behavioral therapy for teaching coping skills and relapse prevention; mindfulness-based stress reduction for high neuroticism or stress-driven smoking; acceptance and commitment therapy for high loss-of-control motives; motivational interviewing for ongoing ambivalence; habit-reversal training for automaticity-driven smoking; and exposure therapy for cue-driven cravings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.11">Step 8: Monitoring Withdrawal Symptoms</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.11.1">Purpose and Functionality</head><p>To track withdrawal severity across physical and psychological domains, enabling real-time program adjustment. Withdrawal is the primary barrier to cessation; structured monitoring ensures that support intensity matches the smoker's current experience and prevents relapse driven by unmanaged discomfort.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.11.2">Withdrawal Assessment and Adaptive Response</head><p>Withdrawal is the primary barrier to cessation. Physical symptoms such as irritability, anxiety, and restlessness peak in the first week and subside over 2 to 4 weeks; psychological cravings may persist for months.</p><p>The assessment captures withdrawal severity across multiple domains including irritability, anxiety, difficulty concentrating, craving intensity, negative affect, restlessness, and hunger. Total scores are interpreted as minimal (0 to 20) suggesting continuation of current plan; mild (21 to 50) suggesting monitoring and standard support; moderate (51 to 80) suggesting increased NRT dose or added counseling; or severe (81 to 112) suggesting increased pharmacotherapy, increased counseling frequency, and assessment for psychiatric complications.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Wisconsin Smoking Withdrawal Scale (WSWS) <ref type="bibr" target="#b203">(Welsch et al., 1999)</ref> : 28-item self-report scale measuring withdrawal across subscales including Irritability/Frustration/Anger (5 items), Anxiety (5 items), Difficulty Concentrating (5 items), Craving (5 items), Negative Affect (4 items), Restlessness (2 items), and Hunger (2 items). Each item rated 0-4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.11.3">Clinician Response Protocol</head><p>For mild-to-moderate withdrawal, reassurance that withdrawal is temporary, behavioral coping strategies such as exercise and mindfulness, and consideration of incremental NRT increases. For severe withdrawal, increased pharmacotherapy, increased counseling to 2 to 3 times weekly, screening for depression and suicidality, and consideration of intensive outpatient programs.</p><p>Withdrawal is reframed for smokers as normal, predictable, temporary, a sign of brain chemistry changing for the better, and manageable with available tools and support.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.12</head><p>Step 9: Program Monitoring and Adjustment</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.12.1">Purpose and Functionality</head><p>To maintain engagement and responsiveness throughout the cessation journey by continuously gathering data on adherence, withdrawal, triggers, and coping success. Real-time adaptive adjustment ensures that treatment evolves alongside the smoker's experience.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.12.2">Weekly Digital Monitoring</head><p>Each week, the smoker completes a digital check-in capturing abstinence status and days of continuous abstinence, withdrawal symptoms via simplified scales, medication adherence and side effects, high-risk situations encountered, coping strategies used and their effectiveness, and motivation and confidence levels.</p><p>The CLEAR-PATH system aims to analyze data in real-time and generate alerts. Green flags would indicate the smoker is on track (abstinent, minimal withdrawal, good adherence, strong coping). Yellow flags would indicate caution (breakthrough withdrawal, missed medications, emerging high-risk situations). Red flags would indicate high risk (lapse or relapse, severe withdrawal, poor adherence, explicit smoking thoughts) requiring immediate clinician alert and urgent follow-up.</p><p>Based on check-in data, clinicians can make targeted adjustments. Severe withdrawal despite adherence calls for increased NRT dose or added pharmacotherapy. Craving linked to specific triggers calls for targeted behavioral intervention. Lapse without full relapse calls for reviewing trigger and coping failure, troubleshooting, increasing counseling frequency, and reframing as learning opportunity. Poor medication adherence calls for simplifying regimen and adding automated reminders.</p><p>The CLEAR-PATH portal displays days of abstinence as a large counter, withdrawal trend as a line graph showing expected decline, medication adherence percentage, craving intensity as a bar chart, and milestones as badges for achievements.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.13</head><p>Step 10: Long-Term Relapse Prevention</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.13.1">Purpose and Functionality</head><p>To prepare smokers for future temptations through identifying high-risk situations, developing personalized coping plans, building resilient non-smoker identity, and creating frameworks for managing lapses without full relapse. Relapse risk remains elevated for months to years; prevention is an ongoing process.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.13.2">High-Risk Situation Mapping</head><p>Relapse risk remains elevated for months to years. Relapse prevention prepares smokers for future temptations by identifying high-risk situations such as stress, social gatherings with smokers, alcohol consumption, and post-meal smoking. For each high-risk situation, specific coping responses are practiced and committed to. Self-efficacy is built through reviewing past successes and celebrating milestones. Lapses are addressed without catastrophizing, with the understanding that a single cigarette is not full relapse and offers information rather than proof of failure.</p><p>Coping strategies are categorized as avoidance or substitution (physically avoiding cues or substituting alternative behaviors); cognitive strategies such as urge surfing and counterrationalizations; behavioral or somatic strategies such as breathing exercises, muscle relaxation, and physical activity; and social strategies such as reaching out to support networks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.13.3">Non-Smoker Identity and Extended Support</head><p>Identity shift from "I am a smoker trying to quit" to "I am a non-smoker" is powerful and increases resilience. Language is shifted to use "I am a non-smoker" rather than "I am trying to quit." Milestones are celebrated to reinforce non-smoker identity. Non-smoking status is shared socially to enlist support. Non-smoking is connected to core values such as health, family, independence, and courage. Some smokers, particularly those with high dependence or repeated relapse history, benefit from extended NRT or pharmacotherapy beyond the initial 12 weeks, typically for 3 to 12 additional months, maintaining neurochemical stability and reducing spontaneous cravings. Example extended regimen: weeks 13 to 24 maintain 7 mg patch daily or switch to as-needed NRT; weeks 25 to 36 further taper or discontinue; behavioral support and check-ins continue throughout.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.13.4">Lapse Management</head><p>A lapse (1 to 3 cigarettes) is not relapse (return to regular smoking). Most smokers experience at least one lapse; the clinician's role is to prevent full relapse. Upon lapsing, the smoker calls the clinician immediately. Functional analysis identifies the trigger, thoughts and emotions leading to smoking, and what could have been done differently. The lapse is reframed as a teaching moment rather than failure. The plan is modified based on analysis. Stress-triggered lapses lead to added stress management; social-triggered lapses lead to rehearsed refusal skills and reduced peer contact; cue-triggered lapses lead to deployed cue avoidance or exposure therapy. The smoker recommits to abstinence with revised strategy and increased contact frequency during the high-risk period.</p><p>Long-term monitoring transitions to reduced frequency: biweekly or monthly during months 3 to 6, monthly during months 6 to 12, and quarterly or as-needed in year 2 and beyond. Focus remains on continued abstinence, high-risk situations encountered, non-smoker identity maintenance, medication status, and future planning.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.14">Program Timeline and Contact Frequency</head><p>First Week (Most Critical): Contact 2 to 3 times via phone or in-person. Assess withdrawal symptoms, medication adherence, urges, and coping successes. Adjust if withdrawal is severe or side effects are intolerable. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.15">Digital Cessation Companion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.15.1">Purpose and Functionality</head><p>The Digital Cessation Companion is a real-time interactive support system that extends the clinician's guidance into the smoker's daily life. It integrates emotional monitoring, motivational feedback, and coping tools into a single digital interface. By simulating reflective questioning and adaptive feedback, the companion helps users respond to urges as they occur, maintain self-awareness, and strengthen resilience during cessation.</p><p>This system has three primary goals: 1. To identify the smoker's current emotional and motivational state through short, selfinitiated check-ins.</p><p>2. To deliver personalized interventions such as mindfulness cues, cognitive reframes, or brief reflective exercises matched to the smoker's immediate state.</p><p>3. To collect reflective data that can motivate the individual through increased mindfulness and recontextualization of their experience, while also informing the clinician's understanding of progress and guiding subsequent adjustments in care.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.15.2">Process Overview</head><p>Each interaction begins with a short prompt such as "How are you feeling right now?" Based on the smoker's response, the companion initiates one of three adaptive paths: calm, mild urge, or strong urge.</p><p>In the Calm Path, the focus is on reflection and reinforcement. The smoker is invited to write a short journal entry about what has been helping them stay smoke-free and may choose to save or skip the entry. The goal is to consolidate self-efficacy and strengthen the identity of being a non-smoker.</p><p>In the Mild Urge Path, the companion explores situational or environmental factors that may be increasing craving. It asks brief questions about medication adherence, recent life changes, and possible triggers. The smoker then completes an eight-hour risk check, identifying whether smoking feels likely in the near future. If the risk feels low, a short written resolution is encouraged. If the risk feels uncertain, the system helps identify rationalizing thoughts, reframe them, and schedule reminders for high-risk periods.</p><p>In the Strong Urge Path, the focus shifts to immediate stabilization. The smoker selects a grounding activity such as guided breathing, watching a calming video, reading a previous journal entry, or using a personalized coping tool. Once the craving subsides, a thirty-minute risk check is completed. If risk remains, the smoker is guided through thought reframing and reminded to adjust nicotine replacement or environmental factors as needed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.15.3">Adaptive Feedback and Learning</head><p>Each use of the digital companion contributes data to a personal feedback loop. Over time, the system learns which interventions are most effective for each individual and prioritizes them in future interactions. For example, if breathing exercises consistently reduce craving intensity, those activities are offered earlier in the process. If journaling supports emotional stability, it appears more frequently during calm or post-craving moments.</p><p>At present, the program allows data to be stored locally on the user's device, ensuring that no information is transmitted externally and that the risk of privacy breaches remains minimal.</p><p>In future iterations, secure cloud-based databases could be implemented to provide enhanced clinical support and data continuity. Such systems would allow clinicians to monitor progress, identify emerging patterns of vulnerability, and make timely, individualized adjustments to the cessation plan.</p><p>In this way, the Digital Cessation Companion functions as an evolving therapeutic partner that embodies the adaptive and personalized principles at the core of the CLEAR-PATH program.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.16">Integrated Web Application for Personalized Cessation Program</head><p>The CLEAR-PATH portal integrates assessment, dosage calculation, program generation, and weekly follow-up into a single adaptive platform. Its key components include:</p><p>1. Smoking Assessment Questionnaires: Structured intake merging smoking history, dependence assessment, motivational scales, personality profiling, and predisposition indicators, producing a multidimensional profile.</p><p>2. Nicotine Dosage Calculator: Estimates baseline blood nicotine levels by factoring in daily cigarette intake, nicotine content, and inhalation depth, guiding precise NRT dosing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Cessation Program Designer:</head><p>Generates tailored first-week plans integrating NRT with behavioral modules, trigger-avoidance strategies, and motivational prompts.</p><p>4. Follow-Up Adjustment: Adapts the program through weekly monitoring of adherence, withdrawal severity, susceptibility, and progress toward dependence reversal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Digital Craving Companion:</head><p>A digital tool that monitors withdrawal severity and resolution to quit. It offers instant access to cognitive reframes, breathing exercises, and personalized coping tools. Users can plan for high-risk situations, schedule regular checkins, or activate support anytime. This continuous feedback loop sustains motivation and strengthens relapse resistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.17">Scope for Improvement</head><p>CLEAR-PATH remains a prototype requiring rigorous validation through pilot studies and clinical trials. Development is iterative, with several areas identified for enhancement:</p><p>‚Ä¢ Clinician training: Creation of structured modules to improve interpretation of assessment data, dosage calculations, and program adjustments.</p><p>‚Ä¢ Health system integration: Linking with electronic health records to streamline data flow, reduce administrative burden, and support continuity of care.</p><p>‚Ä¢ Accessibility: Expanding reach through multilingual support, culturally tailored interventions, and lightweight mobile platforms for underserved settings.</p><p>‚Ä¢ Advanced tools: Development and validation of biofeedback systems, VR-based craving simulations, and bot-assisted cognitive distortion monitoring.</p><p>‚Ä¢ Relapse prevention: Strengthening long-term support through peer networks, extended pharmacotherapy when needed, and structured digital follow-up.</p><p>These enhancements would refine the precision of CLEAR-PATH and increase its scalability, ensuring that the program evolves into a practical and sustainable tool for diverse clinical and community contexts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.18">Our MOTO</head><p>Our goal is simple yet demanding: to reduce the salience of smoking-related thoughts, to strengthen the salience of quitting-related ones, and to reverse the biology of dependence as rapidly as possible, all while walking the fine line that avoids pushing the person into exhaustion and relapse.</p><p>She wanted to quit, not because cigarettes were expensive, not from fear of dying and not from parental disapproval. She wanted to quit because each cigarette made her feel herself slipping away. Smoking was not just about nicotine; it was about losing control of her choices. Without that control, her confidence and sense of purpose drained with each puff. For once, she sought upliftment, autonomy, and the dignity of looking at herself without shame. This change in meaning reshaped each cigarette. It was no longer comfort or rebellion, but a cheap trick keeping her from her strength. She had goals beyond quitting. So each time the craving came, she whispered: Not this time. Not for this empty thing. Moments of resistance became days, days stretched into months, months into years. Eventually, she quit. There were lapses, but she never let them define her. A lapse was an incident, not a collapse of identity or a reason to continue. She learned the next moment is shaped only by what we choose in the present. This thought gave her courage: to let go of the past, focus on the now, and reclaim the power to decide her own fate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.1">Initiation into the Cult</head><p>In a quick conversation: congratulations, you are already initiated into quitting! The very fact that you bothered to go through the earlier chapters, or perhaps not and jumped straight to this one, no matter, means you are motivated to quit, or at least you want to quit. And that already saves me an important job: explaining in detail the harms of cigarettes and why you should quit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2">I won't tell you why to quit</head><p>You might wonder why this book does not begin with a long explanation of why you should quit smoking. I once considered adding a chapter titled Why You Should Quit, but then realized it was unnecessary. If you are reading this, you already know the reasons. You are not here looking for motivation. You are here looking for a way out.</p><p>There is already an ocean of information about the harms of smoking. You see it on every cigarette pack, in public health campaigns, in documentaries, and in the stories of those who have suffered. The warnings could not be clearer or more disturbing. Yet people still buy the same pack, light the same cigarette, and tell themselves it is fine for now.</p><p>That shows the problem is not ignorance or lack of awareness. It lies deeper, in the way the mind separates what it knows from what it feels. This book is written for that deeper part. It is not about convincing you that smoking is bad. It is about helping you understand why you keep doing something you already know you should not.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.3">Why Smokers Think It Won't Happen to Them</head><p>The real problem is not a lack of horror stories about smoking. Everyone has heard them. The problem is that most smokers do not believe those horrors will happen to them. This is called the depersonalization of risk. The thought goes, It will not happen to me. That single belief is one of the strongest shields against change. It makes the danger feel distant and abstract, something that belongs to other people.</p><p>Part of what we aim to do in the CLEAR-PATH method is to break that detachment and bring the risk closer to reality. People need to understand that yes, they too can die from smoking, and yes, their child can die from second-hand smoke. This can not be a soft game, especially for someone who has no interest in quitting or who continues to dismiss the harms.</p><p>But you are different. You already know the harms. You are aware. The real problem is that in moments of crisis, the thoughts of smoking take the driver's seat. You get pushed into the back seat, watching helplessly as the car speeds off. That is okay. It happens to the best of us. What matters is learning how to take the wheel back, one moment at a time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.4">It's Not Because You're Weak</head><p>At this point it is worth clearing up a common misconception: smoking is not just about weakness. Framing smoking as a problem of weak cognitive control has been the norm, and there is some truth in it. But there is more. Even a person with strong cognitive control can succumb if the withdrawal signal is strong enough. The fact is that they perhaps never experience such strong surges to begin with, and so it remains incommensurable. Our SyNAPSE Model (please revisit the summaries of Chapters 4 and 6) captures this dynamic clearly. Which means you should not worry. This is not about you being weak. This is about signals, circuits, and competition. And signals can be weakened. Circuits can be rewired. We can fix this!</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.5">The Voice That Holds You Back</head><p>To really understand what keeps people locked in the cycle, we must talk about the Smoker Identity. I do not think the smoker identity in you is that of an aggressive, proud smoker who flaunts the habit. Rather, the smoker identity that lives within you is the one that weakens you whenever you try to quit. It is the voice that pulls you back with doubts like: "Will I be able to do it?" or "Maybe I should try another time." That hesitant, self-defeating voice is what I call the smoker identity.</p><p>Why do I call it an identity? Because it was not there in the early days of smoking. In those days you were simply someone who smoked. The smoker identity began to form only after your first attempt to quit, when you failed. Each failed attempt after that, each wave of guilt, each moment of lost autonomy, layered itself into a narrative about who you are. Over time, those failures crystallized into an identity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.6">Breaking the Identity</head><p>Fortunately, identities are not set in stone. If repetition of failure could build the smoker identity, repetition of success can dissolve it. And success does not need to mean perfection. Even one small win at a time, repeated, is enough to chip away at it.</p><p>The shift begins with belief. You are not someone who "is a smoker." You are someone who "is in the process of quitting." That small change in perspective matters. One identity keeps you trapped. The other opens a path forward.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.7">The Check-In</head><p>Before moving further, pause for a second. Reading up to here might already fill you with some motivation. But what exactly are your thoughts at this precise moment? Have you decided to not smoke from now?</p><p>If there is even a slight delay in your response, it means the motivation will not hold its strength for long. The peak effect of motivation to quit appears immediately. It either shows itself in the very next moment, or it begins to fade, though it may return again later.</p><p>If you have at least made a promise to yourself to avoid smoking during a few of your usual occasions, then the motivation has already worked. You have taken your first small step forward.</p><p>If not, that is perfectly fine too. What matters most is that you notice the inner voice within you. That voice will reveal whether there is a conflict in your thoughts. And only you can truly hear and understand it.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.8">Why Do You Want to Quit?</head><p>Every attempt to quit must be anchored in something personal. Ask yourself, why do you want to quit? Pay attention to the very first thought that arises in response.</p><p>Smoking is often driven by withdrawal and by the expectation of relief or pleasure. It is tied to memories of comfort, calm, or happiness. Beneath it all lies a strong emotional core. Emotions give power to thoughts and urges. They make them feel real and urgent. Now ask yourself, is your reason to quit strong enough to feel just as real and just as urgent? More importantly, does it stay strong in moments of stress or crisis? Or does it get replaced by the quick justifications your mind creates to excuse another cigarette?</p><p>If your reason fades too easily, find one that runs deeper. Choose something that gives you purpose beyond the act of quitting, something that connects to the kind of life you want after quitting. It could be your health, your children, your sense of self-respect, or the control you want over your own mind. Whatever it is, let it be personal, and make it matter.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.9">When Your Brain Becomes a Battlefield</head><p>Once you know your reason, the real contest begins inside your head. Think of it as a battlefield.</p><p>One side is the craving signal: "Light up, just one, you will feel better." The other side is the quitting signal: "Hold on, you have promised yourself, you do not need this." These signals do not take turns. They fire rapidly, collide, and compete for control. This is why hesitation is not neutral. That moment when you feel torn is itself part of the battle. It is the mind negotiating with itself, and whichever thought you choose to follow becomes stronger the next time.</p><p>Victory does not mean silencing the craving. It means allowing the quitting signal to take control, even for a moment. Each time you do that, you strengthen it. Over time, those small moments of control shift the balance of power.</p><p>So no matter how loud the craving feels right now, the task is the same. The task is to quit. And since that is the task, my job is to move forward with you.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.10">Shifting the Salience</head><p>At the center of our SyNAPSE model of addiction and the CLEAR-PATH cessation program lies one key principle: the effort to reduce the salience of smoking-related thoughts and to shift that salience toward quitting, or even toward something entirely different.</p><p>When you resist a craving, it often feels terrible in the moment. Yet if you look back a short while later, that same unsatisfied craving can feel good in retrospect. You recognize that the impulse has passed, and you did not give in. In the long run, the satisfaction of not smoking always outweighs the fleeting pleasure of smoking.</p><p>The challenge is that in the heat of the moment, the craving feels more vivid and more real than the benefits of restraint. The brain exaggerates the importance of the urge, making it seem impossible to ignore. In those moments, the salience of the craving makes the brain go completely awry. Neural signals, the bastard!</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.11">Seeing Through the Mind's Tricks</head><p>To overcome this, you need to understand how those signals work and how they shape your thinking. Once you learn how they arise and how they distort your thinking, you can modify and attenuate them. That is why we spent so much time reviewing cognitive biases and distortions, and showing their causal role through SyNAPSE modeling. Go back to Chapter 5 if you need a refresher. You might be surprised to see how universal these distortions are. The mind tricks reality in predictable ways. Knowing these tricks makes it easier to discard the rationalizations.</p><p>Of course, the mind will continue to create more distortions. That is what cravings do. But with awareness, you can start to catch them as they appear. The craving itself may still be there, but you will see it for what it is. And if you do lose control and smoke, at least you will know that you lost it.</p><p>That cigarette will likely come with guilt and disappointment, but that is still better than a rationalized one. A rationalized cigarette opens the door to the next, and the next after that.</p><p>A guilt-driven cigarette may hurt your self-esteem for a moment, but it keeps the truth visible.</p><p>When that happens, remember this chapter and this book, and use that guilt as fuel for your next attempt. Turn it into a plan to quit again, and this time, to stay quit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.12">The Traps in Your Environment</head><p>Armed with this understanding of signals, we must now turn outward, to the environment. Smoking is rarely just about nicotine. It is also about the places, the routines, and the small rituals that have trained your brain to expect a cigarette. These are the traps, the cues and triggers that ambush you when you least expect it. The morning coffee that does not feel complete without smoke, the walk after lunch, the stress of a difficult call, or the sight of friends stepping outside together.</p><p>If cues and triggers are what drive you mad, then do not underestimate them. They are not minor. They are the invisible wires that keep the smoker identity alive. In the initial stage, you must either fix them or avoid them. Precommit to something that keeps you away from them. Change the routine, skip the coffee, take a different route, stay away from the smoking crowd. This is not about hiding forever. It is about buying time for your brain to adjust.</p><p>The first days are the most challenging, because those loops of habit and repetition are still intact. Do whatever it takes to close them, even if that means isolating yourself for a while. Think of it as dismantling landmines before you learn how to walk the path with confidence.</p><p>And here is the good news: your body and mind adjust faster than you imagine. The cravings weaken, the triggers lose their sharpness, and you gain room to breathe. Once that happens, once you have created enough distance, we can then move on to more rational, structured steps, where you will no longer fear the triggers but face them on your own terms. In fact, facing them head on at a later stage will give you the courage to defeat them in the future and will resolve even the tiniest bits of fear within.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.13">You Do Not Have to Do This Alone</head><p>And never forget, you do not have to do this alone. It is okay to ask for help. It is okay to register for a cessation program, to seek peer support, to reach out so that you do not feel alone. This book may ideally be enough, but the mind often gives more salience to things that come from outside it.</p><p>Imagine your most esteemed person, or someone you deeply admire, coming to you and asking you not to smoke for the next scheduled break. Would it not work wonders? Somehow, that is how the mind works. External voices sometimes carry more weight than our own.</p><p>So do not hesitate. Let someone you trust know that you are quitting. Share it. You will find that it gives you far more comfort, strength, and accountability than you might expect.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.14">The First Battle: Cravings</head><p>With this foundation set, let us talk about the actual battles. The first, and perhaps the fiercest, is cravings. Cravings feel like life-or-death. Your body screams, your brain tells you a dozen stories about why you "deserve" one smoke. In that moment, quitting feels impossible. But here is the trick: cravings are time-bound. They peak, they hold, and they fall.</p><p>If you can just wait for ten minutes, sometimes even two, something interesting happens. The craving loses its intensity. It feels less urgent, less commanding. Think of it like a storm cloud. It looks massive and scary, but it always drifts away.</p><p>In those minutes, your goal is to hold on, not by sheer willpower but by shifting your focus. Engage yourself in something, anything, that interrupts the craving loop. Watch a short video, breathe deeply, think about a childhood memory, or immerse yourself in a small task that demands thought, such as reading, solving a puzzle, or organizing your desk. If nothing comes to mind, stand up and move. Jump in place, stretch, or walk briskly. Do anything that changes your physical state. Movement alters your breathing and attention, helps regulate physiological arousal, and that alone can weaken the grip of the craving.</p><p>So your first task is not never smoke again. Your first task is outlast this craving. One craving at a time. That is how you win. You can look back at the previous chapter and identify which technique works best for you. The most practical one, to put it simply, is mindfulness of your breath. When you focus on breathing, slow, steady, and aware, you are no longer feeding the craving. You are observing it. And that single act of awareness begins to change everything.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.15">The Second Battle: Triggers</head><p>Closely allied with cravings are their companions: triggers. Morning coffee. After meals. Boredom. Stress. Alcohol. Friends who smoke. You know your triggers better than anyone else.</p><p>As discussed, here is the deal: in the beginning, do not take on every trigger at once. That is like fighting a war on ten fronts, and you will be exhausted. Narrow the battlefield. Skip the coffee, change the routine, step away from the smoking crowd for a while. Later, when you are stronger, you can bring those contexts back and face them directly. But not now. Not yet.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.16">The Third Battle: The Inner Voice</head><p>Then comes the trickiest enemy of all: the inner voice. This voice does not scream like cravings, it whispers. It says things like, "One cigarette will not hurt," or "You can always quit tomorrow," or the most dangerous of all: "You are already failing, so why bother?"</p><p>That voice is the smoker identity in action. And you have to learn to call it out. Treat it like a character in your head, a trickster, not your true self. When you notice it speaking, pause. Even say it out loud if you can: "This is the smoker voice, not me."</p><p>The act of naming it creates distance. That distance gives you the power to choose differently. Without naming it, the voice blends with your own thoughts, and you believe it blindly.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.17">The Fourth Battle: Lapses</head><p>Now let me say something that might sound contradictory but is actually crucial: you will probably slip. Most people do. But the slip itself is not the problem. The meaning you give it is the problem. Do not take this section as permission to slip. In fact, you must not slip. Period. But if you do, life still continues afterwards, and that is why you need to read this.</p><p>If you treat one cigarette as "proof I cannot quit," then you collapse into the old cycle. If you treat it as "an incident, not an identity," then you move on stronger.</p><p>Do not let a lapse harden into relapse. Use it as feedback. Ask: what triggered it? Was it stress, was it boredom, was it social pressure? Learn from it, adjust, and carry on.</p><p>Quitting is not about being flawless. Quitting is about refusing to let the past define the next moment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>9.18</head><p>The Fifth Battle: The Future Self</p><p>Finally, let us look ahead. At this point, you may feel that quitting is an endless struggle, but there is a deeper shift taking place beneath the surface. Each moment of resistance weakens the smoker identity and strengthens the version of you that lives free from it.</p><p>You might sometimes feel cursed by the thought of never being able to smoke again. Even if you try to brush it aside, that thought may return in moments of nostalgia or memory. When it does, do not fight it directly. Tell yourself, "Not now. Maybe later in life, when I am older, I can think about it again." This small mental allowance can quiet the urge in the present, helping you focus on what matters now. And when that "later" truly arrives, chances are you will no longer even want it.</p><p>Imagine yourself six months from now: breathing easier, moving faster, your clothes clean and free of smoke, your mind clearer, your confidence restored. That version of you is not imaginary. It already exists as a possibility waiting to be realized. Every choice not to smoke is a step toward that self. Every cigarette you refuse is a deliberate vote in its favor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.19">So, Dear Quitter</head><p>We arrive here, at the closing. I am not asking you for miracles. I am not asking you for forever. And I am not even asking you for the next few decisions. Rather, just the next one. Because quitting is not a mountain you climb once, it is a path you walk one step at a time.</p><p>When the craving hits, pause. When the inner voice whispers, expose it. When a lapse happens, reframe it. When triggers surround you, step aside. When doubt appears, remember the future self.</p><p>And remember this too: you are not weak. You are not broken. You are not doomed. You are in a battle of signals and circuits, and those can change. They do change. With practice, with persistence, they will change for you.</p><p>So here we are, you, me, this book. You do not need to be scared of the fight ahead. You only need to be willing to keep showing up.</p><p>Because that is how quitting works. Not in one big leap, but in many small refusals. Each refusal is you reclaiming control, reclaiming dignity, reclaiming life.</p><p>And when the day comes, and it will come, when you realize you have not smoked for months and you no longer even think about it, say this to yourself:</p><p>It was always you. You did it.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc>. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.2 From Stages to Processes . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.3 Operational Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dear Smoker, Hear me out! . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.1 Initiation into the Cult . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2 I won't tell you why to quit . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3 Why Smokers Think It Won't Happen to Them . . . . . . . . . . . . . . . . 9.4 It's Not Because You're Weak . . . . . . . . . . . . . . . . . . . . . . . . . 9.5 The Voice That Holds You Back . . . . . . . . . . . . . . . . . . . . . . . . 9.6 Breaking the Identity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.7 The Check-In . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.8 Why Do You Want to Quit? . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.9 When Your Brain Becomes a Battlefield . . . . . . . . . . . . . . . . . . . 9.10 Shifting the Salience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.11 Seeing Through the Mind's Tricks . . . . . . . . . . . . . . . . . . . . . . . 9.12 The Traps in Your Environment . . . . . . . . . . . . . . . . . . . . . . . . 9.13 You Do Not Have to Do This Alone . . . . . . . . . . . . . . . . . . . . . . 9.14 The First Battle: Cravings . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.15 The Second Battle: Triggers . . . . . . . . . . . . . . . . . . . . . . . . . . 9.16 The Third Battle: The Inner Voice . . . . . . . . . . . . . . . . . . . . . . . 9.17 The Fourth Battle: Lapses . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.18 The Fifth Battle: The Future Self . . . . . . . . . . . . . . . . . . . . . . .9.19 So, Dear Quitter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>3. 1</head><label>1</label><figDesc>Possible trajectories following smoking initiation. Arrows indicate potential transitions between states. Continuation tends to bias escalation more than reduction, while stabilized patterns in adolescence often persist into adulthood. 3.2 The Asymmetry in Escalation and Reduction of Dosage . . . . . . . . . . . . . 4.1 Functional states of the nicotinic acetylcholine receptor (nAChR): in the resting state the channel is closed, ligand binding induces the activated state with ion influx (Na + , Ca 2+ ), and prolonged exposure leads to a desensitized state where the ligand remains bound but the channel closes. . . . . . . . . . . . . . . . . . 6.1 Typology of smoking behavior (L0-L7). The majority of the population (L0-L3) follows a bell-curve distribution, while the right-hand tail (L4-L7) represents progressively higher dependence, from light daily smokers to chain smokers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.1 SyNAPSE in a Nutshell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.2 (A) Percent ùõº4ùõΩ2 * nAChR occupancy as a function of plasma nicotine concentration (ng/mL). Reproduced from Brody et al. (2009) (Brody et al., 2009). (B) Plasma nicotine concentration and predicted receptor occupancy following a single cigarette. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3 Upregulation Dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.4 Nicotine dynamics over 1 day for three metabolic half-lives: low (1h), medium (2h), and high (4h) susceptibility. . . . . . . . . . . . . . . . . . . . . . . . . . 7.5 Model of receptor upregulation under fixed smoking schedules (1-4 cigarettes/day)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>xii 7 . 7</head><label>77</label><figDesc>Variation in receptor upregulation and unoccupied nicotine binding sites following abrupt smoking cessation. . . . . . . . . . . . . . . . . . . . . . . . . . 7.8 Variation in receptor upregulation and cigarette dosage over one year with and without the intervening role of sleep. (A) Continuous smoking dosage (shared puffs). (B) Discrete smoking dosage (full cigarettes). . . . . . . . . . . . . . . 7.9 Variation in receptor upregulation over 18 months with a 2-hour nicotine metabolism rate. (A) Continuous smoking dosage (shared puffs). (B) Discrete smoking dosage (whole cigarettes). Real-world trajectories likely fall between these extremes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.10 Nicotine concentration ùëÅ (ùë°) and dopamine burst Œîùê∑ (ùë°) over 12 hours with scheduled smoking events. Dopamine bursts are strongest when baseline nicotine is low and diminish as baseline nicotine accumulates. . . . . . . . . . . . . 7.11 Toy Simulation of asymmetric cue learning. The learned association ùêø ùëñ (ùë°) increases preferentially following positive outcomes, while negative prediction errors are down-weighted. Expected reward values ùëí ùëñ (ùë°) rise over time and influence the probability of smoking after cue presentation. Together, these dynamics illustrate how rewarding cues are persistently reinforced, even in the face of inconsistent or disappointing outcomes. . . . . . . . . . . . . . . . . . 8.1 The Dogma of CLEAR-PATH . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2 Smokers differ: Each patient is unique. . . . . . . . . . . . . . . . . . . . . . .List of Tables3.1 Empirical definitions of smoking states . . . . . . . . . . . . . . . . . . . . . . 3.2 Dimensions shaping outcomes of first smoking experience . . . . . . . . . . . 4.1 Steady-state venous plasma nicotine levels across routes of administration. . . . 4.2 EC 50 values of nicotine for activation of major neuronal nAChR subtypes. . . . 4.3 Desensitization characteristics of major nAChR subtypes. Timescales are approximate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.4 Nicotine-induced desensitization parameters for major neuronal nAChR subtypes (10 min exposure). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.5 Upregulation of major nAChR subtypes during chronic nicotine exposure. . . . 4.6 Distribution of major neuronal nAChR subtypes across brain circuits. . . . . . . 4.7 Circuit-level effects of nicotine across major brain systems. . . . . . . . . . . . changes in ùúÖ over two years, reflecting real-world fluctuations in environmental and personal influences. . . . . . . . . . . . . . . . . . . . . . . 141</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><figDesc>In the dim waiting area outside an ICU, four friends sat in silence. They had known one another since college, when nights were long, futures open, and a cigarette passed around seemed like nothing more than a fleeting dare. Years later, their paths looked very different. One lay behind the ICU doors, battling late-stage lung cancer. Another had survived multiple heart attacks. A third had never touched a cigarette after that first night. One had smoked briefly before quitting in his twenties. Another had walked away only after becoming a parent. The last still smoked "just occasionally," though his body told a harsher truth.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3 . 1 :</head><label>31</label><figDesc>Figure 3.1: Possible trajectories following smoking initiation. Arrows indicate potential transitions between states. Continuation tends to bias escalation more than reduction, while stabilized patterns in adolescence often persist into adulthood.</figDesc><graphic coords="42,117.13,72.00,361.00,164.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 3</head><label>3</label><figDesc>Figure 3.2: The Asymmetry in Escalation and Reduction of Dosage</figDesc><graphic coords="43,83.28,72.00,428.70,256.69" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 4</head><label>4</label><figDesc>Figure 4.1: Functional states of the nicotinic acetylcholine receptor (nAChR): in the resting state the channel is closed, ligand binding induces the activated state with ion influx (Na + , Ca 2+ ), and prolonged exposure leads to a desensitized state where the ligand remains bound but the channel closes.</figDesc><graphic coords="65,139.69,75.39,315.89,192.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><figDesc>He had just finished a book on the benefits of quitting smoking, and for a moment, he was filled with vigor and determination to stop cold turkey. He imagined himself standing on the top of a mountain, having conquered the challenge, and felt almost too good about the possibility of change. Energized, he decided to buy a set of sticky notes to plan his life around this new direction. On the way to the store, he passed a cigarette shop.A thought arose with surprising clarity: since he was about to quit forever, he should allow himself one last cigarette. The idea carried no guilt, no hesitation. In fact it came with a sense of pride, as though it were part of the ritual of quitting. He went inside, bought a pack, stepped outside, and lit up. The relief was instant, but the thought of quitting was postponed. By the next day, the peak of motivation was gone. What remained was the familiar routine of smoking, now justified by the story that he had not yet quit.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Figure 7</head><label>7</label><figDesc>Figure 7.1: SyNAPSE in a Nutshell</figDesc><graphic coords="136,117.13,72.00,361.03,223.66" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>Figure 7</head><label>7</label><figDesc>Figure 7.2: (A) Percent ùõº4ùõΩ2 * nAChR occupancy as a function of plasma nicotine concentration (ng/mL). Reproduced from Brody et al. (2009)<ref type="bibr" target="#b18">(Brody et al., 2009)</ref>. (B) Plasma nicotine concentration and predicted receptor occupancy following a single cigarette.</figDesc><graphic coords="140,184.82,601.70,225.63,94.19" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 7</head><label>7</label><figDesc>Figure 7.3: Upregulation Dynamics</figDesc><graphic coords="143,117.13,72.00,361.02,202.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Figure 7</head><label>7</label><figDesc>Figure 7.4: Nicotine dynamics over 1 day for three metabolic half-lives: low (1h), medium (2h), and high (4h) susceptibility.</figDesc><graphic coords="153,128.41,72.00,338.45,228.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Figure 7 . 5 :</head><label>75</label><figDesc>Figure 7.5: Model of receptor upregulation under fixed smoking schedules (1-4 cigarettes/day).Upregulation initially rises with repeated smoking but then plateaus, forming a stable smoking dosage, where natural receptor decline between cigarettes balances the increase after smoking. This plateau explains how steady, long-term smoking behaviors are biologically sustained. The half-life for this modeling was taken as 2 hours</figDesc><graphic coords="161,105.84,133.87,383.58,491.97" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head>Figure 7</head><label>7</label><figDesc>Figure 7.7: Variation in receptor upregulation and unoccupied nicotine binding sites following abrupt smoking cessation.</figDesc><graphic coords="162,117.13,536.16,361.00,179.78" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head>Figure 7 . 8 :</head><label>78</label><figDesc>Figure 7.8: Variation in receptor upregulation and cigarette dosage over one year with and without the intervening role of sleep. (A) Continuous smoking dosage (shared puffs). (B) Discrete smoking dosage (full cigarettes).</figDesc><graphic coords="163,105.84,238.59,383.59,311.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_16"><head>Figure 7 . 9 :</head><label>79</label><figDesc>Figure 7.9: Variation in receptor upregulation over 18 months with a 2-hour nicotine metabolism rate. (A) Continuous smoking dosage (shared puffs). (B) Discrete smoking dosage (whole cigarettes). Real-world trajectories likely fall between these extremes.</figDesc><graphic coords="164,105.84,182.50,383.58,423.59" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_17"><head>Figure 7 .</head><label>7</label><figDesc>Figure 7.10: Nicotine concentration ùëÅ (ùë°) and dopamine burst Œîùê∑ (ùë°) over 12 hours with scheduled smoking events. Dopamine bursts are strongest when baseline nicotine is low and diminish as baseline nicotine accumulates.</figDesc><graphic coords="165,117.13,127.67,361.02,176.94" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_18"><head>Figure 7 .</head><label>7</label><figDesc>Figure 7.11: Toy Simulation of asymmetric cue learning. The learned association ùêø ùëñ (ùë°) increases preferentially following positive outcomes, while negative prediction errors are downweighted. Expected reward values ùëí ùëñ (ùë°) rise over time and influence the probability of smoking after cue presentation. Together, these dynamics illustrate how rewarding cues are persistently reinforced, even in the face of inconsistent or disappointing outcomes.</figDesc><graphic coords="165,128.41,479.20,338.45,152.83" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_19"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.1: The Dogma of CLEAR-PATH</figDesc><graphic coords="168,117.13,72.00,361.03,258.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_20"><figDesc>represents our effort to answer this need. It flows directly out of the principles established in the SyNAPSE model of addiction, which views smoking as a dynamic competition of neural signals shaped by biological, psychological, and social forces. Whereas the SyNAPSE model provides the theoretical foundation by explaining why cravings and dependence persist, CLEAR-PATH translates those insights into a stepwise, clinician-friendly framework for cessation. Each component of CLEAR-PATH corresponds to a vital step in understanding, supporting, and empowering individuals on their journey to overcome nicotine dependence.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_21"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8.2: Smokers differ: Each patient is unique.</figDesc><graphic coords="169,128.41,72.00,338.47,292.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_22"><head>Weeks 2 to 4 :</head><label>4</label><figDesc>Contact 1 to 2 times weekly. Assess continued abstinence, breakthrough cravings, mood, and behavioral strategy use. Begin discussing medication tapering or continuation. Weeks 5 to 12: Contact 1 time weekly or biweekly. Assess withdrawal during medication tapering and any lapses. Taper medications as tolerated; address relapse risk. Months 3 to 12: Contact monthly or less. Assess sustained abstinence, triggers encountered, and coping successes. Provide ongoing relapse prevention support and celebrate milestones.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="1,105.84,385.26,383.58,223.06" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="122,94.57,72.00,406.14,201.11" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 .</head><label>4</label><figDesc>2: EC 50 values of nicotine for activation of major neuronal nAChR subtypes.</figDesc><table><row><cell>Receptor subtype</cell><cell>EC 50 (nM)</cell></row><row><cell>ùõº4ùõΩ2  *  (high-sensitivity)</cell><cell>1, 610 ¬± 190</cell></row><row><cell>ùõº6ùõΩ2  *</cell><cell>770 ¬± 270</cell></row><row><cell>ùõº7</cell><cell>22, 600 ¬± 540</cell></row><row><cell>ùõº3ùõΩ4  *</cell><cell>64, 400 ¬± 7, 900</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4 .</head><label>4</label><figDesc>3: Desensitization characteristics of major nAChR subtypes. Timescales are approximate.</figDesc><table><row><cell>Receptor sub-</cell><cell cols="2">Timescale of desensiti-</cell><cell>Notes</cell></row><row><cell>type</cell><cell>zation</cell><cell></cell></row><row><cell>ùõº4ùõΩ2  *</cell><cell cols="2">Seconds to minutes</cell><cell>High-affinity; strongly contributes</cell></row><row><cell></cell><cell>(nanomolar</cell><cell>nicotine</cell><cell>to tolerance and dependence; recov-</cell></row><row><cell></cell><cell>sufficient)</cell><cell></cell><cell>ery modulated by phosphorylation</cell></row><row><cell>ùõº6ùõΩ2  *</cell><cell cols="2">Seconds to minutes</cell><cell>Highly expressed in dopaminer-</cell></row><row><cell></cell><cell>(sparse data)</cell><cell></cell><cell>gic terminals; sensitive to nicotine</cell></row><row><cell></cell><cell></cell><cell></cell><cell>and prone to desensitization but at</cell></row><row><cell></cell><cell></cell><cell></cell><cell>higher concentrations.</cell></row><row><cell>ùõº7</cell><cell cols="2">Milliseconds to seconds</cell><cell>Very fast onset; high Ca 2+ perme-</cell></row><row><cell></cell><cell cols="2">(micromolar nicotine)</cell><cell>ability; desensitized state stabilized</cell></row><row><cell></cell><cell></cell><cell></cell><cell>by low agonist levels</cell></row><row><cell>ùõº3ùõΩ4  *</cell><cell cols="2">Slower (hundreds of ms</cell><cell>Less sensitive to nicotine; impor-</cell></row><row><cell></cell><cell>to seconds)</cell><cell></cell><cell>tant in habenula-interpeduncular</cell></row><row><cell></cell><cell></cell><cell></cell><cell>circuits and aversive signaling</cell></row><row><cell>4</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 4 .</head><label>4</label><figDesc>5: Upregulation of major nAChR subtypes during chronic nicotine exposure.</figDesc><table><row><cell>Receptor sub-</cell><cell>Timescale of upregu-</cell><cell>Notes</cell></row><row><cell>type</cell><cell>lation</cell><cell></cell></row><row><cell>ùõº4ùõΩ2  *</cell><cell>Hours to days</cell><cell>Strongest and most consistent up-</cell></row><row><cell></cell><cell></cell><cell>regulation;</cell></row><row><cell>ùõº6ùõΩ2  *</cell><cell>Variable; less well char-</cell><cell>Often modest or region-specific;</cell></row><row><cell></cell><cell>acterized</cell><cell>regulates dopamine release in</cell></row><row><cell></cell><cell></cell><cell>mesolimbic terminals</cell></row><row><cell>ùõº7</cell><cell>Minimal or none</cell><cell>Generally does not upregulate sig-</cell></row><row><cell></cell><cell></cell><cell>nificantly despite desensitization</cell></row><row><cell>ùõº3ùõΩ4  *</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Table 4 .</head><label>4</label><figDesc>6: Distribution of major neuronal nAChR subtypes across brain circuits.</figDesc><table><row><cell cols="2">Receptor sub-</cell><cell>Primary localization</cell><cell cols="2">Key brain regions/cir-</cell><cell>Functional association</cell></row><row><cell>type</cell><cell></cell><cell></cell><cell>cuits</cell><cell></cell></row><row><cell>ùõº4ùõΩ2  *</cell><cell></cell><cell>Presynaptic and postsy-</cell><cell cols="2">VTA, NAc, PFC, hip-</cell><cell>High-affinity; reinforce-</cell></row><row><cell></cell><cell></cell><cell>naptic on excitatory and</cell><cell cols="2">pocampus, thalamus</cell><cell>ment, cognition, arousal</cell></row><row><cell></cell><cell></cell><cell>inhibitory neurons</cell><cell></cell><cell></cell></row><row><cell>ùõº6ùõΩ2  *</cell><cell></cell><cell>Dopamine neurons and</cell><cell cols="2">VTA, substantia nigra,</cell><cell>Control of dopamine re-</cell></row><row><cell></cell><cell></cell><cell>terminals</cell><cell>striatum</cell><cell></cell><cell>lease in reward and motor</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>circuits</cell></row><row><cell>ùõº7</cell><cell></cell><cell>Predominantly presy-</cell><cell cols="2">Cortex, hippocampus,</cell><cell>Facilitates glutamate re-</cell></row><row><cell></cell><cell></cell><cell>naptic; also postsynap-</cell><cell>thalamus</cell><cell></cell><cell>lease and plasticity; atten-</cell></row><row><cell></cell><cell></cell><cell>tic on pyramidal cells;</cell><cell></cell><cell></cell><cell>tion, learning</cell></row><row><cell></cell><cell></cell><cell>highly Ca 2+ -permeable</cell><cell></cell><cell></cell></row><row><cell>ùõº3ùõΩ4  *</cell><cell>(often</cell><cell>Somatodendritic,</cell><cell>Medial</cell><cell>habe-</cell></row><row><cell>with ùõº5)</cell><cell></cell><cell>cholinergic projections</cell><cell cols="2">nula-interpeduncular</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">nucleus (MHb-IPN);</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">autonomic ganglia</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 4 .</head><label>4</label><figDesc>7: Circuit-level effects of nicotine across major brain systems.</figDesc><table><row><cell>Circuit</cell><cell>Receptor subtypes</cell><cell cols="2">Consequence</cell><cell cols="2">Behavioral outcome</cell></row><row><cell>VTA-NAc (re-</cell><cell>ùõº4ùõΩ2  *  , ùõº6ùõΩ2  *  , ùõº7</cell><cell cols="2">DA bursts, glu-</cell><cell cols="2">Reinforcement, incen-</cell></row><row><cell>ward)</cell><cell></cell><cell cols="2">tamate potentia-</cell><cell>tive salience</cell></row><row><cell></cell><cell></cell><cell cols="2">tion, disinhibition</cell><cell></cell></row><row><cell>PFC (executive)</cell><cell>ùõº4ùõΩ2  *  , ùõº7</cell><cell cols="2">Modulated inhi-</cell><cell>Attention,</cell><cell>working</cell></row><row><cell></cell><cell></cell><cell cols="2">bition, enhanced</cell><cell>memory</cell></row><row><cell></cell><cell></cell><cell>glutamate</cell><cell></cell><cell></cell></row><row><cell>Striatum (habit)</cell><cell>ùõº4ùõΩ2  *  , ùõº6</cell><cell cols="2">DA release, CIN</cell><cell cols="2">Habit formation, com-</cell></row><row><cell></cell><cell></cell><cell>modulation</cell><cell></cell><cell>pulsive use</cell></row><row><cell>Hippocampus</cell><cell>ùõº4ùõΩ2  *  , ùõº7</cell><cell cols="2">Enhanced LTP,</cell><cell cols="2">Cue learning, relapse</cell></row><row><cell>(memory)</cell><cell></cell><cell cols="2">altered oscilla-</cell><cell>vulnerability</cell></row><row><cell></cell><cell></cell><cell>tions</cell><cell></cell><cell></cell></row><row><cell>MHb-IPN (aver-</cell><cell>ùõº3ùõΩ4  *  , ùõº5</cell><cell cols="2">Ca 2+ influx, aver-</cell><cell cols="2">Intake brake, with-</cell></row><row><cell>sion)</cell><cell></cell><cell cols="2">sion signaling</cell><cell cols="2">drawal dysphoria</cell></row><row><cell cols="2">Amygdala (stress) ùõº4ùõΩ2  *  , ùõº7</cell><cell cols="2">Associative plas-</cell><cell cols="2">Cue reactivity, stress-</cell></row><row><cell></cell><cell></cell><cell cols="2">ticity, HPA axis</cell><cell cols="2">induced relapse</cell></row><row><cell></cell><cell></cell><cell>drive</cell><cell></cell><cell></cell></row><row><cell>Insula (interocep-</cell><cell>ùõº4ùõΩ2  *  , ùõº7</cell><cell cols="2">Amplified intero-</cell><cell cols="2">Subjective craving, urge</cell></row><row><cell>tion)</cell><cell></cell><cell cols="2">ceptive salience,</cell><cell>awareness</cell></row><row><cell></cell><cell></cell><cell>altered</cell><cell>bodily</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">state signals</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>Table 7 .</head><label>7</label><figDesc>1 shows a hypothetical two-year progression of ùúÖ values, reflecting how smoking and dependence patterns may evolve under changing external and internal conditions.</figDesc><table><row><cell>ùúÖ Value</cell><cell>Duration</cell></row><row><cell>Medium</cell><cell>1 month</cell></row><row><cell>Low</cell><cell>2 months</cell></row><row><cell>High</cell><cell>3 months</cell></row><row><cell>Medium</cell><cell>2 months</cell></row><row><cell>Extreme</cell><cell>1 month</cell></row><row><cell>Medium</cell><cell>1 month</cell></row><row><cell cols="2">Negligible 2 months</cell></row><row><cell>High</cell><cell>1 month</cell></row><row><cell>Medium</cell><cell>3 months</cell></row><row><cell>Extreme</cell><cell>2 months</cell></row><row><cell>High</cell><cell>1 month</cell></row><row><cell>Medium</cell><cell>2 months</cell></row><row><cell>Low</cell><cell>1 month</cell></row><row><cell>High</cell><cell>2 months</cell></row></table></figure>
		</body>
		<back>

			
			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>We aim to treat the patient as an agent and a human being, not as an addict. The journey is personal, never generic. The task is to combine the best techniques that fit the individual, rather than to impose a one-size-fits-all prescription. Each person is different, and each path to quitting must respect that difference.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHAPTER 1</head><p>The Weight of a Cigarette ‚Ä¢ Cultural: Broader cultural attitudes, media representations, and public discourse determine how often smoking cues are encountered, how acceptable smoking feels, and how much stigma or reinforcement is attached to it.</p><p>‚Ä¢ Economic/Structural: Price, accessibility, workplace policies, taxation, and socioeconomic stressors shape the feasibility and motivational weight of smoking relative to alternatives, amplifying or suppressing drug-related signal dominance.</p><p>Together, these modulators explain how micro-level biological changes scale upward into macro-level patterns of thought, behavior, and social practice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.8">Emergence, Maintenance, and Fate of Smoking-Related</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Thoughts</head><p>The Synapse Model explains the emergence, maintenance, and fate of smoking-related thoughts as trajectories of neural signal competition. A smoking-related thought, such as the impulse to smoke, is not a discrete entity that appears fully formed, but a dynamic configuration of neural activity patterns. These patterns gain or lose stability depending on modulatory forces operating across multiple levels. Each hierarchy biases the competition by altering excitability, connectivity, salience, reinforcement, or accessibility of competing signals.</p><p>Through SyNAPSE, we argue that addiction is best understood as the biased competition of neural signals within the brain's decision-making networks. This approach reframes biology, psychology, and social context not as separate causes but as modulatory forces acting on the same competitive process. By focusing on the dynamics of signal dominance, the SYNAPSE model explains both the variability of addictive experience and its long-term persistence.</p><p>The following definitions clarify the key elements of signal competition, which underlie the emergence and persistence of addictive thoughts and behaviors.</p><p>‚Ä¢ A signal is a distributed pattern of neural activity encoding a possible action or outcome (e.g., "smoke a cigarette," "resist smoking," "check phone").</p><p>‚Ä¢ Competition occurs when multiple signals vie for dominance within overlapping brain networks.</p><p>‚Ä¢ Dominance is achieved when one signal reaches sufficient strength and stability to bias attention, occupy working memory, and recruit motor execution systems.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.4</head><p>Step 1: Understanding the Smoker</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.4.1">Purpose and Functionality</head><p>To construct a multidimensional profile of the individual smoker, recognizing that demographic factors, social context, smoking history, psychological readiness, and past experiences uniquely shape each person's cessation trajectory. This foundational profiling lays the groundwork for all subsequent personalized interventions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.4.2">Demographic and Historical Assessment</head><p>Demographic characteristics such as age, gender, marital status, and employment status influence both susceptibility to smoking and severity of dependence. Younger individuals may be more vulnerable to peer influence, while older adults may smoke more heavily due to isolation. Gender differences shape both patterns of smoking and responsiveness to treatment, and social factors such as being single, divorced, unemployed, or under financial stress may increase relapse risk.</p><p>Assessing smoking history is equally important. Duration, age of initiation, daily intensity, and past quit attempts all provide a clinical baseline that guides intervention. Pack-years (calculated as Years of Smoking √ó Packs per Day) indicate cumulative exposure and predict withdrawal severity and relapse likelihood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Smoking History Questionnaire (SHQ) <ref type="bibr" target="#b206">(Strong et al., 2014)</ref>: Structured intake capturing age of initiation, years smoked, daily consumption, pack-year history, previous quit attempts, and family history of addiction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.4.3">Motivation and Readiness Assessment</head><p>Motivation to quit must be assessed early. Low intrinsic motivation, often due to external pressure from family or physicians, is a strong predictor of treatment failure. The clinician's priority should be to enhance readiness through supportive engagement rather than to initiate intensive cessation directly.</p><p>The assessment identifies whether the smoker possesses self-owned reasons for quitting. This is done through open exploration, validating autonomy, making harms tangible and personally support.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.8.2">Predisposition Indicators</head><p>Genetic and biological differences strongly shape susceptibility to nicotine addiction and influence both the ease of quitting and the likelihood of relapse. Metabolic variability due to genetic variation in enzymes such as CYP2A6 affects nicotine clearance rates. Reward sensitivity plays a secondary but significant role. The goal is not to medicalize every smoker but to recognize that biological predisposition shapes the competition of neural signals in decision making. Some brains experience nicotine as more salient and rewarding, while others do not. Acknowledging this variability allows clinicians to move beyond one-size-fits-all and design cessation plans that are biologically and psychologically realistic.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Candidate Assessment Tools:</head><p>‚Ä¢ Dependence Predisposition Assessment (DPA) [a proposed, yet non-validated scale developed for preliminary profiling]: Captures family history of addiction, smoking progression rate, reward sensitivity, and metabolic markers. Low predisposition suggests minimal pharmacological support; moderate predisposition suggests standard NRT dosing and behavioral therapy with monitoring; high predisposition suggests intensive pharmacotherapy warranted from the outset.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.9</head><p>Step 6: Finding the Dip Nicotine Level</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.9.1">Purpose and Functionality</head><p>The goal of this step is to identify the approximate dip nicotine level, the plasma nicotine concentration at which a person typically experiences renewed craving and resumes smoking. This threshold represents the critical point where withdrawal symptoms and cue-driven urges converge, marking the moment when relapse risk sharply increases. Recognizing this individualized level helps clinicians anticipate vulnerability periods and time interventions (behavioral or pharmacological) more effectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHAPTER 9</head><p>Dear Smoker, Hear me out!</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">peer-substitution and identity reconstruction; high cue exposure calls for in-vivo or imaginal exposure therapy; high taste/sensory motives call for sensory substitutes; high weight-control motives call for nutrition counseling and realistic expectation management</title>
	</analytic>
	<monogr>
		<title level="m">Subscales include Primary Dependence, Automaticity, Loss of Control, Craving, Tolerance, Negative Reinforcement, Affiliative Attachment, Behavioral Choice, Cognitive Enhancement, Cue Exposure, Social Goals, Taste/Sensory, and Weight Control. 8.6.3 Motive-Matched Interventions and Real-Time Digital Support Once the dominant motives are identified, behavioral interventions are tailored accordingly</title>
		<imprint/>
	</monogr>
	<note>5 indicate strong influence; scores below 3.5 indicate minimal influence High automaticity calls for habit-reversal training; high negative reinforcement calls for stressmanagement and emotional regulation; high affiliative attachment calls for</note>
	<note type="raw_reference">5 indicate strong influence; scores below 3.5 indicate minimal influence. Subscales in- clude Primary Dependence, Automaticity, Loss of Control, Craving, Tolerance, Negative Reinforcement, Affiliative Attachment, Behavioral Choice, Cognitive Enhancement, Cue Exposure, Social Goals, Taste/Sensory, and Weight Control. 8.6.3 Motive-Matched Interventions and Real-Time Digital Support Once the dominant motives are identified, behavioral interventions are tailored accordingly. High automaticity calls for habit-reversal training; high negative reinforcement calls for stress- management and emotional regulation; high affiliative attachment calls for peer-substitution and identity reconstruction; high cue exposure calls for in-vivo or imaginal exposure therapy; high taste/sensory motives call for sensory substitutes; high weight-control motives call for nutrition counseling and realistic expectation management.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Personality Profiling and Risk Stratification Personality exerts a powerful influence on smoking behavior, relapse risk, and treatment response. Traits such as neuroticism, conscientiousness, extraversion, agreeableness, and openness to experience shape the very biases that influence neural signal competition in moments of choice. High neuroticism predicts greater relapse vulnerability because negative emotions amplify crav-8.8. Step 5: Predisposition Assessment Bibliography</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">7.2 Personality Profiling and Risk Stratification Personality exerts a powerful influence on smoking behavior, relapse risk, and treatment re- sponse. Traits such as neuroticism, conscientiousness, extraversion, agreeableness, and open- ness to experience shape the very biases that influence neural signal competition in moments of choice. High neuroticism predicts greater relapse vulnerability because negative emotions amplify crav- 8.8. Step 5: Predisposition Assessment Bibliography</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Molecular insights into the benefits of nicotine on memory and cognition</title>
		<author>
			<persName><forename type="first">A</forename><surname>Alhowail</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Medicine Reports</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Alhowail, A. (2021). Molecular insights into the benefits of nicotine on memory and cognition. Molecular Medicine Reports, 23(6):1-6.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The habenulointerpeduncular pathway in nicotine aversion and withdrawal</title>
		<author>
			<persName><forename type="first">B</forename><surname>Antolin-Fontes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ables</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>G√∂rlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Iba√±ez-Tallon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="213" to="222" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Antolin-Fontes, B., Ables, J. L., G√∂rlich, A., and Iba√±ez-Tallon, I. (2015). The habenulo- interpeduncular pathway in nicotine aversion and withdrawal. Neuropharmacology, 96:213- 222.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Effects of tobacco taxation and pricing on smoking behavior in high risk populations: a knowledge synthesis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boisclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of environmental research and public health</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="4118" to="4139" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bader, P., Boisclair, D., and Ferrence, R. (2011). Effects of tobacco taxation and pricing on smoking behavior in high risk populations: a knowledge synthesis. International journal of environmental research and public health, 8(11):4118-4139.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Disparities in smoking cessation assistance in us primary care clinics</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heintzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Puro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American journal of public health</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1082" to="1090" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bailey, S. R., Heintzman, J., Jacob, R. L., Puro, J., and Marino, M. (2018). Disparities in smoking cessation assistance in us primary care clinics. American journal of public health, 108(8):1082-1090.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The stereospecificity of nicotine</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Barlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Hamilton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British Journal of Pharmacology and Chemotherapy</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">206</biblScope>
			<date type="published" when="1965">1965</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barlow, R. B. and Hamilton, J. T. (1965). The stereospecificity of nicotine. British Journal of Pharmacology and Chemotherapy, 25(1):206.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Gender differences in smoking behavior</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>G√∂hlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sinning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Economics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="895" to="909" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bauer, T., G√∂hlmann, S., and Sinning, M. (2007). Gender differences in smoking behavior. Health Economics, 16(9):895-909.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Acute effects of nicotine on attention and response inhibition</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bekker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>B√∂cker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Hunsel</surname></persName>
		</author>
		<author>
			<persName><surname>Van Den</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kenemans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacology Biochemistry and Behavior</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="539" to="548" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bekker, E., B√∂cker, K., Van Hunsel, F., Van Den Berg, M., and Kenemans, J. (2005). Acute effects of nicotine on attention and response inhibition. Pharmacology Biochemistry and Behavior, 82(3):539-548.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Benedict</surname></persName>
		</author>
		<title level="m">Golden-Silk Smoke: A History of Tobacco in China, 1550-2010</title>
		<imprint>
			<publisher>University of California Press</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benedict, C. (2011). Golden-Silk Smoke: A History of Tobacco in China, 1550-2010. University of California Press.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking</title>
		<author>
			<persName><forename type="first">N</forename><surname>Benowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zevin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jacob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British journal of clinical pharmacology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="259" to="267" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benowitz, N., Zevin, S., and Jacob, P. (1997). Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. British journal of clinical pharmacology, 43(3):259-267.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Metabolism, pharmacokinetics and pharmacodynamics of nicotine in man</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Benowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jacob</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benowitz, N. L. and Jacob, P. (1987). Metabolism, pharmacokinetics and pharmacodynamics of nicotine in man.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Female sex and oral contraceptive use accelerate nicotine metabolism</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Benowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Lessov-Schlaggar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iii</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Pharmacology &amp; Therapeutics</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="480" to="488" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benowitz, N. L., Lessov-Schlaggar, C. N., Swan, G. E., and Jacob III, P. (2006). Female sex and oral contraceptive use accelerate nicotine metabolism. Clinical Pharmacology &amp; Therapeutics, 79(5):480-488.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A metaanalysis of cue reactivity in tobacco cigarette smokers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Betts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hetelekides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Tiffany</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine and Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="249" to="258" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Betts, J. M., Dowd, A. N., Forney, M., Hetelekides, E., and Tiffany, S. T. (2021). A meta- analysis of cue reactivity in tobacco cigarette smokers. Nicotine and Tobacco Research, 23(2):249-258.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">What proportion of people who try one cigarette become daily smokers? a meta-analysis of representative surveys</title>
		<author>
			<persName><forename type="first">M</forename><surname>Birge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Duffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Miler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hajek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine and Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1427" to="1433" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Birge, M., Duffy, S., Miler, J. A., and Hajek, P. (2018). What proportion of people who try one cigarette become daily smokers? a meta-analysis of representative surveys. Nicotine and Tobacco Research, 20(12):1427-1433.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Barriers to the provision of smoking cessation services reported by clinicians in underserved communities</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Blumenthal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of the American Board of Family Medicine</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="272" to="279" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Blumenthal, D. S. (2007). Barriers to the provision of smoking cessation services reported by clinicians in underserved communities. The Journal of the American Board of Family Medicine, 20(3):272-279.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Social determinants of health and smoking cessation: a challenge</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Brady</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>Unpublished manuscript</note>
	<note type="raw_reference">Brady, K. T. (2020). Social determinants of health and smoking cessation: a challenge. Unpublished manuscript.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Mindfulness training for smoking cessation: results from a randomized controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Brewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mallik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Babuscio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Deleone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Minnix-Cotton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Weinstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol dependence</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="72" to="80" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brewer, J. A., Mallik, S., Babuscio, T. A., Nich, C., Johnson, H. E., Deleone, C. M., Minnix- Cotton, C. A., Byrne, S. A., Kober, H., Weinstein, A. J., et al. (2011). Mindfulness training for smoking cessation: results from a randomized controlled trial. Drug and alcohol dependence, 119(1-2):72-80.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Brody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mandelkern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Costello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Scheibal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Farahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>London</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Olmstead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mukhin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="305" to="316" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brody, A. L., Mandelkern, M. A., Costello, M. R., Abrams, A. L., Scheibal, D., Farahi, J., London, E. D., Olmstead, R. E., Rose, J. E., and Mukhin, A. G. (2009). Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. International Journal of Neuropsychopharmacology, 12(3):305-316.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">In vivo nicotine treatment regulates mesocorticolimbic creb and erk signaling in c57bl/6j mice</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Brunzell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Picciotto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of neurochemistry</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1431" to="1441" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brunzell, D. H., Russell, D. S., and Picciotto, M. R. (2003). In vivo nicotine treatment regulates mesocorticolimbic creb and erk signaling in c57bl/6j mice. Journal of neurochemistry, 84(6):1431-1441.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Quantification of signal amplification for receptors: the k d/ec50 ratio of full agonists as a gain parameter</title>
		<author>
			<persName><forename type="first">P</forename><surname>Buchwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in pharmacology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1541872</biblScope>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Buchwald, P. (2025). Quantification of signal amplification for receptors: the k d/ec50 ratio of full agonists as a gain parameter. Frontiers in pharmacology, 16:1541872.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">What to consider when regulating electronic cigarettes: pros, cons and unintended consequences</title>
		<author>
			<persName><forename type="first">P</forename><surname>Caponnetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Saitta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sweanor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Polosa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Drug Policy</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="554" to="559" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Caponnetto, P., Saitta, D., Sweanor, D., and Polosa, R. (2015). What to consider when regulating electronic cigarettes: pros, cons and unintended consequences. International Journal of Drug Policy, 26(6):554-559.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Affect regulation, nicotine addiction, and smoking cessation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Carmody</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Psychoactive Drugs</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="111" to="122" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carmody, T. P. (1992). Affect regulation, nicotine addiction, and smoking cessation. Journal of Psychoactive Drugs, 24(2):111-122.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Chaiton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diemert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bondy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Selby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Philipneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schwartz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">11045</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chaiton, M., Diemert, L., Cohen, J. E., Bondy, S. J., Selby, P., Philipneri, A., and Schwartz, R. (2016). Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ open, 6(6):e011045.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Which adolescent experimenters progress to established smoking in the united states</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Gilpin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Berry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Preventive Medicine</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="385" to="391" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choi, W. S., Pierce, J. P., Gilpin, E. A., Farkas, A. J., and Berry, C. C. (1997). Which adolescent experimenters progress to established smoking in the united states. American Journal of Preventive Medicine, 13(5):385-391.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Mesolimbic dopamine activation-the key to nicotine reinforcement?</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B S</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Biology of Nicotine Dependence</title>
		<imprint>
			<publisher>Wiley Online Library</publisher>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="153" to="168" />
		</imprint>
	</monogr>
	<note type="raw_reference">Clarke, P. B. S. (2007). Mesolimbic dopamine activation-the key to nicotine reinforcement? In Ciba Foundation Symposium 152: The Biology of Nicotine Dependence, pages 153-168. Wiley Online Library.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Behavioral and neural substrates of habit formation in rats intravenously self-administering nicotine</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Clemens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Castino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Cornish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Goodchild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2584" to="2593" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clemens, K. J., Castino, M. R., Cornish, J. L., Goodchild, A. K., and Holmes, N. M. (2014). Behavioral and neural substrates of habit formation in rats intravenously self-administering nicotine. Neuropsychopharmacology, 39(11):2584-2593.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The epidemiology of smoking during pregnancy: Smoking prevalence, maternal characteristics, and pregnancy outcomes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cnattingius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="125" to="140" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cnattingius, S. (2004). The epidemiology of smoking during pregnancy: Smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine &amp; Tobacco Research, 6:125-140.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Cox</surname></persName>
		</author>
		<title level="m">The Global Cigarette: Origins and Evolution of British American Tobacco, 1880-1945</title>
		<imprint>
			<publisher>Oxford University Press</publisher>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cox, H. (2000). The Global Cigarette: Origins and Evolution of British American Tobacco, 1880-1945. Oxford University Press.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action</title>
		<author>
			<persName><forename type="first">X</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gakidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Lopez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco control</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="129" to="137" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dai, X., Gakidou, E., and Lopez, A. D. (2022). Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tobacco control, 31(2):129-137.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Influence of gender and sex hormones on nicotine acute pharmacological effects in mice</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Damaj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="132" to="140" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Damaj, M. I. (2001). Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. The Journal of Pharmacology and Experimental Therapeutics, 296(1):132- 140.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Overview of nicotinic receptors and their roles in the central nervous system</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Dani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biological Psychiatry</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="166" to="174" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dani, J. A. (2001). Overview of nicotinic receptors and their roles in the central nervous system. Biological Psychiatry, 49(3):166-174.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Dani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International review of neurobiology</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="3" to="19" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dani, J. A. (2015). Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. International review of neurobiology, 124:3-19.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Dani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bertrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annual Review of Pharmacology and Toxicology</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="699" to="729" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dani, J. A. and Bertrand, D. (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annual Review of Pharmacology and Toxicology, 47(1):699-729.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Long-term plasticity of intrinsic excitability: learning rules and mechanisms</title>
		<author>
			<persName><forename type="first">G</forename><surname>Daoudal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Debanne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Learning &amp; memory</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="456" to="465" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Daoudal, G. and Debanne, D. (2003). Long-term plasticity of intrinsic excitability: learning rules and mechanisms. Learning &amp; memory, 10(6):456-465.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Self-efficacy and the stages of self-change of smoking</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Diclemente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Prochaska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gibertini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cognitive Therapy and Research</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="181" to="200" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DiClemente, C. C., Prochaska, J. O., and Gibertini, M. (1985). Self-efficacy and the stages of self-change of smoking. Cognitive Therapy and Research, 9(2):181-200.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Is implementation of the 5 a&apos;s of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness?</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Medoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lucksted</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kreyenbuhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diclemente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Potts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Adams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American journal on addictions</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="386" to="392" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dixon, L. B., Medoff, D., Goldberg, R., Lucksted, A., Kreyenbuhl, J., DiClemente, C., Potts, W., Leith, J., Brown, C., Adams, C., et al. (2009). Is implementation of the 5 a&apos;s of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? The American journal on addictions, 18(5):386-392.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Smoking and carcinoma of the lung</title>
		<author>
			<persName><forename type="first">R</forename><surname>Doll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Hill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4682</biblScope>
			<biblScope unit="page" from="739" to="748" />
			<date type="published" when="1950">1950</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Doll, R. and Hill, A. B. (1950). Smoking and carcinoma of the lung. BMJ, 2(4682):739-748.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Smoking, nicotine and neuropsychiatric disorders</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lazary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Kalapos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rihmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience &amp; Biobehavioral Reviews</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="295" to="342" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dome, P., Lazary, J., Kalapos, M. P., and Rihmer, Z. (2010). Smoking, nicotine and neuropsy- chiatric disorders. Neuroscience &amp; Biobehavioral Reviews, 34(3):295-342.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Attentional bias and smoking</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Drobes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Correa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience of nicotine</title>
		<imprint>
			<biblScope unit="page" from="145" to="150" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drobes, D. J., Oliver, J. A., Correa, J. B., and Evans, D. E. (2019). Attentional bias and smoking. Neuroscience of nicotine, pages 145-150.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cue exposure in understanding and treating addictive behaviours</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Tiffany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Glautier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Remington</forename></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Addictive Behaviour: Cue Exposure Theory and Practice</title>
		<editor>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Drummond</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Tiffany</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><surname>Glautier</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Remington</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">B</forename></persName>
		</editor>
		<imprint>
			<date type="published" when="1995">1995</date>
			<biblScope unit="page" from="1" to="17" />
		</imprint>
	</monogr>
	<note type="raw_reference">Drummond, D. C., Tiffany, S. T., Glautier, S., and Remington, B. (1995). Cue exposure in understanding and treating addictive behaviours. In Drummond, D. C., Tiffany, S. T., Glautier, S., and Remington, B., editors, Addictive Behaviour: Cue Exposure Theory and Practice, pages 1-17.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Beyond experimentation: Five trajectories of cigarette smoking in a longitudinal sample of youth</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dutra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Glantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Lisha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Song</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">171808</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dutra, L. M., Glantz, S. A., Lisha, N. E., and Song, A. V. (2017). Beyond experimentation: Five trajectories of cigarette smoking in a longitudinal sample of youth. PloS one, 12(2):e0171808.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Nicotine and brain development</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Dwyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Broide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Leslie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Birth Defects Research Part C: Embryo Today: Reviews</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="30" to="44" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dwyer, J. B., Broide, R. S., and Leslie, F. M. (2008). Nicotine and brain development. Birth Defects Research Part C: Embryo Today: Reviews, 84(1):30-44.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Smokers, non-smokers and the attribution of addiction</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wober</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British Journal of Social and Clinical Psychology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="329" to="336" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eiser, J. R., Sutton, S. R., and Wober, M. (1977). Smokers, non-smokers and the attribution of addiction. British Journal of Social and Clinical Psychology, 16(4):329-336.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Behavioral and neural consequences of prenatal exposure to nicotine</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Moolchan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Academy of Child &amp; Adolescent Psychiatry</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="630" to="641" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ernst, M., Moolchan, E. T., and Robinson, M. L. (2001). Behavioral and neural consequences of prenatal exposure to nicotine. Journal of the American Academy of Child &amp; Adolescent Psychiatry, 40(6):630-641.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Nicotine replacement therapy for long-term smoking cessation: a meta-analysis</title>
		<author>
			<persName><forename type="first">J.-F</forename><surname>Etter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Stapleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco control</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="280" to="285" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Etter, J.-F. and Stapleton, J. A. (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco control, 15(4):280-285.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking</title>
		<author>
			<persName><forename type="first">N</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gilpin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pierce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JNCI: Journal of the National Cancer Institute</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1538" to="1545" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evans, N., Farkas, A., Gilpin, E., Berry, C., and Pierce, J. P. (1995). Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. JNCI: Journal of the National Cancer Institute, 87(20):1538-1545.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The downside of tobacco control? smoking and self-stigma: A systematic review</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Evans-Polce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Castaldelli-Maia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schomerus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Evans-Lacko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Social science &amp; medicine</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="26" to="34" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evans-Polce, R. J., Castaldelli-Maia, J. M., Schomerus, G., and Evans-Lacko, S. E. (2015). The downside of tobacco control? smoking and self-stigma: A systematic review. Social science &amp; medicine, 145:26-34.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Drug addiction: Updating actions to habits to compulsions ten years on</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Everitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Robbins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annual Review of Psychology</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="23" to="50" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Everitt, B. J. and Robbins, T. W. (2015). Drug addiction: Updating actions to habits to compulsions ten years on. Annual Review of Psychology, 67(1):23-50.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fagerstr√∂m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lunell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="271" to="277" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fagerstr√∂m, K., Schneider, N., and Lunell, E. (1993). Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology, 111(3):271-277.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Applying the transtheoretical model to a representative sample of smokers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Velicer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Prochaska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addictive Behaviors</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="189" to="203" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fava, J. L., Velicer, W. F., and Prochaska, J. O. (1995). Applying the transtheoretical model to a representative sample of smokers. Addictive Behaviors, 20(2):189-203.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Upregulation of surface ùõº4ùõΩ2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Fenster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whitworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Sheffield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Quick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A J</forename><surname>Lester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neuroscience</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4804" to="4814" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fenster, C. P., Whitworth, T. L., Sheffield, E. B., Quick, M. W., and Lester, R. A. J. (1999). Upregulation of surface ùõº4ùõΩ2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. Journal of Neuroscience, 19(12):4804-4814.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Estimation of the leukemia risk in human populations exposed to benzene from tobacco smoke using epidemiological data</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fiebelkorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meredith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Risk Analysis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1490" to="1501" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fiebelkorn, S. and Meredith, C. (2018). Estimation of the leukemia risk in human popula- tions exposed to benzene from tobacco smoke using epidemiological data. Risk Analysis, 38(7):1490-1501.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Discussant comments: Understanding environmental, situational and intrapersonal risk and protective factors for youth tobacco use: The theory of triadic influence</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Flay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">Supplement 1</biblScope>
			<biblScope unit="page" from="111" to="S114" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Flay, B. R. (1999). Discussant comments: Understanding environmental, situational and intrapersonal risk and protective factors for youth tobacco use: The theory of triadic influence. Nicotine &amp; Tobacco Research, 1(Supplement 1):S111-S114.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Tobacco and nicotine use</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Foll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Piper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tonstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bierut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Disease Primers</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Foll, B. L., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., and Hall, W. D. (2022). Tobacco and nicotine use. Nature Reviews Disease Primers, 8(1):19.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Chemical changes in the harvested tobacco leaf</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Frankenburg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Advances in Enzymology</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">344</biblScope>
			<date type="published" when="1946">1946</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Frankenburg, W. G. (1946). Chemical changes in the harvested tobacco leaf. Advances in Enzymology, 6:344.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Ethnic disparities in the use of nicotine replacement therapy for smoking cessation in an equal access health care system</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Ryn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Lanto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Joseph</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Health Promotion</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="108" to="116" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fu, S. S., Sherman, S. E., Yano, E. M., Van Ryn, M., Lanto, A. B., and Joseph, A. M. (2005). Ethnic disparities in the use of nicotine replacement therapy for smoking cessation in an equal access health care system. American Journal of Health Promotion, 20(2):108-116.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Socioeconomic differences in cigarette smoking among sociodemographic groups</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Martell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Caraballo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Preventing Chronic Disease</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garrett, B. E., Martell, B. N., Caraballo, R. S., and King, B. A. (2019). Socioeconomic differ- ences in cigarette smoking among sociodemographic groups. Preventing Chronic Disease, 16.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The hill equation and the origin of quantitative pharmacology</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gesztelyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zsuga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kemeny-Beke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Juhasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tosaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Archive for history of exact sciences</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="427" to="438" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gesztelyi, R., Zsuga, J., Kemeny-Beke, A., Varga, B., Juhasz, B., and Tosaki, A. (2012). The hill equation and the origin of quantitative pharmacology. Archive for history of exact sciences, 66(4):427-438.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Cognitive reactions to smoking relapse: The reciprocal relation between dissonance and self-esteem</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Eggleston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Benthin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Personality and Social Psychology</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="184" to="195" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gibbons, F. X., Eggleston, T. J., and Benthin, A. C. (1997). Cognitive reactions to smoking relapse: The reciprocal relation between dissonance and self-esteem. Journal of Personality and Social Psychology, 72(1):184-195.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Exposing and addressing tobacco industry conduct in low-income and middle-income countries</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Gilmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aguinaga Bialous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="1029" to="1043" />
			<date type="published" when="2015">2015. 9972</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilmore, A. B., Fooks, G., Drope, J., Aguinaga Bialous, S., and Jackson, R. R. (2015). Exposing and addressing tobacco industry conduct in low-income and middle-income countries. Lancet, 385(9972):1029-1043.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Duration of smoking abstinence and success in quitting</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Gilpin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Farkas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the National Cancer Institute</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">572</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilpin, E. A., Pierce, J. P., Farkas, A. J., and Farkas, A. J. (1997). Duration of smoking abstinence and success in quitting. Journal of the National Cancer Institute, 89(8):572.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Upregulation of nicotinic acetylcholine receptor ùõº4ùõΩ2 through a ligand-independent PI3KùõΩ mechanism that is enhanced by TNFùõº and the JAK2/p38MAPK pathways</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lorise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">143319</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rogers, S. W. and Lorise, C. (2015). Upregulation of nicotinic acetylcholine receptor ùõº4ùõΩ2 through a ligand-independent PI3KùõΩ mechanism that is enhanced by TNFùõº and the JAK2/p38MAPK pathways. PLoS ONE, 10(11):e0143319.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">The incentive sensitization theory of addiction: some current issues</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Berridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Philosophical Transactions of the Royal Society B: Biological Sciences</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="issue">1507</biblScope>
			<biblScope unit="page" from="3137" to="3146" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Robinson, T. E. and Berridge, K. C. (2008). The incentive sensitization theory of addiction: some current issues. Philosophical Transactions of the Royal Society B: Biological Sciences, 363(1507):3137-3146.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Predictors of smoking behaviour: an application of ajzen&apos;s theory of planned behaviour</title>
		<author>
			<persName><forename type="first">G</forename><surname>Godin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Valois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lepage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Desharnais</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British Journal of Addiction</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1335" to="1343" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Godin, G., Valois, P., Lepage, L., and Desharnais, R. (1992). Predictors of smoking be- haviour: an application of ajzen&apos;s theory of planned behaviour. British Journal of Addiction, 87(9):1335-1343.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Tobacco in seventeenth-century india</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Gokhale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Agricultural History</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="484" to="492" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gokhale, B. G. (1974). Tobacco in seventeenth-century india. Agricultural History, 48(4):484- 492.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Govind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Green</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neuroscience</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2227" to="2238" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Govind, A. P., Walsh, H., and Green, W. N. (2012). Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. Journal of Neuroscience, 32(6):2227-2238.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Structural differences determine the relative selectivity of nicotinic compounds for native ùõº4ùõΩ2*-, ùõº6ùõΩ2*-, ùõº3ùõΩ4*and ùõº7-nicotine acetylcholine receptors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Drenan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Breining</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yohannes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Wageman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Fedorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mckinney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Whiteaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bencherif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Lester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1054" to="1066" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., et al. (2010). Structural differences determine the relative selectivity of nicotinic compounds for native ùõº4ùõΩ2*-, ùõº6ùõΩ2*-, ùõº3ùõΩ4*- and ùõº7-nicotine acetylcholine receptors. Neuropharmacology, 58(7):1054-1066.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include ùõº5 or ùõº6 subunits and that mediate synaptosomal neurotransmitter release</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Wageman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Patzlaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Marks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1935" to="1943" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grady, S. R., Wageman, C. R., Patzlaff, N. E., and Marks, M. J. (2012). Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include ùõº5 or ùõº6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology, 62(5):1935-1943.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">E-cigarettes: A scientific review</title>
		<author>
			<persName><forename type="first">R</forename><surname>Grana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Benowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Glantz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1972" to="1986" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grana, R., Benowitz, N., and Glantz, S. A. (2014). E-cigarettes: A scientific review. Circulation, 129(19):1972-1986.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Smoking and &quot;early modern&quot; sociability: The great tobacco debate in the ottoman middle east (seventeenth to eighteenth centuries)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grehan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American Historical Review</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1352" to="1377" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grehan, J. (2006). Smoking and &quot;early modern&quot; sociability: The great tobacco debate in the ottoman middle east (seventeenth to eighteenth centuries). The American Historical Review, 111(5):1352-1377.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Enforcement of COTPA in india: Current status, challenges and solutions</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chahar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Indian Journal of Tuberculosis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="94" to="97" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gupta, R., Bhatt, G., Singh, R., Chahar, P., Goel, S., and Singh, R. J. (2025). Enforcement of COTPA in india: Current status, challenges and solutions. Indian Journal of Tuberculosis, 72(1):94-97.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Experiences of self-blame and stigmatisation for self-infliction among individuals living with copd</title>
		<author>
			<persName><forename type="first">A</forename><surname>Halding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Heggdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scandinavian Journal of Caring Sciences</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="100" to="107" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Halding, A., Heggdal, K., and Wahl, A. (2010). Experiences of self-blame and stigmatisation for self-infliction among individuals living with copd. Scandinavian Journal of Caring Sciences, 25(1):100-107.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Epigenetics and addiction</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Nestler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current opinion in neurobiology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="128" to="136" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hamilton, P. J. and Nestler, E. J. (2019). Epigenetics and addiction. Current opinion in neurobiology, 59:128-136.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">The japanese tobacco culture in the edo period (1603-1867)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Handa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aziatische Kunst</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Handa, M. (2014). The japanese tobacco culture in the edo period (1603-1867). Aziatische Kunst, 44(3):3-10.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Tobacco carcinogens, their biomarkers and tobacco-induced cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Hecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Cancer</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="733" to="744" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hecht, S. S. (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature Reviews Cancer, 3(10):733-744.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Heckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Egleston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Hofmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco control</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="410" to="416" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heckman, C. J., Egleston, B. L., and Hofmann, M. T. (2010). Efficacy of motivational inter- viewing for smoking cessation: a systematic review and meta-analysis. Tobacco control, 19(5):410-416.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Motivational interviewing</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hettema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Steele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annual Review of Clinical Psychology</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="91" to="111" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hettema, J., Steele, J., and Miller, W. R. (2004). Motivational interviewing. Annual Review of Clinical Psychology, 1(1):91-111.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Abuse potential of non-nicotine tobacco smoke components: Acetaldehyde, nornicotine, cotinine, and anabasine</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="622" to="632" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoffman, A. C. and Evans, S. E. (2013). Abuse potential of non-nicotine tobacco smoke com- ponents: Acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine &amp; Tobacco Research, 15(3):622-632.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">The introduction of tobacco into southeast asia</title>
		<author>
			<persName><forename type="first">T</forename><surname>H√∂llmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Opiums. Les plantes du plaisir et de la convivialit√© en Asie</title>
		<editor>
			<persName><forename type="first">A</forename><surname>Hubert</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Failler</surname></persName>
		</editor>
		<imprint>
			<publisher>L&apos;Harmattan</publisher>
			<date type="published" when="2000">2000</date>
			<biblScope unit="page">305</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">H√∂llmann, T. (2000). The introduction of tobacco into southeast asia. In Hubert, A. and Failler, P. L., editors, Opiums. Les plantes du plaisir et de la convivialit√© en Asie, page 305. L&apos;Harmattan.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">A review of monoamine oxidase (mao) inhibitors in tobacco or tobacco smoke</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Teesdale-Spittle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Truman</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurotoxicology</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="163" to="172" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hong, S. W., Teesdale-Spittle, P., Page, R., and Truman, P. (2022). A review of monoamine oxidase (mao) inhibitors in tobacco or tobacco smoke. Neurotoxicology, 93:163-172.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">General mass action kinetics</title>
		<author>
			<persName><forename type="first">F</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Archive for rational mechanics and analysis</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="81" to="116" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Horn, F. and Jackson, R. (1972). General mass action kinetics. Archive for rational mechanics and analysis, 47(2):81-116.</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of ltp in the amygdala</title>
		<author>
			<persName><forename type="first">Y.-Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Kandel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Levine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Learning &amp; Memory</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="603" to="610" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang, Y.-Y., Kandel, E. R., and Levine, A. (2008). Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of ltp in the amygdala. Learning &amp; Memory, 15(8):603-610.</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Signs and symptoms of tobacco withdrawal</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hatsukami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Archives of General Psychiatry</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">289</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes, J. R. and Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry, 43(3):289.</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Effectiveness of over-the-counter nicotine replacement therapy: A qualitative review of nonrandomized trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Naud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="512" to="522" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes, J. R., Peters, E. N., and Naud, S. (2011). Effectiveness of over-the-counter nicotine replacement therapy: A qualitative review of nonrandomized trials. Nicotine &amp; Tobacco Research, 13(7):512-522.</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">A meta-analysis of the efficacy of over-the-counter nicotine replacement</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Callas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco control</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="21" to="27" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes, J. R., Shiffman, S., Callas, P., and Zhang, J. (2003). A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tobacco control, 12(1):21-27.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Explaining socio-economic inequalities in daily smoking: a social-ecological approach</title>
		<author>
			<persName><forename type="first">M</forename><surname>Huisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Van Lenthe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Giskes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Kamphuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mackenbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Public Health</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="238" to="243" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huisman, M., Van Lenthe, F. J., Giskes, K., Kamphuis, C. B., Brug, J., and Mackenbach, J. P. (2011). Explaining socio-economic inequalities in daily smoking: a social-ecological approach. European Journal of Public Health, 22(2):238-243.</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Cognitive susceptibility to smoking and initiation of smoking during childhood: a longitudinal study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Preventive medicine</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="129" to="134" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jackson, C. (1998). Cognitive susceptibility to smoking and initiation of smoking during childhood: a longitudinal study. Preventive medicine, 27(1):129-134.</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">New mechanisms and perspectives in nicotine withdrawal</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Muldoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Biasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Damaj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="223" to="234" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jackson, K. J., Muldoon, P. P., De Biasi, M., and Damaj, M. I. (2014). New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology, 96:223-234.</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Varenicline</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jim√©nez-Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Berlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hering</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1319" to="1338" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jim√©nez-Ruiz, C., Berlin, I., and Hering, T. (2009). Varenicline. Drugs, 69(10):1319-1338.</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Nicotine metabolism predicted by cyp2a6 genotypes in relation to smoking cessation: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Froeliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Alberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine and Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="633" to="642" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jones, S. K., Wolf, B. J., Froeliger, B., Wallace, K., Carpenter, M. J., and Alberg, A. J. (2022). Nicotine metabolism predicted by cyp2a6 genotypes in relation to smoking cessation: a systematic review. Nicotine and Tobacco Research, 24(5):633-642.</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Comorbidity between patterns of substance use dependence and psychiatric syndromes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Kandel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F.-Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and Alcohol Dependence</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="233" to="241" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kandel, D. B., Huang, F.-Y., and Davies, M. (2001). Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug and Alcohol Dependence, 64(2):233-241.</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Gould</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular neurobiology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="101" to="121" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kenney, J. W. and Gould, T. J. (2008). Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Molecular neurobiology, 38(1):101-121.</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Drug addiction, dysregulation of reward, and allostasis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Koob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="97" to="129" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koob, G. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychophar- macology, 24(2):97-129.</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Nicotinic receptors regulate the dynamic range of dopamine release in vivo</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Koranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Cone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Mcgehee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Roitman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Beeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neurophysiology</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="103" to="111" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koranda, J. L., Cone, J. J., McGehee, D. S., Roitman, M. F., Beeler, J. A., and Zhuang, X. (2013). Nicotinic receptors regulate the dynamic range of dopamine release in vivo. Journal of Neurophysiology, 111(1):103-111.</note>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<title level="m" type="main">Clear-path smoking assessment tools</title>
		<author>
			<persName><surname>Kshiteesh</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2025-10-08">2025. 2025-10-08</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kshiteesh (2025). Clear-path smoking assessment tools. [Online; accessed 2025-10-08].</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Bidi: A short history</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Science</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1335" to="1337" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lal, P. (2009). Bidi: A short history. Current Science, 96(10):1335-1337.</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Tobacco and Its Use in Africa</title>
		<author>
			<persName><forename type="first">B</forename><surname>Laufer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Hambly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Linton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Field Museum of Natural History</title>
		<imprint>
			<date type="published" when="1930">1930</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Laufer, B., Hambly, W. D., and Linton, R. (1930). Tobacco and Its Use in Africa. Field Museum of Natural History.</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Houezec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The International Journal of Tuberculosis and Lung Disease</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="811" to="819" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Le Houezec, J. (2003). Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. The International Journal of Tuberculosis and Lung Disease, 7(9):811-819.</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">The low tar lie</title>
		<author>
			<persName><forename type="first">N.-R</forename><surname>Leavell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco Control</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="433" to="437" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leavell, N.-R. (1999). The low tar lie. Tobacco Control, 8(4):433-437.</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Monoamine oxidase and tobacco dependence</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Lea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurotoxicology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="182" to="195" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewis, A., Miller, J. H., and Lea, R. A. (2007). Monoamine oxidase and tobacco dependence. Neurotoxicology, 28(1):182-195.</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">The genetics of smoking related behavior: a brief review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American Journal of the Medical Sciences</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="168" to="173" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, M. D. (2003). The genetics of smoking related behavior: a brief review. The American Journal of the Medical Sciences, 326(4):168-173.</note>
</biblStruct>

<biblStruct xml:id="b102">
	<monogr>
		<title level="m" type="main">Dorsal striatal circuits for habits, compulsions and addictions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lipton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Gonzales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Citri</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2019">2019</date>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">28</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Lipton, D. M., Gonzales, B. J., and Citri, A. (2019). Dorsal striatal circuits for habits, compul- sions and addictions. 13:28.</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">The role of nicotine metabolic rate on nicotine dependence and rewarding: nicotine metabolism in chinese male smokers and male mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Neurobiology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="7692" to="7706" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu, M., Wang, H., Fu, Y., Li, X., Wu, P., Liu, G., Wang, R., Zhang, Y., Chen, H., Hou, H., et al. (2024). The role of nicotine metabolic rate on nicotine dependence and rewarding: nicotine metabolism in chinese male smokers and male mice. Molecular Neurobiology, 61(10):7692-7706.</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Differentiating stages of smoking intensity among adolescents: stage-specific psychological and social influences</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Lloyd-Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Papandonatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kazura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stanton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Niaura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of consulting and clinical psychology</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">998</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lloyd-Richardson, E. E., Papandonatos, G., Kazura, A., Stanton, C., and Niaura, R. (2002). Differentiating stages of smoking intensity among adolescents: stage-specific psychological and social influences. Journal of consulting and clinical psychology, 70(4):998.</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Adolescent brain maturation and smoking: What we know and where we&apos;re headed</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lydon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Child</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Geier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience &amp; Biobehavioral Reviews</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="323" to="342" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lydon, D. M., Wilson, S. J., Child, A., and Geier, C. F. (2014). Adolescent brain maturation and smoking: What we know and where we&apos;re headed. Neuroscience &amp; Biobehavioral Reviews, 45:323-342.</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Side effects of using shisha on human health: A systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mahmood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Afreen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rahim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Political Stability Archive</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="36" to="53" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mahmood, K., Afreen, S., Khan, H. M., and Rahim, W. (2024). Side effects of using shisha on human health: A systematic review. Journal of Political Stability Archive, 2(4):36-53.</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Tales tobacco told in sixteenth-century europe</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Mancall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Environmental History</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="648" to="678" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mancall, P. C. (2004). Tales tobacco told in sixteenth-century europe. Environmental History, 9(4):648-678.</note>
</biblStruct>

<biblStruct xml:id="b108">
	<monogr>
		<title level="m" type="main">Volume of Distribution</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mansoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mahabadi</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2025">2025</date>
			<publisher>StatPearls Publishing</publisher>
			<pubPlace>Treasure Island (FL)</pubPlace>
		</imprint>
	</monogr>
	<note>StatPearls [Internet Updated 2023 Jul 24</note>
	<note type="raw_reference">Mansoor, A. and Mahabadi, N. (2025). Volume of Distribution. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). [Updated 2023 Jul 24].</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">A cognitive-behavioral model of the relapse process</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Marlatt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Behavioral Analysis and Treatment of Substance Abuse</title>
		<editor>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Krasnegor</surname></persName>
		</editor>
		<imprint>
			<date type="published" when="1979">1979</date>
		</imprint>
		<respStmt>
			<orgName>U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Research</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Marlatt, G. A. (1979). A cognitive-behavioral model of the relapse process. In Krasnegor, N. A. (Ed.), Behavioral Analysis and Treatment of Substance Abuse, chapter 13. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Research.</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Nicotine modulates multiple regions in the limbic stress network: role of crf and hpa axis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Matta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Desarmenien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neurochemistry</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="7" to="20" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Matta, S. G. and Desarmenien, M. G. (2012). Nicotine modulates multiple regions in the limbic stress network: role of crf and hpa axis. Journal of Neurochemistry, 121(1):7-20.</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Stages in the development of adolescent smoking</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Mayhew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Flay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol dependence</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="61" to="81" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mayhew, K. P., Flay, B. R., and Mott, J. A. (2000). Stages in the development of adolescent smoking. Drug and alcohol dependence, 59:61-81.</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">E-cigarette use, cigarette smoking, dual use, and problem behaviors among u.s. adolescents: results from a national survey</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Veliz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Boyd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Adolescent Health</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="155" to="162" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McCabe, S. E., West, B. T., Veliz, P., and Boyd, C. J. (2017). E-cigarette use, cigarette smoking, dual use, and problem behaviors among u.s. adolescents: results from a national survey. Journal of Adolescent Health, 61(2):155-162.</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Inhale, exhale: Probing the inside-out mechanism of nicotine addiction using novel fluorescent sensors</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">B</forename><surname>Mcmanus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Werley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Dempsey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of General Physiology</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="714" to="717" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McManus, O. B., Werley, C. A., and Dempsey, G. T. (2019). Inhale, exhale: Probing the inside-out mechanism of nicotine addiction using novel fluorescent sensors. The Journal of General Physiology, 151(6):714-717.</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Modification of smoking behavior: A review</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Mees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Keutzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lichtenstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychological Bulletin</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="520" to="533" />
			<date type="published" when="1968">1968</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mees, H. L., Keutzer, C. S., and Lichtenstein, E. (1968). Modification of smoking behavior: A review. Psychological Bulletin, 70(6, Pt.1):520-533.</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Barriers and facilitators of adherence to nicotine replacement therapy: a systematic review and analysis using the capability, opportunity, motivation, and behaviour (com-b) model</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mersha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Gould</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bovill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Eftekhari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of environmental research and public health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page">8895</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mersha, A. G., Gould, G. S., Bovill, M., and Eftekhari, P. (2020). Barriers and facilitators of adherence to nicotine replacement therapy: a systematic review and analysis using the capability, opportunity, motivation, and behaviour (com-b) model. International journal of environmental research and public health, 17(23):8895.</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Tobacco constituents: Their importance in flavor and fragrance chemistry</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Mookherjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Perfumery &amp; Flavor</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="27" to="49" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mookherjee, B. D. and Wilson, R. A. (1990). Tobacco constituents: Their importance in flavor and fragrance chemistry. Perfumery &amp; Flavor, 15(1):27-49.</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Damage to the insula disrupts addiction to cigarette smoking</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Naqvi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rudrauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Damasio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bechara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="issue">5811</biblScope>
			<biblScope unit="page" from="531" to="534" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Naqvi, N. H., Rudrauf, D., Damasio, H., and Bechara, A. (2007). Damage to the insula disrupts addiction to cigarette smoking. Science, 315(5811):531-534.</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Delivering &quot;just-in-time&quot; smoking cessation support via mobile phones: current knowledge and future directions</title>
		<author>
			<persName><forename type="first">F</forename><surname>Naughton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="379" to="383" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Naughton, F. (2017). Delivering &quot;just-in-time&quot; smoking cessation support via mobile phones: current knowledge and future directions. Nicotine &amp; Tobacco Research, 19(3):379-383.</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Functional brain imaging of nicotinic effects on higher cognitive processes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Newhouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Dumas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Thiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemical Pharmacology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="943" to="951" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Newhouse, P. A., Potter, A. S., Dumas, J. A., and Thiel, C. M. (2011). Functional brain imaging of nicotinic effects on higher cognitive processes. Biochemical Pharmacology, 82(8):943-951.</note>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Relevance of cue reactivity to understanding alcohol and smoking relapse</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Niaura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Rohsenow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Binkoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pedraza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Abrams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Abnormal Psychology</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="133" to="152" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Niaura, R. S., Rohsenow, D. J., Binkoff, J. A., Monti, P. M., Pedraza, M., and Abrams, D. B. (1988). Relevance of cue reactivity to understanding alcohol and smoking relapse. Journal of Abnormal Psychology, 97(2):133-152.</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Metacognitions about smoking: a preliminary investigation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Nikƒçeviƒá</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Spada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical psychology &amp; psychotherapy</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="536" to="542" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nikƒçeviƒá, A. V. and Spada, M. M. (2010). Metacognitions about smoking: a preliminary investigation. Clinical psychology &amp; psychotherapy, 17(6):536-542.</note>
</biblStruct>

<biblStruct xml:id="b122">
	<monogr>
		<title level="m" type="main">Trends in the prevalence and factors associated with indoor smoking in 24 countries party to the who fctc: implications for equitable policy implementation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Odo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ayo-Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dinku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mekonnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maddox</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2025">2025</date>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">17110</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Odo, D. B., Ayo-Yusuf, O., Dinku, Y., Mekonnen, A. G., and Maddox, R. (2025). Trends in the prevalence and factors associated with indoor smoking in 24 countries party to the who fctc: implications for equitable policy implementation. 10(2):e017110.</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers</title>
		<author>
			<persName><forename type="first">J</forename><surname>O'loughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Paradis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Difranza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Meshefedjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mcmillan-Davey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Tyndale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco Control</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="422" to="428" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Loughlin, J., Paradis, G., Kim, W., DiFranza, J., Meshefedjian, G., McMillan-Davey, E., Wong, S., Hanley, J., and Tyndale, R. F. (2004). Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco Control, 13(4):422-428.</note>
</biblStruct>

<biblStruct xml:id="b124">
	<monogr>
		<title level="m" type="main">Global report on trends in prevalence of tobacco use 2000-2030</title>
		<imprint>
			<date type="published" when="2024">2024</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization (2024). Global report on trends in prevalence of tobacco use 2000-2030.</note>
</biblStruct>

<biblStruct xml:id="b125">
	<monogr>
		<title level="m" type="main">Merging old and new perspectives on nicotinic acetylcholine receptors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Papke</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="1" to="11" />
		</imprint>
	</monogr>
	<note type="raw_reference">Papke, R. L. (2014). Merging old and new perspectives on nicotinic acetylcholine receptors. 89(1):1-11.</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">The role of health beliefs in compliance with physician advice to quit smoking</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Pederson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wanklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Baskerville</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Social Science &amp; Medicine</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="573" to="580" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pederson, L. L., Wanklin, J. M., and Baskerville, J. C. (1984). The role of health beliefs in compliance with physician advice to quit smoking. Social Science &amp; Medicine, 19(5):573- 580.</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">A randomized clinical trial of cue exposure treatment through virtual reality for smoking cessation</title>
		<author>
			<persName><forename type="first">I</forename><surname>Pericot-Valverde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Secades-Villa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guti√©rrez-Maldonado</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of substance abuse treatment</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="26" to="32" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pericot-Valverde, I., Secades-Villa, R., and Guti√©rrez-Maldonado, J. (2019). A randomized clinical trial of cue exposure treatment through virtual reality for smoking cessation. Journal of substance abuse treatment, 96:26-32.</note>
</biblStruct>

<biblStruct xml:id="b128">
	<monogr>
		<title level="m" type="main">Cognitive-behavioral therapy for smoking cessation: a practical guidebook to the most effective treatments</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Perkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Conklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Levine</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<publisher>Routledge</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Perkins, K. A., Conklin, C. A., and Levine, M. D. (2013). Cognitive-behavioral therapy for smoking cessation: a practical guidebook to the most effective treatments. Routledge.</note>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Placebo effects of tobacco smoking and other nicotine intake</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Perkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sayette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Conklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caggiula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="695" to="709" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Perkins, K. A., Sayette, M., Conklin, C., and Caggiula, A. (2003). Placebo effects of tobacco smoking and other nicotine intake. Nicotine &amp; Tobacco Research, 5(5):695-709.</note>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Fundamental cause theory</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Phelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Link</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Springer eBooks</title>
		<imprint>
			<biblScope unit="page" from="105" to="125" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Phelan, J. C. and Link, B. G. (2013). Fundamental cause theory. In Springer eBooks, pages 105-125.</note>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Molecular mechanisms underlying behaviors related to nicotine addiction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Picciotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Kenny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cold Spring Harbor Perspectives in Medicine</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">12112</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Picciotto, M. R. and Kenny, P. J. (2012). Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harbor Perspectives in Medicine, 3(1):a012112.</note>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Mechanisms of nicotine addiction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Picciotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Kenny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cold Spring Harbor Perspectives in Medicine</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">39610</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Picciotto, M. R. and Kenny, P. J. (2020). Mechanisms of nicotine addiction. Cold Spring Harbor Perspectives in Medicine, 11(5):a039610.</note>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">An improved surveillance measure for adolescent smoking</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Gilpin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco Control</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="47" to="S56" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pierce, J. P., Farkas, A. J., Evans, N., and Gilpin, E. A. (1995). An improved surveillance measure for adolescent smoking. Tobacco Control, 4(Suppl 1):S47-S56.</note>
</biblStruct>

<biblStruct xml:id="b134">
	<monogr>
		<title level="m" type="main">Nicotinic acetylcholine receptors in attention circuitry: the role of layer vi neurons of prefrontal cortex</title>
		<author>
			<persName><forename type="first">E</forename><surname>Proulx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Lambe</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1225" to="1244" />
		</imprint>
	</monogr>
	<note type="raw_reference">Proulx, E., Piva, M., Tian, M. K., Bailey, C. D., and Lambe, E. K. (2014). Nicotinic acetylcholine receptors in attention circuitry: the role of layer vi neurons of prefrontal cortex. 71(7):1225- 1244.</note>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Cigarette smoking behavior: a gateway to opium use disorder -a mendelian randomization analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rajabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shojaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Janani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farjam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Baradaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Khosravi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Motevalian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behavior Genetics</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="385" to="393" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rajabi, A., Shojaei, A., Janani, L., Farjam, M., Baradaran, H. R., Khosravi, P., and Motevalian, S. A. (2021). Cigarette smoking behavior: a gateway to opium use disorder -a mendelian randomization analysis. Behavior Genetics, 51(4):385-393.</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Factors affecting cigarette smoking in adolescents: A systematic review</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ranaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Abasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peyambari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alizadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Pilevar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tobacco and Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="138" to="145" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ranaei, V., Abasi, H., Peyambari, M., Alizadeh, L., and Pilevar, Z. (2022). Factors affecting cigarette smoking in adolescents: A systematic review. Tobacco and Health, 1(3):138-145.</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">The insula in nicotine use disorder: functional neuroimaging and implications for neuromodulation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Regner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tregellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kluger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wylie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Gowin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tanabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience &amp; Biobehavioral Reviews</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="414" to="424" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Regner, M. F., Tregellas, J., Kluger, B., Wylie, K., Gowin, J. L., and Tanabe, J. (2019). The insula in nicotine use disorder: functional neuroimaging and implications for neuromodulation. Neuroscience &amp; Biobehavioral Reviews, 103:414-424.</note>
</biblStruct>

<biblStruct xml:id="b138">
	<monogr>
		<title level="m" type="main">Behavioral Analysis of Substance Use and Dependence: Theoretical-Conceptual Aspects and Possibilities for Intervention</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Reichert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Oliani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Banaco</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2021">2021</date>
			<publisher>Springer eBooks</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Reichert, R. A., Oliani, S. M., and Banaco, R. A. (2021). Behavioral Analysis of Substance Use and Dependence: Theoretical-Conceptual Aspects and Possibilities for Intervention. Springer eBooks.</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">The implicit beliefs and implicit behavioral tendencies towards smoking-related cues among chinese male smokers and non-smokers</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-B</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1000</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ren, L., Cui, L.-B., Chen, C., Dong, X., Wu, Z., Wang, Y., and Yang, Q. (2019). The implicit beliefs and implicit behavioral tendencies towards smoking-related cues among chinese male smokers and non-smokers. BMC Public Health, 19(1):1000.</note>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Reus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Clinical Practice</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1753" to="1768" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Reus, V. I. and Smith, B. J. (2008). Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. International Journal of Clinical Practice, 62(11):1753-1768.</note>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Review of bupropion for smoking cessation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Richmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zwar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and Alcohol Review</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="203" to="220" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Richmond, R. and Zwar, N. (2003a). Review of bupropion for smoking cessation. Drug and Alcohol Review, 22(2):203-220.</note>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Review of bupropion for smoking cessation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Richmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zwar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol review</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="203" to="220" />
			<date type="published" when="2003">2003b</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Richmond, R. and Zwar, N. (2003b). Review of bupropion for smoking cessation. Drug and alcohol review, 22(2):203-220.</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Systematic review of the effectiveness of stage based interventions to promote smoking cessation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Riemsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pattenden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bridle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Sowden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Watt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Walker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bmj</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="issue">7400</biblScope>
			<biblScope unit="page" from="1175" to="1177" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Riemsma, R. P., Pattenden, J., Bridle, C., Sowden, A. J., Mather, L., Watt, I. S., and Walker, A. (2003). Systematic review of the effectiveness of stage based interventions to promote smoking cessation. Bmj, 326(7400):1175-1177.</note>
</biblStruct>

<biblStruct xml:id="b144">
	<monogr>
		<title level="m" type="main">Smoking. Our World in Data</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ritchie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roser</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>Online</note>
	<note type="raw_reference">Ritchie, H. and Roser, M. (2023). Smoking. Our World in Data. [Online].</note>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Incentive salience and the transition to addiction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Berridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biological research on addiction</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="391" to="399" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Robinson, M. J., Robinson, T. E., and Berridge, K. C. (2013). Incentive salience and the transition to addiction. Biological research on addiction, 2:391-399.</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">The hypothalamic-pituitary-adrenal (hpa) axis in habitual smokers</title>
		<author>
			<persName><forename type="first">N</forename><surname>Rohleder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kirschbaum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Psychophysiology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="236" to="243" />
			<date type="published" when="2006">2006</date>
			<publisher>Cortisol and the Addictions</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Rohleder, N. and Kirschbaum, C. (2006). The hypothalamic-pituitary-adrenal (hpa) axis in habitual smokers. International Journal of Psychophysiology, 59(3):236-243. Cortisol and the Addictions.</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Exploring issues of comorbid conditions in people who smoke: Table 1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rojewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baldassarri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Cooperman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Gritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Piper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Toll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Warren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1684" to="1696" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rojewski, A. M., Baldassarri, S., Cooperman, N. A., Gritz, E. R., Leone, F. T., Piper, M. E., Toll, B. A., and Warren, G. W. (2016). Exploring issues of comorbid conditions in people who smoke: Table 1. Nicotine &amp; Tobacco Research, 18(8):1684-1696.</note>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<author>
			<persName><forename type="first">Roper</forename><surname>Organization</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Roper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">A study of people&apos;s cigarette smoking habits and attitudes volume I&quot;. Collection: Depositions and Trial Testimony (DATTA)</title>
		<title level="s">RICO Privilege Downgrades Collection</title>
		<imprint>
			<date type="published" when="1953">1953</date>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">358</biblScope>
		</imprint>
	</monogr>
	<note>report</note>
	<note type="raw_reference">Roper Organization and Roper, B. W. (1953). U.S. exhibit 20,358, report, &quot;A study of people&apos;s cigarette smoking habits and attitudes volume I&quot;. Collection: Depositions and Trial Testimony (DATTA); RICO Privilege Downgrades Collection.</note>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">The health belief model and preventive health behavior</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Rosenstock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Education Monographs</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="354" to="386" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rosenstock, I. M. (1974). The health belief model and preventive health behavior. Health Education Monographs, 2(4):354-386.</note>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Deci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Psychologist</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="68" to="78" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ryan, R. M. and Deci, E. L. (2000). Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. American Psychologist, 55(1):68-78.</note>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Cell-specific transcriptional responses to heat shock in the mouse utricle epithelium</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Ryals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Boger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Morell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hertzano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Cellular Neuroscience</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">123</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sadler, E., Ryals, M. M., May, L. A., Martin, D., Welsh, N., Boger, E. T., Morell, R. J., Hertzano, R., and Cunningham, L. L. (2020). Cell-specific transcriptional responses to heat shock in the mouse utricle epithelium. Frontiers in Cellular Neuroscience, 14:123.</note>
</biblStruct>

<biblStruct xml:id="b152">
	<monogr>
		<title level="m" type="main">Tobacco advertising: Economic theory and international evidence</title>
		<author>
			<persName><forename type="first">H</forename><surname>Saffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J C</forename><surname>Iv</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
			<publisher>National Bureau of Economic Research</publisher>
		</imprint>
	</monogr>
	<note type="report_type">Technical report</note>
	<note type="raw_reference">Saffer, H. and IV, F. J. C. (1999). Tobacco advertising: Economic theory and international evidence. Technical report, National Bureau of Economic Research.</note>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Social networks and smoking: exploring the effects of peer influence and smoker popularity through simulations</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Haas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Education &amp; Behavior</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">1_suppl</biblScope>
			<biblScope unit="page" from="24S" to="32S" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schaefer, D. R., Adams, J., and Haas, S. A. (2013). Social networks and smoking: exploring the effects of peer influence and smoker popularity through simulations. Health Education &amp; Behavior, 40(1_suppl):24S-32S.</note>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Social smoking: Implications for public health, clinical practice, and intervention research</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Schane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Glantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Preventive Medicine</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="124" to="130" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schane, R. E., Glantz, S., and Ling, P. M. (2009). Social smoking: Implications for public health, clinical practice, and intervention research. American Journal of Preventive Medicine, 37(3):124-130.</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Scherphof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Van Den Eijnden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Engels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Vollebergh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol dependence</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="217" to="220" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scherphof, C. S., van den Eijnden, R. J., Engels, R. C., and Vollebergh, W. A. (2014). Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. Drug and alcohol dependence, 140:217-220.</note>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Sellings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baharnouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Mcquade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Neuroscience</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="342" to="352" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sellings, L. H., Baharnouri, G., McQuade, L. E., and Clarke, P. B. (2008). Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. European Journal of Neuroscience, 28(2):342-352.</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system</title>
		<author>
			<persName><forename type="first">J.-X</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Yakel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Pharmacologica Sinica</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="673" to="680" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shen, J.-X. and Yakel, J. L. (2009). Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacologica Sinica, 30(6):673-680.</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Assessing smoking patterns and motives</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shiffman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Consulting and Clinical Psychology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="732" to="742" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shiffman, S. (1993). Assessing smoking patterns and motives. Journal of Consulting and Clinical Psychology, 61(5):732-742.</note>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Dynamic influences on smoking relapse process</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shiffman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Personality</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1715" to="1748" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shiffman, S. (2005). Dynamic influences on smoking relapse process. Journal of Personality, 73(6):1715-1748.</note>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Nicotine biosynthesis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Shoji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hashimoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plant Metabolism and Biotechnology</title>
		<imprint>
			<biblScope unit="page" from="191" to="216" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shoji, T. and Hashimoto, T. (2011). Nicotine biosynthesis. Plant Metabolism and Biotechnology, pages 191-216.</note>
</biblStruct>

<biblStruct xml:id="b161">
	<monogr>
		<title level="m" type="main">Introduction to Syndemics: A Critical Systems Approach to Public and Community Health</title>
		<author>
			<persName><forename type="first">M</forename><surname>Singer</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009">2009</date>
			<publisher>Jossey-Bass</publisher>
			<pubPlace>San Francisco, CA</pubPlace>
		</imprint>
	</monogr>
	<note>1st edition</note>
	<note type="raw_reference">Singer, M. (2009). Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. Jossey-Bass, San Francisco, CA, 1st edition.</note>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Selection by consequences</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Skinner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behavioral and Brain Sciences</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="477" to="481" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Skinner, B. F. (1984). Selection by consequences. Behavioral and Brain Sciences, 7(4):477- 481.</note>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Personality and smoking: A review of the empirical literature</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Learning mechanisms in smoking</title>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="page" from="42" to="71" />
		</imprint>
	</monogr>
	<note type="raw_reference">Smith, G. M. (2017). Personality and smoking: A review of the empirical literature. Learning mechanisms in smoking, pages 42-71.</note>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Nicotinic regulation of microglia: potential contributions to addiction</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Soares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Picciotto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neural Transmission</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="425" to="435" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Soares, A. R. and Picciotto, M. R. (2023). Nicotinic regulation of microglia: potential contri- butions to addiction. Journal of Neural Transmission, 131(5):425-435.</note>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">The opponent-process theory of acquired motivation: The costs of pleasure and the benefits of pain</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Solomon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Psychologist</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="691" to="712" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Solomon, R. L. (1980). The opponent-process theory of acquired motivation: The costs of pleasure and the benefits of pain. American Psychologist, 35(8):691-712.</note>
</biblStruct>

<biblStruct xml:id="b166">
	<monogr>
		<title level="m" type="main">Nicotine replacement therapy for smoking cessation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Stead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Perera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hartmann-Boyce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cahill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lancaster</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Cochrane Library</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., and Lancaster, T. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Library.</note>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">A history of the medicinal use of tobacco 1492-1860</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medical History</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="228" to="268" />
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stewart, G. G. (1967). A history of the medicinal use of tobacco 1492-1860. Medical History, 11(3):228-268.</note>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">The social ecological paradigm of wellness promotion</title>
		<author>
			<persName><forename type="first">D</forename><surname>Stokols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Promoting Human Wellness: New Frontiers for Research, Practice, and Policy</title>
		<editor>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Jamner</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><surname>Stokols</surname></persName>
		</editor>
		<meeting><address><addrLine>Berkeley, CA</addrLine></address></meeting>
		<imprint>
			<publisher>University of California Press</publisher>
			<date type="published" when="2000">2000</date>
			<biblScope unit="page" from="21" to="45" />
		</imprint>
	</monogr>
	<note type="raw_reference">Stokols, D. (2000). The social ecological paradigm of wellness promotion. In Jamner, M. S. and Stokols, D. (Eds.), Promoting Human Wellness: New Frontiers for Research, Practice, and Policy, pages 21-45. University of California Press, Berkeley, CA.</note>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Reflective and impulsive determinants of social behavior</title>
		<author>
			<persName><forename type="first">F</forename><surname>Strack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Deutsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Research on Social Psychology</title>
		<editor>
			<persName><forename type="first">W</forename><surname>Stroebe</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">M</forename><surname>Hewstone</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Psychology Press</publisher>
			<date type="published" when="2004">2004</date>
			<biblScope unit="page" from="45" to="67" />
		</imprint>
	</monogr>
	<note type="raw_reference">Strack, F. and Deutsch, R. (2004). Reflective and impulsive determinants of social behavior. In Stroebe, W. and Hewstone, M., editors, Research on Social Psychology, pages 45-67. Psychology Press, New York.</note>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Clinical pharmacokinetics of nicotine</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Svensson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical pharmacokinetics</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="30" to="40" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Svensson, C. K. (1987). Clinical pharmacokinetics of nicotine. Clinical pharmacokinetics, 12(1):30-40.</note>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Risk factors for late relapse in male and female ex-smokers</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Denk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carmelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Furze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Rosenman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addictive behaviors</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="253" to="266" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Swan, G. E., Denk, C. E., Parker, S. D., Carmelli, D., Furze, C. T., and Rosenman, R. H. (1988). Risk factors for late relapse in male and female ex-smokers. Addictive behaviors, 13(3):253-266.</note>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Sweeney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Fant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Fagerstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Mcgovern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS drugs</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="453" to="467" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sweeney, C. T., Fant, R. V., Fagerstrom, K. O., McGovern, J. F., and Henningfield, J. E. (2001). Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS drugs, 15(6):453-467.</note>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Diverging trends in smoking behaviors according to mental health status</title>
		<author>
			<persName><forename type="first">L</forename><surname>Szatkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcneill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="356" to="360" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Szatkowski, L. and McNeill, A. (2015). Diverging trends in smoking behaviors according to mental health status. Nicotine &amp; Tobacco Research, 17(3):356-360.</note>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">Hazardous compounds in tobacco smoke</title>
		<author>
			<persName><forename type="first">R</forename><surname>Talhout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Florek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Benthem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Opperhuizen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of environmental research and public health</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="613" to="628" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Talhout, R., Schulz, T., Florek, E., Van Benthem, J., Wester, P., and Opperhuizen, A. (2011). Hazardous compounds in tobacco smoke. International journal of environmental research and public health, 8(2):613-628.</note>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Variation in cyp2a6 activity and personalized medicine</title>
		<author>
			<persName><forename type="first">J.-A</forename><surname>Tanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Tyndale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of personalized medicine</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tanner, J.-A. and Tyndale, R. F. (2017). Variation in cyp2a6 activity and personalized medicine. Journal of personalized medicine, 7(4):18.</note>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Classical conditioning in drug addiction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Tiffany</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Addictive Behaviour: Cue Exposure Theory and Practice</title>
		<imprint>
			<date type="published" when="1995">1995</date>
			<biblScope unit="page">47</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Tiffany, S. T. (1995). Classical conditioning in drug addiction. In Addictive Behaviour: Cue Exposure Theory and Practice, pages 47-xx.</note>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">Nicotine addiction: Neurobiology and mechanism</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Tiwari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Shukla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacopuncture</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tiwari, R. K., Sharma, V., Pandey, R. K., and Shukla, S. S. (2020). Nicotine addiction: Neurobiology and mechanism. Journal of Pharmacopuncture, 23(1):1-7.</note>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tonstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>T√∏nnesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hajek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Billing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Reeves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P S</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="64" to="71" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tonstad, S., T√∏nnesen, P., Hajek, P., Williams, K. E., Billing, C. B., Reeves, K. R., Group, V. P. . S., et al. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Jama, 296(1):64-71.</note>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">Nicotine exposure during adolescence leads to changes of synaptic plasticity and intrinsic excitability of mice insular pyramidal cells at later life</title>
		<author>
			<persName><forename type="first">H</forename><surname>Toyoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Molecular Sciences</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">34</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Toyoda, H. and Koga, K. (2022). Nicotine exposure during adolescence leads to changes of synaptic plasticity and intrinsic excitability of mice insular pyramidal cells at later life. International Journal of Molecular Sciences, 23(1):34.</note>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">Predictors of the transition to regular smoking during adolescence and young adulthood</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Tucker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Ellickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Adolescent Health</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="314" to="324" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tucker, J. S., Ellickson, P. L., and Klein, D. J. (2003). Predictors of the transition to regular smoking during adolescence and young adulthood. Journal of Adolescent Health, 32(4):314- 324.</note>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">The presence of chemicals in tobacco and IQOS</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Tudor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Ene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scientific Bulletin &quot;Mircea cel BƒÉtr√¢n&quot; Naval Academy</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="113" to="116" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tudor, C. A. and Ene, B. G. (2024). The presence of chemicals in tobacco and IQOS. Scientific Bulletin &quot;Mircea cel BƒÉtr√¢n&quot; Naval Academy, 27(1):113-116.</note>
</biblStruct>

<biblStruct xml:id="b182">
	<monogr>
		<title level="m" type="main">Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service</title>
		<idno>No. 1103</idno>
		<imprint>
			<date type="published" when="1964">1964</date>
			<publisher>U.S. Government Printing Office. Public Health Service Publication</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">U.S. Department of Health, E. and Welfare (1964). Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. U.S. Government Printing Office. Public Health Service Publication No. 1103.</note>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">Predictors of smoking development in a population-based sample of adolescents: a prospective study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Van Den Bree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Whitmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Pickworth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Adolescent Health</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="172" to="181" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Van Den Bree, M. B., Whitmer, M. D., and Pickworth, W. B. (2004). Predictors of smoking development in a population-based sample of adolescents: a prospective study. Journal of Adolescent Health, 35(3):172-181.</note>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">Smoking behavior in context: Where and when do people smoke?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Gucht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Van Den Bergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Beckers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vansteenwegen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Behavior Therapy and Experimental Psychiatry</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="172" to="177" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Van Gucht, D., Van Den Bergh, O., Beckers, T., and Vansteenwegen, D. (2010). Smoking behavior in context: Where and when do people smoke? Journal of Behavior Therapy and Experimental Psychiatry, 41(2):172-177.</note>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">Tranylcypromine enhancement of nicotine self-administration</title>
		<author>
			<persName><forename type="first">A.-S</forename><surname>Vill√©gier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lotfipour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Mcquown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Belluzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Leslie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1415" to="1425" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vill√©gier, A.-S., Lotfipour, S., McQuown, S. C., Belluzzi, J. D., and Leslie, F. M. (2007). Tranyl- cypromine enhancement of nicotine self-administration. Neuropharmacology, 52(6):1415- 1425.</note>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">Effects of nicotine withdrawal on cognition in a clinical trial setting</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Wesnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Edgar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kezic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Salih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>De Boer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="133" to="140" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wesnes, K. A., Edgar, C. J., Kezic, I., Salih, H. M., and de Boer, P. (2013). Effects of nicotine withdrawal on cognition in a clinical trial setting. Psychopharmacology, 229(1):133-140.</note>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">Tobacco Use by Native North Americans: Sacred Smoke and Silent Killer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="s">Civilization of the American Indian Series</title>
		<imprint>
			<biblScope unit="volume">236</biblScope>
			<date type="published" when="2000">2000</date>
			<publisher>University of Oklahoma Press</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Winter, J. C. (2000). Tobacco Use by Native North Americans: Sacred Smoke and Silent Killer. Number 236 in Civilization of the American Indian Series. University of Oklahoma Press.</note>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Wittenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Wolfman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Biasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Dani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page">108256</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wittenberg, R. E., Wolfman, S. L., De Biasi, M., and Dani, J. A. (2020). Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction. Neuropharmacology, 177:108256.</note>
</biblStruct>

<biblStruct xml:id="b189">
	<monogr>
		<title level="m">WHO Framework Convention on Tobacco Control</title>
		<meeting><address><addrLine>Geneva</addrLine></address></meeting>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2003-09-14">2003. September 14, 2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization (2003). WHO Framework Convention on Tobacco Control. World Health Organization, Geneva. Accessed September 14, 2025.</note>
</biblStruct>

<biblStruct xml:id="b190">
	<monogr>
		<title level="m" type="main">Who global report on trends in prevalence of tobacco smoking 2000</title>
		<imprint>
			<date type="published" when="2018">2018. 2025</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization (2018). Who global report on trends in prevalence of tobacco smoking 2000-2025.</note>
</biblStruct>

<biblStruct xml:id="b191">
	<monogr>
		<title level="m" type="main">Tobacco</title>
		<imprint>
			<date type="published" when="2025-09-14">2025. September 14, 2025</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization (2025). Tobacco. Accessed September 14, 2025.</note>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Nondaily smokers: a descriptive analysis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Wortley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Husten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Trosclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chrismon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Pederson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nicotine &amp; Tobacco Research</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="755" to="759" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wortley, P. M., Husten, C. G., Trosclair, A., Chrismon, J., and Pederson, L. L. (2003). Nondaily smokers: a descriptive analysis. Nicotine &amp; Tobacco Research, 5(5):755-759.</note>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">Effectiveness of smoking cessation therapies: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dimoulas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Mills</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC public health</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">300</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu, P., Wilson, K., Dimoulas, P., and Mills, E. J. (2006). Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC public health, 6(1):300.</note>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">A just-in-time adaptive intervention (jitai) for smoking cessation: Feasibility and acceptability findings</title>
		<author>
			<persName><forename type="first">M.-J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Wetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vinci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addictive behaviors</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page">107467</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yang, M.-J., Sutton, S. K., Hernandez, L. M., Jones, S. R., Wetter, D. W., Kumar, S., and Vinci, C. (2023). A just-in-time adaptive intervention (jitai) for smoking cessation: Feasibility and acceptability findings. Addictive behaviors, 136:107467.</note>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Nicotine, its metabolism and an overview of its biological effects</title>
		<author>
			<persName><forename type="first">D</forename><surname>Yildiz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Toxicon</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="619" to="632" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yildiz, D. (2004). Nicotine, its metabolism and an overview of its biological effects. Toxicon, 43(6):619-632.</note>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Nicotine self-administration differentially regulates hypothalamic corticotropin-releasing factor and arginine vasopressin mrnas and facilitates stress-induced neuronal activation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Matta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Sharp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Neuroscience</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2773" to="2782" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yu, G., Chen, H., Zhao, W., Matta, S. G., and Sharp, B. M. (2008). Nicotine self-administration differentially regulates hypothalamic corticotropin-releasing factor and arginine vasopressin mrnas and facilitates stress-induced neuronal activation. The Journal of Neuroscience, 28(11):2773-2782.</note>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">Abnormal frontostriatal tracts in young male tobacco smokers</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Manza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Shokri-Kojori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Wiers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G.-J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroimage</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="346" to="355" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yuan, K., Yu, D., Zhao, M., Li, M., Wang, R., Li, Y., Manza, P., Shokri-Kojori, E., Wiers, C. E., Wang, G.-J., et al. (2018). Abnormal frontostriatal tracts in young male tobacco smokers. Neuroimage, 183:346-355.</note>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Polonium and lung cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Zaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lygidakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chaouachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gattavecchia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of oncology</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">860103</biblScope>
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zaga, V., Lygidakis, C., Chaouachi, K., and Gattavecchia, E. (2011). Polonium and lung cancer. Journal of oncology, 2011(1):860103.</note>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Impact of prefrontal cortex in nicotine-induced excitation of ventral tegmental area dopamine neurons in anesthetized rats</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W.-X</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Gutkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Steffensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lukas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neuroscience</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">36</biblScope>
			<biblScope unit="page" from="12366" to="12375" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang, D., Gao, M., Xu, D., Shi, W.-X., Gutkin, B. S., Steffensen, S. C., Lukas, R. J., and Wu, J. (2012). Impact of prefrontal cortex in nicotine-induced excitation of ventral tegmental area dopamine neurons in anesthetized rats. Journal of Neuroscience, 32(36):12366-12375.</note>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Nicotine elicits prolonged calcium signaling along ventral hippocampal axons</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Talmage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Role</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">82719</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhong, C., Talmage, D. A., and Role, L. W. (2013). Nicotine elicits prolonged calcium signaling along ventral hippocampal axons. PLoS ONE, 8(12):e82719.</note>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Wisconsin Inventory of Smoking Dependence Motives (WISDM-68)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Piper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Piasecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Federman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Bolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Fiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Baker</surname></persName>
		</author>
		<idno type="DOI">10.1037/t01769-000</idno>
		<ptr target="https://doi.org/10.1037/t01769-000" />
	</analytic>
	<monogr>
		<title level="j">APA PsycTests</title>
		<imprint>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Database record</note>
	<note type="raw_reference">Piper, M. E., Piasecki, T. M., Federman, E. B., Bolt, D. M., Smith, S. S., Fiore, M. C., and Baker, T. B. (2004). Wisconsin Inventory of Smoking Dependence Motives (WISDM-68) [Database record]. APA PsycTests. https://doi.org/10.1037/t01769-000.</note>
</biblStruct>

<biblStruct xml:id="b202">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Costa</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Mccrae</surname></persName>
		</author>
		<title level="m">Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI): Professional Manual</title>
		<meeting><address><addrLine>Odessa, FL, USA</addrLine></address></meeting>
		<imprint>
			<publisher>Psychological Assessment Resources</publisher>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Costa, P. T. Jr. and McCrae, R. R. (1992). Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI): Professional Manual. Psychological Assessment Resources, Odessa, FL, USA.</note>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">Development and validation of the Wisconsin Smoking Withdrawal Scale (WSWS)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Welsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Wetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Jorenby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Fiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Baker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Experimental and Clinical Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="354" to="361" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Welsch, S. K., Smith, S. S., Wetter, D. W., Jorenby, D. E., Fiore, M. C., and Baker, T. B. (1999). Development and validation of the Wisconsin Smoking Withdrawal Scale (WSWS). Experimental and Clinical Psychopharmacology, 7(4):354-361.</note>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">The Fagerstr√∂m Test for Nicotine Dependence: a revision of the Fagerstr√∂m Tolerance Questionnaire</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Heatherton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Kozlowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Frecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Fagerstr√∂m</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British Journal of Addiction</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1119" to="1127" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., and Fagerstr√∂m, K. O. (1991). The Fagerstr√∂m Test for Nicotine Dependence: a revision of the Fagerstr√∂m Tolerance Questionnaire. British Journal of Addiction, 86(9):1119-1127.</note>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">A multiple motives approach to tobacco dependence: The Wisconsin Inventory of Smoking Dependence Motives (WISDM-68)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Piper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Piasecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Federman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Bolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Fiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Baker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Consulting and Clinical Psychology</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="139" to="154" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Piper, M. E., Piasecki, T. M., Federman, E. B., Bolt, D. M., Smith, S. S., Fiore, M. C., and Baker, T. B. (2004). A multiple motives approach to tobacco dependence: The Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). Journal of Consulting and Clinical Psychology, 72(2):139-154.</note>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">Smoking History Questionnaire (SHQ)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Strong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Uebelacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fokas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Saritelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Matsko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Abrantes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Schonbrun</surname></persName>
		</author>
		<idno type="DOI">10.1037/t70008-000</idno>
		<ptr target="https://doi.org/10.1037/t70008-000" />
	</analytic>
	<monogr>
		<title level="j">APA PsycTests</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Database record</note>
	<note type="raw_reference">Strong, D. R., Uebelacker, L., Fokas, K., Saritelli, J., Matsko, S., Abrantes, A. M., and Schonbrun, Y. (2014). Smoking History Questionnaire (SHQ) [Database record]. APA PsycTests. https://doi.org/10.1037/t70008-000.</note>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">Motivation To Stop Scale (MTSS)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>West</surname></persName>
		</author>
		<idno type="DOI">10.1037/t30482-000</idno>
		<ptr target="https://doi.org/10.1037/t30482-000" />
	</analytic>
	<monogr>
		<title level="j">APA PsycTests</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Database record</note>
	<note type="raw_reference">Kotz, D., Brown, J., and West, R. (2013). Motivation To Stop Scale (MTSS) [Database record]. APA PsycTests. https://doi.org/10.1037/t30482-000.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
